0000878526-20-000022.txt : 20200302 0000878526-20-000022.hdr.sgml : 20200302 20200302160230 ACCESSION NUMBER: 0000878526-20-000022 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 118 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATUS MEDICAL INC CENTRAL INDEX KEY: 0000878526 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770154833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33001 FILM NUMBER: 20676736 BUSINESS ADDRESS: STREET 1: 6701 KOLL CENTER PARKWAY, SUITE 120 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252236700 MAIL ADDRESS: STREET 1: 6701 KOLL CENTER PARKWAY, SUITE 120 CITY: PLEASANTON STATE: CA ZIP: 94566 10-K 1 ntus12311910-k.htm 10-K Document
false--12-31FY20190000878526696000073840000.00112000000033804379341487003380437934148700P1Y0.001100000000000P3YP1YP2YP3YP4YP3YP1YP4YP4YP10Y 0000878526 2019-01-01 2019-12-31 0000878526 2018-01-01 2018-12-31 0000878526 2020-02-19 0000878526 2019-06-30 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2019-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000878526 us-gaap:WarrantyReservesMember 2018-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2016-12-31 0000878526 us-gaap:WarrantyReservesMember 2019-01-01 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2017-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000878526 us-gaap:WarrantyReservesMember 2017-01-01 2017-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2018-01-01 2018-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000878526 2018-12-31 0000878526 2019-12-31 0000878526 2017-01-01 2017-12-31 0000878526 us-gaap:CommonStockMember 2017-12-31 0000878526 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000878526 2019-01-01 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000878526 us-gaap:RetainedEarningsMember 2019-12-31 0000878526 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 2018-12-31 0000878526 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000878526 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000878526 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0000878526 us-gaap:CommonStockMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000878526 2016-12-31 0000878526 us-gaap:RetainedEarningsMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000878526 us-gaap:RetainedEarningsMember 2018-12-31 0000878526 us-gaap:CommonStockMember 2019-12-31 0000878526 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 0000878526 us-gaap:CommonStockMember 2018-12-31 0000878526 us-gaap:RetainedEarningsMember 2017-12-31 0000878526 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2019-01-01 0000878526 2017-12-31 0000878526 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000878526 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000878526 srt:MaximumMember us-gaap:BuildingMember 2019-01-01 2019-12-31 0000878526 srt:MinimumMember us-gaap:BuildingMember 2019-01-01 2019-12-31 0000878526 srt:MinimumMember 2019-01-01 2019-12-31 0000878526 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000878526 srt:MaximumMember 2019-01-01 2019-12-31 0000878526 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000878526 srt:DirectorMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000878526 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000878526 2018-07-01 2018-12-31 0000878526 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000878526 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000878526 ntus:EmployeesMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000878526 ntus:IntegraMember 2017-10-06 0000878526 ntus:IntegraMember 2017-01-01 2017-12-31 0000878526 ntus:IntegraMember 2017-10-06 2017-10-06 0000878526 ntus:OtometricsMember 2017-01-03 2017-01-03 0000878526 us-gaap:UnbilledRevenuesMember 2019-12-31 0000878526 2022-01-01 2019-12-31 0000878526 2021-01-01 2019-12-31 0000878526 2020-01-01 2019-12-31 0000878526 2019-01-01 2019-12-31 0000878526 2023-01-01 2019-12-31 0000878526 us-gaap:UnbilledRevenuesMember 2019-01-01 2019-12-31 0000878526 us-gaap:UnbilledRevenuesMember 2018-12-31 0000878526 us-gaap:ComputerEquipmentMember 2018-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2018-12-31 0000878526 ntus:DemonstrationAndLoanedEquipmentMember 2018-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000878526 ntus:DemonstrationAndLoanedEquipmentMember 2019-12-31 0000878526 us-gaap:LandMember 2019-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2019-12-31 0000878526 us-gaap:LandMember 2018-12-31 0000878526 us-gaap:BuildingMember 2018-12-31 0000878526 us-gaap:ComputerEquipmentMember 2019-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000878526 us-gaap:BuildingMember 2019-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000878526 us-gaap:CoreMember 2018-01-01 2018-12-31 0000878526 us-gaap:PatentsMember 2019-01-01 2019-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000878526 us-gaap:ServiceAgreementsMember 2019-01-01 2019-12-31 0000878526 us-gaap:NonCoreMember 2018-01-01 2018-12-31 0000878526 2018-10-01 2018-12-31 0000878526 us-gaap:TradeNamesMember 2019-01-01 2019-12-31 0000878526 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2019-01-01 2019-12-31 0000878526 us-gaap:ServiceAgreementsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000878526 us-gaap:ServiceAgreementsMember 2018-01-01 2018-12-31 0000878526 us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000878526 us-gaap:PatentsMember 2018-01-01 2018-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2017-01-01 2017-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2018-01-01 2018-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000878526 us-gaap:PatentsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000878526 us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2018-12-31 0000878526 us-gaap:PatentsMember 2019-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2019-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2019-12-31 0000878526 us-gaap:ServiceAgreementsMember 2019-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2018-12-31 0000878526 us-gaap:TradeNamesMember 2019-12-31 0000878526 us-gaap:TradeNamesMember 2018-12-31 0000878526 us-gaap:ServiceAgreementsMember 2018-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000878526 us-gaap:PatentsMember 2018-12-31 0000878526 srt:MaximumMember 2019-12-31 0000878526 srt:MinimumMember 2019-12-31 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-12-31 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2017-07-01 2017-09-30 0000878526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000878526 srt:MinimumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-12-31 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2017-09-30 0000878526 srt:MaximumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0000878526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-12-31 0000878526 srt:MinimumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0000878526 srt:MaximumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-12-31 0000878526 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-12-31 0000878526 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000878526 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000878526 us-gaap:EmployeeStockMember 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000878526 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000878526 us-gaap:EmployeeStockOptionMember 2019-12-31 0000878526 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2017-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000878526 us-gaap:RestrictedStockMember 2018-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000878526 country:DE 2019-12-31 0000878526 country:FR 2019-12-31 0000878526 us-gaap:ResearchMember 2019-12-31 0000878526 country:IE 2019-01-01 2019-12-31 0000878526 us-gaap:ForeignCountryMember 2019-12-31 0000878526 country:CA 2019-01-01 2019-12-31 0000878526 ntus:IncomeTaxProvisionMember 2019-01-01 2019-12-31 0000878526 country:DK 2019-12-31 0000878526 country:US 2019-12-31 0000878526 country:CA 2019-12-31 0000878526 ntus:ForeignCountriesMember 2019-12-31 0000878526 country:IE 2019-12-31 0000878526 country:AR 2019-12-31 0000878526 ntus:ForeignCountriesMember 2018-12-31 0000878526 country:US 2019-12-31 0000878526 country:CA 2018-12-31 0000878526 country:DK 2018-12-31 0000878526 country:AR 2018-12-31 0000878526 country:IE 2018-12-31 0000878526 country:US 2018-12-31 0000878526 ntus:ServicesMember ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 us-gaap:NonUsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 ntus:ServicesMember ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 ntus:SuppliesMember ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:SuppliesMember ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 us-gaap:NonUsMember 2017-01-01 2017-12-31 0000878526 country:US 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 us-gaap:NonUsMember 2019-01-01 2019-12-31 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 ntus:SuppliesMember ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 ntus:SuppliesMember ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 country:US 2018-01-01 2018-12-31 0000878526 country:US 2017-01-01 2017-12-31 0000878526 ntus:SuppliesMember ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-01-01 2019-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2018-12-31 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-04-02 2019-04-02 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-08-02 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-04-02 xbrli:pure iso4217:USD iso4217:USD xbrli:shares xbrli:shares ntus:Segment

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 10-K

☒
ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number: 000-33001
 
 NATUS MEDICAL INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware
 
77-0154833
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566
(Address of principal executive offices) (Zip Code)
(925) 223-6700
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
NTUS
The Nasdaq Stock Market LLC
(The Nasdaq Global Select Market)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒    No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒  No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
 
Large Accelerated Filer
☒
 
Accelerated filer
☐
 
 
 
 
 
 
 
Non-accelerated filer
☐

 
Smaller reporting company
☐
 
 
 
 
 
 
 
 
 
 
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒
As of June 30, 2019, the last business day of Registrant’s most recently completed second fiscal quarter, there were 34,040,230 shares of Registrant’s common stock outstanding, and the aggregate market value of such shares held by non-affiliates of Registrant (based upon the closing sale price of such shares on the Nasdaq Global Select Market on June 28, 2019) was $874,493,509. Shares of Registrant’s common stock held by each executive officer and director and by each entity that owns 5% or more of Registrant’s outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
On February 24, 2020, the registrant had 34,105,116 shares of its common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the Registrant's Definitive Proxy Statement for the 2020 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K, to be filed with the Securities and Exchange Commission, are incorporated by reference into Part III of this Annual Report on Form 10-K.


NATUS MEDICAL INCORPORATED
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
 
 
 
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
ITEM 4.
 
 
ITEM 5.
ITEM 6.
ITEM 7.
ITEM 7A.
ITEM 8.
ITEM 9.
ITEM 9A.
 
 
ITEM 10.
ITEM 11.
ITEM 12.
ITEM 13.
ITEM 14.
 
 
ITEM 15.
ITEM 16.


PART I 
ITEM 1.    Business
This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated (“Natus,” “we,” “us,” or “our”). These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 1 include, but are not limited to, statements regarding the effectiveness and advantages of our products, factors relating to demand for and economic advantages of our products, our plan to develop and acquire additional technologies, products or businesses, our marketing, technology enhancement, and product development strategies, our ability to complete all of our backlog orders, and the anticipated timing and effect of the implementation of our new organizational structure.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause our actual results to differ materially from those that we predicted in the forward-looking statements. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A for a description of risks and uncertainties that could cause actual results to differ from those that we predicted. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements, except as required by Federal Securities laws.
“Natus” and other trademarks of ours appearing in this report are our property.
Overview
Natus provides innovative healthcare solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.
Our broad product portfolio represents a heritage of innovation and leadership. Natus brands have been setting the standard for patient care for over eighty (80) years. Our products are trusted by medical professionals in university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and other sites around the world.
We use our clinical expertise to support our customers' evolving needs with advanced products, continuing education and outstanding technical service. 
Natus provides product solutions for three end markets: Neuro, Newborn Care and Hearing & Balance.
On January 15, 2019, Natus announced the implementation of a new organizational structure designed to improve operational performance and make it a stronger, more profitable company. We consolidated our three strategic business units, Neuro, Newborn Care, and Hearing & Balance into "One Natus". The initiative is designed to create a single, unified company with globally led operational teams in Sales & Marketing, Manufacturing, Research & Development, Quality, and General and Administrative functions. As part of our refocus on more profitable core medical device businesses, we also exited non-core businesses which included Global Neuro-Diagnostic Services, the NeuroCom balance product line, and Medix. In January 2020 we also announced we completed the transition of the Peloton hearing screening services business to an external provider, Pediatrix Medical Group, as part of the implementation of the new organizational structure.
Markets
Neuro — Includes products and services that provide diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery. Neuro's comprehensive neurodiagnostic solutions include electroencephalography (“EEG”) and long-term monitoring (“LTM”), Intensive Care Unit (“ICU”) monitoring, electromyography (“EMG”), sleep analysis or polysomnography (“PSG”), and intraoperative monitoring (“IOM”). These solutions enhance the diagnosis of neurological conditions such as epilepsy, sleep disorders and neuromuscular diseases.
Our neurocritical care solutions include management of traumatic brain injury by continuous monitoring of intracranial pressure (“ICP”) and cerebrospinal fluid (“CSF”) drainage, as well as cranial access kits for entry into the cranium. Our neurosurgical solutions such as dural grafts facilitate dural repair in the cranium as well as valves, shunts and related treatment solutions for procedures involving hydrocephalus.
Newborn Care — Includes products and services for newborn care including hearing screening, brain monitoring, eye imaging, jaundice management, and various disposable newborn care supplies.
Hearing & Balance — The Hearing portfolio includes products for hearing assessment and diagnostics, and hearing aid fitting, including computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing care professionals. Our Balance portfolio provides diagnosis and assessment of vestibular and balance disorders. These solutions have

1

a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets.
Neuro
Our Neuro portfolio is comprised of a comprehensive line of neurodiagnostic, neurocritical care, and neurosurgical products that are used by healthcare practitioners in the diagnosis and monitoring of neurological disorders. The environments in which these products are used include outpatient private practice facilities and inpatient hospital environments. Our products can be used throughout the continuum of care through diagnostic procedures and monitoring of patients during admissions, surgery, while under sedation, in post-operative care, and in intensive care units. Our Neuro products and services include:
Neurodiagnostic
•
Electroencephalography — Equipment, supplies and services used to monitor and visually display the electrical activity generated by the brain and other key physiological signals for both diagnosis and monitoring of neurological disorders in the hospital, research laboratory, clinician office and patient’s home.
•
Electromyography — Equipment and supplies used to measure electrical activity in nerves, muscles, and critical pathways includes EMG, nerve conduction and evoked potential functionality.
•
Polysomnography — Equipment and supplies used to measure a variety of respiratory and physiologic functions to assist in the diagnosis and monitoring of sleep disorders, such as insomnia and obstructive sleep apnea.
•
Intraoperative monitoring — Equipment and supplies used to monitor the functional integrity of certain neural structures (i.e. nerves, spinal cord and parts of the brain) during surgery. The goal of IOM is to provide real time guidance to the surgeon and anesthesiologist, which will reduce the risk to the patient during surgery.
Neurocritical Care
•
Intracranial pressure monitoring — Equipment and catheters used to monitor pressure in the cranium/brain and catheters to drain cerebrospinal fluid from the brain to aid in hydrocephalus and traumatic brain injury cases.
•
Cranial access kits — Convenient, pre-packaged sterile sets containing all necessary components for entry into the cranium, to monitor intracranial pressure and provide temporary drainage of CSF.
Neurosurgery
•
Shunts and Dural grafts — Shunts are used to manage the drainage of cerebrospinal fluid from the brain to maintain appropriate levels of CSF when treating hydrocephalus. Dural grafts are used in procedures to repair or substitute a patient's dura mater which surrounds the brain.
Diagnostic EEG and Long-term Monitoring
We design, manufacture, and market a full line of instruments and supplies used to help diagnose the presence of seizure disorders and epilepsy, look for causes of confusion, evaluate head injuries, tumors, infections, degenerative diseases, and metabolic disturbances that affect the brain; and assist in surgical planning. This type of testing is also done to diagnose brain death in comatose patients. These systems and instruments work by detecting, amplifying, and recording the brain’s electrical impulses, as well as other physiological signals needed to support clinical findings. Routine clinical EEG recording is done by placing electrodes on a patient’s scalp over various areas of the brain to record and detect patterns of activity and specific types of electrical events. EEG technologists perform the tests, and neurologists, neurophysiologists and epileptologists review and interpret the results.
Routine outpatient clinical EEG testing is performed in hospital neurology laboratories, private physician offices, and in ambulatory settings such as the patient’s home, providing physicians with a clinical assessment of a patient’s condition. Long-term inpatient monitoring of EEG and video to monitor behavior (LTM) is used to determine complex treatment plans, and for patients with seizures that do not respond to conventional therapeutic approaches, surgical solutions may be appropriate. Patients suffering from severe head trauma and other acute conditions that may affect the brain are monitored in ICUs. In addition, research facilities use EEG equipment to conduct research on humans and laboratory animals.
Diagnostic Electroencephalograph Monitoring Product Lines
Our EEG diagnostic monitoring product lines for neurology consist of signal amplifiers, workstations to capture and store synchronized video and EEG data, and proprietary software. These products are typically used in concert, as part of an EEG “system” by the neurology/neurophysiology department of a hospital or clinic to assist in the diagnosis and monitoring of neurological conditions.
•
NeuroWorks; NicoletOne.    Our EEG Systems include a broad range of products, from software licenses and ambulatory monitoring systems to advanced laboratory systems with multiple capabilities for EEG, ICU monitoring,

2

long-term monitoring of up to 256 channels, as well as nursing stations to monitor patients and physician review stations with quantitative EEG analysis capabilities.
•
Stellate/Gotman Spike and Seizure; GridView; NicoletOne Trends.    Our proprietary spike and seizure detection algorithm detects, summarizes, and reports EEG events that save health-care professionals time by increasing the speed and accuracy of interpretation. GridView is a tool that allows the clinician to correlate EEG patterns with electrode contacts on a 3D view of the patient brain using magnetic resonance (“MR”) or computed tomography (“CT”) images, thus enabling the visualization and annotation of the brain surface and internal structures involved in the diagnosis of epilepsy. NicoletOne Trends provides a comprehensive set of EEG analysis algorithms that are used to generate compressed trends of large amounts of data to assist in the clinical evaluation and data review process.
•
Proprietary Signal Amplifiers.    Our proprietary signal amplifiers function as the interface between the patient and the computer. The headbox connects electrodes attached to the patient’s head to our EEG monitoring systems.
•
Nicolet Cortical Stimulator.    This product is our proprietary device that provides cortical stimulation to the brain during functional brain mapping either before or during surgery to help the surgeon protect the eloquent parts of the brain (parts of the brain that control speech, motor and sensory functionality). The device can be used as a standalone unit or with the fully integrated NicoletOne or NeuroWorks software that supports control of the device from the software, automated mapping and comprehensive report generation.
•
Supplies.    We also manufacture and market a full line of proprietary EEG electrodes and other supplies used in the electroencephalography field.
Electrodiagnostic Monitoring
Our electrodiagnostic systems include electromyography (EMG), nerve conduction (“NCS”), and evoked potential (“EP”) functionality. EMG and NCS involve the measurement of electrical activity of muscles and nerves both at rest and during contraction. Measuring the electrical activity in muscles and nerves can help diagnose diseases of the peripheral, central nervous system or musculature system. An electromyogram is performed to determine if there is any disease present that effects muscle tissue, nerves, or the junctions between nerve and muscle (neuromuscular junctions). An electromyogram can also be used to diagnose the cause of weakness, paralysis, and muscle twitching, and is also used as a primary diagnosis for carpal tunnel syndrome, which is the most frequently encountered peripheral compressive neuropathy. EMG is also used for clinical applications of botox to relieve muscle spasm and pain. We market both the clinical system and the needles used for these procedures.
Evoked brain potentials are elicited in response to a stimulus. These evoked potentials can come from the sensory pathways (such as hearing and visual) or from the motor pathways. An examination tests the integrity of these pathways including the associated area of the brain. Sophisticated amplifiers are required to recognize and average evoked potential EMG and NCS signals.
Electrodiagnostic Product Lines
•
Dantec Keypoint.    The Dantec Keypoint G-4 and Focus EMG and EP family of products features amplifiers, stimulators, and strong signal quality. The Keypoint G4 is used for advanced neurodiagnostic applications such as single fiber EMG, visual and auditory evoked potentials, and in routine nerve conduction studies. The Keypoint Focus system is also available in a portable laptop configuration.
•
Dantec Clavis.    The Dantec Clavis device is a hand-held EMG stimulation device that provides muscle and nerve localization information to assist with medication and botox injections. In conjunction with the Bo-ject or Myoject hypodermic needle and electrodes, physicians can better localize the site of the injection.
•
Nicolet EDX family.    A hardware platform of amplifiers, base control units, stimulators and hand-held probes that are sold with Nicolet brand proprietary software. These mid- to high-end systems have full functionality, strong signal quality, and flexibility. They include EMG, NCS, EP’s, IOM and advanced data analysis features.
•
Nicolet VikingQuest.    An EMG system for the mid-range market. The device runs on our proprietary software.
•
Natus UltraPro.    This is an entry level product with add on capabilities that offers high quality data collection using the Dantec Keypoint amplifiers and the proprietary Natus EMG/EP software.
•
Supplies.    We also manufacture and market a full line of proprietary EMG needles and other supplies used in the electrodiagnostic field.
Diagnostic Polysomnography Monitoring
Polysomnography (“PSG”), which involves the analysis of respiratory patterns, brain electrical activity and other physiological data, has proven critical for the diagnosis and treatment of sleep-related diseases such as apnea, insomnia, and narcolepsy. A full polysomnographic sleep study entails a whole-night recording of brain electrical activity, muscle movement, airflow, respiratory effort, oxygen levels, electrical activity of the heart, and other parameters. In some studies, patients are fitted

3

with treatment devices using Positive Airway Pressure technology (“PAP”) during the sleep study and the proper settings for the treatment devices are determined. In many cases, the sleep study is performed in the patient’s home.
Diagnostic PSG Monitoring Product Lines
We market dedicated diagnostic PSG monitoring products that can be used individually or as part of a networked system for overnight sleep studies to assist in the diagnosis of sleep disorders. Additionally, we offer products that are specifically designed to be used in the patient’s home. Some of our EEG systems described above can also be configured to perform diagnostic PSG monitoring. These products include software licenses, ambulatory monitoring systems, and laboratory systems that combine multiple capabilities, including EEG monitoring, physician review stations, and quantitative PSG analysis capabilities.
•
Embla REMlogic, Sandman; and Xltek SleepWorks.    Our diagnostic PSG systems capture and store all data digitally. The systems enable users to specify rules and personal preferences to be used during analysis, summarizing the results graphically and incorporating them in detailed reports.
•
Proprietary Amplifiers.    Our data acquisition systems incorporate recent developments in superior amplifiers for sleep analysis. Our amplifiers are used in both hospitals and stand-alone clinics. In addition to exceptional signal quality, headboxes include various tools such as built-in oximeters and controls to allow the user to start and stop a study or perform electrode impedance testing either at the patient’s bedside or from the monitoring room.
•
Supplies.    We also market a broad line of supplies, disposable products and accessories for the PSG laboratory including the XactTrace respiratory monitoring belts.
Intraoperative Monitoring
Intraoperative monitoring (“IOM”) is the use of electrophysiological methods such as EEG, EMG, and evoked potentials to monitor the functional integrity of certain neural structures (i.e. nerves, spinal cord and parts of the brain) during surgery. The purpose of IOM is to reduce the risk to the patient’s nervous system, and/or to provide functional guidance to the surgeon and anesthesiologist during surgery.
Diagnostic IOM Product Lines
•
Xltek Protektor.    The Protektor system is an IOM system that provides medical professionals with all information necessary to make immediate and critical surgical decisions. The system combines flexibility with multi-modality allowing full coverage of IOM techniques. The Protektor comes in 16 or 32 channel options.
•
Nicolet EDX.    These combo systems are used in IOM applications where a smaller number of channels is sufficient. This approach is primarily followed in international markets that utilize the integrated system approach that allows for the use of the system in EMG clinical applications as well as in IOM applications.
Neurocritical Care Products
Intracranial pressure and temperature provide insight into the health of the brain, especially in patients experiencing a traumatic brain injury, other traumatic, ischemic or hemorrhagic incidents, or a major neurosurgical procedure. A small hole is drilled into the cranium to allow insertion of a catheter that contains a pressure/temperature or pressure only transducer that allows continuous monitoring of brain temperature and/or pressure.
•
Camino ICP Monitor. The Camino ICP Monitor is a compact, portable device that provides tools for continuously determining and monitoring intracranial pressure and intracranial temperature. It has a touch screen interface, physiological alarms, and can output data to either a patient bedside monitor or to remote media types via a USB drive. These systems are used in the intensive care unit (ICU) environment.
•
Camino Catheters. Camino catheters use either fiber optic or strain gauge technology to measure either pressure and temperature or just pressure. Camino catheters measure their respective values at the tip of the catheter, which eliminates the need for a fluid-filled system that uses an external transducer to measure pressure. The Camino Flex Ventricular Intracranial Pressure Monitoring Kit has a catheter that allows both the measurement of ICP and CSF drainage.
•
Cranial Access Kits. Cranial Access Kits are convenient procedural kits that include all the instrumentation and items needed to access the subarachnoid space or the lateral ventricles of the brain. The kit is intended to be used with an external drainage and monitoring system in selected patients to reduce intracranial pressure, to provide temporary drainage of CSF, and to monitor ICP. The kit is a convenient, pre-packaged sterile set containing all necessary components for entry into the cranium and is available with or without drugs and with a variety of drill bits and instrumentation.
Neurosurgical Products

4

During brain surgery, the dura of the brain may need to be repaired or replaced. A dural graft is used to serve as a substitute for the surgical repair of dural defects. Moreover, brain surgery is performed to place shunts in the brain to help drain excess CSF either externally or into the body for reabsorption to help treat hydrocephalus.
•
DURAFORM. DURAFORM Dural Graft Implant is an absorbable collagen matrix to provide a soft, conforming, and easy to use dural substitute. This product is used in the operating room to provide repair of the dura mater and promote dural healing.
•
Shunts. Shunts are used in the operating room to provide solutions for hydrocephalus or brain trauma. Shunts are used to manage the drainage of cerebrospinal fluid from the brain to maintain appropriate levels of CSF when treating hydrocephalus.
Newborn Care
Our newborn care products and services are used by healthcare practitioners in the diagnosis and treatment of common medical ailments in newborn care. Our products are organized in eight modalities and include:
•
Newborn Hearing Screening — Products used to screen hearing in newborns.
•
Diagnostic Hearing Assessment — Products used to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages.
•
Jaundice Management — Products used to treat jaundice, the single largest cause for hospital readmission of newborns in the U.S.
•
Newborn Brain Injury — Products used to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity and monitor general neurological status.
•
Eye Imaging — Systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging.
•
Essentials — Products used in the everyday operation of neonatal intensive care unit (“NICU”) and well-baby nursery department within the hospital environment.
•
NICVIEW — Live streaming video for families with babies in the NICU that enables family members and approved friends to see the new baby, 24/7, from anywhere in the world - from any Internet connected device, within a secured environment.
Newborn Hearing Screening
Hearing impairment is the most common treatable chronic disorder in newborns, affecting as many as five babies out of every 1,000 newborns. It is estimated that 20,000 hearing-impaired babies are born in the United States (“U.S.”) every year, and as many as 60,000 more in the rest of the developed world. Until the introduction of newborn hearing screening programs, screening was generally performed only on those newborns that had identifiable risk factors for hearing impairment. However, screening only those newborns with risk factors for hearing impairment overlooks approximately half of newborns with some level of hearing impairment.
Early identification of hearing impairment and early intervention has been shown to improve language development significantly. Undetected hearing impairment often results in the failure to learn, process spoken language, and speak.
Newborn Hearing Screening Techniques
The two traditional technologies used to screen newborns and infants for hearing impairment are auditory brainstem response and otoacoustic emissions.
Auditory brainstem response (“ABR”).    ABR technology is the most accurate and comprehensive method for screening and diagnosing hearing impairment. ABR technology is based on detecting the brain’s electrical impulses resulting from a specific auditory stimulus.
Otoacoustic emission (“OAE”).    OAEs are sounds created by the active biomechanical processes within the sensory cells of the cochlea. They occur both spontaneously and in response to acoustic stimuli. OAE screening uses a probe placed in the ear canal to deliver auditory stimuli and to measure the response of the sensory cells with a sensitive microphone.
Newborn Hearing Screening Product Lines
Our newborn hearing screening product lines consist of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners. These hearing screening products utilize proprietary signal detection technologies to provide accurate and non-invasive hearing screening for newborns and are designed to detect hearing loss at 30 or 35 dB nHL or higher. Each of these devices is designed to generate a PASS or REFER result.

5

•
ALGO 5 and 3i Newborn Hearing Screeners.    These Automated Auditory Brainstem Responses (“AABR”) devices deliver thousands of soft audible clicks to the newborn’s ears through sound cables and disposable earphones connected to the instrument. Each click elicits an identifiable brain wave, which is detected by disposable electrodes placed on the head of the child and analyzed by the screening device. These devices use our proprietary AABR signal detection algorithm.
•
ABaer Newborn Hearing Screener.    The ABaer, which is a PC-based newborn hearing screening device, offers a combination of AABR, OAE, and diagnostic ABR technologies in one system.
•
Echo-Screen.    Our hand-held Echo-Screen products provide a choice or combination of proprietary ABR and OAE technologies that can also be used for children through adults. The Echo-Screen III device is a compact, multi-modality handheld hearing screener that is tightly integrated with audible Lite Hearing Screening Data Management.
Hearing Screening Supply Products
For infection control, accuracy, and ease of use, the supply products used with our newborn hearing screening devices are designed as single-use, disposable products. Each screening supply product is designed for a specific hearing screening technology.
•
ABR Screening Supply Kits.    Each ABR screen is carried out with single-use earphones and electrodes, which are alcohol and latex-free. The adhesives used in these supply products are specially formulated for use on the sensitive skin of newborns. To meet the needs of our customers we offer a variety of packaging options. Echo-Screen and ABaer offer the choice of either an earphone or use of ear tips for perform ABR screening.
•
OAE Supply Products.    Each OAE screen is carried out with single-use ear tips that are supplied in a variety of sizes and packaging options.
Peloton Screening Services
Peloton Screening Services is a nationwide service offering that provides hearing screening services to hospital-based customers.
Jaundice Management
The American Academy of Pediatrics estimates that each year 60% of the approximately four million newborns in the U.S. become jaundiced. According to the Journal of the American Medical Association, neonatal jaundice is the single largest cause for hospital readmission of newborns in the U.S., and accounts for approximately 50% of readmissions. Because of the serious consequences of hyperbilirubinemia, the American Academy of Pediatrics recommends that all newborns be closely monitored for jaundice and that phototherapy is the standard of care for the treatment of hyperbilirubinemia. The guidelines further recommend that all nurseries have the necessary equipment to provide intensive phototherapy, and specifically recommend the use of the “blue” light as incorporated into our neoBLUE products.
Jaundice Management Products
•
neoBLUE Product Family.    This product line consists of our neoBLUE Overhead, neoBLUE Mini, neoBLUE Cozy, neoBLUE Compact and neoBLUE blanket devices, which utilize light emitting diodes (“LEDs”) to generate a high-intensity, narrow spectrum of blue light that is clinically proven to be most effective in the treatment of newborn jaundice. Our neoBLUE phototherapy devices emit significantly less ultraviolet light and heat than conventional phototherapy devices, reducing the risk of skin damage and dehydration for infants undergoing treatment. Because of the high intensity of these lights, the treatment time associated with phototherapy is reduced.
Newborn Brain Injury
For many years, newborn infants admitted to the NICU of a hospital have been routinely monitored for heart activity, temperature, respiration, oxygen saturation, and blood pressure. Recently it has also been considered important to monitor brain activity. A cerebral function monitor, utilizing amplitude-integrated EEGs (“aEEGs”), is a device for monitoring background neurological activity. Our simplified aEEG devices, introduced over ten years ago, are designed to be simple for use by nurses and neonatologists.
Newborn Brain Injury Products
Our newborn brain injury products record and display parameters that the neonatologist uses to assess and monitor neurological status in the newborn. These devices continuously monitor and record brain activity, aiding in the detection and treatment of hypoxic-ischemic encephalopathy ("HIE"), and seizures. The devices also monitor the effects of drugs and other therapies on brain activity and improve the accuracy of newborn neurological assessments. They are used with electrodes attached to the head of the newborn to acquire an EEG signal that is then filtered, compressed, and displayed graphically on the device or as a hardcopy printout. The monitors have touch screens for easy navigation and onscreen keyboards for data entry at the bedside.

6

•
Olympic Brainz Monitor.    The Olympic Brainz Monitor is our latest generation Cerebral Function Monitor. The device can be used in single-channel, two-channel or three-channel modes to continuously monitor and record brain activity.
Eye Imaging
Our RetCam devices incorporate a camera combined with proprietary imaging software that are used to diagnose and monitor a range of ophthalmic maladies in premature infants. RetCam specializes in NICU ophthalmic imaging used in the detection of retinopathy of prematurity (ROP) and Retinoblastoma (RB) in newborns. ROP and RB are diseases of the retina that must be detected very early after birth and treated immediately, so the RetCam diagnostic camera is a fundamental tool in preventing vision loss and total blindness in infants.
Eye Imaging Products
RetCam images assist physicians in the evaluation of pediatric ocular disease, which have preserved the vision in thousands of infants. Each of the RetCam systems deliver objective and interpretable detail, allow image comparison over time, enable remote consultations, and provide reliable and defensible medico-legal documentation.
•
RetCam 3. Full-featured imaging system with a range of interchangeable lenses, Fluorescein Angiography module option.
•
RetCam Shuttle. Laptop-based system with a smaller cart and dual wheel casters for improved transportability.
•
RetCam Portable. Laptop-based version in a case for maximum portability.
Essentials
The Newborn Care Essentials products include such items as: Biliband eye protectors, MiniMuffs noise attenuators, NeatNick heal lancets, Olympic Circumstraint, Olympic Papoose Boards, Olympic Smart Scales, OraSwab, Save the Gonads x-ray protection devices and SugarPlum glucose lancets.
Live Video Streaming
Live video streaming offers parents and families secured access to a live video stream of their baby. For hospitals, the system offers a step into family centered care.
Live Video Steaming Products
NICVIEW and NICVIEW 2 are user-friendly, web-based video systems for real-time streaming on any online device via a standard downloadable app. Password-protected access ensures parents can view only their own child, with end-to-end encryption and SSL authentication. The video stream can be turned on/off and repositioned at will, so that NICU staff remain in control of the care process at all times.
Hearing & Balance
Our Hearing & Balance product portfolio provides hearing diagnostic, hearing aid fitting and balance instrumentation and software solutions to hearing and balance care professionals worldwide. For more than 50 years, we have helped hearing and balance care professionals succeed in improving the quality of life for their clients and patients by delivering expert knowledge, reliable solutions and services and trusted partnerships. We will continue this tradition and legacy as we develop, manufacture and market computer-based audiological, otoneurologic and vestibular instrumentation in the future.
Our solutions portfolio covers key application areas within hearing assessment, hearing screening, hearing instrument fitting and balance assessment. Many of our hearing and balance care solutions have set precedent within the hearing care industry and are used by thousands of clinicians around the world.
As an independent provider of hearing care diagnostic solutions, we work closely with leading hearing aid manufacturers to develop new solutions within hearing assessment and hearing aid fitting.
Hearing Assessment
From otoacoustic emissions (OAE) and immittance screening to advanced audiological testing and 3D digital ear scanning, we offer a wide range of flexible devices and PC-based solutions that are designed to screen, test and assess patients of all ages. Our hearing assessment solutions offer a range of functionality to support basic audiometric testing to advanced tinnitus and pediatric hearing assessment. Our hearing care solutions help streamline the hearing screening and assessment process making it easier and convenient for the professional and the patient. We also manufacturer and market a broad line of supplies and disposable products and accessories for hearing assessment.
Hearing Instrument Fitting and Verification

7

Hearing fitting solutions help professionals manage the entire hearing aid fitting process - from fitting and verifying the hearing aid to patient counseling and follow up. Used by hearing aid dispensers, audiologists and clinicians around the world, our fitting solutions support otoscopy, audiometry, hearing aid testing and programming, fitting and verification with wireless design and binaural fitting capability. Our fitting solutions are PC-based and supported by integrated audiometric software that helps to streamline the fitting process for greater efficiency and patient satisfaction. We also manufacturers and market a broad line of supplies and disposable products and accessories for hearing instrument fitting and verification.
3D Digital Ear Scanning
Hearing assessment solutions include the breakthrough 3D digital ear scanning solutions Otoscan® that gives hearing care professionals innovative ways to attract and convert more clients while delivering customized hearing care in an efficient way. Otoscan enables hearing care professionals to make digital impressions for custom in-the-ear pieces such as earmolds and hearing aids. The scanner solution applies breakthrough technology to transform images of the ear into 3D digital files that are uploaded to the cloud service, Otocloud, for immediate use in production of custom products, delivering significant efficiency and quality gains in the production of hearing aids. Otocloud is a web-based portal supported by a dedicated Microsoft Azure server domain.
Audiometric Sound Rooms
We manufacture and market a wide range of sound room solutions specifically designed for audiometric testing. Hearing & Balance Genie sound rooms are built to deliver a quality audiometry testing environment while providing efficiency for staff and comfort for patients. Certified staff help in the planning, choice and installation of each sound room so it becomes an integrated part of the clinic, equipment and workflow. Hearing & Balance Genie sound rooms deliver unique features such as the Cam-Lock assembly system, high performance/low profile floor, window in the door, and excellent attenuation and acoustic capabilities to ensure acoustic performance, efficient workflow and maximum testing comfort.
Balance Assessment
Professionals who evaluate patients with balance disorders use our vestibular diagnostic and ENG/VNG (electronystagmography/videonystamography) systems and services. These solutions are used by audiologists, otolaryngologists, otologists and neurologists for identifying auditory and vestibular abnormalities. Our balance care solutions are compact and include the world's first portable, gold standard video head impulse test (“vHIT”) and offer modular functionality to support vHIT, video frenzel, positional, oculomotor and SHIMP (suppression head impulse) testing. We also manufacture and market a broad line of supplies, disposable face cushions, and accessories for balance assessment.

Segment and Geographic Information
We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, our operating segments were based on three strategic business units. In January 2019, we announced the transition of our operating structure from three strategic business units to a single, unified company with globally-led operational teams in Sales and Marketing, Manufacturing, Research and Development, Quality, and General and Administrative functions.
Following the reorganization, we operate as one operating segment and one reportable segment, which provides healthcare products, and services focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Financial information is reviewed on a consolidated basis for purposes of making operating decisions and assessing financial performance. Consolidated financial information is accompanied by disaggregated information about revenues by end market and geographic region. We do not assess the performance of our end markets or geographic regions on measures of profit or loss, or asset-based metrics. We have disclosed the revenues for each of our end markets and geographic regions to provide the reader of the financial statements transparency into our operations.
Information regarding our revenues and long-lived assets in the U.S. and in countries outside the U.S. is contained in Note 20—Segment, Customer and Geographic Information of our Consolidated Financial Statements included in this report and is incorporated in this section by this reference.
Revenue by Product Market and Product Category
For the years ended December 31, 2019, 2018 and 2017, revenue from our product markets as a percent of total revenue was approximately as follows: 

8

 
Year Ended December 31,
 
2019
 
2018
 
2017
Neuro
58
%
 
53
%
 
49
%
Newborn Care
22
%
 
25
%
 
31
%
Hearing & Balance
20
%
 
22
%
 
20
%
Total
100
%
 
100
%
 
100
%
We also look at revenue as either being generated from sales of Devices and Systems, which are generally non-recurring, or related Supplies and Services, which are generally recurring. The products that are attributable to these categories are described above. Revenue from Devices and Systems, Supplies and Services as a percent of total revenue for the years ending December 31, 2019, 2018 and 2017 is as follows: 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Devices and Systems
74
%
 
72
%
 
67
%
Supplies
22
%
 
22
%
 
26
%
Services
4
%
 
6
%
 
7
%
Total
100
%
 
100
%
 
100
%
In 2019, 2018 and 2017, no single end-user customer comprised more than 10% of our revenue.
Backlog
In general, we do not manufacture our products against a backlog of orders and do not consider backlog to be a significant indicator of the level of future sales activity. Production and inventory levels are based on the level of incoming orders as well as projections of future demand. Therefore, we believe that backlog information is not meaningful to understanding our overall business and should not be considered a reliable indicator of our ability to achieve any particular level of revenue or financial performance.
Marketing and Sales
Marketing
Our marketing strategies differ by product market, incorporating market dynamics, trends and competition in the positioning, promotion and pricing of each product. The value proposition that we communicate is focused on the quality, clinical performance, and customer benefit. We invest in educating our customers worldwide about our products through trade conferences and direct presentations to healthcare professionals.
Domestic Direct and Distributor Sales
We sell our products in North America primarily through a direct sales organization. We believe this direct sales organization allows us to maintain a higher level of customer service and satisfaction than would otherwise be possible by other distribution methods. We also sell certain products under private label and distribution arrangements.
For the years ended December 31, 2019, 2018 and 2017, domestic revenue as a percent of total revenue was approximately as follows: 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Domestic revenue
59.0
%
 
56.7
%
 
54.1
%
International Direct and Distributor Sales
We sell some of our products outside the U.S. through direct sales channels in Australia, Canada, China, Denmark, France, Germany, Italy, the Netherlands, New Zealand, the Nordics (Finland, Sweden, Norway), Spain, and the United Kingdom; we sell other products in those regions and into more than 100 other countries through a distributor sales channel.
For the years ended December 31, 2019, 2018 and 2017, international revenue as a percent of total revenue was approximately as follows: 

9

 
Year Ended December 31,
 
2019
 
2018
 
2017
International revenue
41.0
%
 
43.3
%
 
45.9
%
We sell products to our distributors under substantially the same terms as sales through our direct sales channels. Terms of sales to international distributors are generally “ex works,” where title and risk of loss are assumed by the distributor at the shipping point. Distributors are generally given exclusive rights in their territories to purchase products from Natus and to resell to end users or sub-distributors in their respective markets. Our distributors typically perform marketing, sales, and technical support functions in their respective markets. Each distributor may sell Natus products to their customer directly, via other distributors or resellers, or both. We actively train our distributors in product marketing, selling, and technical service techniques.
Seasonality in Revenue
We experience seasonality in our revenue. Demand for our products is historically higher in the second half of the year compared to the first. Our seasonality results from the purchasing habits of our hospital-based customers, whose purchases are often governed by calendar year budgets.
Group Purchasing Organizations
More than 90% of the hospitals in the U.S. are members of group purchasing organizations (“GPO”s), which negotiate volume purchase agreements for member hospitals, group practices, and other clinics.
For the years ended December 31, 2019, 2018 and 2017, revenue from direct purchases under a GPO contract as a percent of total revenue was approximately as follows: 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Direct purchases by GPO members
18.7
%
 
13.3
%
 
14.5
%

Third-Party Reimbursement
In the U.S., healthcare providers generally rely on third-party payors, including private health insurance plans, federal Medicare, state Medicaid, and managed care organizations, to reimburse all or part of the cost of the procedures they perform. Third-party payors can affect the pricing or the relative attractiveness of our products by regulating the maximum amount of reimbursement these payors provide for services utilizing our products.
Customer Service and Support
We generally provide a one-year warranty on our medical device and system products. We also sell extended service agreements on our medical device and system products. Service, repair, and calibration services for our domestic customers are provided by Company-owned service centers and our field service specialists. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
Manufacturing
We procure a significant portion of the components used in our products from other manufacturers; however, we perform final assembly, testing, and packaging of many of the devices ourselves to control quality and manufacturing efficiency and we are the manufacture of record. We also use contract manufacturers to manufacture some of our disposable supply and medical device products. We perform regular quality assessments of these contract manufacturers, which include on-site quality audits.
We purchase materials and components from qualified suppliers that are subject to our quality specifications and inspections. We conduct quality audits of our key suppliers, several of which are experienced in the supply of components to manufacturers of finished medical devices, or supplies for use with medical devices. Most of our purchased components are available from more than one supplier.
Our manufacturing, service, and repair facilities are subject to periodic inspection by local and foreign regulatory authorities. Our quality assurance system is subject to regulation by the U.S. Food and Drug Administration (“FDA”) and other government agencies. We are required to conduct our product design, testing, manufacturing, and control activities in conformance with the FDA’s quality system regulations and to maintain our documentation of these activities in a prescribed manner. In addition, our production facilities have received International Organization for Standardization (“ISO”) 13485 certification. ISO 13485 certification standards for quality operations have been developed to ensure that medical device companies meet the standards of quality on a worldwide basis. We have also received the EC Certificate pursuant to the European Union Medical Device Directive 93/42/EEC, which allows us to place a CE mark on our products.

10

Research and Development
We are committed to introducing new products and supporting current product offerings in our markets through a combination of internal as well as external efforts that are consistent with our corporate strategy.
Internal product development capabilities.    We believe the ability to develop innovative products is essential to providing our customers with new product offerings. We plan to leverage our core technologies by introducing product line extensions as well as new product offerings.
Partnerships that complement our expertise.    We continue to seek strategic partners in order to develop products that may not otherwise be available to us. By taking advantage of our core competencies, we believe that we can bring acquired or distributed products to market in an efficient manner and leverage our distribution channels.
New opportunities through technology acquisition.    We continue to evaluate new, emerging, and complementary technologies in order to identify new product opportunities. With our knowledge of our current markets we believe that we can effectively develop acquired technologies into successful new products.
Proprietary Rights
We protect our intellectual property through a combination of patent, copyright, trade secret, and trademark laws. We attempt to protect our intellectual property rights by filing patent applications for new features and products we develop. We enter into confidentiality or license agreements with our employees, consultants, and corporate partners, and seek to control access to our intellectual property, distribution channels, documentation, and other proprietary information. However, we believe that these measures afford only limited protection.
The intellectual rights to some of the original patents for technology incorporated into our products are now in the public domain. However, we do not consider these patents, or any currently viable patent or related group of patents, to be of such importance that their expiration or termination would materially affect our business.
We capitalize the cost of purchased technology and intellectual property, as well as certain costs incurred in obtaining patent rights, and amortize these costs over the estimated economic lives of the related assets.
We have numerous registered trademarks and service marks. Our marks are pending or registered trademarks in the United States and several foreign countries. We intend to file for additional trademarks to strengthen our trademark rights, but we cannot be certain that our trademark applications will result in registration or that our trademarks will be enforceable.
Competition
We sell our products in competitive and rapidly evolving markets. We face competition from other companies in all of our product lines. Our competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.
We derive a significant portion of our revenue from the sale of disposable supplies that are used with our medical devices. In the U.S., we sell our supply products in a mature market and we expect that our products could face increasing competition, including competitors offering lower prices, which could have an adverse effect on our revenue and profit margins.
We believe the principal factors that will draw clinicians and other buyers to our products, include:
•
The clinical performance of our products including the level of specificity, sensitivity, and reliability of the product;
•
Time required to obtain results with the product, such as to test for or treat a clinical condition;
•
Relative ease of use of the product;
•
Our level of expertise in these fields which produces the depth and breadth of the products features;
•
Quality of customer support for the product;
•
Frequency of product updates;
•
Extent of third-party reimbursement of the cost of the product or procedure;
•
Extent to which the products conform to standard of care guidelines; and
•
Price of the product.
We believe that our primary competitive strength relates to the clinical functionality and reliability of our products.
Government Regulation
FDA’s Premarket Clearance and Approval Requirements

11

Unless an exemption applies, the medical devices we sell in the United States, must first receive one of the following types of FDA premarket review authorizations under the Food, Drug, and Cosmetics Act, as amended:
•
Clearance via Section 510(k); or
•
Premarket approval via Section 515 if the FDA has determined that the medical device in question poses a greater risk of injury.
The FDA’s 510(k) clearance process usually takes from three to six months, but can take longer. The process of obtaining premarket approval via Section 515 is much more costly, lengthy, and uncertain. Premarket approval generally takes from one to three years, but can take longer. We cannot be sure that the FDA will ever grant either 510(k) clearance or premarket approval for any product we propose to market in the United States.
The FDA decides whether a device must undergo either the 510(k) clearance or premarket approval process based upon statutory criteria. These criteria include the level of risk that the FDA perceives to be associated with the device and a determination of whether the product is a type of device that is substantially equivalent to devices that are already legally marketed. The FDA places devices deemed to pose relatively less risk in either Class I or Class II, which requires the manufacturer to submit a premarket notification requesting 510(k) clearance, unless an exemption applies. The premarket notification under Section 510(k) must demonstrate that the proposed device is substantially equivalent in intended use and in safety and effectiveness to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of premarket approval applications.
The FDA places devices deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed to be not substantially equivalent to a predicate device, in its Class III classification. The FDA requires these devices to undergo the premarket approval process via Section 515 in which the manufacturer must prove the safety and effectiveness of the device. A premarket approval application must provide extensive pre-clinical and clinical trial data.
The FDA may require results of clinical trials in support of a 510(k) submission and generally requires clinical trial results for a premarket approval application. In order to conduct a clinical trial on a significant-risk device, the FDA requires manufacturers to apply for and obtain, in advance, an investigational-device exemption. The investigational-device exemption application must be supported by appropriate data, such as animal and laboratory testing results. If the FDA and the Institutional Review Boards at the clinical trial sites approve the investigational-device exemption application for a significant-risk device, the manufacturer may begin the clinical trial. An investigational-device exemption approval provides for a specified clinical protocol, including the number of patients and study sites. If the manufacturer deems the product a non-significant risk device, the product will be eligible for more abbreviated investigational-device exemption requirements. If the Institutional Review Boards at the clinical trial sites concur with the non-significant risk determination, the manufacturer may begin the clinical trial.
Most of our products have been cleared by the FDA as Class II devices.
FDA Regulation
Numerous FDA regulatory requirements apply to our products. These requirements include:
•
FDA quality system regulations which require manufacturers to create, implement, and follow design, testing, control, documentation, and other quality assurance procedures;
•
Medical device reporting regulations, which require that manufacturers report to the FDA certain types of adverse and other events involving their products; and
•
FDA general prohibitions against promoting products for unapproved uses.
Class II and III devices may also be subject to special controls applied to them, such as performance standards, post-market surveillance, patient registries, and FDA guidelines that may not apply to Class I devices. We believe we are in compliance with applicable FDA guidelines, but we could be required to change our compliance activities or be subject to other special controls if the FDA changes existing regulations or adopts new requirements.
We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to adequately comply, the FDA can institute a wide variety of enforcement actions, including:
•
Issuance of a Form 483 citation;
•
Fines, injunctions, and civil penalties;
•
Recall or seizure of our products;
•
Issuance of public notices or warnings;
•
Imposition of operating restrictions, partial suspension, or total shutdown of production;

12

•
Refusal of our requests for 510(k) clearance or pre-market approval of new products;
•
Withdrawal of 510(k) clearance or pre-market approval already granted; or
•
Criminal prosecution.
The FDA also has the authority to require us to repair or replace any misbranded or adulterated medical device manufactured or distributed by us.
Other Regulations
We also must comply with numerous additional federal, state, and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, biohazards, fire hazard control, and hazardous substance disposal. We believe we are currently in compliance with such regulations.
Countries outside of the U.S. regulate medical devices in a manner similar to that of the FDA. Our manufacturing facilities are subject to audit and have been certified to be ISO 13485:2016, Medical Device Directive 93/42/EEC, and MDSAP compliant, which allows us to sell our products in Europe, Canada, and other territories around the world. All of our manufacturing facilities are subject to inspection by our notified bodies or other competent authorities, and in some cases without advance notice. We plan to seek approval to sell our products in additional countries, while maintaining our current approvals. The time and cost of obtaining new, and maintaining existing, market authorizations from countries outside of North America, and the requirements for licensing products in these countries may differ significantly from FDA requirements.
In 2017, the European Union ("EU") adopted the EU Medical Device Regulation (Council Regulations 2017/745) which imposes stricter requirements for the marketing and sale of medical devices, including new quality system and post-market surveillance requirements. The regulation has a three-year implementation period ending in May 2020 and will replace the existing directives on medical devices in the EU. After May 2020, medical devices marketed in the EU will require certification according to these new requirements, except that devices with valid CE certificates, issued pursuant to the Medical Device Directive before May 2020, may be placed on the market until 2024. Complying with this new regulation requires us to incur significant costs on product design history file remediation and transition. Failure to meet the requirements of the regulation could adversely impact our business in the European Union and other countries that utilize or rely on European Union requirements for medical device registrations.
Employees
On December 31, 2019, we had approximately 1,484 full time employees worldwide. Our employees in Germany are represented by a Works Council. We have not experienced any work stoppages, and we consider our relations with our employees to be good.
Executives
The following table lists our executive officers and their ages as of March 2, 2020: 
Name
 
Age
 
Position(s)
Jonathan A. Kennedy
 
49

 
President and Chief Executive Officer
B. Drew Davies
 
54

 
Executive Vice President and Chief Financial Officer
D. Christopher Chung, M.D.

 
56

 
Vice President of Quality, Regulatory Affairs and Chief Medical Officer
Austin F. Noll, III

 
53

 
Executive Vice President and Chief Commercial Officer

Jonathan A. Kennedy has served as Chief Executive Officer, and as a member of the Board of Directors since July 2018. Mr. Kennedy joined Natus as Senior Vice President and Chief Financial Officer in April 2013 and was appointed Executive Vice President and Chief Financial Officer in September 2016. Before joining Natus, Mr. Kennedy was Senior Vice President and Chief Financial Officer of Intersil Corporation, a global semiconductor manufacturer, since 2009. Prior to that, he was Intersil’s Corporate Controller since 2005 and Director of Finance since 2004. Before joining Intersil, Mr. Kennedy held management roles in Finance and Information Technology with Alcon Inc. and Harris Corporation. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida.
B. Drew Davies joined Natus as Executive Vice President and Chief Financial Officer in October 2018. Mr. Davies most recently served as Executive Vice President and Chief Financial Officer of Extreme Networks since June 2016. Before joining Natus, Mr. Davies served as Vice President and Corporate Controller at Marvell Semiconductor Inc. from December 2015 until May 2016. Prior to that, Mr. Davies was the Senior Vice President, Corporate Controller at Spansion, Inc. from August 2012 to December 2015. Prior to Spansion, Mr. Davies was Corporate Controller at Intersil Corporation from April 2009 to August 2012, and served as Operations Controller from March 2008 to April 2009. Mr. Davies also served as Chief Financial Officer of Nanoconduction, Inc. from March 2007 to March 2008, Director of Finance and Administration for STATSChipPac from September

13

1999 to March 2007, held various finance roles at Micron Custom Manufacturing Services from November 1992 to September 1999. Mr. Davies holds a Master of Business Administration degree from Santa Clara University and a Bachelor of Science, Business Accounting degree from the University of Idaho.
D. Christopher Chung, joined Natus in 2000 as the Medical Director. He has also served as Vice President of R&D and most recently since 2011 as Vice President Medical Affairs, Quality and Regulatory. From 2000 to 2007, Dr. Chung also served as a Pediatric Hospitalist at the California Pacific Medical Center in San Francisco providing patient care in the Neonatal Intensive Care Unit and Newborn Nursery. From 1997 to 2000, Dr. Chung trained as a pediatric resident at Boston Children’s Hospital and Harvard Medical School. From 1986 to 1993, Dr. Chung worked as an R&D engineer at Nellcor Incorporated, a medical device company that pioneered the development of pulse oximetry. Dr. Chung holds a Bachelor of Arts degree in Computer Mathematics from the University of Pennsylvania and a Doctor of Medicine degree from the Medical College of Pennsylvania-Hahnemann University School of Medicine. He is board certified in Pediatrics and is a Fellow of the American Academy of Pediatrics. Dr. Chung has also been awarded nine U.S. Patents in the medical device field.
Austin F. Noll, III joined Natus in August 2012 as the Vice President and General Manager, Neuro. Prior to joining Natus, Mr. Noll served as the President and CEO of Simpirica Spine, a California-based start-up company that developed and commercialized a novel device for spinal stabilization. Prior to joining Simpirica Spine, Mr. Noll served as the President and CEO of NeoGuide Systems, a medical robotics company acquired by Intuitive Surgical. Prior to joining NeoGuide Systems, Mr. Noll held numerous management positions at Medtronic over a 13-year period, where he served as the Vice President and General Manager of the Powered Surgical Solutions and the Neurosurgery businesses. Before Medtronic, he held sales positions at C.R. Bard and Baxter Healthcare. He received a Bachelor of Science degree in Business Administration from Miami University and a Master of Business Administration degree from the University of Michigan.
Other Information
Natus was incorporated in California in May 1987 and reincorporated in Delaware in August 2000.
We maintain corporate offices at 6701 Koll Center Parkway Suite 120, Pleasanton, California 94566. Our telephone number is (925) 223-6700. We maintain a corporate website at www.natus.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.
We make available, free of charge on our corporate website, copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and all amendments to these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act. We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. This information may also be obtained from the SEC’s on-line database, which is located at www.sec.gov. Our common stock is traded on the Nasdaq Stock Market under the symbol “NTUS”.

Item 1A.    Risk Factors
Risks Related to Our Business and Industry
Our business results depend on our ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
On January 15, 2019 Natus announced the implementation of a new organizational structure, “One Natus,” designed to improve operational performance and make it a stronger, more profitable company. While the implementation is substantially complete, there can be no assurance that we will realize, in full or in part, the anticipated benefits of this new structure. Our financial goals assume a level of increased productivity. If we are unable to deliver these expected improvements, or continue to invest in business growth, or if the volume and nature of change require additional resources, our business operations and financial results could be materially and adversely impacted. Our ability to successfully manage and execute these initiatives and realize expected savings and benefits in the amounts and at the times anticipated is important to our business success. Any failure to do so, which could result from our inability to successfully execute organizational change and business transformation plans, changes in global or regional economic conditions, competition, changes in the industries in which we compete, unanticipated costs or charges, loss of key personnel and other factors described herein, could have a material adverse effect on our businesses, financial condition and results of operations.
Our growth in prior years has depended substantially on the completion of acquisitions and we may not be able to complete acquisitions of the same nature or relative size in the future to support a similar level of growth.
The acquisitions that we have completed have contributed to our growth in prior years. We have expended considerable effort in seeking to identify attractive acquisition candidates, and ultimately, to negotiate mutually agreeable acquisition terms.

14

The market for attractive acquisitions is competitive and others with different strategic objectives or greater financial resources than we have may be better positioned than we are to acquire desirable targets. Further, we may not be able to negotiate acquisition terms with target companies that will allow us to achieve acceptable financial returns from the transaction.
If we do not remediate a material weakness in our internal control over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected.
Under Section 404 of the Sarbanes-Oxley Act of 2002 and rules promulgated by the SEC, companies are required to conduct an annual comprehensive evaluation of their internal control over financial reporting. Further, each year our independent registered public accounting firm is required to attest to and report on the effectiveness of our internal control over financial reporting. Management concluded that as of December 31, 2019, our internal control over financial reporting was not effective. Immaterial errors identified as part of the closing of our books for the fourth quarter 2019 indicated certain deficiencies existed in the Company’s internal control over financial reporting. Specifically, we did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of our controls over payroll accounts contributed to an error in the period end accrual. The Company has concluded that these deficiencies could have resulted in a material misstatement of the consolidated financial statements that would not have been prevented or detected on a timely basis, and as such, these control deficiencies result in a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. This material weakness is more fully described in Item 9A. Controls and Procedures-Management’s Report on Internal Control Over Financial Reporting. The existence of this material weakness and of any other ineffective controls over our financial reporting could result in one or more of the following:
•Revision of previously filed financial statements;
•Failure to meet our reporting obligations;
•Loss of investor confidence; and
•Negative impact on the trading price of our common stock.
If we are not able to maintain effective internal control over financial reporting in the future, the accuracy and timeliness of our financial reporting may be adversely affected.
A material weakness is defined under the standards issued by the Public Company Accounting Oversight Board as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected and corrected on a timely basis.
We reported a material weakness in our internal control over financial reporting for the year ended December 31, 2017 related to missing controls over a significant business combination, which we remediated in 2018. Separate from the material weakness identified for the year ended December 31, 2017, during the fourth quarter of 2018, in connection with a change in control owner, management identified an existing control that was not designed at a sufficient precision to adequately review our analysis of separate reporting units, which could have resulted in a material misstatement. Although we took steps to remediate both these issues in 2018 and believe both material weaknesses were remediated as of December 31, 2018, these measures may not be sufficient to avoid similar weaknesses or other deficiencies in the future.
During the fourth quarter of 2019, we identified errors as part of closing our books and concluded that certain deficiencies existed in the Company’s internal control over financial reporting. Specifically, we did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of our controls over payroll accounts contributed to an error in the period end accrual. The Company has concluded that these deficiencies could have resulted in a material misstatement of the consolidated financial statements that would not have been prevented or detected on a timely basis, and as such, these control deficiencies resulted in a material weakness in our internal control over financial reporting. We plan to make substantive changes to enhance our design of controls intended to identify and assess contracts that include research and development and to aid in confirming the accuracy of the payroll accrual accounts. There can be no assurances that these remediation steps will be successful.
The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and disclosure controls and procedures quarterly. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on, and our independent registered public accounting firm to attest to, the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. If other material weaknesses are identified in the future or we are not able to comply with the requirements of Section 404 in a timely manner, our reported financial results could be materially misstated or could be restated, we could receive an adverse opinion regarding our controls from our independent registered accounting firm and we could be subject to

15

investigations or sanctions by regulatory authorities, which would require additional financial and management resources, and the market price of our stock could decline.
Our operating results may decline if we do not succeed in developing, acquiring, and marketing additional products or improving our existing products.
We intend to develop additional products and technologies, including enhancements of existing products, for the screening, detection, treatment, monitoring and tracking of common medical ailments. Developing new products and improving our existing products to meet the needs of current and future customers requires significant investments in research and development. Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials, which can be time consuming and expensive. Unfavorable or inconsistent clinical data from existing or future clinical trials may adversely affect our ability to secure marketing authorization for certain products. Furthermore, all results, even positive ones, are subject to the interpretation of FDA and other regulatory agencies. If we fail to sell new products, update existing products, or timely react to changes in technology, our operating results may decline as our existing products reach the end of their commercial life cycles.
Adverse economic conditions in markets in which we operate may harm our business.
Unfavorable changes in U.S. and international economic environments may adversely affect our business and financial results. Concerns over the economic stability, the level of U.S. national debt, currency fluctuations and volatility, the rate of growth of Japan, China, and other Asian economies, unemployment, the availability and cost of credit, inflation levels, trade relations, energy costs and geopolitical uncertainty have contributed to increased volatility and diminished expectations for the economy and the markets. During challenging economic times, and in tight credit markets, our customers may delay or reduce capital expenditures. This could result in reductions in sales of our products, longer sales cycles, difficulties in collection of accounts receivable, slower adoption of new technologies, and increased price competition, all of which could impact our results of operations and financial condition. In addition, we expect these factors will cause us to be more cautious in evaluating potential acquisition opportunities, which could hinder our ability to grow through acquisition while these conditions persist.
In addition, we are susceptible to risks related to the outbreak of a novel strain of coronavirus (“COVID-19”) in China and its spread to other countries. In particular, the continued spread of COVID-19 globally could adversely affect our operations, including our manufacturing and supply chain and sales and marketing. Parts of our direct and indirect supply chain are in China, and are accordingly subject to disruption or product contamination. Additionally, our results of operations could be adversely affected to the extent that COVID-19 or any other epidemic harms our business or the economy in general either in China or in any other region in which we do business. For example, our customers may delay, cancel or redirect planned capital expenditures in order to focus resources on COVID-19 or in response to economic disruption related to COVID-19. The extent to which COVID-19 affected our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, and could have an adverse effect on our business and financial condition.
Further, the U.S. federal government has called for, or enacted, substantial changes to healthcare, trade, fiscal, and tax policies, which may include changes to existing trade agreements and may have a significant impact on our operations. For example, the current administration has initiated the imposition of tariffs on certain foreign products, including from China, that have resulted in and may result in future retaliatory tariffs on U.S. goods and products. We cannot predict the impact, if any, that these changes could have on our business. If economic conditions worsen or new legislation is passed related to the healthcare system, trade, fiscal or tax policies, customer demand may not materialize to levels we require to achieve our anticipated financial results, which could have a material adverse effect on our business, financial condition and results of operations.
Uncertain credit markets and concerns regarding the availability of credit could impact consumer and customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers and creditors, including financial institutions. If the current situation continues to deteriorate or does not improve, our business could be negatively affected by factors such as reduced demand for our products resulting from a slow‑down or volatility in the general economy, supplier or customer disruptions and/or temporary interruptions in our ability to conduct day‑to‑day transactions through our financial intermediaries involving the payment to or collection of funds from our customers, vendors and suppliers.
The United Kingdom's withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business and operations.
In 2016 voters in the United Kingdom approved the United Kingdom to withdraw from the European Union (often referred to as “Brexit”). The U.K. exited from the European Union on January 31, 2020. Under the current withdrawal agreement between the United Kingdom and the European Union, the United Kingdom will be subject to a transition period until December 31, 2020, during which European Union rules will continue to apply. The relationship between the United Kingdom and the European Union after the transition period has not been determined yet. As a result, the impact of Brexit is not yet known and depends on any

16

agreements the United Kingdom may make to retain access to European Union or other markets after the transition period. The withdrawal could potentially disrupt the free movement of goods, services and people between the U.K. and the European Union, undermine bilateral cooperation in key geographic areas and significantly disrupt trade between the U.K. and the European Union or other nations as the U.K. pursues independent trade relations. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which European Union laws to replace or replicate. Any of these events, along with any political, economic and regulatory changes that may occur, could cause political and economic uncertainty in Europe and internationally and harm our business and financial results. Natus has not identified any trends or potential changes to critical accounting estimates as a result of Brexit at this time, however, we will continue to assess the potential impact of Brexit on our business and operations, and on accounting and reporting considerations. The effects of Brexit could adversely affect our business, financial condition or future results.
Our operating results may suffer because of our exposure to foreign currency exchange rate fluctuations.
Substantially all of our sales contracts with our U.S. based customers provide for payment in U.S. dollars. With the exception of our Canadian operations, substantially all of the revenue and expenses of our foreign subsidiaries are denominated in the applicable foreign currency. To date we have executed only limited foreign currency contracts to hedge these currency risks. Our future revenue and expenses may be subject to volatility due to exchange rate fluctuations that could result in foreign exchange gains and losses associated with foreign currency transactions and the translation of assets and liabilities denominated in foreign currencies.
Substantially all our sales from our U.S. operations to our international distributors provide for payment in U.S. dollars. A strengthening of the U.S. dollar relative to other foreign currencies could increase the effective cost of our products to our international distributors as their functional currency is typically not the U.S. dollar. This could have a potential adverse effect on our ability to increase or maintain average selling prices of our products to our foreign-based customers.
The interest rates on our revolving credit facility are priced using a spread over LIBOR.
LIBOR, the London interbank offered rate, is the basic rate of interest used in lending between banks on the London interbank market and is widely used as a reference for setting the interest rate on loans globally. We typically use LIBOR as a reference rate in our term loans such that the interest due to our creditors pursuant to a term loan extended to us is calculated using LIBOR. Most of our term loan agreements contain a stated minimum value for LIBOR.
Our credit facility permits interest on the outstanding principal balance to be calculated based on LIBOR. On July 27, 2017, the U.K. Financial Conduct Authority (the "FCA") announced that it will no longer require banks to submit rates for the calculation of LIBOR after 2021, and the U.S. Federal Reserve and the Bank of England have begun publishing a Secured Overnight Funding Rate and a reformed Sterling Overnight Index Average, respectively, which are currently intended to serve as alternative reference rates to LIBOR. Considerable uncertainty exists around what will replace LIBOR and how it will be implemented. At this time, it is not possible to predict the effect of any such changes, any establishment of alternative reference rates or any other reforms to LIBOR that may be implemented in the United Kingdom or elsewhere. Actions in the meantime, by the FCA, other regulators, or law enforcement agencies are expected to influence the method by which LIBOR is calculated. At this time, it is not possible to predict the effect of any such changes or any other reforms to LIBOR that may be enacted in the U.K. or elsewhere. Uncertainty as to the nature of such potential changes, alternative reference rates or other reforms may adversely affect our indebtedness that bear interest at a floating rate determined by reference to LIBOR.
If we fail in our efforts to educate clinicians, government agency personnel, and third-party payors about the effectiveness of our products, we may not achieve future sales growth.
It is critical to the success of our sales efforts that we educate a sufficient number of clinicians, hospital administrators, and government agencies about our products and the costs and benefits of their use. The commercial success of our products depends upon clinician, government agency, and other third-party payor confidence in the economic and clinical benefits of our products as well as their comfort with the efficacy, reliability, sensitivity and specificity of our products. We believe that clinicians will not use our products unless they determine, based on published peer-reviewed journal articles and experience, that our products provide an accurate and cost-effective alternative to other means of testing or treatment. Our customers may choose to use competitive products, which may be less expensive or may provide faster results than our devices. Clinicians are traditionally slow to adopt new products, testing practices and clinical treatments, partly because of perceived liability risks and the uncertainty of third-party reimbursement. If clinicians, government agencies and hospital administrators do not adopt our products, we may not maintain profitability. Factors that may adversely affect the medical community’s acceptance of our products include:
•
Publication of clinical study results that demonstrate a lack of efficacy or cost-effectiveness of our products;
•
Changing governmental and physician group guidelines;
•
Actual or perceived performance, quality, price, and total cost of ownership deficiencies of our products relative to other competitive products;
•
Our ability to maintain and enhance our existing relationships and to form new relationships with leading physicians, physician organizations, hospitals, state laboratory personnel, and third-party payors;

17

•
Changes in federal, state and third-party payor reimbursement policies for our products; and
•
Repeal of laws requiring universal newborn hearing screening and metabolic screening.
Sales to members under group purchasing agreements and sales to high volume purchasers may reduce our average selling prices, which could reduce our operating margins.
We have entered and expect in the future to enter into agreements with customers who purchase a high volume of our products. Our agreements with these customers may contain discounts from our normal selling prices and other special pricing considerations, which could cause our operating margins to decline. In addition, we have entered into agreements to sell our products to members of GPOs, which negotiate volume purchase prices for medical devices and supplies for member hospitals, group practices and other clinics. While we make sales directly to GPO members, the GPO members receive volume discounts from our normal selling price and may receive other special pricing considerations from us. Sales to members of all GPOs accounted for approximately 18.7%, 13.3% and 14.5% of our total revenue during 2019, 2018 and 2017, respectively. Certain other existing customers may be members of GPOs with which we do not have agreements. If we enter into agreements with new GPOs and some of our existing customers begin purchasing our products through those GPOs, our operating margins could decline.
Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
Many healthcare industry companies, including our customers and competitors, are consolidating to create new companies with greater market power. As the healthcare industry consolidates, competition to provide goods and services to our customers could become more intense. Our customers may try to use their market power to negotiate price concessions and our competitors may utilize their size and broad product lines to offer cheaper alternatives to our products. If we are forced to reduce our prices because of consolidation in the healthcare industry, our revenues would decrease and our consolidated earnings, financial condition, or cash flow would suffer.
Demand for some of our products depends on the capital spending policies of our customers, and changes in these policies could harm our business.
A majority of customers for our products are hospitals, physician offices, and clinics. Many factors, including public policy spending provisions, available resources, and economic cycles have a significant effect on the capital spending policies of these entities and the amount that they can spend on our equipment products. If budget resources limit the capital spending of our customers, they will be unlikely to either purchase any new equipment from us or upgrade to any of our newer equipment products. Lack of liquidity in credit markets and uncertainty about future economic conditions can have an adverse effect on the spending patterns of our customers. These factors can have a significant adverse effect on the demand for our products.
Our markets are very competitive and in the United States we sell certain of our products in a mature market.
We face competition from other companies in all of our product lines. Our competitors range from small privately held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.
The markets for certain of our products in the United States, including the newborn hearing screening and EEG monitoring markets, are mature and we are unlikely to see significant growth for such products in the United States. The market for newborn care products is affected by birthrates, and a declining U.S. birthrate has adversely affected our operating results in recent periods. In the United States we derive a significant portion of our revenue from the sale of disposable supplies. Our disposable supply products could face increasing competition, including competitors offering lower prices, which could have an adverse effect on our revenue and margins.
Our competitors may have certain competitive advantages, which include the ability to devote greater resources to the development, promotion, and sale of their products. Consequently, we may need to increase our efforts, and related expenses for research and development, marketing, and selling to maintain or improve our position.
We expect recurring sales to our existing customers to generate a majority of our revenue in the future, and if our existing customers do not continue to purchase products from us, our revenue may decline.
Future changes in technology or market conditions could result in adjustments to our recorded asset balance for intangible assets, including goodwill, resulting in additional charges that could significantly impact our operating results.
Our balance sheet includes significant intangible assets, including goodwill and other acquired intangible assets. The determination of related estimated useful lives and whether these assets are impaired involves significant judgment. Our ability to accurately predict future cash flows related to these intangible assets might be hindered by events over which we have no control. Due to the highly competitive nature of the medical device industry, new technologies could impair the value of our intangible assets if they create market conditions that adversely affect the competitiveness of our products. Further, declines in our market capitalization may be an indicator that our intangible assets or goodwill carrying values exceed their fair values which could lead

18

to potential impairment charges that could impact our operating results. In the past we have recorded charges for goodwill impairment and impairments of our trade names.
If healthcare providers are not adequately reimbursed for procedures conducted with our devices or supplies, or if reimbursement policies change adversely, we may not be successful marketing and selling our products or technologies.
Clinicians, hospitals, and government agencies are unlikely to purchase our products if they are not adequately reimbursed for the procedures conducted with our devices or supplies. Unless a sufficient amount of conclusive, peer-reviewed clinical data about our products has been published, third-party payors, including insurance companies and government agencies, may refuse to provide reimbursement. Furthermore, even if reimbursement is provided, it may not be adequate to fully compensate the clinicians or hospitals. Some third-party payors may impose restrictions on the procedures for which they will provide reimbursement. If healthcare providers cannot obtain sufficient reimbursement from third-party payors for our products or the screenings conducted with our products, we may not achieve significant market acceptance of our products. Acceptance of our products in international markets will depend upon the availability of adequate reimbursement or funding within prevailing healthcare payment systems. Reimbursement, funding, and healthcare payment systems vary significantly by country. We may not obtain approvals for reimbursement in a timely manner or at all.
Adverse changes in reimbursement policies in general could harm our business. We are unable to predict changes in the reimbursement methods used by third-party healthcare payors, particularly those in countries and regions outside the United States. For example, some payors are moving toward a managed care system in which providers contract to provide comprehensive healthcare for a fixed cost per person. In a managed care system, the cost of our products may not be incorporated into the overall payment for patient care or there may not be adequate reimbursement for our products separate from reimbursement for other procedures.
Because we rely on distributors or sub-distributors to sell our products in most of our markets outside of the United States, our revenue could decline if our existing distributors reduce the volume of purchases from us, or if our relationship with any of these distributors is terminated.
We currently rely on our distributors or sub-distributors for a majority of our sales outside the United States. Some distributors also assist us with regulatory approvals and education of clinicians and government agencies. Our contracts with our distributors or sub-distributors do not assure us significant minimum purchase volume. If a contract with a distributor or sub-distributor is terminated for cause or by us for convenience, the distributor or sub-distributor will have no obligation to purchase products from us. We intend to continue our efforts to increase our sales in Europe, Japan, and other developed markets. If we fail to sell our products through our international distributors, we would experience a decline in revenue unless we begin to sell our products directly in those markets. We cannot be certain that we will be able to attract new international distributors to market our products effectively or provide timely and cost-effective customer support and service. Even if we are successful in selling our products through new distributors, the rate of growth of our revenue could be harmed if our existing distributors do not continue to sell a large dollar volume of our products. None of our existing distributors are obligated to continue selling our products.
We may be subject to foreign laws governing our relationships with our international distributors. These laws may require us to make payments to our distributors if we terminate our relationship for any reason, including for cause. Some countries require termination payments under local law or legislation that may supersede our contractual relationship with the distributor. Any required payments would adversely affect our operating results.
We are subject to a variety of operational risks inherent in our business which may disrupt our business and negatively impact our results of operations.
We are exposed to many types of operational risks, including business continuity, direct or indirect loss resulting from inadequate or failed internal and external processes, systems or human error, the effects of natural or man-made catastrophic events (such as natural disasters, pandemics, cyber-attacks, acts of terrorism, civil unrest and other catastrophes) or from other external events. For example, we conduct a significant portion of our activities, including administration and data processing, at facilities located in California which has experienced major earthquakes in the past, as well as other natural disasters. In addition, the ongoing outbreak of COVID-19 since December 2019 has resulted in increased travel restrictions and extended shutdown of certain businesses in the region, as well as reports of dramatically reduced economic activity in the region, which may negatively affect our operation particularly in Asia. Exposure to such events could disrupt our systems and operations significantly, which may result in financial loss and reputational damage.
If we lose our relationship with any supplier of key product components or our relationship with a supplier deteriorates or key components are not available in sufficient quantities, our manufacturing could be delayed and our business could suffer.
We contract with third parties for the supply of some of the components used in our products and the production of our disposable products. Some of our suppliers are not obligated to continue to supply us. We have relatively few sources of supply for some of the components used in our products and in some cases we rely entirely on sole-source suppliers. In addition, the lead-time involved in the manufacturing of some of these components can be lengthy and unpredictable. If our suppliers become

19

unwilling or unable to supply us with components meeting our requirements, it might be difficult to establish additional or replacement suppliers in a timely manner, or at all. This would cause our product sales to be disrupted and our revenue and operating results to suffer.
Replacement or alternative sources might not be readily obtainable due to regulatory requirements and other factors applicable to our manufacturing operations. Incorporation of components from a new supplier into our products may require a new or supplemental filing with applicable regulatory authorities and clearance or approval of the filing before we could resume product sales. This process may take a substantial period of time, and we may not be able to obtain the necessary regulatory clearance or approval. This could create supply disruptions that would harm our product sales and operating results.
We have substantial international operations which are subject to numerous risks; if our international operations are not successful, our business will be adversely affected.
In 2019, approximately 41.0% of our sales were made outside the United States. We plan to expand our international sales and marketing efforts to increase sales of our products in foreign countries. We may not realize corresponding growth in revenue from growth in international unit sales, due to the lower average selling prices we receive on sales outside of the United States. Even if we are able to successfully expand our international selling efforts, we cannot be certain that we will be able to create or increase demand for our products outside of the United States. Our international operations are subject to other risks, which include:
•
Impact of possible recessions in economies outside the United States;
•
Political and economic instability, including instability related to war and terrorist attacks and to political and diplomatic matters such as Brexit;
•
Adverse changes in tariffs and trade protection measures;
•
Difficulty in obtaining and maintaining foreign regulatory approval and complying with foreign regulations, including the EU Medical Device Regulation;
•
An outbreak of a contagious disease, such as COVID-19, which may cause us or our distributors, vendors and/or customers to temporarily suspend our or their respective operations in the affected city or country;
•
Contractual provisions governed by foreign law, such as local law rights to sales commissions by terminated distributors;
•
Decreased healthcare spending by foreign governments that would reduce international demand for our products;
•
Strengthening of the U.S. dollar relative to foreign currencies that could make our products less competitive because approximately half of our international sales are denominated in U.S. dollars;
•
Changes in capital and exchange controls affecting international trade;
•
Greater difficulty in accounts receivable collection and longer collection periods;
•
Difficulties of staffing and managing foreign operations;
•
Reduced protection for intellectual property rights in some countries and potentially conflicting intellectual property rights of third parties under the laws of various foreign jurisdictions;
•
Attitudes by clinicians, and cost reimbursement policies, towards use of disposable supplies that are potentially unfavorable to our business;
•
Complying with U.S. regulations that apply to international operations, including trade laws, the U.S. Foreign Corrupt Practices Act, and anti-boycott laws, as well as international laws such as the U.K. Bribery Act;
•
Loss of business through government tenders that are held annually in many cases; and
•
Potentially negative consequences from changes in tax laws, including legislative changes concerning taxation of income earned outside of the United States.
In particular, our international sales could be adversely affected by a strengthening of the U.S. dollar relative to other foreign currencies, which makes our products more costly to international customers for sales denominated in U.S. dollars.
We depend upon key employees in a competitive market for skilled personnel, and, without additional employees, we cannot grow or maintain profitability.
Our products and technologies are complex, and we depend substantially on the continued service of our senior management team. The loss of any of our key employees could adversely affect our business and slow our product development process. Our future success will depend, in part, on the continued service of our key management personnel, software engineers, and other research and development employees, and our ability to identify, hire, and retain additional personnel, including customer service, marketing, and sales staff. Demand for these skilled employees in our industry is very competitive due to the limited number of people available with the necessary technical skills and understanding of our product technologies. We may be unable to attract and retain personnel necessary for the development of our business.
We have experienced seasonality in the sale of our products.
We experience seasonality in our revenue. For example, our sales typically decline from the second half of our fiscal year to the first half of the fiscal year, due to patterns in the capital budgeting and purchasing cycles of our customers, many of which

20

are government agencies, and the compensation arrangements of our direct sales employees, as those arrangements are tied to calendar-year sales plans. We anticipate that we will continue to experience seasonal fluctuations, which may lead to fluctuations in our quarterly operating results. We believe that you should not rely on our results of operations for interim periods as an indication of our expected results in any future period.
We have initiated changes to our information systems that could disrupt our business and our financial results.
We plan to continuously improve our information systems to support the form, functionality, and scale of our business. These types of transitions frequently prove disruptive to the underlying business of an enterprise and may cause us to incur higher costs than we anticipate. Failure to manage a smooth transition to the new systems and the ongoing operations and support of the new systems could materially harm our business operations.
Risks Related to Our Compliance and Regulatory Environment
Our ability to market and sell products depends upon receipt of domestic and foreign regulatory approval of our products and manufacturing operations. Our failure to obtain or maintain regulatory approvals and compliance could negatively affect our business.
Our products and manufacturing operations are subject to extensive regulation in the United States by the FDA and by similar regulatory agencies in other countries. Our products are classified as medical devices. Medical devices are subject to extensive regulation by the FDA pursuant to regulations that are wide ranging and govern, among other things: design and development; manufacturing and testing; labeling; storage and record keeping; advertising, promotion, marketing, sales distribution and export; and surveillance and reporting of deaths or serious injuries.
Unless an exemption applies, each medical device that we propose to market in the United States must first receive one of the following types of FDA premarket review authorizations:
•
Clearance via Section 510(k) of the Food, Drug, and Cosmetics Act of 1938, as amended; or
•
Premarket approval via Section 515 of the Food, Drug, and Cosmetics Act if the FDA has determined that the medical device in question poses a greater risk of injury.
The FDA will clear marketing of a medical device through the 510(k) process if it is demonstrated that the new product is substantially equivalent to other 510(k)-cleared products. The premarket approval application process is much more costly, lengthy and uncertain than the 510(k) process, and must be supported by extensive data from preclinical studies and human clinical trials. The FDA may not grant either 510(k) clearance or premarket approval for any product we propose to market. Further, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a premarket approval application. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. If the FDA requires us to seek 510(k) clearance or premarket approval for modification of a previously cleared product for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective.
Delays in receipt of, or failure to receive, clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could adversely impact our operating results. If the FDA finds that we have failed to comply with these requirements, the FDA can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions such as:
•
Fines, injunctions and civil penalties;
•
Recall or seizure of our products;
•
Issuance of public notices or warnings;
•
Imposition of operating restrictions, partial suspension, or total shutdown of production;
•
Refusal of our requests for Section 510(k) clearance or premarket approval of new products;
•
Withdrawal of Section 510(k) clearance or premarket approvals already granted;
•
Criminal prosecution;
•
Domestic regulation of our products and manufacturing operations, other than that which is administered by the FDA, includes the Environmental Protection Act, the Occupational Safety and Health Act, and state and local counterparts to these Acts; or
Foreign governments and regulatory authorities have, and may continue to, propose and implement regulations that apply to our products and operations. For example, in 2017 the European Union adopted the EU Medical Device Regulation, which imposes stricter requirements for the marketing and sale of medical devices, including new quality system and post-market surveillance requirements once it is fully implemented in 2020. Penalties for regulatory non-compliance could be severe, including

21

fines and revocation or suspension of a company's business license, mandatory price reductions, and criminal sanctions. Future laws and regulations may have a material adverse effect on our business.
Our business would be harmed if the FDA determines that we have failed to comply with applicable regulations governing the manufacture of our products and/or we do not pass an inspection.
We and our suppliers are required to demonstrate and maintain compliance with the FDA’s Quality System Regulation. The Quality System Regulation sets forth the FDA’s requirements for good manufacturing practices of medical devices and includes requirements for, among other things, the design, testing, production processes, controls, quality assurance, labeling, packaging, storage and shipping of such products. In addition, we and our suppliers must engage in extensive recordkeeping and reporting and must make available our manufacturing facility and records for periodic unscheduled inspections by federal, state and foreign agencies, including the FDA. We cannot assure you that we and our suppliers are or will continue to be in full compliance with the Quality System Regulation, nor that we will not encounter any manufacturing difficulties.
In 2014 and 2016 we received formal communications from the FDA regarding deficiencies in our manufacturing processes in our Seattle facility. As a result, we imposed ship-holds on certain of our products produced there and have discontinued certain other products produced in that facility. We are dedicating substantial resources to the resolution of the conditions identified by the FDA. These actions had an adverse effect on our results of operations in 2016 and 2017.
Our inability to address issues that have been raised by the FDA, or failure of us or our third party suppliers and manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including, among other things, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, seizures or recalls of products and manufacturing restrictions, any of which could harm our business.
Our business may suffer if we are required to revise our labeling or promotional materials, or if the FDA takes an enforcement action against us for off-label uses.
We are prohibited by the FDA from promoting or advertising our medical device products for uses not within the scope of our clearances or approvals, or from making unsupported promotional claims about the benefits of our products. If the FDA determines that our claims are outside the scope of our clearances, or are unsupported, it could require us to revise our promotional claims or take enforcement action against us. If we were subject to such an action by the FDA, our sales could be delayed, our revenue could decline, and our reputation among clinicians could be harmed. Likewise, if we acquire new products, either through the purchase of products, technology assets, or businesses, that are subsequently deemed to have inadequate supporting data, we may be required to (i) obtain adequate data, which could be costly and impede our ability to market these products, or (ii) modify the labeling on these products, which could impair their marketability, as described above.
We are subject to data privacy laws and our failure to comply with them may require us to make significant changes to our products or incur penalties or other liabilities.
Our business relies on the secure electronic transmission, storage and hosting of sensitive information, including personally identifiable information (“PII”), personal health information, financial information, intellectual property and other sensitive information related to our customers and workforce. The collection, maintenance, protection, use, transmission, disclosure and disposal of certain personal information and the security of medical devices are regulated at the U.S. federal and state, international and industry levels. U.S. federal and state laws, such as the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information. We sign business associate agreements with certain customers for which we perform services as business associates under HIPAA, and therefore we are directly subject to certain provisions of HIPAA that are applicable to business associates. Noncompliance with laws and regulations relating to privacy and security of personal information, including HIPAA, or with contractual obligations under any business associate agreement may lead to significant fines, civil and criminal penalties, or liabilities.  We also may be required to report breaches of protected health information that we experience. The U.S. Department of Health and Human Services (“HHS”), audits the compliance of business associates and enforces HIPAA privacy and security standards. HHS enforcement activity has become more significant over the last few years and HHS has signaled its intent to continue this trend.
In addition to the regulation of personal health information, a number of states have also adopted laws and regulations that may affect our privacy and data security practices for other kinds of PII, such as state laws that govern the use, disclosure and protection of personal information, such as social security numbers, or that are designed to protect credit card account data. State consumer protection laws, including the California Consumer Privacy Act of 2018 (“CCPA”), which became effective on January 1, 2020, may also establish privacy and security standards for use and management of PII, including information related to customers, suppliers and care providers. The CCPA provides individuals certain rights regarding the collection or processing of personal data related to California residents, which may restrict our ability to use personal data, of California residents. Failure to comply with the CCPA could result in penalties of up to $7,500 per violation.

22

Outside the United States, we are impacted by the privacy and data security requirements at the international, national and regional level, and on an industry specific basis. We serve customers across the globe. Legal requirements in these countries relating to the collection, storage, handling and transfer of personal data and potentially intellectual property continue to evolve with increasingly strict enforcement regimes. More privacy and security laws and regulations are being adopted, and more are be enforced, with potential for significant financial penalties. In the European Union, increasingly stringent data protection and privacy rules that will have substantial impact on the use of patient data across the healthcare industry became effective in May 2018. The European Union General Data Protection Regulation (“GDPR”) applies uniformly across the European Union and to businesses in other countries that target European Union residents and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR also requires companies processing personal data of individuals, including employees, residing in the European Union to comply with European Union privacy and data protection rules. Other international jurisdictions, have issued privacy laws that mirror many of the requirements of GDPR. As we expand our international operations, we may be required to expend significant time and resources to put in place additional mechanisms to ensure compliance with multiple data privacy laws. Failure to comply with these laws may result in significant fines and other administrative penalties and harm our business.
Compliance with these laws and regulations may require significant additional costs or changes in our business, which could adversely affect our results of operations or financial condition. Noncompliance with these laws and regulations could result in the imposition of fines and penalties or could result in significant civil and other liabilities. Additionally, the restrictions imposed by these laws and regulations may limit the use and adoption of our products, reduce overall demand for our products, require us to modify our data handling practices and impose additional costs and burdens.
An interruption in or breach of security of our information or manufacturing systems, including the occurrence of a cyber-incident or a vulnerability in our cybersecurity, or disclosure of private patient health information, may result in a loss of business or damage to our reputation.
We rely on communications, information and manufacturing systems to conduct our business. Any failure, interruption or cyber incident affecting these systems could result in failures or disruptions in our customer relationship management or product manufacturing. Similarly, there can be no assurance that our third-party collaborators, distributors and other contractors and consultants will be successful in protecting our data that is stored on their systems. A cyber incident is an intentional attack or an unintentional event that can include an unauthorized actor gaining access to our systems to disrupt operations, corrupt data, or steal confidential information. The occurrence of any failures, interruptions or cyber incidents could result in a loss of customer business or reputation and have a material effect on our business, financial condition, results of operations and cash flows. In addition, our products are used in customer networks transmitting a range of sensitive information and any actual or perceived exposure of our products used in customer networks to malicious software or cyber-attacks could adversely affect our business and results of operations.
In the course of performing our business we obtain, from time to time, confidential patient health information. For example, we may learn patient names and be exposed to confidential patient health information when we provide training on our products to our customers’ staff. Complying with federal and state privacy and security requirements imposes compliance related costs, subjects us to potential regulatory audits, and may restrict our business operations. These various laws may be subject to varying interpretations by courts and government agencies creating potentially complex compliance issues for our business. If we were to violate any of our legal obligations to safeguard any confidential patient health information or protected health information against improper use and disclosure, we could lose customers and be exposed to liability, and our reputation and business could be harmed. Concerns or allegations about our practices with regard to the privacy or security of personal health information or other privacy-related matters, even if unfounded, could damage our reputation and harm our business.
We are also subject to new U.S. laws as well as laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than previous corresponding U.S. laws. These laws and regulations impose technical and organizational measures to ensure the security of personal data and may require that we notify regulatory agencies, individuals or the public about any data security breaches. In particular, in the United States, the newly passed CCPA imposes a private right of action with damages of up to $750 per person in the event of certain data breaches. Other states are considering similar laws. As these laws and regulations develop in the United States and we expand our international operations, we may be required to expend significant time and resources to put in place additional mechanisms to ensure compliance with multiple cybersecurity laws. Failure to comply with these laws may result in significant fines and other administrative penalties and harm our business, and could expose us to significant civil damages.
The FDA has issued guidance advising manufacturers to take cybersecurity risks into account in product design for connected medical devices and systems, to assure that appropriate safeguards are in place to reduce the risk of unauthorized access or modification to medical devices that contain software and reduce the risk of introducing threats into hospital systems that are connected to such devices. The FDA also issued guidance on post market management of cyber security in medical devices. Compliance with these requirements may require changes in business practices, complicate our operations, and add complexity and additional management and oversight needs. They also may complicate our clinical research activities, as well as product

23

offerings that involve transmission or use of clinical data. Failure to comply with these laws could result in vulnerabilities that would make us susceptible to hackers and other cyber attacks, as well as fines or administrative penalties that, if imposed, would harm our business.
Healthcare reforms, changes in healthcare policies, and changes to third-party reimbursements for our products may affect demand for our products.
Uncertainty in the U.S. healthcare system may influence the way our customers spend on medical devices, supplies, and services in the future. The U.S. Patient Protection and Affordable Care Act and the Healthcare and Education Reconciliation Act of 2010 (“ACA”) may be modified, repealed, or otherwise invalidated, in whole or in part. Future rulemakings could affect rebates, prices, or the rate of price increase for healthcare products and services. Cost-containing measures implemented by healthcare providers worldwide could harm our profitability. If we fail to effectively react to healthcare reforms, our business may be adversely affected.
Regulations related to “conflict minerals” may force us to incur additional expenses, may result in damage to our business reputation and may adversely impact our ability to conduct our business.
The Dodd‑Frank Wall Street Reform and Consumer Protection Act and the rules promulgated by the SEC thereunder require companies, including Natus, to disclose the existence in their products of certain metals, known as “conflict minerals,” which are metals mined from the Democratic Republic of the Congo and adjoining countries. These rules requires investigative efforts, which has and will continue to cause us to incur associated costs, could adversely affect the sourcing, availability and pricing of minerals used in our products and may cause reputational harm if we determine that certain of our components contain such conflict minerals or if we are unable to alter our processes or sources of supply to avoid using such materials, all of which could adversely impact sales of our products and results of operations.
Risks Related to our Intellectual Property and Potential Litigation
We may not be able to preserve the value of our intellectual property because we may not be able to protect access to it or we may lose our intellectual property rights due to expiration of our licenses or patents.
If we fail to protect our intellectual property rights or if our intellectual property rights do not adequately cover the technology we employ, other medical device companies could sell products with features similar to ours, and this could reduce demand for our products. We protect our intellectual property through a combination of patent, copyright, trade secret and trademark laws. Despite our efforts to protect our proprietary rights, others may attempt to copy or otherwise improperly obtain and use our products or technology. Policing unauthorized use of our technology is difficult and expensive, and we cannot be certain that the steps we have taken will prevent misappropriation. Our means of protecting our proprietary rights may be inadequate. Enforcing our intellectual property rights could be costly and time consuming and may divert our management’s attention and resources. Failing to enforce our intellectual property rights could also result in the loss of those rights.
U.S. tax reform legislation could materially affect our business and financial condition.
The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law in December 2017. The new law made numerous changes to federal corporate tax law that we expect will impact our effective tax rate in future periods. The changes included in the Tax Act were broad and complex and included, among others, reducing the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limiting the tax deduction for interest expense to 30% of adjusted earnings, eliminating net operating loss carrybacks, imposing a one-time tax on offshore earnings at reduced rates regardless of whether they are repatriated, allowing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. The final impacts of the Tax Act may differ from our current estimates, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates we have utilized to calculate the transition impacts.
If guidelines mandating universal newborn hearing screening do not continue to develop in foreign countries and governments do not mandate testing of all newborns as we anticipate, or if those guidelines have a long phase-in period, our sales of newborn hearing screening products may not achieve the revenue growth we have achieved in the past.
We estimate that approximately 95% of the children born in the United States are currently being tested for hearing impairment prior to discharge from the hospital. To date, there has been only limited adoption of newborn hearing screening prior to hospital discharge by foreign governments, and when newborn hearing screening programs are enacted by foreign governments there can be a phase-in period spanning several years. The widespread adoption of guidelines depends, in part, on our ability to educate foreign government agencies, neonatologists, pediatricians, third-party payors, and hospital administrators about the benefits of universal newborn hearing screening as well as the use of our products to perform the screening and monitoring. Our revenue from our newborn hearing screening product lines may not grow if foreign governments do not require universal newborn

24

hearing screening prior to hospital discharge, if physicians or hospitals are slow to comply with those guidelines, or if governments provide for a lengthy phase-in period for compliance.
If we deliver products with defects, we may incur costs to repair and, possibly, recall that product and market acceptance of our products may decrease.
The manufacturing and marketing of our products involve an inherent risk of our delivering a defective product or products that do not otherwise perform as we expect. We may incur substantial expense to repair any such products and may determine to recall such a product, even if not required to do so under applicable regulations. Any such recall would be time consuming and expensive. Product defects or recalls may adversely affect our customers’ acceptance of the recalled and other of our products.
If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
We could be subject to healthcare fraud regulation and enforcement by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: (i) the federal healthcare programs Anti-Kickback Law, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as Medicare or Medicaid, (ii) federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing advice to customers, and/or (iii) state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, many of which differ from their federal counterparts in significant ways, thus complicating compliance efforts.
If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
Our operating results would suffer if we were subject to a protracted infringement claim.
The medical technology industry is characterized by a substantial amount of litigation and related administrative proceedings regarding patents and intellectual property rights. We expect that medical screening and diagnostic products may become increasingly subject to third-party infringement claims as the number of competitors in our industry grows and the functionality of products overlap. Third parties such as individuals, educational institutions, or other medical device companies may claim that we infringe their intellectual property rights. Any claims, with or without merit, could have any of the following negative consequences:
•
Result in costly litigation and damage awards;
•
Divert our management’s attention and resources;
•
Cause product shipment delays or suspensions; or
•
Require us to seek to enter into royalty or licensing agreements.
We are currently subject to cases based on third-party patent infringement claims. A successful claim of infringement against us from any current or future claim could result in a substantial damage award and materially harm our financial condition. Our failure or inability to license the infringed or similar technology, or design and build non-infringing products, could prevent us from selling our products and adversely affect our business and financial results.
We may also find it necessary to bring infringement actions against third parties to seek to protect our intellectual property rights. Litigation of this nature, even if successful, is often expensive and disruptive of our management’s attention, and in any event may not lead to a successful result relative to the resources dedicated to any such litigation.
We license intellectual property rights from third parties and would be adversely affected if our licensors do not appropriately defend their proprietary rights or if we breach any of the agreements under which we license commercialization rights to products or technology from others.
We license rights from third parties for products and technology that are important to our business. If our licensors are unsuccessful in asserting and defending their proprietary rights, including patent rights and trade secrets, we may lose the competitive advantages we have through selling products that we license from third parties. Additionally, if it is found that our licensors infringe on the proprietary rights of others, we may be prohibited from marketing our existing products that incorporate

25

those proprietary rights. Under our licenses, we are subject to commercialization and development, sublicensing, royalty, insurance and other obligations. If we fail to comply with any of these requirements, or otherwise breach a license agreement, the licensor may have the right to terminate the license in whole or to terminate the exclusive nature of the license.
Product liability suits against us could result in expensive and time consuming litigation, payment of substantial damages, and an increase in our insurance rates.
The sale and use of our products could lead to the filing of a product liability claim by someone claiming to have been injured using one of our products or claiming that one of our products failed to perform properly. A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business reputation or financial condition. Our product liability insurance may not protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing any coverage in the future.
Our stock price may be volatile, which may cause the value of our stock to decline or subject us to a securities class action litigation.
The trading price of our common stock price may be volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:
•
general economic, industry and market conditions;
•
actions by institutional or other large stockholders;
•
the depth and liquidity of the market for our common stock;
•
volume and timing of orders for our products;
•
developments generally affecting medical device companies;
•
the announcement of new products or product enhancements by us or our competitors;
•
changes in earnings estimates or recommendations by securities analysts;
•
investor perceptions of us and our business, including changes in market valuations of medical device companies; and
•
our results of operations and financial performance.
In addition, the stock market in general, and the Nasdaq Stock Market and the market for medical devices in particular, have experienced substantial price and volume volatility that is often seemingly unrelated to the operating performance of particular companies. These broad market fluctuations may cause the trading price of our common stock to decline. In the past, securities class action litigation has often been brought against a company after a period of volatility in the market price of its common stock. We may become involved in this type of litigation in the future. Any securities litigation claims brought against us could result in substantial expense and the diversion of management’s attention from our business.

ITEM 1B.    Unresolved Staff Comments.
None.
ITEM 2.    Properties
Our corporate headquarters is located in Pleasanton, California, in a facility covering 8,200 square feet pursuant to a lease that expires in January 2025.
We also utilize the following properties:
Company-owned Facilities:
•
62,400 square feet in Gort, Ireland, utilized substantially for manufacturing;
•
44,900 square feet in Oakville, Ontario, Canada, primarily utilized for research and development and technical support; and
•
6,400 square feet in Old Woking, England, utilized substantially for research and development.
Leased Facilities:
Following is a listing of our most significant leased properties; we have a number of smaller facilities under lease in various countries where we operate.
•
124,000 square feet in Middleton, Wisconsin, pursuant to a lease that expires in April 2024, that is primarily utilized for manufacturing, technical support, customer service, marketing and research and development;

26

•
65,000 square feet in Seattle, Washington, pursuant to a lease that expires in December 2020, that is utilized substantially for manufacturing;
•
52,000 square feet in Taastrup, Denmark, pursuant to a lease with the option to terminate with six months-notice beginning January 2022, that is utilized for manufacturing, research and development, marketing and sales, and general and administrative;
•
37,200 square feet in San Diego, California, pursuant to a lease that expires in June 2022, that is utilized substantially for manufacturing;
•
25,100 square feet in Schaumburg, Illinois, pursuant to a lease that expires in November 2026, that is utilized substantially for marketing and sales; and
•
23,800 square feet in Quebec, Canada, pursuant to a lease that expires in December 2024, that is utilized substantially for manufacturing.

ITEM 3.    Legal Proceedings
We may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. We are not currently involved in any legal or administrative proceedings that we believe are likely to have a material effect on our business, financial condition, or results of operations, although we cannot be assured of the outcome of such matters.

ITEM 4.    Mine Safety Disclosures
The disclosure required by this item is not applicable.

PART II
ITEM 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock trades on the Nasdaq Global Select Market under the symbol “NTUS”. The following table sets forth, for the periods indicated, the high and low sale price per share of our common stock, as reported on the Nasdaq Global Select Market. 
 
High
 
Low
Fiscal Year Ended December 31, 2019:
 
 
 
Fourth Quarter
$
34.89

 
$
29.67

Third Quarter
32.85

 
22.25

Second Quarter
27.90

 
23.54

First Quarter
34.63

 
24.88

Fiscal Year Ended December 31, 2018:
 
 
 
Fourth Quarter
$
36.85

 
$
27.69

Third Quarter
37.90

 
31.05

Second Quarter
37.95

 
31.10

First Quarter
39.25

 
28.00

As of February 24, 2020, there were 34,105,116 shares of our common stock issued and outstanding and held by approximately 101 stockholders of record. We estimate that there are approximately 14,518 beneficial owners of our common stock.
In December 2019, the Board of Directors approved a share repurchase program, which authorized the repurchase from time to time of up to a maximum of $50 million of our outstanding common stock. The program is scheduled to expire on December 12, 2021. No shares have been repurchased as of February 28, 2020.
Dividends

27

We have never declared or paid cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future.
Stock Performance Graph
The following information of Part II Item 5 is being furnished and shall not be deemed to be “soliciting material” or to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor will it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference thereto.
The following graph shows a comparison, from January 1, 2015 through December 31, 2019, of cumulative total return for our common stock, the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index assumes reinvestment of dividends.
chart-5bdaf063b6f2531ead0.jpg
 
 
 
 
 
2014
 
2015
 
2016
 
2017
 
2018
 
2019
Natus Medical Inc.
 
Return %
 
 
 
33.32

 
(27.58
)
 
9.77

 
(10.92
)
 
(3.06
)
 
 
Cum $
 
100.00

 
133.32

 
96.56

 
105.99

 
94.42

 
91.53

NASDAQ Composite-Total Returns
 
Return %
 
 
 
6.96

 
8.87

 
29.64

 
(2.84
)
 
36.69

 
 
Cum $
 
100.00

 
106.96

 
116.45

 
150.96

 
146.67

 
200.49

S&P 500 Health Care Equipment Index
 
Return %
 
 
 
5.97

 
6.48

 
30.90

 
16.24

 
29.32

 
 
Cum $
 
100.00

 
105.97

 
112.85

 
147.71

 
171.70

 
222.04


Purchases of Equity Securities by the Issuer

None.


28

ITEM 6.    Selected Financial Data
The following tables set forth certain selected consolidated financial data for each of the years in the five-year period ended December 31, 2019, and is derived from the Consolidated Financial Statements of Natus Medical Incorporated and its subsidiaries. The Consolidated Financial Statements for each of the years in the three-year period ended December 31, 2019 are included elsewhere in this report. The selected consolidated balance sheet data as of December 31, 2017, 2016 and 2015 and the consolidated statements of operations data for the years ended December 31, 2016 and 2015 are derived from our Consolidated Financial Statements, which are not included in this report. The selected consolidated financial data set forth below is qualified in its entirety by, and should be read in conjunction with, the Consolidated Financial Statements and Notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this report. 
 
Year ended December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
 
(in thousands, except per share amounts)
Consolidated Statement of Operations Data (a)(b):
 
 
 
 
 
 
 
 
Revenue
$
495,175

 
$
530,891

 
$
500,970

 
$
381,892

 
$
375,865

Cost of revenue
196,551

 
217,952

 
213,376

 
144,632

 
145,492

Intangibles amortization
6,916

 
8,924

 
6,380

 
2,327

 
2,836

Gross profit
291,708

 
304,015

 
281,214

 
234,933

 
227,537

Operating expenses:
 
 
 
 
 
 
 
 
 
Marketing and selling
129,109

 
136,680

 
126,166

 
84,834

 
87,675

Research and development
58,733

 
61,482

 
51,822

 
33,443

 
30,434

General and administrative
59,649

 
70,599

 
74,424

 
50,877

 
46,363

Intangibles amortization
15,144

 
22,585

 
19,171

 
8,983

 
7,447

Restructuring
44,739

 
37,231

 
914

 
1,536

 
2,145

Total operating expense
307,374

 
328,577

 
272,497

 
179,673

 
174,064

Income from operations
(15,666
)
 
(24,562
)
 
8,717

 
55,260

 
53,473

Other expense, net
(5,591
)
 
(7,698
)
 
(3,567
)
 
(357
)
 
(1,064
)
Income (loss) before provision (benefit) for income tax
(21,257
)
 
(32,260
)
 
5,150

 
54,903

 
52,409

Provision (benefit) for income tax
(5,586
)
 
(9,325
)
 
25,443

 
12,309

 
14,485

Net income (loss)
$
(15,671
)
 
$
(22,935
)
 
$
(20,293
)
 
$
42,594

 
$
37,924

Earnings (loss) per share:
 
 
 
 
 
 
 
 
 
Basic
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
 
$
1.31

 
$
1.17

Diluted
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
 
$
1.29

 
$
1.14

Weighted average shares used in the calculation of earnings per share:
 
 
 
 
 
 
 
 
 
Basic
33,696

 
33,111

 
32,564

 
32,460

 
32,348

Diluted
33,696

 
33,111

 
32,564

 
33,056

 
33,241

 
December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
 
(in thousands)
Consolidated Balance Sheet Data:
 
 
 
 
 
 
 
 
 
Cash, cash equivalents, and short-term investments
$
63,297

 
$
56,373

 
$
88,950

 
$
247,750

 
$
82,469

Working capital
126,928

 
152,329

 
213,491

 
325,858

 
164,248

Total assets
622,527

 
638,140

 
709,919

 
649,012

 
479,496

Long-term debt (including current portion) and short-term borrowings
54,665

 
104,474

 
154,283

 
140,000

 
—

Total stockholders’ equity
416,123

 
398,444

 
422,097

 
417,374

 
390,710


29

(a)
Results of operations and financial position of the businesses we have acquired are included from their acquisition dates as follows: GND and NICVIEW in January 2015, Monarch in November 2015, NeuroQuest in March 2016, RetCam in July 2016, Otometrics in January 2017, and Integra asset acquisition in October 2017.
(b)
Results of operations and financial position of the businesses we have divested or exited are not included from their exited dates as follows: GND and Neurocom in January 2019, and Medix in April 2019.
ITEM 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and the accompanying footnotes. MD&A includes the following sections:
Business
We are a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.
Year 2019 Overview
Our consolidated revenue decreased by $35.7 million for the year ended December 31, 2019 compared to the year ended December 31, 2018. This decrease was driven by the exit of GND and Neurocom businesses, the sale of our Medix business in Argentina, the impact of product discontinuations in our Newborn Care market, and ship holds within Newborn Care and Hearing & Balance markets.
Net loss was $15.7 million, or $0.47 per share in the year ended December 31, 2019, compared with net loss of $22.9 million, or $0.69 per share in the prior year. This increase in income was primarily driven by our restructuring initiative announced in 2019. While we experienced a net loss driven by our reorganization efforts, we generated cash flow from operations of $60.1 million.
Reorganization
On January 15, 2019, we announced the implementation of a new organizational structure designed to improve operational performance and make us a stronger, more profitable company. We consolidated our three business units, Neuro, Newborn Care and Hearing & Balance, formerly Otometrics, into “One Natus." This initiative was designed to create a single, unified company with globally led operational teams in Sales & Marketing, Manufacturing, R&D, Quality, and General and Administrative functions. We expect to continue to see increased transparency, efficiency and cross-functional collaboration across common technologies, processes and customer channels.
Application of Critical Accounting Policies
We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In so doing, we must often make estimates and use assumptions that can be subjective and, consequently, our actual results could differ from those estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable.
We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments. The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities, revenue, expenses, and related disclosures as of the date of the financial statements and during the reporting period.
Revenue recognition
Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services.
For the majority of devices and supplies, we transfer control and recognizes revenue when products ship from the warehouse to the customer. We generally do not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue.

30

Depending on the terms of the arrangement, we may also defer the recognition of a portion of the consideration received because we have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price (“SSP”) for each distinct performance obligation. Our estimate of SSP is a point estimate.  The estimate is calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs.
We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond the base agreements to customers. The separately priced service contracts range from twelve (12) months to sixty (60) months. We receive payment at the inception of the contract and recognize revenue ratably over the service period.
For products containing embedded software, we determine the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products.
Acquisition Accounting
We have made a number of acquisitions in the past and may continue to make acquisitions in the future. We account for acquired business combinations using the acquisition method of accounting. The assets acquired and liabilities assumed are recorded based on their respective fair values at the date of acquisition. Valuations are generally completed for business acquisitions using a discounted cash flow analysis. The most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, the discounted rate used to measure the risks inherent in the future cash flows, the assessment of the asset's life cycle, and the competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. Each of these factors and assumptions can significantly affect the value of the intangible asset. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.
Determining the useful life of an intangible asset also requires judgment, as different types of intangibles assets will have different useful lives and certain assets may even be considered to have indefinite useful lives. Useful life is the period over which the intangible asset is expected to contribute directly and indirectly to our future cash flows. We determine the useful lives of intangible assets based on a number of factors, such as legal, regulatory, or contractual provisions that may limit the useful life, and the effects of obsolescence, anticipated demand, existence or absence of competition, and other economic factors on useful life.
Inventory Valuation
Inventories are carried at the lower of cost or net realizable value, with cost being determined using the first-in, first-out method. The carrying value of our inventory is reduced for any difference between cost and estimated net realizable value of the inventory. We determine net realizable value by evaluating ending inventories for excess quantities, obsolescence, and other factors that could impact our ability to consume inventory for its intended use. Our evaluation includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, we may sell inventory that had previously been written down.

Results of Operations
The following table sets forth for the periods indicated selected consolidated statement of income data as a percentage of total revenue. Our historical operating results are not necessarily indicative of the results for any future period.
 

31

 
Percent of Revenue
Years Ended December 31,
 
2019
 
2018
 
2017
Revenue
100.0
 %
 
100.0
 %
 
100.0
 %
Cost of revenue
39.7
 %
 
41.1
 %
 
42.6
 %
Intangibles amortization
1.4
 %
 
1.7
 %
 
1.3
 %
Gross profit
58.9
 %
 
57.3
 %
 
56.1
 %
Operating expenses:
 
 
 
 
 
Marketing and selling
26.1
 %
 
25.7
 %
 
25.2
 %
Research and development
11.9
 %
 
11.6
 %
 
10.3
 %
General and administrative
12.0
 %
 
13.3
 %
 
14.9
 %
Intangibles amortization
3.1
 %
 
4.3
 %
 
3.8
 %
Restructuring
9.0
 %
 
7.0
 %
 
0.2
 %
Total operating expenses
62.1
 %
 
61.9
 %
 
54.4
 %
Income (loss) from operations
(3.2
)%
 
(4.6
)%
 
1.7
 %
Other expense, net
(1.1
)%
 
(1.5
)%
 
(0.7
)%
Income (loss) before provision (benefit) for income tax
(4.3
)%
 
(6.1
)%
 
1.0
 %
Provision (benefit) for income tax expense
(1.1
)%
 
(1.8
)%
 
5.1
 %
Net loss
(3.2
)%
 
(4.3
)%
 
(4.1
)%
Comparison of 2019 and 2018
Revenue 
 
Years ended December 31,
 
2019
 
2018
 
Change
Neuro
 
 
 
 
 
Devices and Systems
$
220,306

 
$
200,762

 
10
 %
Supplies
66,059

 
67,025

 
(1
)%
Services
871

 
12,000

 
(93
)%
Total Neuro Revenue
287,236

 
279,787

 
3
 %
Newborn Care
 
 
 
 
 
Devices and Systems
53,465

 
72,807

 
(27
)%
Supplies
38,264

 
40,669

 
(6
)%
Services
19,183

 
20,396

 
(6
)%
Total Newborn Care Revenue
110,912

 
133,872

 
(17
)%
Hearing & Balance
 
 
 
 
 
Devices and Systems
$
92,050

 
$
110,597

 
(17
)%
Supplies
4,977

 
6,635

 
(25
)%
Services
—

 
—

 
—
 %
Total Hearing & Balance Revenue
97,027

 
117,232

 
(17
)%
Total Revenue
$
495,175

 
$
530,891

 
(7
)%
For the year ended December 31, 2019, Neuro revenue increased by 3% compared to the prior year. Devices and Systems revenue increased by 10% compared to the prior year due primarily to growth in EEG sales. Supplies revenue for 2019 decreased 1%, which was driven by declines in our international markets. Services revenue from GND decreased 93% compared to the prior year due to our exit from this business in January 2019.
For the year ended December 31, 2019, Newborn Care revenue decreased by 17% compared to the prior year. Devices and Systems revenue decreased by 27%. The decrease is primarily due to the divestiture of Medix, exit from our balance and mobility product line, and planned product line rationalization. Supplies revenue decreased 6% compared to the prior year related to divestiture of Medix business and product line rationalization. Services revenue decreased by 6% compared to the prior year

32

primarily due to a lower collection per screen and decrease in screening volume on our Peloton hearing screening service, which was exited as of December 31, 2019.
For the year ended December 31, 2019, Hearing & Balance revenue decreased 17% compared to the prior year. Revenue from Devices and Systems decreased 17% and revenue from Supplies decreased 25% in 2019 compared to 2018. The overall decline in Hearing & Balance was driven by the impact of product rationalization and ship holds on some products.
Cost of Revenue and Gross Profit 
 
Years ended December 31,
 
2019
 
2018
Revenue
$
495,175

 
$
530,891

Cost of revenue
196,551

 
217,952

Intangibles amortization
6,916

 
8,924

Gross profit
291,708

 
304,015

Gross profit percentage
58.9
%
 
57.3
%
For the year ended December 31, 2019, our gross profit as a percentage of sales increased by 160 basis points compared to the prior year. This increase was primarily attributable to cost reductions in our operations overhead and our exit from lower margin businesses as a result of our corporate reorganization announced in January 2019 and a reduction in intangible amortization and restructuring costs incurred in 2018 related to business line exits.
Operating Costs 
 
Years ended December 31,
 
2019
 
2018
Marketing and selling
$
129,109

 
$
136,680

Percentage of revenue
26.1
%
 
25.7
%
Research and development
$
58,733

 
$
61,482

Percentage of revenue
11.9
%
 
11.6
%
General and administrative
$
59,649

 
$
70,599

Percentage of revenue
12.0
%
 
13.3
%
Intangibles amortization
$
15,144

 
$
22,585

Percentage of revenue
3.1
%
 
4.3
%
Restructuring
$
44,739

 
$
37,231

Percentage of revenue
9.0
%
 
7.0
%
Marketing and Selling
Marketing and selling expenses as a percentage of revenue remained relatively flat in the year ended December 31, 2019 as compared to the prior year. The decrease in expense is mainly attributable to the benefits of our corporate reorganization initiated in January 2019.
Research and Development
Research and development expenses decreased during the year ended December 31, 2019 compared to the prior year. The decrease relates to lower compensation related expenses due to our corporate reorganization initiatives.
General and Administrative
General and administrative expenses decreased during the year ended December 31, 2019 compared to the prior year. This decrease was due to a reduction in employee expenses, consulting fees and travel expenses due to our corporate reorganization and exit from non-core businesses.
Intangibles Amortization

33

Intangibles amortization decreased in the year ended December 31, 2019 compared to the prior year. The decrease is related to our restructuring initiatives, which included an impairment charge of $5.6 million in 2018 related to the end of life of our Bio-Logic core technology that did not recur in 2019.
Restructuring
Restructuring costs increased during the year ended December 31, 2019 compared to the prior year. This increase was driven by the restructuring initiatives announced in January 2019. We recorded an impairment related to the sale of Medix, which included the recognition of deferred foreign currency related adjustments in accumulated other comprehensive income, of $24.8 million, net of tax, and an adjustment of $4.6 million for assets with a book value in excess of their fair market value. The increase was also driven by restructuring expenses incurred related to exiting the GND business and our restructuring initiatives.
Other Income (Expense), net
Other income (expense), net consists of interest income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other expense, net of $5.6 million in the year ended December 31, 2019, compared to $7.7 million in the prior year. We reported $0.8 million of foreign currency exchange losses in the year ended December 31, 2019 versus $0.8 million of foreign currency losses in the prior year. Interest expense was $4.9 million in the year ended December 31, 2019 compared to $6.8 million in the prior year. The reduction in interest expense was driven by accelerated payments on our outstanding debt. Interest income was $0.3 million in both the year ended December 31, 2019 and the prior year.
Provision for Income Tax
The effective tax rate (“ETR”) for the year ended December 31, 2019 was 26.3% as compared to 28.9% for the prior year. Significant items that impact the effective tax rate are the change in geographic mix of income, adjustments and reversals of uncertain tax positions and SAB 118 adjustments arising from the 2017 Tax Act that were recorded in 2018.
Comparison of 2018 and 2017
Revenue 
 
Years ended December 31,
 
2018
 
2017
 
Change
Neuro
 
 
 
 
 
Devices and Systems
$
200,762

 
$
171,315

 
17
 %
Supplies
67,025

 
59,955

 
12
 %
Services
12,000

 
11,886

 
1
 %
Total Neuro Revenue
279,787

 
243,156

 
15
 %
Newborn Care
 
 
 
 
 
Devices and Systems
72,807

 
89,027

 
(18
)%
Supplies
40,669

 
43,928

 
(7
)%
Services
20,396

 
22,325

 
(9
)%
Total Newborn Care Revenue
133,872

 
155,280

 
(14
)%
Hearing & Balance
 
 
 
 
 
Devices and Systems
110,597

 
75,466

 
47
 %
Supplies
6,635

 
27,068

 
(75
)%
Services
—

 
—

 
—
 %
Total Hearing & Balance Revenue
117,232

 
102,534

 
14
 %
Total Revenue
$
530,891

 
$
500,970

 
6
 %
For the year ended December 31, 2018, Neuro revenue increased by 15% compared to the prior year. Devices and Systems revenue increased by 17% compared to the prior year due primarily to the addition of acquired Neurosurgery products and growth in EEG sales. Supplies revenue for 2018 increased 12%, which was also driven by the addition of our Neurosurgery business and organic growth in our Neurodiagnostic supply business. Services revenue from GND increased 1% compared to the prior year.

For the year ended December 31, 2018, Newborn Care revenue decreased by 14% compared to the prior year. Devices and Systems revenue decreased by 18%. The decrease is primarily due to the recognition of $10.0 million of revenue in the first half of 2017 from our contract with the government of Venezuela, which did not reoccur in 2018. We also experienced a one-

34

time shipment of neoBLUE blanket backlog in the first quarter of 2017 and a one-time shipment of hearing devices and supplies to China, Japan, and Australia in the second quarter of 2017. Supplies revenue decreased 7% compared to the prior year related to revenue contract with the government of Venezuela, which did not reoccur in 2018, as well as product line rationalization. Services revenue decreased by 9% compared to the prior year primarily due to a lower collection per screen on our Peloton hearing screening service.

For the year ended December 31, 2018, Hearing & Balance revenue increased 14% compared to the prior year. Revenue from Devices and Systems increased 47% and revenue from Supplies decreased 75% in 2018 compared to 2017. The overall growth in Hearing & Balances was driven by increased market share primarily in Europe and China. In addition to increased market share, Hearing & Balance also benefited from favorable exchanges rates and the launch of our new Otoscan product in 2018.
Cost of Revenue and Gross Profit 
 
Years ended December 31,
 
2018
 
2017
Revenue
$
530,891

 
$
500,970

Cost of revenue
217,952

 
213,376

Intangibles amortization
8,924

 
6,380

Gross profit
304,015

 
281,214

Gross profit percentage
57.3
%
 
56.1
%
For the year ended December 31, 2018, our gross profit as a percentage of sales increased by 1.2% compared to the prior year. This increase was primarily attributable to the improvement in Newborn Care gross profit, which was lower in the prior year due to sales to the government of Venezuela which carry a lower gross margin. We also experienced an increase on gross profit on our Neurosurgery products where we experienced higher sales in the U.S. which carry higher margins.
Operating Costs 
 
Years ended December 31,
 
2018
 
2017
Marketing and selling
$
136,680

 
$
126,166

Percentage of revenue
25.7
%
 
25.2
%
Research and development
$
61,482

 
$
51,822

Percentage of revenue
11.6
%
 
10.3
%
General and administrative
$
70,599

 
$
74,424

Percentage of revenue
13.3
%
 
14.9
%
Intangibles Amortization
$
22,585

 
$
19,171

Percentage of revenue
4.3
%
 
3.8
%
Restructuring
$
37,231

 
$
914

Percentage of revenue
7.0
%
 
0.2
%
Marketing and Selling
Marketing and selling expenses as a percentage of revenue remained relatively flat in the year ended December 31, 2018 as compared to the prior year. The increase in expense is for incremental costs of payroll, commissions, and travel associated with higher revenue.
Research and Development
Research and development expenses increased during the year ended December 31, 2018 compared to the prior year. The increase relates to increased spend on new product development, including Otoscan and RetCam products, and the addition of Neurosurgery products. These increases were partially offset by a reduction in spend related to remediation activities within our Newborn Care business.
General and Administrative

35

General and administrative expenses decreased during the year ended December 31, 2018 compared to the prior year. This decrease was due to a reduction in bad debt expense related to our GND and Peloton businesses.
Intangibles Amortization
Intangibles amortization increased in the year ended December 31, 2018 compared to the prior year. The increase is related to the impairment charge incurred in 2018 in relation to an end of life decision on our Bio-logic core technology of $5.6 million. This impairment charge was partially offset by purchase accounting adjustments in 2017 related to our Integra and RetCam acquisitions which did not recur in 2018.
Restructuring
Restructuring costs increased during the year ended December 31, 2018 compared to the prior year. This increase included costs associated with our executive management transition, which were approximately $10.0 million and were primarily comprised of accelerated vesting of stock compensation and severance expense. In 2018 we experienced impairment charges associated with exiting two of our non-core businesses, GND and Neurocom, which were categorized as restructuring expenses. We recorded a $14.8 million goodwill impairment charge related to GND. Impairment charges were also recorded for intangible and fixed assets related to GND and Neurocom, which totaled $2.8 million. Restructuring expenses were also incurred in 2018 in relation to the announcement of our new organizational structure, "One Natus."
Other Income (Expense), net
Other income (expense), net consists of interest income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other expense, net of $7.7 million in the year ended December 31, 2018, compared to $3.6 million in the prior year. We reported $0.8 million of foreign currency exchange losses in the year ended December 31, 2018 versus $1.0 million of foreign currency gains in the prior year. This increase was driven primarily by the changing value of foreign currencies in which we transact. Interest expense was $6.8 million in the year ended December 31, 2018 compared to $5.1 million in the prior year related to interest expense payments on our outstanding debt while interest income of $0.3 million in the year ended December 31, 2018 was $0.1 million less than the amount reported for the prior year.
Provision for Income Tax
The effective tax rate for the year ended December 31, 2018 was 28.9% as compared to 494.0% for the prior year. The significantly lower effective rate in the year ended December 31, 2018 compared with the prior year is primarily due to the impacts of the 2017 Tax Act, including the repatriation tax on accumulated foreign earnings and re-measurement of net deferred tax assets recorded in the prior year, a reduction in withholding taxes from distribution of income, and reduction in the U.S. Federal corporate rate from 35% to 21%.

Liquidity and Capital Resources
Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing and to raise capital. Therefore, liquidity cannot be considered separately from capital resources that consist of our current funds and the potential to increase those funds in the future. We plan to use these resources in meeting our commitments and in achieving our business objectives.
We believe that our current cash and cash equivalents and any cash generated from operations will be sufficient to meet our ongoing operating requirements for the foreseeable future.
As of December 31, 2019, we had cash and cash equivalents outside the U.S. in certain of our foreign operations of $51.0 million. We intend to permanently reinvest this cash held by our foreign subsidiaries except for Excel-Tech and Natus Ireland subsidiaries, which we intend to repatriate. If, however, a portion of these permanently reinvested funds were needed and distributed to our operations in the United States, we may be subject to additional U.S. income taxes and foreign withholding taxes depending on facts and circumstances at the time of distribution. The amount of taxes due would depend on the amount and manner of repatriation, as well as the location from where the funds were repatriated.
On September 23, 2016, we entered into a Credit Agreement with JP Morgan Chase Bank (“JP Morgan”), Citibank, NA (“Citibank”) and Wells Fargo Bank, National Association (“Wells Fargo”). The Credit Agreement provides for an aggregate $150.0 million of secured revolving credit facility (the “Credit Facility”). On September 15, 2017, we exercised our right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants, including covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties,

36

investments, issuance of debt, lease obligations and capital expenditures. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have no other significant credit facilities. As of December 31, 2019 we had $55.0 million outstanding under the Credit Facility.
 
December 31, 2019
 
December 31, 2018
 
December 31, 2017
Cash, cash equivalents, and investments
$
63,297

 
$
56,373

 
$
88,950

Debt
54,665

 
104,474

 
154,283

Working capital
126,928

 
152,329

 
213,491

 
Year Ended
 
December 31, 2019
 
December 31, 2018
 
December 31, 2017
Net cash provided by operating activities
$
60,060

 
$
33,020

 
$
19,726

Net cash used in investing activities
(5,339
)
 
(8,389
)
 
(160,935
)
Net cash provided by (used in) financing activities
(48,532
)
 
(49,512
)
 
5,826

Comparison of 2019, 2018, and 2017
During 2019 cash generated from operating activities of $60.1 million was the result of $15.7 million of net loss, non-cash adjustments to net loss of $63.2 million, and net cash outflows of $12.5 million from changes in operating assets and liabilities. The non-cash adjustments were $30.7 million of depreciation and amortization expense, $24.6 million of impairment for the sale of Medix, $8.4 million from share-based compensation, $2.9 million of warranty reserves, and $1.6 million of accounts receivable reserves, offset by deferred taxes of $5.4 million. Cash used in investing activities during the period was $5.3 million and consisted of cash used to acquire other property and equipment. Cash used in financing activities during the year ended December 31, 2019 was $48.5 million and consisted of repayments of $50.0 million of our outstanding debt under the Credit Facility, $1.7 million for taxes paid related to net share settlement of equity awards, $0.5 million of principal payments of financing lease liability, offset by proceeds from stock option exercises and Employee Stock Purchase Program (“ESPP”) purchases of $3.6 million.
During 2018 cash generated from operating activities of $33.0 million was the result of $22.9 million of net loss, non-cash adjustments to net loss of $70.1 million, and net cash outflows of $14.1 million from changes in operating assets and liabilities. The non-cash adjustments were $33.9 million of depreciation and amortization expense, $17.1 million from share-based compensation, a $14.8 million goodwill impairment charge related to GND, $8.2 million from intangible impairments, $6.9 million of accounts receivable reserves, and $2.2 million of warranty reserves, offset by deferred taxes of $13.7 million. Cash used in investing activities during the period was $8.4 million and consisted primarily of cash used to acquire other property and equipment of $7.9 million. Cash used in financing activities during the year ended December 31, 2018 was $49.5 million and consisted of repayments of $50.0 million of our outstanding debt under the Credit Facility, $5.6 million for repurchases of common stock under our share repurchase program, $5.2 million for taxes paid related to net share settlement of equity awards, offset by proceeds from stock option exercises and Employee Stock Purchase Program purchases of $11.5 million.
During 2017 cash generated from operating activities of $19.7 million was the result of $20.3 million of net loss, non-cash adjustments to net loss of $60.6 million, and net cash outflows of $20.6 million from changes in operating assets and liabilities. The non-cash adjustments were $30.1 million of depreciation and amortization expense, $10.0 million of accounts receivable reserves, $9.4 million from share-based compensation, $5.4 million of warranty reserves, $4.0 of deferred taxes and $1.7 million from intangible impairments. The change in operating assets and liabilities was driven primarily by an increase in accounts receivable and lower collections during the year compared to the prior year, and a decrease in deferred revenue related to the Venezuelan contract, partially offset by an increase in accrued liabilities for the transition tax under the Act for the deemed repatriation of foreign earnings and decreases in inventories and other assets. Cash used in investing activities during the period was $161.1 million and consisted primarily of the acquisition of Otometrics for $143.6 million, net of cash, and the Integra asset acquisition for $46.4 million, offset by sales of short-term investments of $34.0 million. Cash used to acquire other property and equipment was $4.1 million. Cash provided by financing activities during the year ended December 31, 2017 was $5.8 million and consisted of proceeds from borrowings under the Credit Facility of $60.0 million along with proceeds from stock option exercises and Employee Stock Purchase Program purchases of $3.5 million, offset by $45.0 million repayment of debt under the Credit Facility, $7.0 million for taxes paid related to net share settlement of equity awards, $3.0 million for contingent acquisition consideration, $2.3 million for repurchases of common stock under our share repurchase program, and $0.3 million of deferred debt issuance costs.
Future Liquidity

37

Our future liquidity and capital requirements will depend on numerous factors, including the:
•
Amount and timing of revenue;
•
Extent to which our existing and new products gain market acceptance;
•
Extent to which we make acquisitions;
•
Cost and timing of product development efforts and the success of these development efforts;
•
Cost and timing of marketing and selling activities; and
•
Availability of borrowings under line of credit arrangements and the availability of other means of financing.
Contractual Obligations
In the normal course of business, we enter into obligations and commitments that require future contractual payments. The commitments result primarily from purchase orders placed with contract vendors that manufacture some of the components used in our medical devices and related disposable supply products, purchase orders placed for employee benefits and outside services, as well as commitments for leased office space, leased equipment, and bank debt. The following table summarizes our contractual obligations and commercial commitments as of December 31, 2019 (in thousands): 
 
 
 
Payments Due by Period
 
Total
 
Less than
1 Year
 
1-3 Years
 
4-5 Years
 
More than
5 Years
Unconditional purchase obligations
$
44,955

 
$
44,955

 
$
—

 
$
—

 
$
—

Bank debt
55,000

 
—

 
55,000

 
—

 
—

Interest payments
2,390

 
1,907

 
483

 
—

 
—

Repatriation tax
9,113

 
797

 
1,751

 
3,830

 
2,735

Total
$
111,458

 
$
47,659

 
$
57,234

 
$
3,830

 
$
2,735

Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding. Included in the purchase obligations category above are obligations related to purchase orders for inventory purchases under our standard terms and conditions and under negotiated agreements with vendors. We expect to receive consideration (products or services) for these purchase obligations. The purchase obligation amounts do not represent all anticipated purchases in the future, but represent only those items for which we are contractually obligated. The table above does not include obligations under employment agreements for services rendered in the ordinary course of business.
We have a Credit Agreement with JP Morgan Chase Bank, Citibank, and Wells Fargo which matures in 2021. We have recorded this obligation in the payments due in one to three years category in the table above based on the maturity date of the Agreement. As of December 31, 2019 we have classified $35.0 million out of the $55.0 million outstanding as short-term on our balance sheet due to our intent to repay this portion over the next twelve months.
We are not able to reasonably estimate the timing of any potential payments for uncertain tax positions under Accounting Standards Codification ("ASC") 740, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement 109. As a result, the preceding table excludes any potential future payments related to our ASC 740 liability for uncertain tax positions. See Note 17 of our Consolidated Financial Statements for further discussion on income taxes.
Quantitative and Qualitative Disclosures about Market Risk
We are exposed to various market risks, including changes in foreign currency exchange rates and interest rates that could adversely affect our results of operations and financial condition. We are exposed to interest rate risk on our LIBOR-indexed floating-rate debt. We have entered into an interest rate swap agreement to effectively covert a portion of our floating-rate debt to a fixed-rate. The principal objective of the swap contract is to reduce the variability of future earnings and cash flows associated with our floating-rate debt. We do not hold or issue derivative instruments for trading or other speculative purposes.

Foreign Exchange Rate Risk
We develop products in the U.S, Canada, and Europe, and sell those products into more than 100 countries throughout the world. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Most of our sales in Europe and Asia are denominated in the U.S. Dollar and Euro, with a portion of our sales denominated in the Canadian dollar and British pound. As our sales in currencies other than the U.S. dollar increase, our exposure to foreign currency fluctuations may increase.

38

In addition, changes in exchange rates also may affect the end-user prices of our products compared to those of our foreign competitors, who may be selling their products based on local currency pricing. These factors may make our products less competitive in some countries.
If the U.S. Dollar uniformly increased or decreased in strength by 10% relative to the currencies in which our sales were denominated, our net income would have correspondingly increased or decreased by an immaterial amount for the year ended December 31, 2019.
All of the potential changes noted above are based on sensitivity analyses performed on our financial position as of December 31, 2019. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.
Interest Rate Risk
In 2018, we entered into an interest rate swap agreement with a notional amount of $40.0 million, designated as a cash flow hedge, to hedge the variability of cash flows in interest payments associated with our floating-rate debt. This interest rate swap agreement matures in September 2021 and converts a portion of our LIBOR floating-Rate debt to fixed-rate debt. The fair value of the interest rate swap agreement is based upon inputs corroborated by observable market data. Changes in the fair value of the interest rate swap agreement are recorded as a component of accumulated other comprehensive income (loss) within stockholders' equity and are amortized to interest expense over the term of the related debt.
As of December 31, 2019, accumulated other comprehensive income (loss) related to the interest rate swap agreement included a net unrealized loss of approximately $143 thousand, net of tax, which will be recognized in interest expense after the following 12 months, at the then current values on a pre-tax basis. See Note 12 to these Condensed Consolidated Financial Statements for additional discussion on our financial instruments and derivatives.
Interest Rate Risk Sensitivity Analysis
Our remaining indebtedness is at variable rates of interest. Accordingly, changes in interest rates would impact our results of operations in future periods. Based on a sensitivity analysis on actual rates experienced during 2019, a hypothetical increase in interest rates of 50 basis points would have resulted in increased interest expense of $0.4 million during the year ended December 31, 2019.
Recently Issued Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Credit Losses (Topic 326). This update requires financial assets measured at amortized cost, such as trade receivables and contract assets, to be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial assets. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In May 2019, the FASB issued ASU 2019-05 which provides targeted transition relief guidance intended to increase comparability of financial statement information. The guidance for both updates is effective beginning January 1, 2020. We do not believe adoption will have a material impact to our consolidated financial statements.
    In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement (Topic 813), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. This update amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosure. For calendar year-end entities, the update will be effective for annual periods beginning January 1, 2020, and interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in any interim period. As the standard relates only to disclosures, we do not expect the adoption to have a material impact on our consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Tax. This update includes removal of certain exceptions to the general principles of ASC 740, Income taxes, and simplification in several other areas such as accounting for franchise tax (or similar tax) that is partially based on income. The ASU is effective for us on January 1, 2021. We are in the process of evaluating the impact of this standard on our consolidated financial statements.
Cautionary Information Regarding Forward Looking Statements
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated. Forward-looking statements can be identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. These forward-looking statements within Item 7 include, without limitation, statements regarding our ability to capitalize on improving market conditions, the sufficiency of our current cash, cash equivalents and short-

39

term investment balances, any cash generated from operations to meet our ongoing operating and capital requirements for the foreseeable future, outcomes of new product development, improved operations performance and profitability as the result of restructuring activities, and our intent to acquire additional technologies, products or businesses.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results predicted in the forward-looking statements as well as our future financial condition and results of operations to differ materially from our historical results or currently anticipated results. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A of this report for a description of risks and uncertainties. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
ITEM 7A.     Quantitative and Qualitative Disclosures About Market Risk
The information required by this Item is set forth in the section entitled Management’s Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk, and is incorporated by reference in this section.
ITEM 8.     Financial Statements and Supplementary Data
The Consolidated Financial Statements and Supplementary Data required by this Item are set forth where indicated in Item 15 of this report.
Selected Quarterly Financial Data (Unaudited)
The following table presents our operating results for each of the eight quarters in the period ending December 31, 2019. The information for each of these quarters is unaudited and has been prepared on the same basis as our audited financial statements appearing elsewhere in this report.
In the opinion of our management all necessary adjustments, including normal recurring adjustments, have been included to present fairly the unaudited quarterly results when read in conjunction with our audited Consolidated Financial Statements and the related notes appearing elsewhere in this report. These operating results are not necessarily indicative of the results of any future period.




40

 
Quarters Ended
 
December 31, 2019
 
September 30, 2019 (1)
 
June 30, 2019 (1)
 
March 31, 2019 (1)
 
December 31, 2018
 
September 30, 2018
 
June 30, 2018
 
March 31, 2018
 
(in thousands, except per amounts)
Revenue
$
131,416

 
$
123,463

 
$
125,539

 
$
114,757

 
$
140,991

 
$
130,638

 
$
130,653

 
$
128,609

Cost of revenue (a)
49,259

 
48,389

 
52,393

 
46,510

 
58,103

 
51,583

 
52,897

 
55,369

Intangibles amortization
1,679

 
1,736

 
1,746

 
1,756

 
2,689

 
1,930

 
2,717

 
1,587

Gross profit
80,478

 
73,338

 
71,400

 
66,491

 
80,199

 
77,125

 
75,039

 
71,653

Operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing and selling (b)
32,268

 
30,787

 
32,324

 
33,729

 
34,206

 
33,200

 
33,401

 
35,872

Research and development (c)
17,567

 
14,447

 
13,324

 
13,394

 
15,296

 
15,127

 
15,616

 
15,443

General and administrative (d)
15,261

 
15,394

 
12,690

 
16,306

 
13,632

 
15,799

 
23,721

 
17,448

Intangibles amortization
3,844

 
3,751

 
3,763

 
3,786

 
9,151

 
4,477

 
4,151

 
4,806

Restructuring
3,592

 
1,106

 
2,668

 
37,372

 
23,049

 
11,432

 
1,938

 
812

Total operating expenses
72,532

 
65,485

 
64,769

 
104,587

 
95,334

 
80,035

 
78,827

 
74,381

Income (loss) from operations
7,946

 
7,853

 
6,631

 
(38,096
)
 
(15,135
)
 
(2,910
)
 
(3,788
)
 
(2,728
)
Other income (expense), net
(670
)
 
(1,609
)
 
(1,200
)
 
(2,112
)
 
(2,754
)
 
(726
)
 
(2,398
)
 
(1,821
)
Income (loss) before provision for (benefit from) income tax
7,276

 
6,244

 
5,431

 
(40,208
)
 
(17,889
)
 
(3,636
)
 
(6,186
)
 
(4,549
)
Provision for (benefit from) income tax (e)
4,266

 
(1,987
)
 
1,944

 
(9,809
)
 
(6,256
)
 
1,940

 
(3,609
)
 
(1,401
)
Net income (loss)
$
3,010

 
$
8,231

 
$
3,487

 
$
(30,399
)
 
$
(11,633
)
 
$
(5,576
)
 
$
(2,577
)
 
$
(3,148
)
Earnings (loss) per share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
$
0.09

 
$
0.24

 
$
0.10

 
$
(0.91
)
 
$
(0.35
)
 
$
(0.17
)
 
$
(0.08
)
 
$
(0.10
)
Diluted
$
0.09

 
$
0.24

 
$
0.10

 
$
(0.91
)
 
$
(0.35
)
 
$
(0.17
)
 
$
(0.08
)
 
$
(0.10
)
Weighted average shares used in the calculation of net earnings (loss) per share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
33,691

 
33,655

 
33,639

 
33,590

 
33,495

 
33,321

 
32,859

 
32,760

Diluted
33,829

 
33,738

 
33,690

 
33,590

 
33,495

 
33,321

 
32,859

 
32,760

(1) During the fourth quarter of 2019, we corrected certain previously reported financial information for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019 related to the accounting for certain research and development activities in an arrangement with a third party, certain invoice accruals, adjustments resulting from physical inventory observations, and the income tax impacts of these immaterial adjustments. The correction of the immaterial errors resulted in the following:
(a)
Cost of revenue increased $0.1 million and $0.2 million for the quarters ended March 31, 2019 and June 30, 2019, respectively. Cost of revenue decreased $0.3 million for the quarter ended September 30, 2019.
(b)
Marketing and selling expense increased $0.1 million for the quarter ended June 30, 2019 and decreased $0.1 million for the quarter ended September 30, 2019.
(c)
Research and development expense increased $0.3 million, $0.6 million, and $0.3 million for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019 respectively.

41

(d)
General and administrative expense increased $0.3 million for the quarter ended September 30, 2019.
(e)
Provision for income tax decreased by $0.1 million, $0.2 million, and $6 thousand for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019, respectively.

ITEM 9.    Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
ITEM 9A.     Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the rules of the Securities and Exchange Commission, “disclosure controls and procedures” are controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud due to inherent limitations of internal controls. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
Our management, with the participation of our chief executive officer and our chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our management, including our chief executive officer and chief financial officer, has concluded that our disclosure controls and procedures were not effective as of December 31, 2019. This conclusion was based on the material weakness in our internal control over financial reporting further described below.
In light of the material weaknesses described below, management performed additional analysis and other procedures to ensure that our consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP). Accordingly, management believes that the consolidated financial statements included in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented, in accordance with U.S. GAAP.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of the inherent limitations of any system of internal control. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses of judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper overriding of controls. As a result of such limitations, there is risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
Based on our evaluation under the criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management concluded that we did not maintain effective internal control over financial reporting as of December 31, 2019 due to a material weakness that existed in the Company’s internal control over financial reporting as further described below. A material weakness is a deficiency, or a combination of deficiencies, in internal

42

control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
As part of closing our books for the fourth quarter of 2019 we identified immaterial errors that indicated certain deficiencies existed in the Company’s internal control over financial reporting.  Specifically, we did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of our controls over payroll accounts contributed to an error in the period end accrual. The Company has concluded that these deficiencies could have resulted in a material misstatement of the consolidated financial statements that would not have been prevented or detected on a timely basis, and as such, these control deficiencies result in a material weakness in internal control over financial reporting as of December 31, 2019.
Our independent registered public accounting firm, KPMG LLP, has audited the consolidated financial statements included in this Annual Report on Form 10-K, and, as part of its audit, has issued an adverse opinion on the effectiveness of our internal control over financial reporting. KPMG LLP’s report is included herein in Part II, Item 9A of this Annual Report on Form 10-K.
Remediation Efforts to Address Material Weakness
To remediate the material weakness in our internal control over financial reporting described above, we plan to make substantive changes to enhance our design of controls intended to identify and assess contracts that include research and development activities and to aid in confirming the accuracy of our payroll accounts.  Specifically, we plan to formalize a policy that provides guidance on proper identification, analysis and treatment of contracts that include research and development activities.  We also intend to provide training to the finance team to ensure the policy is communicated, understood and followed.  We intend to strengthen the control design for payroll accounts to require that specific review procedures be completed and to formalize the results of required review procedures in a checklist format including reviewer signoff. Additionally, we plan to institute a process to monitor changes to our control operators responsible for key controls over financial reporting and implement a control to verify that appropriate training is provided to new control operators to mitigate this risk of change in our system of control.
Changes in Internal Control over Financial Reporting
Except for the material weakness identified above, there has been no change in our internal control over financial reporting during the fourth quarter of 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

    

43

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Natus Medical Incorporated:
Opinion on Internal Control Over Financial Reporting
We have audited Natus Medical Incorporated and subsidiaries’ (the Company) internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness, described below, on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes and financial statement schedule II: Valuation and Qualifying Accounts (collectively, the consolidated financial statements), and our report dated March 2, 2020 expressed an unqualified opinion on those consolidated financial statements.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment:
The Company did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of the Company’s controls over payroll accounts contributed to an error in the period-end accrual.
The material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2019 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting in Item 9A. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

44

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
(signed) KPMG LLP
San Francisco, California
March 2, 2020


45

ITEM 9B.    Other Information
None.

PART III
We will provide information that is responsive to this Part III in our Definitive Proxy Statement for our 2020 Annual Meeting of Stockholders (our “2020 Proxy Statement”) or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Part III by reference.
ITEM 10.    Directors, Executive Officers, and Corporate Governance
We will provide certain other information that is responsive to this Item 10 in our 2020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 10 by reference.
Audit Committee and Audit Committee Financial Expert
The members of the Audit Committee of our Board of Directors are Kenneth E. Ludlum, Thomas J. Sullivan, and Alice D. Schroeder. Our Board of Directors has determined that Kenneth E. Ludlum is an audit committee financial expert as defined in Item 407(d) of Regulation S-K. All of the members of our audit committee are considered “independent” as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the Exchange Act.
Code of Conduct and Ethics
We have a code of conduct and ethics that applies to all of our employees, including our principal executive officer, principal financial officer, and principal accounting officer or controller. This code of conduct and ethics is posted on our internet website. The internet address for our website is www.natus.com, and the code of conduct and ethics may be found in the “Governance” section of our “Investor” webpage.
We intend to satisfy the disclosure requirement under Item 10 of Form 8-K regarding certain amendments to, or waivers from, provisions of this code of conduct and ethics by posting such information on our website, at the address and location specified above, or as otherwise required by The Nasdaq Stock Market.
ITEM 11.    Executive Compensation
We will provide information that is responsive to this Item 11 in our 2020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 11 by reference.
ITEM 12.     Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Equity Compensation Plan Information
The following table sets forth information about the number of shares of common stock that can be issued under our 2018 Stock Awards Plan and our 2011 Employee Stock Purchase Plan as of December 31, 2019. 
Plan Category
 
Number of Securities
to be Issued upon
Exercise of
Outstanding
Options, Warrants,
Awards and Rights
 
Weighted-Average
Exercise Price of
Outstanding
Options, Warrants,
Awards and Rights
 
Number of Securities
Remaining Available for
Future Issuance under
Equity Compensation Plans
(excluding securities
reflected in the first column)
Equity compensation plans approved by security holders
 
247,029

 
$
35.31

 
2,764,603

Equity compensation plans not approved by security holders
 
—

 
—

 
—

Total
 
247,029

 
35.31

 
2,764,603

We will provide certain other information that is responsive to this Item 12 in our 2020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 12 by reference.
ITEM 13.     Certain Relationships and Related Transactions, and Director Independence

46

We will provide information that is responsive to this Item 13 in our 2020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 13 by reference.
ITEM 14.     Principal Accounting Fees and Services
We will provide information that is responsive to this Item 14 in our 2020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 14 by reference.
PART IV 
ITEM 15.    Exhibits, Financial Statement Schedules
(a)(2) Financial Statement Schedule
SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
For the years ended December 31, 2019, 2018 and 2017
(In thousands) 
 
Balance at
Beginning
of Period
 
Additions
Charged to
Expense
 
Deductions
 
Balance
at End
of Period
Year ended December 31, 2019
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
6,960

 
$
1,584

 
$
(1,160
)
 
$
7,384

Valuation allowance
637

 
—

 
(31
)
 
606

Warranty reserve
9,391

 
3,949

 
(6,936
)
 
6,404

Year ended December 31, 2018
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
8,978

 
$
6,423

 
$
(8,441
)
 
$
6,960

Valuation allowance
5,862

 
—

 
(5,225
)
 
637

Warranty reserve
10,995

 
4,487

 
(6,091
)
 
9,391

Year ended December 31, 2017
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,182

 
$
10,017

 
$
(5,221
)
 
$
8,978

Valuation allowance
3,706

 
2,156

 
—

 
5,862

Warranty reserve
10,670

 
5,370

 
(5,045
)
 
10,995


(a)(3) Exhibits 
The Exhibits listed in the Index to Exhibits, which appears immediately following the signature page and is incorporated herein by reference, are filed as part of this 10-K.


47

 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
3.1
 
Natus Medical Incorporated Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of July 25, 2001
 
S-1
 
3.1.1

 
333-44138
 
8/18/2000
3.2
 
Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of September 12, 2012
 
8-K
 
3.1

 
000-33001
 
9/13/2012
3.3
 
Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of June 5, 2019
 
8-K
 
3.1

 
000-33001
 
6/7/2019
3.4
 
Second Amended and Restated Bylaws of Natus Medical Incorporated
 
8-K
 
3.1

 
000-33001
 
12/16/2019
4.1
 
Specimen stock certificate for shares of common stock, par value $0.001 per share
 
S-1/A
 
4.1

 
333-44138
 
2/9/2001
4.2
 
Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock
 
8-A
 
3.1.2

 
000-33001
 
9/6/2002
4.3
 
Description of Common Stock
 
 
 
 
 
 
 
 
10.1
 
Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers
 
S-1
 
10.1

 
333-44138
 
8/18/2000
10.1.1*
 
2018 Equity Incentive Plan
 
8-K
 
10.1

 
000-33001
 
12/18/2018
10.1.2*
 
Form of Stock Option Awards Agreement under the 2018 Equity Incentive Plan
 
8-K
 
10.1.1

 
000-33001
 
12/18/2018
10.1.3*
 
Form of Restricted Stock Award Agreement under the 2018 Equity Incentive Plan
 
8-K
 
10.1.2

 
000-33001
 
12/18/2018
10.1.4
 
Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan
 
8-K
 
10.1.3

 
000-33001
 
12/18/2018
10.1.5*
 
Form of Performance Stock Unit Agreement under the 2018 Equity Incentive Plan
 
8-K
 
10.1.4

 
000-33001
 
12/18/2018
10.2*
 
Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan
 
8-K
 
10.1

 
000-33001
 
1/4/2006
10.2.1*
 
Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan
 
S-1
 
10.3.1

 
333-44138
 
8/18/2000
10.2.2*
 
Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan
 
10-Q
 
10.2

 
000-33001
 
8/9/2006
10.2.3*
 
Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan
 
10-K
 
10.2.3

 
000-33001
 
3/14/2008
10.3*
 
Natus Medical Incorporated 2000 Director Option Plan
 
10-Q
 
10.02

 
000-33001
 
5/9/2008
10.3.1*
 
Form of Option Agreement under the 2000 Director Option Plan
 
S-1
 
10.4.1

 
333-44138
 
8/18/2000
10.4*
 
Natus Medical Incorporated 2000 Supplemental Stock Option Plan
 
S-1
 
10.15

 
333-44138
 
2/9/2001
10.4.1*
 
Form of Option Agreement for 2000 Supplemental Stock Option Plan
 
S-1
 
10.15.1

 
333-44138
 
2/9/2001
10.5*
 
Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder
 
8-K
 
10.2

 
000-33001
 
1/4/2006
10.6*
 
[Amended] 2011 Stock Awards Plan
 
14-A
 
—

 
000-33001
 
4/20/2011

48

 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
10.6.1*
 
Form of Stock Option Award Agreement under the [Amended] 2011 Stock Plan
 
10-Q
 
10.1

 
000-33001
 
11/7/2011
10.6.2*
 
Form of Restricted Stock Award Purchase Agreement
 
10-Q
 
10.2

 
000-33001
 
11/7/2011
10.6.3*
 
Form of Restricted Stock Unit Agreement
 
10-Q
 
10.3

 
000-33001
 
11/7/2011
10.7*
 
2011 Employee Stock Purchase Plan
 
14-A
 
—

 
000-33001
 
4/20/2011
10.7.1*
 
2011 Employee Stock Purchase Plan Subscription Agreement
 
14-A
 
—

 
000-33001
 
4/20/2011
10.8*
 
Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer
 
10-K
 
10.10

 
000-33001
 
3/10/2009
10.8.1*
 
Form of Amendment to Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer
 
10-K
 
 
 
000-33001
 
3/16/2015
10.9*
 
Amended employment agreement between Natus Medical Incorporated and its Chief Executive Officer, James B. Hawkins dated April 19, 2013
 
8-K
 
99.1

 
000-33001
 
4/22/2013
10.10*
 
Terms of Resignation between Natus Medical Incorporated and James B. Hawkins dated July 11, 2018
 
10-Q
 
10.16

 
000-33001
 
8/8/2018
10.11
 
Credit Agreement between Natus Medical Incorporated and CitiBank, NA dated October 9, 2015
 
8-K
 
10.1

 
000-33001
 
10/9/2015
10.12
 
Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015
 
10-Q
 
 
 
000-33001
 
2/29/2016
10.13
 
Amendment to Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015
 
10-Q
 
10.2

 
000-33001
 
11/3/2016
10.14
 
Credit Agreement, dated September 23, 2016, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A.
 
10-Q
 
10.1

 
000-33001
 
11/3/2016
10.15
 
Master Purchase Agreement, dated September 25, 2016, between GN Hearing A/S, GN Nord A/S and the Company
 
10-Q
 
10.3

 
000-33001
 
11/3/2016
10.16*
 
Forms of Employment Agreement between Natus Medical Incorporated and Jonathan A. Kennedy dated August 24, 2018
 
8-K
 
99.1

 
000-33001
 
8/29/2018
10.17*
 
Form of Employment Agreement between Natus Medical Incorporated and Drew Davies dated October 1, 2018
 
10-Q
 
10.18

 
000-33001
 
11/8/2018
21.1
 
Significant Subsidiaries of the Registrant
 
 
 
 
 
 
 
 
23.1
 
Consent of Independent Registered Public Accounting Firm
 
 
 
 
 
 
 
 
24.1
 
Power of Attorney (included on signature page)
 
 
 
 
 
 
 
 
31.1
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 

49



 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
31.2
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
32.1
 
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
101
 
The following financial information from Natus Medical Incorporated Annual Report on Form 10-K for the fiscal year ended December 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2019 and December 31, 2018, (ii) Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017, (iii) Consolidated Statements of Comprehensive Income for the years ended December 31, 2019, 2018 and 2017 (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017, (v) Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2019, 2018 and 2017, and (vi) the Notes to Consolidated Financial Statements.
 
 
 
 
 
 
 
 
104
 
The cover page of the Annual Report on Form 10-K formatted in Inline XBRL (included in Exhibit 101).
 
 
 
 
 
 
 
 
 *    Indicates a management contract or compensatory plan or arrangement

50

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized. 
 
 
 
NATUS MEDICAL INCORPORATED
 
 
By
 
/s/    JONATHAN A. KENNEDY        
 
 
Jonathan A. Kennedy
President and Chief Executive Officer
 
 
By
 
/s/    B. DREW DAVIES        
 
 
B. Drew Davies
Executive Vice President and Chief Financial Officer
Dated: March 2, 2020
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jonathan A. Kennedy and B. Drew Davies and each of them acting individually, as his or her attorney-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacity and dates indicated: 
Signature
  
Title
 
Date
 
 
 
 
 
/S/    JONATHAN A. KENNEDY
  
President and Chief Executive Officer (Principal Executive Officer)
 
March 2, 2020
(Jonathan A. Kennedy)
 
 
 
 
/S/    B. DREW DAVIES
  
Executive Vice President & Chief Financial Officer (Principal Financial and Accounting Officer)
 
March 2, 2020
(B. Drew Davies)
 
 
 
 
/S/    BARBARA R. PAUL
  
Chairperson of the Board of Directors
 
March 2, 2020
(Barbara R. Paul)
 
 
 
 
/S/    LISA W. HEINE
  
Director
 
March 2, 2020
(Lisa W. Heine)
 
 
 
 
/S/    JOSHUA H. LEVINE
  
Director
 
March 2, 2020
(Joshua H. Levine)
 
 
 
 
/S/    KENNETH E. LUDLUM
  
Director
 
March 2, 2020
(Kenneth E. Ludlum)
 
 
 
 
/S/    ALICE D. SCHROEDER
  
Director
 
March 2, 2020
(Alice D. Schroeder)
 
 
 
 
/S/    THOMAS J. SULLIVAN
  
Director
 
March 2, 2020
(Thomas J. Sullivan)
 
 
 
 

51

NATUS MEDICAL INCORPORATED
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Natus Medical Incorporated:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Natus Medical Incorporated and subsidiaries (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes and financial statement schedule II: Valuation and Qualifying Accounts (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 2, 2020 expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting.
Change in Accounting Principle
As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases due to the adoption of Financial Accounting Standards Board Accounting Standards Codification Topic 842, Leases, on a modified retrospective basis as of January 1, 2019.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Evaluation of net realizable value adjustments for inventory excess and obsolescence
As discussed in Notes 1 and 4 to the consolidated financial statements, the Company has inventory with a carrying value of $89.6 million at December 31, 2019, of which $71.4 million is classified as current and $18.2 million is classified as noncurrent. Within noncurrent inventory are service components for products the Company no longer sells and inventory purchased for lifetime buys, which are required by regulation given the nature of the Company’s products. The Company reduces the carrying value of inventory for any differences between its cost and estimated net realizable value. Net realizable value is estimated by evaluating ending inventories for excess quantities, obsolescence, and other factors that potentially impact the Company’s ability to consume inventory for its intended use. In making its estimate of net realizable value, the Company’s evaluation includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product.

F-2

We identified the evaluation of net realizable value adjustments for inventory excess and obsolescence as a critical audit matter given the high degree of auditor judgement required. The degree of auditor judgment required was considered high given the inherent uncertainty in projecting future demand and complexity involved in assessing whether the Company’s analysis of historical sales by product, projections of future demand, and assessment of obsolescence effectively captured the subset of inventory requiring net realizable value adjustments.
The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company’s process to identify inventory subject to risk of excess and obsolescence and reduce this inventory to an estimate of net realizable value. In evaluating potential excess inventory, we compared on hand inventory to the Company’s estimate of future inventory consumption. We evaluated the estimate of future inventory consumption through an analysis of historical inventory usage by product and information obtained from the Company’s manufacturing planning department. We obtained internal and external product inspection reports to identify inventory subject to remediation and evaluated the Company’s assessment of obsolescence. We also compared the Company’s estimate of net realizable value adjustments for identified excess and obsolete to the prior period estimate and to actual inventory scrapping history.

(signed) KPMG LLP
We have served as the Company's auditor since 2014.

San Francisco, California
March 2, 2020


F-3

NATUS MEDICAL INCORPORATED
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts) 
 
December 31,
 
2019
 
2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
63,297

 
$
56,373

Accounts receivable, net of allowance for doubtful accounts of $7,384 and $6,960
115,889

 
127,041

Inventories
71,368

 
79,736

Prepaid expenses and other current assets
19,195

 
22,625

Total current assets
269,749

 
285,775

Property and equipment, net
24,702

 
22,913

Operating lease right-of-use assets
15,046

 
—

Intangible assets, net
114,799

 
139,453

Goodwill
146,367

 
147,644

Deferred income tax
30,355

 
22,639

Other assets
21,509

 
19,716

Total assets
$
622,527

 
$
638,140

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
27,253

 
$
28,805

Current portion of long-term debt
35,000

 
35,000

Current portion of operating lease liabilities
5,871

 
—

Accrued liabilities
54,451

 
52,568

Deferred revenue
20,246

 
17,073

Total current liabilities
142,821

 
133,446

Long-term liabilities:
 
 
 
Other liabilities
17,616

 
19,845

Long-term debt
19,665

 
69,474

Operating lease liabilities
12,051

 
—

Deferred income tax
14,251

 
16,931

Total liabilities
206,404

 
239,696

Commitments and contingencies (Note 21)

 

Stockholders’ equity:
 
 
 
Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 34,148,700 in 2019 and 33,804,379 in 2018
344,476

 
334,215

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and in 2018
—

 
—

Retained earnings
87,922

 
102,261

Accumulated other comprehensive loss
(16,275
)
 
(38,032
)
Total stockholders’ equity
416,123

 
398,444

Total liabilities and stockholders’ equity
$
622,527

 
$
638,140

The accompanying notes are an integral part of these Consolidated Financial Statements.

F-4

NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts) 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Revenue
$
495,175

 
$
530,891

 
$
500,970

Cost of revenue
196,551

 
217,952

 
213,376

Intangibles amortization
6,916

 
8,924

 
6,380

Gross profit
291,708

 
304,015

 
281,214

Operating expenses:
 
 
 
 
 
Marketing and selling
129,109

 
136,680

 
126,166

Research and development
58,733

 
61,482

 
51,822

General and administrative
59,649

 
70,599

 
74,424

Intangibles amortization
15,144

 
22,585

 
19,171

Restructuring
44,739

 
37,231

 
914

Total operating expenses
307,374

 
328,577

 
272,497

Income (loss) from operations
(15,666
)
 
(24,562
)
 
8,717

Other expense, net
(5,591
)
 
(7,698
)
 
(3,567
)
Income (loss) before provision (benefit) for income tax
(21,257
)
 
(32,260
)
 
5,150

Provision (benefit) for income tax
(5,586
)
 
(9,325
)
 
25,443

Net loss
$
(15,671
)
 
$
(22,935
)
 
$
(20,293
)
Net loss per share:
 
 
 
 
 
Basic
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Diluted
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Weighted average shares used in the calculation of net loss per share:
 
 
 
 
 
Basic
33,696

 
33,111

 
32,564

Diluted
33,696

 
33,111

 
32,564


The accompanying notes are an integral part of these Consolidated Financial Statements.

F-5

NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands, except per share amounts) 

 
Years Ended December 31,
 
2019
 
2018
 
2017
Net loss
(15,671
)
 
(22,935
)
 
(20,293
)
Other comprehensive income (loss):
 
 
 
 
 
Unrealized losses on available-for-sale investments
$
—

 
$
—

 
$
(45
)
Foreign currency translation adjustment
(1,576
)
 
(14,360
)
 
21,470

Interest rate swap designated as a cash flow hedge
(180
)
 
(77
)
 
—

Reclassification of stranded tax effects upon adoption of ASU 2018-02
(1,332
)
 
—

 
—

Reclassification of deferred foreign currency related adjustments related to the sale of Medix (See FN 23)
24,845

 
—

 
—

Total other comprehensive income (loss)
21,757

 
(14,437
)
 
21,425

Comprehensive income (loss)
$
6,086

 
$
(37,372
)
 
$
1,132

The accompanying notes are an integral part of these Consolidated Financial Statements.



F-6

NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts) 
 
Common Stock
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Loss
 
Stockholders’
Equity
 
Shares
 
Amount
 
Balances, December 31, 2016
32,920,246

 
$
312,986

 
$
149,408

 
$
(45,020
)
 
$
417,374

Vesting of restricted stock units
35,929

 
—

 
—

 
—

 
—

Net issuance of restricted stock awards
249,366

 
—

 
—

 
—

 
—

Employee stock purchase plan
48,470

 
1,581

 
—

 
—

 
1,581

Stock-based compensation expense
—

 
9,445

 
—

 
—

 
9,445

Repurchase of company stock
(60,800
)
 
(2,268
)
 
—

 
—

 
(2,268
)
Taxes paid related to net share settlement of equity awards
(193,212
)
 
(7,052
)
 
—

 
—

 
(7,052
)
Exercise of stock options
134,102

 
1,885

 
—

 
—

 
1,885

Other comprehensive income
—

 
—

 
—

 
21,425

 
21,425

Net loss
—

 
—

 
(20,293
)
 
—

 
(20,293
)
Balances, December 31, 2017
33,134,101

 
$
316,577

 
$
129,115

 
$
(23,595
)
 
$
422,097

Cumulative-effect adjustment for ASU 2016-16
—

 
—

 
(3,919
)
 
—

 
(3,919
)
Vesting of restricted stock units
266

 
—

 
—

 
—

 
—

Net issuance of restricted stock awards
272,941

 
—

 
—

 
—

 
—

Employee stock purchase plan
63,649

 
1,700

 
—

 
—

 
1,700

Stock-based compensation expense
—

 
17,003

 
—

 
—

 
17,003

Repurchase of company stock
(173,545
)
 
(5,630
)
 
—

 
—

 
(5,630
)
Taxes paid related to net share settlement of equity awards
(160,700
)
 
(5,183
)
 
—

 
—

 
(5,183
)
Exercise of stock options
667,667

 
9,748

 
—

 
—

 
9,748

Other comprehensive loss
—

 
—

 
—

 
(14,437
)
 
(14,437
)
Net loss
—

 
—

 
(22,935
)
 
—

 
(22,935
)
Balances, December 31, 2018
33,804,379

 
$
334,215

 
$
102,261

 
$
(38,032
)
 
$
398,444

Reclassification of stranded tax effects for ASU 2018-02
 
 
 
 
1,332

 
(1,332
)
 
—

Vesting of restricted stock units
42,130

 
—

 
—

 
—

 
—

Net issuance of restricted stock awards
175,833

 
—

 
—

 
—

 
—

Employee stock purchase plan
53,839

 
1,354

 
—

 
—

 
1,354

Stock-based compensation expense
—

 
8,315

 
—

 
—

 
8,315

Taxes paid related to net share settlement of equity awards
(51,784
)
 
(1,689
)
 
—

 
—

 
(1,689
)
Exercise of stock options
124,303

 
2,281

 
—

 
—

 
2,281

Other comprehensive income
—

 
—

 
—

 
23,089

 
23,089

Net loss
—

 
—

 
(15,671
)
 
—

 
(15,671
)
Balances, December 31, 2019
34,148,700

 
$
344,476

 
$
87,922

 
$
(16,275
)
 
$
416,123

The accompanying notes are an integral part of these Consolidated Financial Statements.

F-7

NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Operating activities:
 
 
 
 
 
Net loss
$
(15,671
)
 
$
(22,935
)
 
$
(20,293
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 
 
 
 
Provision for losses on accounts receivable
1,584

 
6,909

 
10,017

Depreciation and amortization
30,722

 
33,863

 
30,098

(Gain) loss on disposal of property and equipment
449

 
746

 
(21
)
Impairment of intangible assets
—

 
8,192

 
1,674

Impairment charge for sale of entity
24,571

 
—

 
—

Goodwill impairment charge
—

 
14,846

 
—

Warranty reserve
2,886

 
2,168

 
5,370

Stock-based compensation
8,352

 
17,051

 
9,445

Deferred taxes
(5,364
)
 
(13,714
)
 
4,032

Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:
 
 
 
 
 
Accounts receivable
9,817

 
(5,199
)
 
(30,473
)
Inventories
7,185

 
(7,443
)
 
7,581

Other assets
(2,486
)
 
(5,118
)
 
5,492

Accounts payable
(1,367
)
 
4,105

 
(1,385
)
Accrued liabilities
(4,010
)
 
(2,527
)
 
5,421

Deferred revenue
3,392

 
2,076

 
(7,232
)
Net cash provided by operating activities
60,060

 
33,020

 
19,726

Investing activities:
 
 
 
 
 
Acquisition of businesses, net of cash acquired
—

 
151

 
(190,888
)
Acquisition of property and equipment
(5,326
)
 
(7,875
)
 
(4,066
)
Acquisition of intangible assets
(13
)
 
(665
)
 
—

Sales of short-term investments
—

 
—

 
34,019

Net cash used in investing activities
(5,339
)
 
(8,389
)
 
(160,935
)
Financing activities:
 
 
 
 
 
Proceeds from stock option exercises and ESPP
3,635

 
11,448

 
3,466

Principal payments of financing lease liability
(478
)
 
—

 
—

Repurchase of company stock
—

 
(5,630
)
 
(2,268
)
Taxes paid related to net share settlement of equity awards
(1,689
)
 
(5,183
)
 
(7,052
)
Proceeds from long-term borrowings
—

 
—

 
60,000

Deferred debt issuance costs
—

 
—

 
(354
)
Contingent consideration earn-out
—

 
(147
)
 
(2,966
)
Payments on borrowings
(50,000
)
 
(50,000
)
 
(45,000
)
Net cash provided by (used in) financing activities
(48,532
)
 
(49,512
)
 
5,826

Exchange rate effect on cash and cash equivalents
735

 
(7,696
)
 
10,782

Net increase (decrease) in cash and cash equivalents
6,924

 
(32,577
)
 
(124,601
)
Cash and cash equivalents, beginning of year
56,373

 
88,950

 
213,551

Cash and cash equivalents, end of year
$
63,297

 
$
56,373

 
$
88,950

Supplemental disclosure of cash flow information:
 
 
 
 
 
Cash paid for interest
$
4,580

 
$
6,169

 
$
4,464

Cash paid for income taxes
$
6,445

 
$
9,247

 
$
5,740

Non-cash investing activities:
 
 
 
 
 
Property and equipment included in accounts payable
$
69

 
$
167

 
$
148

Inventory transferred to property and equipment
$
300

 
$
1,211

 
$
1,006

 The accompanying notes are an integral part of these Consolidated Financial Statements.

F-8

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended December 31, 2019, 2018 and 2017
1—ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
Organization
Natus Medical Incorporated (“we”, “our”, “us”) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. We are a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, software systems for managing and tracking disorders and diseases for public health laboratories, computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals.
Basis of Presentation and Principles of Consolidation
The accompanying Consolidated Financial Statements includes our accounts and accounts of our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.
Revenue recognition
Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services.
For the majority of devices and supplies, we transfer control and recognize revenue when products ship from the warehouse to the customer. We generally do not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue.
Depending on the terms of the arrangement, we may also defer the recognition of a portion of the consideration received because we have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price for each distinct performance obligation. Our estimate of SSP is a point estimate.  The estimate is calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs.
We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond the base agreements to customers. The separately priced service contracts range from 12 months to 60 months. We receive payment at the inception of the contract and recognize revenue ratably over the service period.
For products containing embedded software, we have determined that the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products.
Inventory Valuation
Inventories are carried at the lower of cost or net realizable value, with cost being determined using the first-in, first-out method. The carrying value of our inventory is reduced for any difference between cost and estimated net realizable value of the inventory. We determine net realizable value by evaluating ending inventories for excess quantities, obsolescence, and other factors that could impact our ability to consume inventory for its intended use. Our evaluation includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, we may sell inventory that had previously been written down.

F-9
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

Intangible assets
We amortize intangible assets with finite lives over the estimate of their useful lives. Any future changes that would limit their useful lives or any determination that these assets are carried at amounts greater than their estimated fair value could result in acceleration of amortization over a revised useful life.
We review intangible assets with finite lives for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of the finite-lived intangible assets is assessed based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the finite-lived intangible assets are considered to be impaired. The amount of the impairment loss, if any, is measured as the difference between the carrying amount of the asset and its fair value. We estimate the fair value of finite-lived intangible assets by using an income approach or, when available and appropriate, using a market approach.
Goodwill
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired.
Goodwill is tested for impairment at the reporting unit level. In 2018 and 2017 we had four reporting units for purposes of goodwill impairment testing. In early 2019 we announced the implementation of a new organizational structure which consolidated our three strategic business units, Neuro, Newborn Care and Hearing & Balance into “One Natus”. As a result of these organizational changes we have concluded we have one operating segment and one reporting unit for purposes of goodwill impairment testing in 2019.
In accordance with accounting standards we perform a qualitative assessment to test goodwill for impairment prior to the performing the first step of the goodwill impairment process. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting the reporting unit.
Prior to the adoption of ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) in 2019, which simplified the goodwill impairment test, if the fair value of a reporting unit was less than its carrying amount, we would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Based on the qualitative assessment in 2019 and 2017, we determined the fair value of goodwill was more likely than not greater than its carrying amount, and no further analysis was needed.
Due to organizational changes announced in late 2018 our evaluation of our GND reporting unit, which was part of our Neuro business unit, was determined to be impaired. Prior to calculating the goodwill impairment loss, we analyzed the recoverability of GND long-lived assets (other than goodwill). As a result, we recorded a goodwill impairment charge of $14.8 million within restructuring expense on our income statement. There was no remaining goodwill in the GND reporting unit as of December 31, 2018.
In 2019 we elected to early adopt ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The adoption of this standard eliminates the second step of the two-step impairment test described above and allows a Company to expense the difference between carrying amount in excess of the fair value of the reporting unit as a reduction in goodwill. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements as we concluded based on the qualitative assessment performed in 2019 that the fair value of the reporting unit was more likely than not to be greater than its carrying amount, and no further analysis was needed.
Leases
We determine if an arrangement is a lease at inception of the lease. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the

F-10
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit borrowing rate, generally we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the lease commencement date. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term.
Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet.
We have lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, we account for these components separately. For equipment leases, such as office equipment and vehicles, we account for the lease and non-lease components as a single lease component.
Long lived assets
We continually monitor events and changes in circumstances that could indicate that carrying amounts of our long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, we will assess the recoverability by determining whether the carrying value of an asset group will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of the asset group, we will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Liability for product warranties
We provide a warranty for products that is generally one year in length. In some cases, regulations may require us to provide repair or remediation beyond the typical warranty period. If any products contain defects, we may be required to incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis.
We accrue estimated product warranty costs at the time of sale based on historical experience. A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Share-based compensation
We recognize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 16 of the Consolidated Financial Statements.
For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.
We recognize share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 25% on each of the annual anniversaries. RSAs and RSUs for non-employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
We grant market stock unit (“MSU”) awards to certain employees. We estimate the fair value of MSUs at the date of grant using a Monte Carlo simulation model and amortize those fair values over the requisite service period, which is generally three years. The Monte Carlo simulation model that we use to estimate the fair value of market-based MSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the market-based MSUs, which is determined at the date of grant, must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.
We issue new shares of common stock upon the exercise of stock options and the vesting of RSAs, RSUs, and MSUs.

F-11
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.
Cash Equivalents
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents.
Allowance for Doubtful Accounts
We estimate the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which we operate and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.
Assets and Liabilities Held for Sale
We consider assets and liabilities to be held for sale when all of the following criteria are met:
•Management approves and commits to a formal plan to sell the asset or disposal group;
•The assets or disposal group is available for immediate sale in its present condition;
•An active program to locate a buyer and other actions required to complete the sale have been initiated;
•The sale of the asset or disposal group is expected to be completed within one year;
•The asset or disposal group is being actively marketed for sale at the price that is reasonable in relation to the current fair value; and
•It is unlikely that significant changes will be made to the plan.
Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, we record the asset or disposal group at the lower of its carrying value or its estimated fair value, less estimated costs of sale. We consider deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on our income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. We assess the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and report any reduction in fair value as an adjustment to the carrying value of the assets held for sale.
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate their fair values due to the short-term maturities.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to five years for office furniture and equipment, computer software and hardware, demonstration and loaned equipment, and 30 to 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over three years.
Research & Development Costs
Costs incurred in research and development are charged to operations as incurred.
Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements carrying value of assets and liabilities and the tax basis of those assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

F-12
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

We record net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, we adjust the valuation allowance which reduces the provision for income taxes.
We recognize the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05. 
Foreign Currency
The functional currency of our subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. We have recorded $(1.6) million, $(14.4) million, and $21.5 million of foreign currency translation gains (losses) for the years ended December 31, 2019, 2018 and 2017, respectively.
Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2019, 2018, and 2017, net foreign currency transaction gains (losses) were $(0.8) million, $(0.8) million, and $1.0 million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. dollar, Canadian dollar, Euro, British pound, and Danish kroner.
Effective July 1, 2018, Argentina's economy is considered to be highly inflationary under U.S. GAAP since it has experienced a rate of general inflation in excess of 100% over the latest three-year period, based upon the cumulative inflation rates published by Center for Audit Quality (CAQ) SEC Regulations Committee and its International Practices Task Force (IPTF). As a result, beginning July 1, 2018, the U.S. dollar is the functional currency for our subsidiary in Argentina, Medix I.C.S.A. (“Medix”). Accordingly, all gains and losses resulting from the translation of our Argentinian operations are required to be recorded directly in the statement of operations. Through June 30, 2018, prior to being designated as highly inflationary, currency translation adjustments of Medix's balance sheet are reflected in shareholders' equity as part of Accumulated Other Comprehensive Income; however subsequent to July 1, 2018, such adjustments are reflected in earnings. Currency adjustments recorded in earnings for Medix subsequent to July 1, 2018 represented a gain of $0.9 million.
We divested our wholly owned subsidiary, Medix, on April 2, 2019 via a stock sale. Included in the year ended December 31, 2019 is the impact of the sale of Medix, which was completed as of June 30, 2019, and the deferred foreign currency related translation adjustments previously in accumulated other comprehensive income have been released from the balance sheet along with the held for sale accrual (See Note 23 - Sale of a Certain Subsidiary).
Comprehensive Income
We report by major components and as a single total the change in net assets during the period as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income (loss) has been separately stated from the consolidated statements of operations. Accumulated other comprehensive loss consists of translation gains and losses on foreign subsidiary financial statements, interest rate swap designated as a cash flow hedge, reclassifications from the adoption of ASU 2018-02, and reclassification of previously recorded deferred foreign currency related translation adjustment losses upon the divestiture of Medix.
Basic and Diluted Net Income per Share
We compute net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted, shares of restricted stock, and shares of market stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires lease assets and lease liabilities arising from operating leases to be presented in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees and lessors to meet the objective of enabling users of financial statements to

F-13
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. In July 2018, FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance issued in the amendments in Update 2016-02. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements. The amendments in ASU 2018-11 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02.
The new standard provides a number of optional practical expedients in transition. We have elected the package of practical expedients, which permits an entity to not reassess prior conclusions about lease identification, lease classification and initial direct costs under the new standard. We have not elected the use-of-hindsight practical expedient or the practical expedient pertaining to land easements; the latter of which is not applicable to us. We made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term.
The new standard became effective for us on January 1, 2019. We adopted the new standard using the modified retrospective transition method with the effective date as the date of initial application. Upon adoption, we recognized additional new lease assets of approximately $19.5 million and additional lease liabilities of approximately $22.3 million as of January 1, 2019. The standard did not materially affect consolidated net earnings. By electing the effective date as the date of initial application, financial performance has not been adjusted and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019. See Significant Accounting Policies and Note 8 for additional discussion and disclosure.
The adoption of the new standard did not impact our liquidity or debt-covenant compliance under its current agreements.
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for our annual and any interim goodwill impairment tests performed on or after January 1, 2020. We elected to early adopt. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements.
In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220). This update permits a company to reclassify its disproportionate income tax effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) on items within accumulated other comprehensive income (“AOCI”) to retained earnings (termed “stranded tax effects”). Only the stranded tax effects resulting from the 2017 Act are eligible for reclassification. The ASU was effective for us on January 1, 2019. Upon adoption, we reclassified its stranded tax effects resulting from the 2017 Act of $1.3 million, resulting in a decrease to AOCI and an increase to retained earnings as of January 1, 2019.
2—BUSINESS COMBINATIONS
The assets acquired and liabilities assumed at the date of acquisition are recorded in the Consolidated Financial Statements at the respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets is recorded as goodwill. 
The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. We determine the fair value by applying established valuation techniques, based on information that management believes to be relevant to this determination. We also utilize independent third parties to assist in the valuation of goodwill and intangible assets.
The results of operations from acquisitions are included in the Consolidated Financial Statements from the date of the acquisition.
Integra
On October 6, 2017, we acquired certain neurosurgery business assets from Integra LifeSciences (“Integra” or “Neurosurgery”) for $46.2 million in cash. As part of the acquisition, we acquired a global product line, including the manufacturing facility it leases from a third party and the U.S. rights related to four other product lines. The total purchase price has been allocated to $13.7 million of tangible assets, $25.7 million of intangible assets with an associated weighted average life of 9 years being

F-14
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

amortized on the straight line method, and $8.1 million of goodwill, offset by $1.3 million of net liabilities. Besides pro forma revenue, pro forma financial information for the Integra acquisition is not presented as certain Integra expense data necessary to present pro forma net income and pro forma earnings per share is not available. Pro forma revenue assuming the acquisition occurred on January 1, 2017 would be $539.1 million for the year ended December 31, 2017.
Otometrics
On January 3, 2017, we acquired the Otometrics business from GN Store Nord A/S for a cash purchase price of $149.2 million, which includes a $4.2 million net working capital adjustment. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software. Otometrics provides computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms to hearing and balance care professionals worldwide. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets.
Management worked with an independent valuation firm to determine fair values of the identifiable intangible assets. We used a combination of income approaches including relief from royalty and multi-period excess earnings methods. The valuation models were based on estimates of future operating projections of the acquired business and rights to sell products as well as judgments on the discount rates used and other variables. We determined the forecasts based on a number of factors, including our best estimate of near-term net sales expectations and long-term projections, which included a review of internal and independent market analyses.

3—REVENUE
Contract assets for the periods presented primarily represent the difference between revenue recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented was primarily related to extended service contracts, installation, and training, for which the service fees are billed up-front. The associated deferred revenue is generally recognized ratably over the extended service period or when installation and training are complete.

The following table summarized the changes in the contract assets and contract liability balances for the year ended December 31, 2019 (in thousands):
Unbilled AR, December 31, 2018
$
3,012

Additions
354

Transferred to Trade Receivable
(699
)
Unbilled AR, December 31, 2019
$
2,667

Deferred Revenue, December 31, 2018
$
21,410

Additions
19,465

Revenue Recognized
(16,067
)
Deferred Revenue, December 31, 2019
$
24,808


At December 31, 2019, the contract assets of $2.7 million were included in accounts receivable in the consolidated balance sheet. At December 31, 2019, the short-term portion of the contract liability of $20.2 million and the long-term portion of $4.6 million were included in deferred revenue and other long-term liabilities respectively, in the consolidated balance sheet. As of December 31, 2019, we expect to recognize revenue associated with deferred revenue of approximately $20.2 million in 2020, $2.2 million in 2021, $1.2 million in 2022, $0.7 million in 2023, and $0.5 million thereafter.

4—INVENTORIES
Inventories consist of (in thousands): 

F-15
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

 
December 31,
 
2019
 
2018
Raw materials and subassemblies
$
37,259

 
$
31,459

Work in process
1,780

 
2,424

Finished goods
50,521

 
63,932

Total Inventories
89,560

 
97,815

Less: Non-current Inventories
(18,192
)
 
(18,079
)
Inventories
$
71,368

 
$
79,736


Non-current inventory consists of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products that we no longer sell, inventory purchased for lifetime buys, inventory built as a last-time build, and inventory that is turning at a slow rate. We believe that these inventories will be utilized for their intended purpose.

5—PROPERTY AND EQUIPMENT
Property and equipment consist of (in thousands): 
 
December 31,
 
2019
 
2018
Land
$
1,719

 
$
1,828

Buildings
6,943

 
7,036

Leasehold improvements
8,664

 
4,649

Finance lease right-of-use assets
2,377

 
—

Office furniture and equipment
22,819

 
23,487

Computer software and hardware
12,610

 
12,803

Demonstration and loaned equipment
11,621

 
12,843

 
66,753

 
62,646

Accumulated depreciation
(42,051
)
 
(39,733
)
Total
$
24,702

 
$
22,913


Depreciation expense of property and equipment was $6.6 million, $6.0 million, and $4.1 million in the years ending December 31, 2019, 2018 and 2017, respectively.

6—INTANGIBLE ASSETS
The following table summarizes the components of gross and net intangible asset balances (in thousands): 
 
December 31, 2019
 
December 31, 2018
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Technology
$
108,400

 
(6,035
)
 
$
(55,408
)
 
$
46,957

 
$
111,198

 
(6,768
)
 
$
(50,046
)
 
$
54,384

Customer related
90,351

 
(50
)
 
(40,527
)
 
49,774

 
99,440

 
(1,961
)
 
(38,574
)
 
58,905

Trade names
45,874

 
(3,237
)
 
(25,355
)
 
17,282

 
47,217

 
(4,397
)
 
(19,250
)
 
23,570

Internally developed software
13,281

 
—

 
(12,606
)
 
675

 
16,264

 
—

 
(14,164
)
 
2,100

Patents
2,692

 
(133
)
 
(2,559
)
 
—

 
2,718

 
(133
)
 
(2,524
)
 
61

Service Agreements
1,190

 
—

 
(1,079
)
 
111

 
1,190

 
—

 
(757
)
 
433

Total Definite-lived intangible assets
261,788

 
(9,455
)
 
(137,534
)
 
114,799

 
278,027

 
(13,259
)
 
(125,315
)
 
139,453



F-16
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

Finite lived intangible assets are amortized over their weighted average lives, which are 14 years for technology, 13 years for patents, 10 years for customer-related intangibles, 7 years for trade names, 6 years for internally developed software, 2 years for service agreements, and 11 years weighted average in total.
Internally developed software consists of $11.1 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold.
During the fourth quarter of 2018 we recorded an impairment charge related to intangible assets of $8.2 million. These impairments relate to end of life decisions for the core technology utilized in our Bio-logic products and our GND and Neurocom product lines. We acquired Bio-logic core technology as part of the acquisition of Bio-logic Systems Corp in 2006 and have maintained the technology since its acquisition. In 2018 we partnered with one of our contract manufacturers to develop and manufacture the next generation technology to be used in its Bio-logic products. The decision to develop this new technology resulted in an impairment of the originally acquired core technology of $5.6 million, which was recorded within intangibles amortization expense on our income statement.
On January 15, 2019, we announced the implementation of a new organizational structure, "One Natus." As a result of this new organizational structure, we announced we exited two of our non-core businesses, GND and Neurocom. The decision to exit these non-core businesses resulted in the impairment of intangible assets of $2.6 million as of December 31, 2018. These impairments were the result of deterioration of expected future cash flows as compared to the carrying value of the assets. Impairments were determined by performing an undiscounted cash flow analysis on intangibles assets. The impairment charge for GND and Neurocom is recorded on our income statement within restructuring expense.
Amortization expense related to intangible assets with finite lives, including impairment charges described above, was as follows (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Technology
$
6,906

 
$
14,100

 
$
7,705

Customer related
8,662

 
12,244

 
10,945

Trade names
6,111

 
6,736

 
6,479

Internally developed software
1,438

 
2,123

 
2,117

Patents
60

 
84

 
244

Service Agreements
322

 
757

 
—

Total amortization
$
23,499

 
$
36,044

 
$
27,490


The amortization expense amounts shown above include internally developed software not held for sale of $1.3 million, $1.9 million, and $1.9 million for the years ended 2019, 2018, and 2017, respectively. The amortization expense for internally developed software not held for sale is recorded within our income statement as a general and administrative operating expense.
Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): 
2020
$
21,616

2021
20,724

2022
17,329

2023
16,375

2024
14,483

Thereafter
24,272

Total expected amortization expense
$
114,799


        
7—GOODWILL
The carrying amount of goodwill and the changes in those balances are as follows (in thousands): 

F-17
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

As of December 31, 2017
$
172,998

Purchase Accounting Adjustments
(7,324
)
Impairment charge
(14,846
)
Foreign currency translation
(3,184
)
As of December 31, 2018
$
147,644

Foreign currency translation
(1,277
)
As of December 31, 2019
$
146,367



8—LEASES
We have operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to eight years, some of which include options to extend the leases for up to ten years. Our leases do not have any residual value guarantees or any restrictions or covenants imposed by leases.

Components of lease cost were as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Operating lease cost
$
6,823

Finance lease cost:
 
Amortization of right-of-use assets (principal payments)
466

Interest on lease liabilities
58

Short-term lease cost
51

Variable lease cost
2,836

Sublease income
(179
)
Total lease cost
$
10,055

Supplemental cash flow information related to leases was as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
13,612

Operating cash flows from finance leases
42

Financing cash flows from finance leases
478

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
2,697

Finance leases
300



Supplemental balance sheet information related to leases was as follows (in thousands):

F-18

 
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
15,046

 
 
Current portion of operating lease liabilities
$
5,871

Operating lease liabilities
12,051

Total operating lease liabilities
$
17,922

 
 
Finance Leases
 
Property and equipment, gross
$
2,377

Accumulated amortization
(1,418
)
Property and equipment, net
$
959

 
 
Accrued liabilities
$
390

Other liabilities
599

Total finance lease liabilities
$
989

 
 
Weighted Average Remaining Lease Term
 
Operating leases
3.75 years

Finance leases
2.92 years

Weighted Average Discount Rate
 
Operating leases
5.3
%
Finance leases
5.1
%


As of December 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
Year ending December 31,
Operating Leases
 
Finance Leases
2020
$
6,788

 
$
401

2021
5,302

 
346

2022
3,657

 
176

2023
2,498

 
97

2024
1,277

 
5

Thereafter
842

 
—

Total lease payments
20,364

 
1,025

Less imputed interest
(2,442
)
 
(36
)
Total
$
17,922

 
$
989





9—ACCRUED LIABILITIES
Accrued liabilities consist of (in thousands): 

F-19
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

 
December 31,
 
2019
 
2018
Compensation and related benefits
$
26,991

 
$
24,891

Warranty reserve
6,404

 
9,391

Accrued federal, state, and local taxes

11,156

 
8,285

Accrued amounts due to customers
3,008

 
5,507

Accrued professional fees
2,083

 
1,820

Accrued selling expenses
507

 
246

Self-funded insurance expense
950

 
—

Accrued travel
224

 
201

Deferred rent
—

 
205

Other
3,128

 
2,022

Total
$
54,451

 
$
52,568



10—LONG-TERM OTHER LIABILITIES
Long-term other liabilities consist of (in thousands): 
 
December 31,
 
2019
 
2018
Long-term taxes payable
$
12,330

 
$
15,425

Non-current deferred revenue
4,563

 
4,338

Finance lease liabilities
599

 
—

Other
124

 
82

Total
$
17,616

 
$
19,845



11—DEBT AND CREDIT ARRANGEMENTS
We have a Credit Agreement with JP Morgan, Citibank and Wells Fargo. The Credit Agreement provides for an aggregate $150 million of secured revolving credit facility. In the third quarter of 2017, we exercised the right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of our assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have no other significant credit facilities.
In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require us to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:
•Leverage Ratio, as defined, to be no higher than 2.75 to 1.00.
•Interest Coverage Ratio, as defined, to be at least 1.75 to 1.00 at all times.
As of December 31, 2019, we were in compliance with the Leverage Ratio and the Interest Coverage Ratio covenants as defined in the Credit Agreement.
As of December 31, 2019, we have $55 million outstanding under the Credit Agreement.
Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on the leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between 1.75% to 2.75%. The effective interest rate during the twelve months ended December 31, 2019 was 4.54%.

F-20
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable.

Long-term debt consists of (in thousands):
 
December 31,
 
2019
 
2018
Revolving credit facility
$
55,000

 
$
105,000

Debt issuance costs
(335
)
 
(526
)
Less: current portion of long-term debt
35,000

 
35,000

Total long-term debt
$
19,665

 
$
69,474


Maturities of long-term debt as of December 31, 2019 are as follows (in thousands):
 
December 31,
 
2019
 
2018
2019
$
—

 
$
—

2020
—

 
—

2021
55,000

 
105,000

Thereafter
—

 
—

Total
$
55,000

 
$
105,000


As of December 31, 2019, the carrying value of the total debt approximated fair market value.
12—FINANCIAL INSTRUMENTS AND DERIVATIVES
We use interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of our expected LIBOR-indexed floating-rate borrowings. We held the following interest rate swaps as of December 31, 2019 (in thousands):


Hedged Item
Current Notional Amount
Designation Date
Effective Date
Termination Date
Fixed Interest Rate
Floating Rate
Estimated Fair Value
1-month USD LIBOR loan
$
40,000

May 31, 2018
June 1, 2018
September 23, 2021
2.611%
1-month USD LIBOR
$
313

Total interest rate derivatives designated as cash flow hedge
$
40,000

 
 
 
 
 
$
313



We designated these derivative instruments as cash flow hedges. We assess the effectiveness of these derivative instruments and record the changes in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income, net of tax. Once the hedged item affects earnings, the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, we will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.

As of December 31, 2019, we expect that approximately $143 thousand of losses associated with the cash flow hedge, net of tax, could be reclassified from AOCI into earnings within the next twelve months.

13—RESERVE FOR PRODUCT WARRANTIES
We provide a warranty for products that is generally one year in length and in some cases, regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, we may be required to

F-21
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management's best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
As of December 31, 2019, we have accrued $6.4 million for product related warranties. The estimates we use in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations.

14—STOCKHOLDERS’ EQUITY
Common Stock—We have 120,000,000 shares of common stock authorized at a par value or $0.001 per share. 
Preferred Stock—We have 10,000,000 shares of preferred stock authorized at a par value of $0.001 per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of December 31, 2019, no shares of preferred stock were issued and outstanding.

15—EARNINGS PER SHARE
The components of basic and diluted EPS are as follows (in thousands, except per share amounts): 
 
December 31,
 
2019
 
2018
 
2017
Net loss
$
(15,671
)
 
$
(22,935
)
 
$
(20,293
)
Weighted average common shares
33,696

 
33,111

 
32,564

Dilutive effect of stock based awards
—

 
—

 
—

Diluted Shares
33,696

 
33,111

 
32,564

Basic loss per share
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Diluted loss per share
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Shares excluded from calculation of diluted EPS
104

 
343

 
565



16—SHARE-BASED COMPENSATION
Share-Based Compensation Expense—We account for share-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation. Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Cost of revenue
$
264

 
$
218

 
$
232

Marketing and selling
800

 
801

 
540

Research and development
1,024

 
1,039

 
1,332

General and administrative
6,227

 
14,945

 
7,341

Total expense
$
8,315

 
$
17,003

 
$
9,445


Stock Awards Plans—Natus' 2018 Stock Awards Plan (the “Plan”) provides for the granting of the following:
•
Incentive stock options to employees;

F-22
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

•
Non-statutory stock options to employees, directors and consultants;
•
Restricted stock awards and restricted stock units;
•
Market stock units;
•
Stock bonuses; and
•
Stock appreciation rights.
As of December 31, 2019, there were 2,764,603 shares available for future awards under the plan.
Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than six years after the date of grant. Most options vest ratably over four years.
Stock Option Activity—Stock option activity under the stock awards plans for the year ended December 31, 2019 is summarized as follows:  
 
Number of
Shares
 
Weighted
Average
Exercise Price
Outstanding, December 31, 2018 (127,453 shares exercisable at a weighted average exercise price of $18.22 per share)
201,542

 
$
24.48

Granted
—

 
$
—

Exercised
(124,303
)
 
$
18.35

Forfeited
—

 
$
—

Expired
(3,150
)
 
$
13.35

Outstanding, December 31, 2019 (18,531 shares exercisable at a weighted average exercise price of $35.25 per share)
74,089

 
$
35.25


As of December 31, 2019, unrecognized compensation related to the unvested portion of stock options was approximately $0.5 million, which is expected to be recognized over a weighted average period of 2.7 years. The intrinsic value of options exercised, representing the difference between the closing stock price of common stock on the date of the exercise and the exercise price, in the years ended December 31, 2019, 2018 and 2017 was $1.4 million, $13.6 million, and $3.1 million, respectively.
As of December 31, 2019, there were: (i) 70,990 options vested and expected to vest with a weighted average exercise price of $35.25, an intrinsic value of $0.0 million, and a weighted average remaining contractual term of 4.5 years; and (ii) 18,531 options exercisable with a weighted average exercise price of $35.25, an intrinsic value of $0.0 million, and a weighted average remaining contractual term of 4.5 years.
Black-Scholes Inputs—The fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:
 
December 31,
 
2018
Weighted-average fair value of options granted
$
11.03

Expected life in years
4.0

Risk-free interest rate
2.7
%
Expected volatility
35
%
Dividend yield
None

We did not grant any stock options during the years ended December 31, 2019 and December 31, 2017.
The expected life of options is based primarily on historical share option exercise experience of the employees for options granted. All options are treated as a single group in the determination of expected life, as we do not currently expect substantially different exercise or post-vesting termination behavior among the employee population. The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based primarily on historical volatility data of our common stock. We have no history or expectation of paying dividends on common stock.

F-23
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, we estimate the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated we will record additional expense and if the actual forfeiture is higher than estimated we will record a recovery of prior expense.
Restricted Stock Awards Activity—The following table summarizes the activity for restricted stock awards during the year ended December 31, 2019:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Unvested at December 31, 2018
293,588

 
$
37.04

Granted
197,333

 
$
31.53

Vested
(129,659
)
 
$
36.46

Forfeited
(21,500
)
 
$
35.76

Unvested at December 31, 2019
339,762

 
$
34.14


As of December 31, 2019, unrecognized compensation related to the unvested portion of stock awards was $6.4 million, which is expected to be recognized over a weighted average period of 2.3 years. The fair market value of outstanding restricted stock awards at December 31, 2019 was $11.2 million. For the restricted stock awards granted during the years ended December 31, 2019, 2018, 2017, the weighted average grant date fair values were $31.53, $37.22, and $34.94, respectively. The total grant date fair value of restricted stock awards vested during fiscal year 2019, 2018, and 2017 was $4.7 million, $12.9 million, and $12.7 million, respectively. For the restricted stock awards that vested during the years ended December 31, 2019, 2018, and 2017, the total intrinsic value was $4.0 million, $11.2 million, and $14.3 million, respectively.
Restricted Stock Units Activity—The following table summarizes restricted stock units activity for the year ended December 31, 2019:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Outstanding at December 31, 2018
112,805

 
$
36.80

Awarded
118,740

 
$
38.62

Released
(42,130
)
 
$
34.11

Forfeited
(16,319
)
 
$
37.60

Outstanding at December 31, 2019
173,096

 
$
38.62

*Includes the MSUs granted at the valuation date, which may be subject to additional awards or forfeitures depending on the outcome of the performance measures at the end of the performance period.
As of December 31, 2019, unrecognized compensation related to the unvested portion of stock units was $3.7 million, which is expected to be recognized over a weighted average period of 2.0 years. The aggregate intrinsic value of outstanding restricted stock units at December 31, 2019 was $5.7 million. For the restricted stock units granted during the years December 31, 2019, 2018, 2017, the weighted average grant date fair values were $38.62, $36.77, and $35.16, respectively. The total grant date fair value of restricted stock units vested during fiscal year 2019, 2018, and 2017 was $1.4 million, $10.0 thousand, and $1.2 million, respectively. For the restricted stock units that vested during the years ended December 31, 2019, 2018, and 2017, the total intrinsic value was $1.3 million, $8.7 thousand, and $1.3 million, respectively.
Employee Stock Purchase Plan—Under Natus' 2011 Employee Stock Purchase Plan (the “ESPP”), U.S. employees can elect to have salary withholdings of up to 15% of eligible compensation to a maximum of $10,625 per offering period, to purchase shares of common stock on April 30 and October 31 of each year. The purchase price for shares acquired under the ESPP is 85% of the fair market value on the last day of the offering period. As of December 31, 2019, there were 499,431 shares reserved for future issuance under the ESPP.

F-24
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

Because the ESPP does not have a “look back” feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of common stock on the last day of the offering period and the purchase price for the offering period, which is 85% of the fair market value. Compensation expense associated with the ESPP for the years ended December 31, 2019, 2018 and 2017, respectively, was $0.2 million, $0.3 million, and $0.3 million. 

17—OTHER INCOME (EXPENSE), NET
Other income (expense), net consists of (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Interest income
$
250

 
$
334

 
$
425

Interest expense
(4,941
)
 
(6,794
)
 
(5,081
)
Foreign currency gain (loss)
(765
)
 
(800
)
 
1,013

Other
(135
)
 
(438
)
 
76

Total other expense, net
$
(5,591
)
 
$
(7,698
)
 
$
(3,567
)


18—INCOME TAXES
Income (loss) before provision for income tax is as follows (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
U.S.
$
(22,851
)
 
$
(54,370
)
 
$
(18,059
)
Foreign
1,594

 
22,110

 
23,209

Income (loss) before provision for income tax
$
(21,257
)
 
$
(32,260
)
 
$
5,150



The components of income tax expense (benefit) for the years ended December 31, 2019, 2018 and 2017 (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Current
 
 
 
 
 
U.S. Federal
$
(948
)
 
$
(1,872
)
 
$
10,110

U.S. State and local
561

 
(59
)
 
1,079

Non-U.S.
8,386

 
5,732

 
12,764

Total current tax expense
7,999

 
3,801

 
23,953

Deferred
 
 
 
 
 
U.S. Federal
(7,491
)
 
(8,248
)
 
6,345

U.S. State and local
(816
)
 
(1,751
)
 
(1,333
)
Non-U.S.
(5,278
)
 
(3,127
)
 
(3,522
)
Total deferred tax expense (benefit)
(13,585
)
 
(13,126
)
 
1,490

Total income tax expense (benefit)
$
(5,586
)
 
$
(9,325
)
 
$
25,443


Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands): 

F-25
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

 
December 31,
 
2019
 
2018
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
3,035

 
$
3,192

Credit carryforwards
2,415

 
2,882

Accruals deductible in different periods
23,672

 
15,197

Employee benefits
1,554

 
1,262

Operating leases
4,643

 
—

Total deferred tax assets
35,319

 
22,533

Valuation allowance
(606
)
 
(637
)
Total net deferred tax assets
$
34,713

 
$
21,896

Deferred tax liabilities:
 
Basis difference in fixed and intangible assets
(13,850
)
 
(15,687
)
Operating leases
(3,959
)
 
—

Foreign earnings to be repatriated
(800
)
 
(500
)
Total deferred tax liabilities
(18,609
)
 
(16,187
)
Total net deferred tax assets
$
16,104

 
$
5,709


The income tax expense (benefit) in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of 21%, 21%, and 35% in 2019, 2018, and 2017, respectively to income before taxes due to the following: 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Federal statutory tax expense
$
(4,464
)
 
$
(6,775
)
 
$
1,802

State tax expense
(300
)
 
(1,160
)
 
(318
)
Foreign taxes at rates less than U.S. rates
(2,205
)
 
(1,071
)
 
(3,101
)
Deferred charges on sales of U.S. intellectual property
—

 
—

 
980

Equity compensation
824

 
519

 
606

Tax credits
(1,428
)
 
(2,021
)
 
(1,498
)
Uncertain tax position
2,910

 
1,311

 
2,048

Lapse of statute
(3,961
)
 
(1,214
)
 
(1,521
)
Change of valuation allowance on foreign tax credit
—

 
—

 
314

Earnout adjustment
—

 
—

 
(190
)
Repatriation tax net of foreign tax credits
172

 
—

 
16,564

Net deferred tax asset re-measurement

—

 
—

 
3,883

Tax audits
—

 
658

 
726

Withholding taxes
1,107

 
1,185

 
2,880

Global intangible low-taxed income net of foreign tax credits
1,601

 
2,326

 
—

Return to provision
560

 
(1,417
)
 
711

AMT on acquisition
—

 
—

 
621

SAB 118 adjustments
—

 
(2,676
)
 
—

Other
(402
)
 
1,010

 
936

Total expense (benefit)
$
(5,586
)
 
$
(9,325
)
 
$
25,443


At December 31, 2019, we had U.S. state net operating loss carryforwards of $23.7 million, of which an immaterial amount will begin to expire in 2020. At December 31, 2019, we had U.S. federal and state R&D credit carryforwards of $1.2 million and $0.6 million, respectively. These R&D credit carryforwards will begin to expire in 2039 and 2021, respectively. At December 31, 2019, we had $0.1 million of U.S. foreign tax credit carryforwards that can be used to offset future U.S. tax liabilities related to foreign source taxable income. The foreign tax credits will start to expire in 2022.

F-26
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

At December 31, 2019, certain foreign subsidiaries had deferred tax assets attributable to net operating loss carryforwards as follows: $1.0 million in France, $0.4 million in Denmark, $0.4 million in Canada, and $0.1 million in Germany. These foreign net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028.
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of $0.6 million and $0.6 million were recorded at December 31, 2019 and 2018, respectively. The decrease of $31.0 thousand in valuation allowance was primarily due to a valuation allowance recorded against our net operating loss carryforward in Canada due to utilization in the current year.
The realizability of the deferred tax assets is primarily dependent on our ability to generate sufficient taxable income in future periods. Management weighs the aggregate effect of all positive evidence and negative evidence in determining the likelihood of realization of the deferred tax assets. The factors used by management to collect evidence included historical earnings of the applicable taxing jurisdiction, the cash refund opportunity to utilize the tax losses, and the future forecast of profitability in the jurisdiction. Weighing all the positive and negative evidence, we have recorded a valuation allowance related primarily to net operating losses in certain foreign jurisdictions and U.S. foreign tax credits where it is more likely than not that the tax benefit of the net operating losses and tax credits will not be realized.
There are no changes to the position on our permanent reinvestment of earnings from foreign operations. As of December 31, 2019, we intend to distribute all of the earnings from Excel-Tech and Natus Ireland in excess of their operational needs. We have recorded a deferred tax liability of $0.8 million accordingly for 5% Canadian withholding tax on the expected Excel-Tech distribution to Natus Ireland. Natus Ireland has 0% withholding tax under domestic exemption and therefore, no liability has been recorded. We intend on permanently reinvesting the earnings of remaining foreign subsidiaries. The other remaining foreign subsidiaries have both the intent and ability to indefinitely reinvest its undistributed earnings.
Uncertain Tax Positions
A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands): 
Balance at January 1, 2017
$
5,898

Increases for tax positions related to prior years
747

Increases for tax positions related to the current year
1,712

Lapse of statutes of limitations
(1,393
)
Foreign exchange difference
53

Balance at January 1, 2018
$
7,017

Increases for tax positions related to prior years
526

Increases for tax positions related to the current year
699

Lapse of statutes of limitations
(965
)
Foreign exchange difference
(50
)
Balance at January 1, 2019
$
7,227

Decreases for tax positions related to prior years
(48
)
Increases for tax positions related to the current year
495

Lapse of statutes of limitations
(3,763
)
Foreign exchange difference
6

Balance at December 31, 2019
$
3,917


For the year ended December 31, 2019, unrecognized tax benefits decreased by $3.3 million and $3.5 million of income tax benefit in the income tax provision were recorded. The decrease was primarily attributable to the lapse of the statute of limitations in uncertain tax positions and adjustments related to the prior years in certain jurisdictions.
The unrecognized tax benefits for the tax years ended December 31, 2019, 2018 and 2017 were $3.9 million, $7.2 million and $7.0 million, respectively which include $3.6 million, $6.5 million and $4.0 million, respectively that would impact the effective tax rate if recognized.
We expect a range from zero to $2.4 million of unrecognized tax benefit that will impact the effective tax rate in the next 12 months due to the lapse of statute of limitations provided that no taxing authority conducts a new examination.

F-27
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

At December 31, 2019, 2018 and 2017, we had cumulatively accrued $0.4 million, $0.5 million, and $0.6 million for estimated interest and penalties related to uncertain tax positions. We record interest and penalties related to unrecognized tax positions as a component of income tax expense (benefit), which totaled approximately $(80.0) thousand, $(80.0) thousand, and $(10.0) thousand for the years ended December 31, 2019, 2018, and 2017, respectively.
We are currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next 12 months.
Our tax returns remain open to examination as follows: U.S. federal, 2015 through 2018; U.S. states, generally 2014 through 2018; and significant foreign jurisdictions, generally 2014 through 2018.

19—EMPLOYEE BENEFIT PLAN
We offer pre-tax and after-tax 401(k) savings plan options under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were $3.6 million, $4.7 million, and $2.5 million respectively, in the years ended December 31, 2019, 2018, and 2017. For new hires, employer contributions vest ratably over the first two years of employment.

20—SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION
We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, our operating segments were based on its three strategic business units. In January 2019 we announced the transition of our operating structure from three strategic business units to a single, unified company with globally led operational teams in Sales and Marketing, Manufacturing, Research and Development, Quality, and General and Administrative functions.
Following the reorganization, we operate as one operating segment and one reportable segment, which provides medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Financial information is reviewed on a consolidated basis for purposes of making operating decisions and assessing financial performance. Consolidated financial information is accompanied by disaggregated information about revenues by end market and geographic region. We do not assess the performance of our end markets or geographic regions on measures of profit or loss, or asset-based metrics. We have disclosed the revenues for each end market and geographic region to provide the reader of the financial statements transparency into our operations.
The following tables present revenue and long-lived asset information by end market and geographic region. Revenue is based on the destination of the shipments and long-lived assets are based on the physical location of the assets (in thousands):

F-28
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Consolidated Revenue:
 
United States
$
292,400

 
$
300,860

 
$
270,860

Foreign countries
202,775

 
230,031

 
230,110

 
$
495,175

 
$
530,891

 
$
500,970

Revenue by End Market:
 
Neuro
 
Devices and Systems
$
220,306

 
$
200,762

 
$
171,315

Supplies
66,059

 
67,025

 
59,955

Services
871

 
12,000

 
11,886

Total Neuro Revenue
$
287,236

 
$
279,787

 
$
243,156

Newborn Care
 
Devices and Systems
$
53,465

 
$
72,807

 
$
89,027

Supplies
38,264

 
40,669

 
43,928

Services
19,183

 
20,396

 
22,325

Total Newborn Care Revenue
$
110,912

 
$
133,872

 
$
155,280

Hearing & Balance
 
Devices and Systems
$
92,050

 
$
110,597

 
$
75,466

Supplies
4,977

 
6,635

 
27,068

Services
—

 
—

 
—

Total Hearing & Balance Revenue
$
97,027

 
$
117,232

 
$
102,534

Total Revenue
$
495,175

 
$
530,891

 
$
500,970

Long-lived asset information by geographic region is as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
Property and equipment, net:
 
 
 
United States
$
11,868

 
$
10,019

Ireland
5,732

 
5,083

Canada
4,140

 
4,504

Denmark
1,799

 
1,371

Argentina
—

 
999

Other foreign countries
1,163

 
937

 
$
24,702

 
$
22,913

During the years ended December 31, 2019, 2018 and 2017, no single customer or foreign country contributed to more than 10% of revenue.

21—COMMITMENTS AND CONTINGENCIES
Purchase commitments—We have various purchase obligations for goods or services totaling $45.0 million at December 31, 2019, which are expected to be paid within the next year.
Legal matters—We currently are, and may from time to time become, a party to various legal proceedings or claims that arise in the ordinary course of business. Our managements reviews these matters if and when they arise and believes that the resolution of any such matters currently known will not have a material effect on our results of operations or financial position.


F-29
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

22—FAIR VALUE MEASUREMENTS
ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:
Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
On April 1, 2019, as part of the sale of our Argentinian subsidiary, Medix, we provided a loan to Medix for $2.2 million. This asset was measured at fair value less costs to sell as of December 31, 2019 and is classified as Level 3 asset. The loan is classified within other assets on our consolidated balance sheet. Subsequent changes in the fair value of the loan receivable are recorded within our income statement as an operating expense.
 
December 31, 2018
 
Additions
 
Payments
 
Adjustments
 
December 31, 2019
Other assets:
 
 
 
 
 
 
 
 
 
Loan receivable
$
—

 
$
2,200

 
$
—

 
$
(294
)
 
$
1,906

Total
$
—

 
$
2,200

 
$
—

 
$
(294
)
 
$
1,906

The derivative financial instruments described in Note 12 are measured at fair value on a recurring basis and are presented on the consolidated balance sheets at fair value. The table below presents the fair value of the derivative financial instruments as well as the classification on the consolidated balance sheet (in thousands):
 
December 31, 2018
 
Additions
 
Payments
 
Adjustments
 
December 31, 2019
Liabilities:
 
 
 
 
 
 
 
 
 
Interest Rate Swap
$
77

 
$
—

 
$
—

 
$
236

 
$
313

Total
$
77

 
$
—

 
$
—

 
$
236

 
$
313

We estimate the fair value of the interest rate swaps by calculating the present value of the expected future cash flows of each swap. The calculation incorporated the contractual terms of the derivatives, observable market interest rates which are considered to be Level 2 inputs, and credit risk adjustments, if any, to reflect the counterpart's as well as our nonperformance risk. As of December 31, 2019, there have been no events of default under the interest rate swap agreement.
The following financial instruments are not measured at fair value on the consolidated balance sheet as of December 31, 2019 and 2018, but require disclosure of fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of the relatively short maturity.
The carrying amount of our short-term and long-term debt approximates fair value based on Level 2 inputs since the debt carries a variable interest rate that is tied to the current LIBOR rate plus a spread.

23—SALE OF CERTAIN SUBSIDIARY
We divested our wholly owned subsidiary, Medix, on April 2, 2019 via a stock sale to the local managing director, a related party. In exchange for the stock, we received $2.5 thousand in cash and provided Medix with a $2.2 million limited-recourse loan. The loan is secured by a real estate assets of Medix and repayment is conditional upon the sale of the real estate asset.


F-30
NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2019, 2018 and 2017

The held for sale criteria under GAAP was met in the first quarter of 2019. As such, we completed an asset impairment analysis which resulted in the full impairment of all assets held for sale. We recognized an impairment loss of $24.6 million which included an accrual for the anticipated realization of deferred foreign currency related translation adjustments in accumulated other comprehensive income of $24.8 million, net of tax, and an adjustment of $4.6 million for assets with a book value in excess of their fair market value. Included in the year ended December 31, 2019 is the impact of the sale of Medix, which was completed as of June 30, 2019, and the deferred foreign currency related translation adjustments previously in accumulated other comprehensive income have been released from the balance sheet along with the held for sale accrual.

ITEM 16.    Form 10-K Summary
Not Applicable.


F-31

EXHIBIT INDEX 
 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
 
 
S-1
 
3.1.1

 
333-44138
 
8/18/2000
 
 
8-K
 
3.1

 
000-33001
 
9/13/2012
 
 
8-K
 
3.1

 
000-33001
 
6/7/2019
 
 
8-K
 
3.1

 
000-33001
 
12/16/2019
 
 
S-1/A
 
4.1

 
333-44138
 
2/9/2001
 
 
8-A
 
3.1.2

 
000-33001
 
9/6/2002
 
 
 
 
 
 
 
 
 
 
 
S-1
 
10.1

 
333-44138
 
8/18/2000
 
 
8-K
 
10.1

 
000-33001
 
12/18/2018
 
 
8-K
 
10.1.1

 
000-33001
 
12/18/2018
 
 
8-K
 
10.1.2

 
000-33001
 
12/18/2018
 
 
8-K
 
10.1.3

 
000-33001
 
12/18/2018
 
 
8-K
 
10.1.4

 
000-33001
 
12/18/2018
 
 
8-K
 
10.1

 
000-33001
 
1/4/2006
 
 
S-1
 
10.3.1

 
333-44138
 
8/18/2000
 
 
10-Q
 
10.2

 
000-33001
 
8/9/2006
 
 
10-K
 
10.2.3

 
000-33001
 
3/14/2008
 
 
10-Q
 
10.02

 
000-33001
 
5/9/2008
 
 
S-1
 
10.4.1

 
333-44138
 
8/18/2000
 
 
S-1
 
10.15

 
333-44138
 
2/9/2001
 
 
S-1
 
10.15.1

 
333-44138
 
2/9/2001
 
 
 
 
Incorporated By Reference


Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
 
 
8-K
 
10.2

 
000-33001
 
1/4/2006
 
 
14-A
 
—

 
000-33001
 
4/20/2011
 
 
10-Q
 
10.1

 
000-33001
 
11/7/2011
 
 
10-Q
 
10.2

 
000-33001
 
11/7/2011
 
 
10-Q
 
10.3

 
000-33001
 
11/7/2011
 
 
14-A
 
—

 
000-33001
 
4/20/2011
 
 
14-A
 
—

 
000-33001
 
4/20/2011
 
 
10-K
 
10.10

 
000-33001
 
3/10/2009
 
 
10-K
 
 
 
000-33001
 
3/16/2015
 
 
8-K
 
99.1

 
000-33001
 
4/22/2013
 
 
10-Q
 
10.16

 
000-33001
 
8/8/2018
 
 
8-K
 
10.1

 
000-33001
 
10/9/2015
 
 
10-Q
 
 
 
000-33001
 
2/29/2016
 
 
10-Q
 
10.2

 
000-33001
 
11/3/2016
 
 
10-Q
 
10.1

 
000-33001
 
11/3/2016
 
 
10-Q
 
10.3

 
000-33001
 
11/3/2016
 
 
8-K
 
99.1

 
000-33001
 
8/29/2018
 
 
10-Q
 
10.18

 
000-33001
 
11/8/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101
 
The following financial information from Natus Medical Incorporated Annual Report on Form 10-K for the fiscal year ended December 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2019 and December 31, 2018, (ii) Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017, (iii) Consolidated Statements of Comprehensive Income for the years ended December 31, 2019, 2018 and 2017 (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017, (v) Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2019, 2018 and 2017, and (vi) the Notes to Consolidated Financial Statements.
 
 
 
 
 
 
 
 
104
 
The cover page of the Annual Report on Form 10-K formatted in Inline XBRL (included in Exhibit 101).
 
 
 
 
 
 
 
 

 *    Indicates a management contract or compensatory plan or arrangement

 EX-4.3 2 exhibit43-descriptiono.htm EXHIBIT 4.3 Exhibit
Exhibit 4.3

DESCRIPTION OF REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
DESCRIPTION OF COMMON STOCK
The following description of the common stock, par value $0.001 per share of Natus Medical Incorporated (“Natus,” we,” “us,” and “our”) is based upon our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) Company’s certificate of incorporation as currently in effect (the “Certificate of Incorporation”), our Second Amended and Restated Bylaws (the “Bylaws”) and applicable provisions of law. We have summarized certain portions of the Certificate of Incorporation and Bylaws below. The summary is not complete and is subject to, and is qualified in its entirety by express reference to, the provisions of the our Certificate of Incorporation and Bylaws, each of which is filed as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part.
Authorized Capital Stock
Under the Certificate of Incorporation, our authorized capital stock consists of 120,000,000 shares of common stock and 10,000,000 shares of preferred stock, par value $0.001 per share.
Common Stock
Voting Rights
Holders of our common stock are entitled to one vote per share for the election of directors and on all matters that require stockholder approval.
Dividend Rights
Subject to any preferential dividend rights granted to the holders of any shares of any preferred stock that may at the time be outstanding, holders of the common stock are entitled to receive dividends when, as and if declared from time to time by our board of directors out of funds legally available therefor.
Rights upon Liquidation
Subject to any preferential rights of any then outstanding preferred stock, the holders of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock.
Other Rights
Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of our common stock, or any conversion, call or redemption rights.
Transfer Agent and Exchange Listing
The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc., P.O. Box 1342, Brentwood, NY 11717. Our common stock is listed on the Nasdaq Stock Market under the trading symbol “NTUS.”
Preferred Stock
The board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to determine and alter the powers, rights, preferences and privileges and the qualifications, limitations and restrictions granted to or imposed upon such series. The issuance of preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation may have the effect of delaying, deferring or preventing a change in control of Natus.
Certain Provisions of the Certificate of Incorporation and Bylaws





Certain additional provisions of our Certificate of Incorporation and Bylaws could make it more difficult to acquire us by means of a tender offer, a proxy contest or otherwise and the removal of incumbent officers and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms.
Action by Written Consent; Special Meetings of Stockholders. Our Certificate of Incorporation and Bylaws require that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of the stockholders and may not be effected by a consent in writing. In addition, special meetings of our stockholders may be called only by a majority of the board of directors, the Chairman of the Board, the Chief Executive Officer or holders of at least 10% of the shares of our capital stock entitled to vote at such a meeting.
Removal of Directors and Vacancies. Our Certificate of Incorporation provides that our directors may be removed without cause by the affirmative vote of at least 66-2/3% of the voting power of all outstanding stock. This requirement of a supermajority vote to remove directors without cause could enable a minority of our stockholders to prevent a change in the composition of our board. Vacancies in the board of directors may be filled by a majority of the remaining directors, even if less than a quorum, or by a sole remaining director; however, a vacancy created by the removal of a director by the vote or written consent of the stockholders or by a court order may be filled only by the affirmative vote of a majority of shares represented and voting at a duly held meeting at which a quorum is present, or by the unanimous written consent of all shares entitled to vote thereon.
Advance Notice Procedures. Our Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder’s intention to bring that business before the meeting. Although the Bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company.

Certain Anti-Takeover Effects of Delaware Law
 
We are subject to Section 203 of the General Corporation Law of the State of Delaware (“Section 203”). In general, Section 203 prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the time that such stockholder became an interested stockholder, unless:

•
Prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

•
Upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or





•
At or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock which is not owned by the interested stockholder.


 EX-21.1 3 exhibit211123119.htm EXHIBIT 21.1 Exhibit
EXHIBIT 21.1
SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT
 
 
 
 
 
 
 
 
 
 
STATE or JURISDICTION
of INCORPORATION
 
PERCENT of
OWNERSHIP
 
Natus Medical Incorporated
 
Delaware
 
 
 
 
Natus Manufacturing Ireland, Ltd.
 
Ireland
 
 
100
%
Natus Medical Denmark ApS
 
Denmark
 
 
100
%
Excel Tech Corp. (Xltek)
 
Canada
 
 
100
%


 EX-23.1 4 exhibit231123119.htm EXHIBIT 23.1 Exhibit
EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm
The Board of Directors
Natus Medical Incorporated:
We consent to the incorporation by reference in the registration statements (Nos. 333‑65584, 333-133657, 333-174702, and 333-229314) on Form S-8 and registration statements (Nos. 333-133480, 333-150503, and 333-171489) on Form S-3 of Natus Medical Incorporated of our reports dated March 2, 2020, with respect to the consolidated balance sheets of Natus Medical Incorporated as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes and financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2019, which reports appear in the December 31, 2019 annual report on Form 10‑K of Natus Medical Incorporated.
Our report dated March 2, 2020, on the effectiveness of internal control over financial reporting as of December 31, 2019, expresses our opinion that Natus Medical Incorporated did not maintain effective internal control over financial reporting as of December 31, 2019 because of the effect of a material weakness on the achievement of the objectives of the control criteria and contains an explanatory paragraph that states that Natus Medical Incorporated did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of the Company’s controls over payroll accounts contributed to an error in the period end accrual.
(signed) KPMG LLP
San Francisco, California
March 2, 2020


 EX-31.1 5 exhibit311123119.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jonathan A. Kennedy, certify that:
1. I have reviewed this report on Form 10-K of Natus Medical Incorporated, (the "Registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
 
 
 
 
 
 
 
 
Date:
March 2, 2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/s/ Jonathan A. Kennedy
 
 
 
 
 
 
Jonathan A. Kennedy
 
 
 
 
 
 
President and Chief Executive Officer


 EX-31.2 6 exhibit312123119.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, B. Drew Davies, certify that:
1. I have reviewed this report on Form 10-K of Natus Medical Incorporated, (the "Registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
 
 
 
 
 
 
 
 
Date:
March 2, 2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/s/ B. Drew Davies
 
 
 
 
 
 
B. Drew Davies
 
 
 
 
 
 
Executive Vice President
 
 
 
 
 
 
and Chief Financial Officer


 EX-32.1 7 exhibit321123119.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO TITLE 18, UNITED STATES CODE, SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Natus Medical Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jonathan A. Kennedy, President and Chief Executive Officer of the Company, certify, pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
/s/ Jonathan A. Kennedy
Print Name: Jonathan A. Kennedy
Title: President and Chief Executive Officer
Date:
March 2, 2020
In connection with the Annual Report of Natus Medical Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, B. Drew Davies, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
/s/ B. Drew Davies
Print Name: B. Drew Davies
Title: Executive Vice President and Chief Financial Officer
Date:
March 2, 2020


 EX-101.SCH 8 ntus-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2109100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business Combinations - Integra Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - Business Combinations - NeuroQuest Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Business Combinations - Otometrics Acquisition Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Commitments And Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Commitments And Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Consolidated Statement of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Debt and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Debt and Credit Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Debt and Credit Arrangements - Schedule of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Debt and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Earnings Per Share - Components of Basic and Diluted EPS (Detail) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 2423401 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2426402 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Financial Instruments and Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Financial Instruments and Derivatives (Notes) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Financial Instruments and Derivatives (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2421403 - Disclosure - Income Taxes - Component of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2421404 - Disclosure - Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2421405 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2421406 - Disclosure - Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2421407 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Intangible Assets - Schedule of Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Leases - Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Leases - Supplemental Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Leases - Supplemental Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Long-Term Other Liabilities link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Long-Term Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Long-Term Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Other Income (Expense), Net link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Other Income (Expense), Net (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Other Income (Expense), Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Reserve for Product Warranties link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Reserve for Product Warranties (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Revenue (Notes) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Revenue - Unbilled AR and Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets link:presentationLink link:calculationLink link:definitionLink 2427401 - Disclosure - Sale of Certain Subsidiary (Details) link:presentationLink link:calculationLink link:definitionLink 2128100 - Schedule - Schedule II: Valuation And Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2428401 - Schedule - Schedule II: Valuation And Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Segment, Customer and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Segment, Customer and Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Segment, Customer and Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Segment, Customer and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - Share-Based Compensation - Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Share-Based Compensation - Restricted Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Share-Based Compensation - Share-based Compensation Expense Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2418405 - Disclosure - Share-Based Compensation - Valuation Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 ntus-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 ntus-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 ntus-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Payment Arrangement [Abstract] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, beginning of period, Shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Awarded, units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Release, units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited, units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, end of period, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning of period, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, end of period, Weighted - average grant date fair value Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Medix Medical Devices, SRL [Member] Medix Medical Devices, SRL [Member] Medix Medical Devices, SRL [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related Party Transaction, Amounts of Transaction Related Party Transaction, Amounts of Transaction Notes Receivable, Related Parties Notes Receivable, Related Parties Gain (Loss) on Sale of Assets and Asset Impairment Charges Gain (Loss) on Sale of Assets and Asset Impairment Charges Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Assets, Fair Value Adjustment Assets, Fair Value Adjustment Revenue from Contract with Customer [Abstract] Revenue Revenue from Contract with Customer [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Commitments and Contingencies Disclosure [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill Goodwill Disclosure [Text Block] Income Tax Disclosure [Abstract] Federal statutory tax expense Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State tax expense Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Foreign taxes at rates less than U.S. rates Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Deferred charges on sales of U.S. intellectual property Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount Equity compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Uncertain tax position Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Lapse of statute Income Tax Reconciliation Lapse Of Statute And Audit Settlement On Uncertain Tax Position Income tax reconciliation lapse of statute and audit settlement on uncertain tax position. Change of valuation allowance on foreign tax credit Income Tax Reconciliation Change Of Valuation Allowance On Foreign Tax Credit Income tax reconciliation change of valuation allowance on foreign tax credit. Earnout adjustment Effective Income Tax Rate Reconciliation, Other Reconciling Items, Earnout Adjustment Effective Income Tax Rate Reconciliation, Other Reconciling Items, Earnout Adjustment Repatriation tax net of foreign tax credits Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Net deferred tax asset re-measurement Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount Withholding taxes Effective Income Tax Rate Reconciliation, Tax Audit Effective Income Tax Rate Reconciliation, Tax Audit Withholding taxes Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Global intangible low-taxed income net of foreign tax credits Effective Income Tax Rate Reconciliation, Global Intangible Low-Taxed Income Net of Foreign Tax Credits, Amount Effective Income Tax Rate Reconciliation, Global Intangible Low-Taxed Income Net of Foreign Tax Credits, Amount Return to provision Effective Income Tax Rate Reconciliation, Return To Provision Effective Income Tax Rate Reconciliation, Return To Provision AMT on acquisition Effective, Income Tax Rate Reconciliation, Alternative Minimum Tax On Acquisitions Effective, Income Tax Rate Reconciliation, Alternative Minimum Tax On Acquisitions SAB 118 adjustments Effective Income Tax Rate Reconciliation, SAB 118 Adjustments, Amount Effective Income Tax Rate Reconciliation, SAB 118 Adjustments, Amount Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Total expense (benefit) Income Tax Expense (Benefit) Payables and Accruals [Abstract] Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Statement of Comprehensive Income [Abstract] Net loss Net Income (Loss) Attributable to Parent Unrealized losses on available-for-sale investments Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Interest rate swap designated as a cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Reclassification of stranded tax effects upon adoption of ASU 2018-02 Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Reclassification of deferred foreign currency related adjustments related to the sale of Medix (See FN 23) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred tax assets: Deferred Tax Assets, Net [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Accruals deductible in different periods Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Employee benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Operating leases Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Basis difference in fixed and intangible assets Deferred Tax Liabilities Basis Difference In Fixed And Intangible Assets Deferred tax liabilities basis difference in fixed and intangible assets. Operating leases Deferred Tax Liabilities, Right-Of-Use Assets Deferred Tax Liabilities, Right-Of-Use Assets Foreign earnings to be repatriated Deferred Tax Liabilities, Undistributed Foreign Earnings Total deferred tax liabilities Deferred Tax Liabilities, Gross Deferred Tax Assets, Net Deferred Tax Assets, Net Other Liabilities Disclosure [Abstract] Long-Term Other Liabilities Other Liabilities Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Billing Status, Type [Axis] Billing Status, Type [Axis] Receivables Billing Status [Domain] Receivables Billing Status [Domain] Unbilled Revenues [Member] Unbilled Revenues [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Movement in Unbilled AR [Roll Forward] Movement in Unbilled Receivables [Roll Forward] Movement in Unbilled Receivables [Roll Forward] Unbilled AR, December 31, 2018 Contract with Customer, Asset, after Allowance for Credit Loss Additions Contract With Customer, Asset, Increase From Performance Obligation Satisfied Contract With Customer, Asset, Increase From Performance Obligation Satisfied Transferred to Trade Receivable Contract with Customer, Asset, Reclassified to Receivable Unbilled AR, December 31, 2019 Movement in Deferred Revenue [Roll Forward] Movement in Deferred Revenue [Roll Forward] Deferred Revenue, December 31, 2018 Contract with Customer, Liability Additions Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Revenue Recognized Contract with Customer, Liability, Revenue Recognized Deferred Revenue, December 31, 2019 Income Statement [Abstract] Statement [Table] Statement [Table] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Statement [Line Items] Statement [Line Items] Revenue Revenues Cost of revenue Cost of Goods and Services Sold Intangibles amortization Cost, Amortization Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Marketing and selling Selling and Marketing Expense Research and development Research and Development Expense General and administrative General and Administrative Expense Intangibles amortization Amortization of Intangible Assets Restructuring Restructuring Charges Total operating expenses Operating Expenses Income (loss) from operations Operating Income (Loss) Other expense, net Nonoperating Income (Expense) Income (loss) before provision (benefit) for income tax Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision (benefit) for income tax Net loss Net loss per share: Earnings Per Share [Abstract] Basic Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average shares used in the calculation of net loss per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Leases [Abstract] Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total Operating Lease, Liability Finance Leases Finance Lease, Liability, Payment, Due [Abstract] 2020 Finance Lease, Liability, Payments, Due Next Twelve Months 2021 Finance Lease, Liability, Payments, Due Year Two 2022 Finance Lease, Liability, Payments, Due Year Three 2023 Finance Lease, Liability, Payments, Due Year Four 2024 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total lease payments Finance Lease, Liability, Payment, Due Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Total Finance Lease, Liability Debt Disclosure [Abstract] 2019 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2020 Long-term Debt, Maturities, Repayments of Principal in Year Three 2021 Long-term Debt, Maturities, Repayments of Principal in Year Four Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five Long-term Debt Long-term Debt Finite-Lived Intangible Assets, Net [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Technology [Member] Developed Technology Rights [Member] Customer related [Member] Customer Relationships [Member] Trade names [Member] Trade Names [Member] Internally Developed Software [Member] Software Development [Member] Patents [Member] Patents [Member] Service Agreements [Member] Service Agreements [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total amortization Amortization of Intangible Assets, Production and Nonproduction Amortization of Intangible Assets, Production and Nonproduction Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding, end of period (shares) Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cancelled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, end of period (in dollars per share) Defined Contribution Plan [Abstract] Employer matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Non-current Inventories Inventory, Noncurrent Components of Gross and Net Intangible Asset Balances Schedule of Finite and Indefinite Lived Intangible Assets [Table Text Block] Schedule of finite and indefinite lived intangible assets. Amortization expense related to intangible assets with definite lives Schedule of Finite-Lived Intangible Assets [Table Text Block] Expected annual amortization expense related to amortizable intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Other Income and Expenses [Abstract] Other Income (Expense), Net Other Income and Other Expense Disclosure [Text Block] Cover page. Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Restricted Stock Awards [Member] Restricted Stock [Member] Unvested, beginning of period, Shares Granted, Shares Vested, Shares Forfeited, Shares Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Beginning-Unrecognized Tax Benefits Unrecognized Tax Benefits Decreases for tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Increases for tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Lapse of statutes of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Foreign exchange difference Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Foreign exchange difference Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Ending-Unrecognized Tax Benefits Contract with Customer, Liability, Current Contract with Customer, Liability, Current Contract with Customer, Liability, Noncurrent Contract with Customer, Liability, Noncurrent Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Operating cash flows from operating leases Operating Lease, Payments Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Financing cash flows from finance leases Finance Lease, Principal Payments Right-of-use assets obtained in exchange for lease obligations: operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for lease obligations: finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Accounting Policies [Abstract] Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenue recognition Revenue [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Carrying value of intangible assets and goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Long lived assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Liability for product warranties Standard Product Warranty, Policy [Policy Text Block] Share-based compensation Share-based Payment Arrangement [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Investments Investment, Policy [Policy Text Block] Allowance for Doubtful Accounts Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Assets and Liabilities Held for Sale Assets And Liabilities Held For Sale Policy [Policy Text Block] Assets And Liabilities Held For Sale Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Research & Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Basic and Diluted Net Income per Share Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Product Warranties Disclosures [Abstract] Reserve for Product Warranties Product Warranty Disclosure [Text Block] Raw materials and subassemblies Inventory, Raw Materials and Supplies, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventories Inventory Current and Noncurrent Inventory current and noncurrent. Less: Non-current Inventories Inventories Inventory, Net Intangible Assets Intangible Assets Disclosure [Text Block] Leases Lessee, Operating Leases [Text Block] Leases Lessee, Finance Leases [Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Trade Names [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Impairment of Intangible Assets Defined Lived (excluding Goodwill) Impairment of Intangible Assets Defined Lived (excluding Goodwill) Impairment of Intangible Assets Defined Lived (excluding Goodwill) Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Total expected amortization expense Finite-Lived Intangible Assets, Net Inventories Schedule of Inventory, Current [Table Text Block] Operating lease, right-of-use asset Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock Options Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Restricted Stock Awards Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenue [Member] Cost of Sales [Member] Marketing and sales [Member] Selling and Marketing Expense [Member] Research and development [Member] Research and Development Expense [Member] General and administrative [Member] General and Administrative Expense [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total expense Share-based Payment Arrangement, Expense Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Retained Earnings Retained Earnings [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2018-02 [Member] Accounting Standards Update 2018-02 [Member] Share-based Payment Arrangement, Option [Member] Share-based Payment Arrangement, Option [Member] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Employees [Member] Employees [Member] Employees [Member] Executives RSAs and RSUs [Member] Executive Officer [Member] Director [Member] Director [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] On each of the third and fourth anniversaries of the vesting date[Member] Share-based Payment Arrangement, Tranche Two [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Office furniture and equipment [Member] Furniture and Fixtures [Member] Computer software and hardware [Member] Computer Equipment [Member] Demonstration and loaned equipment [Member] Demonstration and Loaned Equipment [Member] Demonstration and loaned equipment. Buildings [Member] Building [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items] Intangible asset impairment Impairment of Intangible Assets (Excluding Goodwill) Goodwill impairment charge Goodwill, Impairment Loss Contract With Customer, Service Period Contract With Customer, Service Period Contract With Customer, Service Period Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share based compensation, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Undiscounted future minimum operating lease commitments Estimated useful lives of property and equipment Property, Plant and Equipment, Useful Life Recorded foreign currency translation gains (losses) Net foreign currency transaction gains (losses) Foreign Currency Transaction Gain (Loss), before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Cumulative effect of new accounting principle in period of adoption Cumulative Effect of New Accounting Principle in Period of Adoption Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Compensation and related benefits Employee-related Liabilities, Current Warranty reserve Taxes Payable, Current Accrued federal, state, and local taxes Product Warranty Accrual, Current Accrued amounts due to customers Customer Refund Liability, Current Accrued professional fees Accrued Professional Fees, Current Accrued selling expenses Accrued Selling Expense, Current Accrued Selling Expense, Current Self-funded insurance expense Self Insurance Reserve, Current Accrued travel Accrued Travel, Current Accrued Travel, Current Deferred rent Deferred Rent Credit, Current Other Other Accrued Liabilities, Current Total Accrued Liabilities, Current Share-Based Compensation Share-based Payment Arrangement [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Land [Member] Land [Member] Leasehold improvements [Member] Leaseholds and Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and Equipment, Gross Property, Plant and Equipment, Gross Finance Lease, Right-of-Use Asset Finance Lease, Right-of-Use Asset Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total Property, Plant and Equipment, Net Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Otometrics [Member] Otometrics [Member] Otometrics [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Purchase price paid in cash to acquire entity Payments to Acquire Businesses, Gross Inventory purchase commitment Other Payments to Acquire Businesses Income from operations Product warranty period Standard Product Warranty Period Standard product warranty period. Product reserve warranty Standard and Extended Product Warranty Accrual Employee Benefit Plan Compensation and Employee Benefit Plans [Text Block] Derivative Instrument [Abstract] Derivative Instrument [Abstract] Financial Instruments and Derivatives Derivative Instruments and Hedging Activities Disclosure [Text Block] Segment Reporting [Abstract] Segment, Customer and Geographic Information Segment Reporting Disclosure [Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Schedule II: of Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Earnings Per Share Earnings Per Share [Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Remaining lease term Operating Lease, Weighted Average Remaining Lease Term Lease renewal term Lessee, Operating Lease, Renewal Term Core [Member] Core [Member] Non-core [Member] Non-core [Member] Internally developed software [Member] Computer Software, Intangible Asset [Member] Weighted average life of intangible assets Finite-Lived Intangible Asset, Useful Life Costs incurred for development of internal use computer software Costs Incurred for Development of Internal Use Computer Software Costs incurred for development of internal use computer software. Costs incurred for development of software to be sold Capitalized Software Development Costs for Software Sold to Customers Common Stock, shares authorized Common Stock, Shares Authorized Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Preferred stock authorized Preferred Stock, Shares Authorized Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock issued Preferred Stock, Shares Issued Preferred stock outstanding Preferred Stock, Shares Outstanding Long-Term Other Liabilities Other Noncurrent Liabilities [Table Text Block] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2019 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Integra [Member] Integra [Member] Integra [Member] Tangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Identifiable intangible assets acquired, average useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Goodwill Goodwill Liabilities assumed in acquisition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Revenue Business Acquisition, Pro Forma Revenue U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Weighted average common shares Dilutive effect of stock based awards Weighted Average Number Diluted Shares Outstanding Adjustment Diluted Shares (in dollars per share) Basic earnings per share (in dollars per share) Diluted earnings per share (in dollars per share) Shares excluded from calculations of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for losses on accounts receivable Accounts Receivable, Credit Loss Expense (Reversal) Depreciation and amortization Depreciation, Depletion and Amortization (Gain) loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Impairment of intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment charge for sale of entity Impairment Charge on Reclassified Assets Warranty reserve Product Warranty Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense Deferred taxes Increase (Decrease) in Deferred Income Taxes Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of intangible assets Payments to Acquire Intangible Assets Sales of short-term investments Proceeds from Sale of Short-term Investments Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from stock option exercises and ESPP Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Repurchase of company stock Payments for Repurchase of Common Stock Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Proceeds from long-term borrowings Proceeds from Issuance of Long-term Debt Deferred debt issuance costs Payments of Debt Issuance Costs Contingent consideration earn-out Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payments on borrowings Repayments of Debt Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Exchange rate effect on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of year Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of year Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for income taxes Income Taxes Paid Non-cash investing activities: Other Noncash Investing and Financing Items [Abstract] Property and equipment included in accounts payable Noncash or Part Noncash Acquisition, Fixed Assets Acquired Inventory transferred to property and equipment Property, Plant and Equipment, Gross, Period Increase (Decrease) Finance Lease, Principal Payments Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Foreign countries [Member] Non-US [Member] Canada [Member] CANADA Argentina [Member] ARGENTINA Ireland [Member] IRELAND Denmark [Member] DENMARK Other Foreign countries [Member] Foreign Countries [Member] Foreign countries. Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Neurology Products [Member] Neurology Products [Member] Neurology Products [Member] Newborn Care Products [Member] Newborn Care Products [Member] Newborn Care Products [Member] OtometricsProducts [Member] OtometricsProducts [Member] OtometricsProducts [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Devices and Systems [Member] Devices and Systems [Member] Devices and systems. Supplies [Member] Supplies [Member] Supplies [Member] Services [Member] Services [Member] Services [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-lived assets Long-Lived Assets Components of Basic and Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Purchase commitments for inventory, total Long-term Purchase Commitment, Amount Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning Balance Acquisitions/Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Goodwill impairment charge Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Ending Balance Revolving credit facility Long-term Debt, Gross Debt Issuance Costs, Net Debt Issuance Costs, Net Less: current portion of long-term debt Long-term Debt, Current Maturities Total long-term debt Long-term Debt, Excluding Current Maturities SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] SEC Schedule, 12-09, Reserve, Warranty [Member] SEC Schedule, 12-09, Reserve, Warranty [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Additions Charged to Expense SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Balance at End of Period Revenue and long-lived asset information by geographic region Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $7,384 and $6,960 Accounts Receivable, after Allowance for Credit Loss, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Deferred income tax Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Current portion of long-term debt Current portion of operating lease liabilities Operating Lease, Liability, Current Accrued liabilities Deferred revenue Deferred Revenue, Current Total current liabilities Liabilities, Current Long-term liabilities: Liabilities, Noncurrent [Abstract] Other liabilities Other Liabilities, Noncurrent Long-term debt Operating lease liabilities Operating Lease, Liability, Noncurrent Deferred income tax Deferred Income Tax Liabilities, Net Total liabilities Liabilities Commitments and contingencies (Note 21) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 34,148,700 in 2019 and 33,804,379 in 2018 Common Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and in 2018 Preferred Stock, Value, Issued Retained earnings Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Lease, Cost Lease, Cost [Table Text Block] Assets and Liabilities, Lessee Assets and Liabilities, Lessee [Table Text Block] Assets and Liabilities, Lessee [Table Text Block] Finance Lease, Liability, Maturity Finance Lease, Liability, Maturity [Table Text Block] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Sale of Certain Subsidiary Assets Related Party Transactions Disclosure [Text Block] Income (loss) before provision (benefit) for income tax Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Summary of components of income tax expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Reconciliation of effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Uncertain Tax Positions Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement [Member] Credit Agreement [Member] Credit Agreement [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Citibank, National Association [Member] Citibank, National Association [Member] Citibank, National Association [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving credit facility [Member] Revolving Credit Facility [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit [Member] Line of Credit [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Revolving credit facility with Wells Fargo Bank Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Increase (Decrease), Net Line of Credit Facility, Increase (Decrease), Net Ratio of Indebtedness to Net Capital Ratio of Indebtedness to Net Capital Ratio of Interest Coverage Ratio of Interest Coverage Ratio of Interest Coverage Available amount under credit facility Long-term Line of Credit Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Statement of Stockholders' Equity [Abstract] Common Stock Common Stock [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Beginning balance (shares) Shares, Issued Vesting of restricted stock units Vesting Of Restricted Stock Units Vesting of restricted stock units. Vesting of restricted stock units (shares) Vesting Of Restricted Stock Units Shares Vesting of restricted stock units shares. Net issuance of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Net issuance of restricted stock awards (shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Employee stock purchase plan (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock-based compensation expense Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Stock-based compensation expense (shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Repurchase of company stock Stock Repurchased During Period, Value Repurchase of company stock (shares) Stock Repurchased During Period, Shares Taxes paid related to net share settlement of equity awards Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Taxes paid related to net share settlement of equity awards (shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (shares) Other comprehensive income Other comprehensive income, net of ASU adoption impact Other Comprehensive Income (Loss), Net Of Tax And ASU Adoption Impact Other Comprehensive Income (Loss), Net Of Tax And ASU Adoption Impact Ending balance Ending balance (shares) Derivative Liability, Additions Derivative Liability, Additions Derivative Liability, Additions Derivative Liability, Payments Derivative Liability, Payments Derivative Liability, Payments Derivative Liability, Adjustments Derivative Liability, Adjustments Derivative Liability, Adjustments Income Taxes Income Tax Disclosure [Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Common Stock, shares issued Common Stock, Shares, Issued Common Stock, shares outstanding Common Stock, Shares, Outstanding Preferred stock, shares authorized Preferred stock, issued Preferred stock, outstanding Total operating lease liabilities Finance Leases, property and equipment Finance Lease, Right-Of-Use Asset, Gross Finance Lease, Right-Of-Use Asset, Gross Finance leases, accumulated amortization Finance Lease, Right-Of-Use Asset, Accumulated Depreciation Finance Lease, Right-Of-Use Asset, Accumulated Depreciation Finance leases, property and equipment, net Finance Lease, Right-of-Use Asset, Net Finance Lease, Right-of-Use Asset, Net Finance leases, accrued liabilities Finance Lease, Liability, Current Finance leases, other liabilities Finance Lease, Liability, Noncurrent Total finance lease liabilities Weighted average remaining lease term, operating leases Weighted average remaining lease term, finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate, finance leases Finance Lease, Weighted Average Discount Rate, Percent Weighted-average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Business Combinations Business Combination Disclosure [Text Block] Operating lease cost Operating Lease, Cost Amortization of right-of-use assets (principal payments) Finance Lease, Right-of-Use Asset, Amortization Interest on lease liabilities Finance Lease, Interest Expense Short-term lease cost Short-term Lease, Cost Variable lease cost Variable Lease, Cost Sublease income Sublease Income Total lease cost Lease, Cost Employee Stock Purchase Plan [Member] Employee Stock [Member] Fair value, vested in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Shares available for future awards Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share based compensation, vesting period Unrecognized compensation expense related to unvested portion of stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average vested options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted average exercise price of vested stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Intrinsic value of options vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Intrinsic value of options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Weighted average remaining contractual term, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Unrecognized compensation of unvested awards Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Weighted average period of recognition of unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Fair market value of outstanding awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Fair Value Aggregate intrinsic value of outstanding restricted stock units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Employee maximum withholding rate (percent) Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Eligible compensation of employees Maximum Eligible Compensation Maximum eligible compensation. Purchase price for shares acquired Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Offering price, percentage of fair market value Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Compensation expense associated with the ESPP Employee Stock Ownership Plan (ESOP), Compensation Expense Property, Plant and Equipment, Net [Abstract] Depreciation expense Depreciation Number of reporting segments Number of Reportable Segments Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] U.S. Federal Current Federal Tax Expense (Benefit) U.S. State and local Current State and Local Tax Expense (Benefit) Non-U.S. Current Foreign Tax Expense (Benefit) Total current tax expense Current Income Tax Expense (Benefit) Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] U.S. Federal Deferred Federal Income Tax Expense (Benefit) U.S. State and local Deferred State and Local Income Tax Expense (Benefit) Non-U.S. Deferred Foreign Income Tax Expense (Benefit) Total deferred tax expense (benefit) Deferred Income Tax Expense (Benefit) Schedule Of Income Taxes [Table] Schedule Of Income Taxes [Table] Schedule Of Income Taxes [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Significant foreign jurisdictions [Member] Foreign Tax Authority [Member] Geographical [Domain] GERMANY GERMANY France [Member] FRANCE DENMARK Income Tax Provision [Member] Income Tax Provision [Member] Income Tax Provision [Member] Schedule Of Income Taxes [Line Items] Schedule Of Income Taxes [Line Items] Schedule Of Income Taxes [Line Items] Statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Tax net operating loss carryforwards Operating Loss Carryforwards Tax credits carryforwards Tax Credit Carryforward, Amount Valuation allowances Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred tax liabilities related to foreign earnings Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability Withholding Tax, Percent Withholding Tax, Percent Withholding Tax, Percent Increase in unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Unrecognized Tax Benefits Unrecognized tax would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Lapse of statutes of limitations Interest and penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Total Interest and penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Goodwill Schedule of Goodwill [Table Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Liability Derivative Liability Loans and Leases Receivable, Related Parties, Additions Loans and Leases Receivable, Related Parties, Additions Loans and Leases Receivable, Related Parties, Proceeds Loans and Leases Receivable, Related Parties, Proceeds Loans and Leases Receivable, Related Parties, Period Increase (Decrease) Loans and Leases Receivable, Related Parties, Period Increase (Decrease) Other expense, net Nonoperating Income (Expense) [Abstract] Interest income Investment Income, Interest Interest expense Interest Expense Foreign currency gain (loss) Other Other Nonoperating Income (Expense) Total other expense, net Debt and Credit Arrangements Debt Disclosure [Text Block] Contingent tax obligations Liability for Uncertainty in Income Taxes, Noncurrent Non-current deferred revenue Deferred Revenue, Noncurrent Finance Lease, Liability, Noncurrent Other Other Sundry Liabilities, Noncurrent Total Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap [Member] Interest Rate Swap [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Liability, Notional Amount Derivative Liability, Notional Amount Derivative, Fixed Interest Rate Derivative, Fixed Interest Rate Derivative Liability Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net EX-101.PRE 12 ntus-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 chart-5bdaf063b6f2531ead0.jpg begin 644 chart-5bdaf063b6f2531ead0.jpg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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating activities:      
Net loss $ (15,671) $ (22,935) $ (20,293)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Provision for losses on accounts receivable 1,584 6,909 10,017
Depreciation and amortization 30,722 33,863 30,098
(Gain) loss on disposal of property and equipment 449 746 (21)
Impairment of intangible assets 0 8,192 1,674
Impairment charge for sale of entity 24,571 0 0
Goodwill impairment charge 0 14,846 0
Warranty reserve 2,886 2,168 5,370
Stock-based compensation 8,352 17,051 9,445
Deferred taxes (5,364) (13,714) 4,032
Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:      
Accounts receivable 9,817 (5,199) (30,473)
Inventories 7,185 (7,443) 7,581
Other assets (2,486) (5,118) 5,492
Accounts payable (1,367) 4,105 (1,385)
Accrued liabilities (4,010) (2,527) 5,421
Deferred revenue 3,392 2,076 (7,232)
Net cash provided by operating activities 60,060 33,020 19,726
Investing activities:      
Acquisition of businesses, net of cash acquired 0 151 (190,888)
Acquisition of property and equipment (5,326) (7,875) (4,066)
Acquisition of intangible assets (13) (665) 0
Sales of short-term investments 0 0 34,019
Net cash used in investing activities (5,339) (8,389) (160,935)
Financing activities:      
Proceeds from stock option exercises and ESPP 3,635 11,448 3,466
Repurchase of company stock 0 (5,630) (2,268)
Taxes paid related to net share settlement of equity awards (1,689) (5,183) (7,052)
Proceeds from long-term borrowings 0 0 60,000
Deferred debt issuance costs 0 0 (354)
Contingent consideration earn-out 0 (147) (2,966)
Payments on borrowings (50,000) (50,000) (45,000)
Net cash provided by (used in) financing activities (48,532) (49,512) 5,826
Exchange rate effect on cash and cash equivalents 735 (7,696) 10,782
Net increase (decrease) in cash and cash equivalents 6,924 (32,577) (124,601)
Cash and cash equivalents, beginning of year 56,373 88,950 213,551
Cash and cash equivalents, end of year 63,297 56,373 88,950
Supplemental disclosure of cash flow information:      
Cash paid for interest 4,580 6,169 4,464
Cash paid for income taxes 6,445 9,247 5,740
Non-cash investing activities:      
Property and equipment included in accounts payable 69 167 148
Inventory transferred to property and equipment 300 1,211 1,006
Finance Lease, Principal Payments $ (478) $ 0 $ 0
XML 15 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment PROPERTY AND EQUIPMENT
Property and equipment consist of (in thousands): 
 
December 31,
 
2019
 
2018
Land
$
1,719

 
$
1,828

Buildings
6,943

 
7,036

Leasehold improvements
8,664

 
4,649

Finance lease right-of-use assets
2,377

 
—

Office furniture and equipment
22,819

 
23,487

Computer software and hardware
12,610

 
12,803

Demonstration and loaned equipment
11,621

 
12,843

 
66,753

 
62,646

Accumulated depreciation
(42,051
)
 
(39,733
)
Total
$
24,702

 
$
22,913


Depreciation expense of property and equipment was $6.6 million, $6.0 million, and $4.1 million in the years ending December 31, 2019, 2018 and 2017, respectively.
XML 16 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Liabilities
 12 Months Ended
Dec. 31, 2018
Payables and Accruals [Abstract]  
Accrued Liabilities ACCRUED LIABILITIES
Accrued liabilities consist of (in thousands): 
 
December 31,
 
2019
 
2018
Compensation and related benefits
$
26,991

 
$
24,891

Warranty reserve
6,404

 
9,391

Accrued federal, state, and local taxes

11,156

 
8,285

Accrued amounts due to customers
3,008

 
5,507

Accrued professional fees
2,083

 
1,820

Accrued selling expenses
507

 
246

Self-funded insurance expense
950

 
—

Accrued travel
224

 
201

Deferred rent
—

 
205

Other
3,128

 
2,022

Total
$
54,451

 
$
52,568
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 7,384 $ 6,960
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common Stock, shares authorized 120,000,000 120,000,000
Common Stock, shares issued 34,148,700 33,804,379
Common Stock, shares outstanding 34,148,700 33,804,379
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
XML 18 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consist of (in thousands): 
 
December 31,
 
2019
 
2018
Land
$
1,719

 
$
1,828

Buildings
6,943

 
7,036

Leasehold improvements
8,664

 
4,649

Finance lease right-of-use assets
2,377

 
—

Office furniture and equipment
22,819

 
23,487

Computer software and hardware
12,610

 
12,803

Demonstration and loaned equipment
11,621

 
12,843

 
66,753

 
62,646

Accumulated depreciation
(42,051
)
 
(39,733
)
Total
$
24,702

 
$
22,913
XML 19 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule II: Valuation And Qualifying Accounts
 12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II: of Valuation and Qualifying Accounts
SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
For the years ended December 31, 2019, 2018 and 2017
(In thousands) 
 
Balance at
Beginning
of Period
 
Additions
Charged to
Expense
 
Deductions
 
Balance
at End
of Period
Year ended December 31, 2019
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
6,960

 
$
1,584

 
$
(1,160
)
 
$
7,384

Valuation allowance
637

 
—

 
(31
)
 
606

Warranty reserve
9,391

 
3,949

 
(6,936
)
 
6,404

Year ended December 31, 2018
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
8,978

 
$
6,423

 
$
(8,441
)
 
$
6,960

Valuation allowance
5,862

 
—

 
(5,225
)
 
637

Warranty reserve
10,995

 
4,487

 
(6,091
)
 
9,391

Year ended December 31, 2017
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,182

 
$
10,017

 
$
(5,221
)
 
$
8,978

Valuation allowance
3,706

 
2,156

 
—

 
5,862

Warranty reserve
10,670

 
5,370

 
(5,045
)
 
10,995
XML 20 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2018
Payables and Accruals [Abstract]  
Accrued Liabilities
Accrued liabilities consist of (in thousands): 
 
December 31,
 
2019
 
2018
Compensation and related benefits
$
26,991

 
$
24,891

Warranty reserve
6,404

 
9,391

Accrued federal, state, and local taxes

11,156

 
8,285

Accrued amounts due to customers
3,008

 
5,507

Accrued professional fees
2,083

 
1,820

Accrued selling expenses
507

 
246

Self-funded insurance expense
950

 
—

Accrued travel
224

 
201

Deferred rent
—

 
205

Other
3,128

 
2,022

Total
$
54,451

 
$
52,568
ZIP 21 0000878526-20-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000878526-20-000022-xbrl.zip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

CX9?1N/1?)1N M6BZTD_4&*T#;[ >&N136 >==L*64DI"B"%J-F';F9=!6TUXRP'4)5-J7[^V, MHW5V'83WAW@PM-+3.@ -V4QMX90''X41PJ2TQDO&:*XAM25"([M4%I#/9#SH M>!?OA<)>%^X&QEX08'\;SD9YR+TUZ.VA A2X04I,*6-0$F18T(5 BO!/Q*21 MUF.!EQ1@-<'O DDT$+CO0[,[FB\F\478%3T"^UJY9P%(&TW L2(X-J/U4%JH M'$,P'O92RQU U"SQ15237+08[1)]D'='Q]D7P97[]G%>X[:@^05169 :;W2* MT"?$]PGQ+PI(7B=-8<,@4=1JB32%6%L/:1"0+$^=)_")I*EWL$P@& #:9GN2 M \B)7Y-'[YEL(_CJ 9;?>&M"V]GB]G:]MNXR"^YBNQ-E'3KF [Y"N]+:^MJC-OK8[8M?WZ4I]NM)V;YX^ M76G?9(Z)"O=V&.8YIND7;-Q9E==_67!OI\E-T+J+6:ZDZUSBQN'7IGD+AY&> ML+\GHW72V[T!%XRSV?2F42546&X]K\N^\;KDCJ3DS4XX!C*IM#.>0"4\C $V MI3DRV!CG],O)5L'SDGQY6'=XL,>_LI%K@9T1 M7BI'E(-04FZYB_6['"MB&:-DG5R+$H4GDT^EDK_K-#^J;[6W!T9 L8\Z!^D> M'A1#T,S>0!Q 2J&G'#ICN5<*%,0DE%$KGFHH?0_?SU7.Z'MH4<+[;*F=\?-. MGT@QGGZ)9?B%EY?^7K1;RMW PK^;?@DCR .PO7]WX*+]9"TO[K!%.*U)\ZF# M6%J,N$ (0^N(%2Q:8)0!P(A?(LU_E)9^4N+R:.)*5/KI[*&7]"YF&1HPV2H? MU5Z(^&V%[Z-ZHL/UA2#@C?X51A",A%=<*F2Y=$S "$5&*-%"+>7"K@/%IL7U M+D#$ .R-@]1]9]TUB4K>?-"](5')9+[(?BX:/0\GEY_J('K!0K.:M@0Q1SAD M%G'/A.+,*1X9RI"D%G*H<8.VQ 1WGPB#H6<60&R$T#$4@!127"OVVB'PO0KKU M+K.&:.CS;IZD"0(?)>;=)]VLESVSE'2S7J[.7@5&^J2;%S(@EMK?[D9ZS<;; MXHFIJ$,@G]9QKWXP4\,K,FFV+XZV(Y+C,=//$RP.6Y.ROW^9^?N1@ \A@XV6 MMH90AY5ABACAK78.>P0%EAP0L'QP^XBP]&'DHCN>>CH [?;E6YF2O[V9]R_* MLFT@Y;DWNF];X11MQUHZA G9*U57] &:)[>1+Z?@+'J4V/> "N49Q/2<=UL7 M*D>@3CQ@7BKK*);:,6.P9H33J'ZTM4"[Y8XHSYQ(E7NE,_U#!X+W%!([4I>P M_IERSZ7T,E!AG6!+-0 <6<2QD%@1!)7A$:C>4N@%=&L"]7@ZN>@8JQ -0*M\ M+_MQA+RMQ>A5S?E+NKWW:'N/]F5)11JT;\&<4,!SQR4F"%N+K*=*2X2XY)[# M-255=_*)#\)8>E]VMWS9EOIC[(\OV_6$_#A?MHM(?I4FU4H9681TS=*'$#*+<0K$PN%A. M/LC:>H%*^J^SY9[8[=DI:(!;[8.]'V[4EHJ;G_ZB+BX6-XLB=6S8X!C?XY3< M%4Q\$$-98TXA@:"FS#BJ*%<<6!(QAQT5T@"[+N8:TVS3VUD RU-,[BUZ"P," MVRQY6MZ9VQ#P[JGXUC<3)FG/RM>S\K5OH)"Z%5%X30G#C2;8$FVL1#QF;$KB MM34 ^)>%Y?1>6!YWF!(@:7<,IGM"T;=.<.4]0P9XBV(H^_3+7$ RS:K MZ'H7NMODVGEXH\V<@!UFN5\!1-+(X2'8:1%@I\.+B@77VI@8UY*,"VF)63IP M>Q*([Y 80.5[T/]L93+!;MD.7;K'VR+34,.X<-X83[SG MA H"H*, 1YG&"; =J>_ MGL@=^"W_*SBX*CSV\&N:G*8WP]%D5)4%)K&-WBZGE/SXS;,;1D_KG%@[X(!4 M!">/=;6HC].]YA!IHQ3"2BB-C*:1ID *X[#D?JG-W<.$OPI=);CNL96_&9$% MGU/C#07](4LO?KY$G1E$(,26K,Z0^^UP=+(\"9DB%D> MF=ADD,1 2JY>91A5.(PP_)S.+M:)U$X6D*H(QP?T,O!VH_X/0Y.MC,= MZ@][[\CTM*$E7%D=-!A9S 43NQVC/!$3+/4Q>L)[>':QMUEON M&":[(1==8FBL+KH&.6$;8W@5O6C=GC6RB3Y34/?+<+X(=[];338J,5,8&J^0 M=DS%'@0BGNQCP GU'- &V:CVP?6'F$@+/8 (&YZ3C6*$ 0Y?9TMLH6]ZKB>C M^^L_CS*2>\\@D8Y1+)DS#$3F0FLT$5JHQO- ;?(.X80#1*5Q80YBFC)RQH0_ MB=Q=]E.510:/-W^]8H4K;./'U'"OOMP@N5J$Y4N3F^!DWBQNRG/"V[*%Q:N; MT273XG-A0^7'P'D:_@..UT'>Y2!^IN!QC5;LU>A;^',4A6SAE^:YOC$+(4OHW_$KSI:V\DVUSO9GN5U9,W M<4TG\;;) V[)GG]S ]+)K9N:]XS#]-MDC8KF+3RV[4"Z((! GVV\G]G&C-6Q M-.4!]]1#8*E4S$D"HW-N ONN==JB?_H15>HZI1F%^EQ>+CS[^GX6_I+&.-U M=^6\;,#%?O=.^\$\(EM*?]Q+HGV01(UT!V6H5X(!!B'S!&N!@ J2"/(@AS@R M;*W@Q8^00 3TK&P[XS4%NP8>;EB>R9HY 98&>2$%AP!XSE1W$3-CS'DQ*&E ML/RZFC_ZI>??IQUREF*P%SV.MR''][V\R3W&%(>B/NK2TCBHJ%4><\.49,I& M'4:$M0#P)6MZE0[K&DNX5?+Y+==0N^V2OV 7!)V&^I2196#B&IC6&!_<7"RA MX]X(P8V04=E9S1#39JD=Q*N4W?4L3;N#Z(#1_::KVFJ>S&U1D'L)4-HH3 .> M6\@9\I "222A%$3-Z9GBR''P)LW9*3##8/<:EOOF]N$#-E%Y#31/G/0:(>PQ M]80Y@32)FM )9I&A2V&6UVA"/UW,.N1M)++-0._6ZKM#4FN[#"I9$XLYC7%0 M8-A+KI4$R D?8Y<(8* (>[E Y(> 2;9I4FZYBMIGOX_T9N42, 5DC3Y,6@-L MO*'42<89-X1%;><)IP#H)6"^2MN-OG5H70[0GK,4]V[?H>(3U^D'SD-$D?3* M$26]MQY+&A4G1)YS@_F;%&>7N*1[C[ZS9[%(&U@$#DJ&J?52 M

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end XML 22 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]      
Depreciation expense $ 6.6 $ 6.0 $ 4.1

XML 23 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Combinations - Otometrics Acquisition Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 03, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]        
Revenue   $ 495,175 $ 530,891 $ 500,970
Income from operations   $ 15,666 $ 24,562 $ (8,717)
Otometrics [Member]        
Business Acquisition [Line Items]        
Purchase price paid in cash to acquire entity $ 149,200      
Inventory purchase commitment $ 4,200      
XML 24 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Unbilled AR and Deferred Revenue (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Movement in Deferred Revenue [Roll Forward]  
Deferred Revenue, December 31, 2018 $ 21,410
Additions 19,465
Revenue Recognized (16,067)
Deferred Revenue, December 31, 2019 24,808
Unbilled Revenues [Member]  
Movement in Unbilled AR [Roll Forward]  
Unbilled AR, December 31, 2018 3,012
Additions 354
Transferred to Trade Receivable (699)
Unbilled AR, December 31, 2019 $ 2,667
XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 26 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share - Components of Basic and Diluted EPS (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Earnings Per Share [Abstract]      
Net loss $ (15,671) $ (22,935) $ (20,293)
Weighted average common shares 33,696 33,111 32,564
Dilutive effect of stock based awards 0 0 0
Diluted Shares (in dollars per share) 33,696 33,111 32,564
Basic earnings per share (in dollars per share) $ (0.47) $ (0.69) $ (0.62)
Diluted earnings per share (in dollars per share) $ (0.47) $ (0.69) $ (0.62)
Shares excluded from calculations of diluted EPS 104 343 565
XML 27 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:    
Net operating loss carryforwards $ 3,035 $ 3,192
Credit carryforwards 2,415 2,882
Accruals deductible in different periods 23,672 15,197
Employee benefits 1,554 1,262
Operating leases 4,643 0
Total deferred tax assets 35,319 22,533
Valuation allowance (606) (637)
Total net deferred tax assets 34,713 21,896
Deferred tax liabilities:    
Basis difference in fixed and intangible assets (13,850) (15,687)
Operating leases (3,959) 0
Foreign earnings to be repatriated (800) (500)
Total deferred tax liabilities (18,609) (16,187)
Deferred Tax Assets, Net $ 16,104 $ 5,709
XML 28 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation - Restricted Unit Activity (Details) - Restricted Stock Units [Member] - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Shares      
Unvested, beginning of period, Shares 112,805    
Awarded, units 118,740    
Release, units (42,130)    
Forfeited, units (16,319)    
Unvested, end of period, Shares 173,096    
Weighted Average Grant Date Fair Value      
Unvested, beginning of period, Weighted - average grant date fair value $ 36.80    
Granted, Weighted - average grant date fair value 38.62 $ 36.77 $ 35.16
Vested, Weighted - average grant date fair value 34.11    
Forfeited, Weighted - average grant date fair value 37.60    
Unvested, end of period, Weighted - average grant date fair value $ 38.62 $ 36.80  
JSON 29 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ntus12311910-k.htm": { "axisCustom": 0, "axisStandard": 29, "contextCount": 238, "dts": { "calculationLink": { "local": [ "ntus-20191231_cal.xml" ] }, "definitionLink": { "local": [ "ntus-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "ntus12311910-k.htm" ] }, "labelLink": { "local": [ "ntus-20191231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ntus-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ntus-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 705, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 26, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 31 }, "keyCustom": 38, "keyStandard": 499, "memberCustom": 15, "memberStandard": 57, "nsprefix": "ntus", "nsuri": "http://www.natus.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.natus.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Revenue (Notes)", "role": "http://www.natus.com/role/RevenueNotes", "shortName": "Revenue (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Inventories", "role": "http://www.natus.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Property and Equipment", "role": "http://www.natus.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Intangible Assets", "role": "http://www.natus.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Goodwill", "role": "http://www.natus.com/role/Goodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Leases (Notes)", "role": "http://www.natus.com/role/LeasesNotes", "shortName": "Leases (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Accrued Liabilities", "role": "http://www.natus.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Long-Term Other Liabilities", "role": "http://www.natus.com/role/LongTermOtherLiabilities", "shortName": "Long-Term Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Debt and Credit Arrangements", "role": "http://www.natus.com/role/DebtAndCreditArrangements", "shortName": "Debt and Credit Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Financial Instruments and Derivatives (Notes)", "role": "http://www.natus.com/role/FinancialInstrumentsAndDerivativesNotes", "shortName": "Financial Instruments and Derivatives (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.natus.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Reserve for Product Warranties", "role": "http://www.natus.com/role/ReserveForProductWarranties", "shortName": "Reserve for Product Warranties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Stockholders' Equity", "role": "http://www.natus.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Earnings Per Share", "role": "http://www.natus.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Share-Based Compensation", "role": "http://www.natus.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Other Income (Expense), Net", "role": "http://www.natus.com/role/OtherIncomeExpenseNet", "shortName": "Other Income (Expense), Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Income Taxes", "role": "http://www.natus.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - Employee Benefit Plan", "role": "http://www.natus.com/role/EmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - Segment, Customer and Geographic Information", "role": "http://www.natus.com/role/SegmentCustomerAndGeographicInformation", "shortName": "Segment, Customer and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - Commitments And Contingencies", "role": "http://www.natus.com/role/CommitmentsAndContingencies", "shortName": "Commitments And Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126100 - Disclosure - Fair Value Measurements", "role": "http://www.natus.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127100 - Disclosure - Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets", "role": "http://www.natus.com/role/SaleOfCertainSubsidiaryAssetsSaleOfCertainSubsidiaryAssets", "shortName": "Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2128100 - Schedule - Schedule II: Valuation And Qualifying Accounts", "role": "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccounts", "shortName": "Schedule II: Valuation And Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Organization and Significant Accounting Policies (Policies)", "role": "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies", "shortName": "Organization and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Revenue (Tables)", "role": "http://www.natus.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Inventories (Tables)", "role": "http://www.natus.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Property and Equipment (Tables)", "role": "http://www.natus.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ntus:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Intangible Assets (Tables)", "role": "http://www.natus.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ntus:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Goodwill (Tables)", "role": "http://www.natus.com/role/GoodwillTables", "shortName": "Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Leases (Tables)", "role": "http://www.natus.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Accrued Liabilities (Tables)", "role": "http://www.natus.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Operations", "role": "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Long-Term Other Liabilities (Tables)", "role": "http://www.natus.com/role/LongTermOtherLiabilitiesTables", "shortName": "Long-Term Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Debt and Credit Arrangements (Tables)", "role": "http://www.natus.com/role/DebtAndCreditArrangementsTables", "shortName": "Debt and Credit Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Financial Instruments and Derivatives (Tables)", "role": "http://www.natus.com/role/FinancialInstrumentsAndDerivativesTables", "shortName": "Financial Instruments and Derivatives (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.natus.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.natus.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Other Income (Expense), Net (Tables)", "role": "http://www.natus.com/role/OtherIncomeExpenseNetTables", "shortName": "Other Income (Expense), Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - Income Taxes (Tables)", "role": "http://www.natus.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323301 - Disclosure - Segment, Customer and Geographic Information (Tables)", "role": "http://www.natus.com/role/SegmentCustomerAndGeographicInformationTables", "shortName": "Segment, Customer and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - Commitments And Contingencies (Tables)", "role": "http://www.natus.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments And Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Business Combinations - Integra Acquisition (Details)", "role": "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "shortName": "Business Combinations - Integra Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "D2017Q4Oct6_us-gaap_BusinessAcquisitionAxis_ntus_IntegraMember", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Consolidated Statement of Comprehensive Income (Loss)", "role": "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss) Consolidated Statement of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Business Combinations - Otometrics Acquisition Narrative (Details)", "role": "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails", "shortName": "Business Combinations - Otometrics Acquisition Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "D2017Q1Jan3_us-gaap_BusinessAcquisitionAxis_ntus_OtometricsMember", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)", "role": "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "shortName": "Organization and Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "I2019Q1Jan1", "decimals": "-3", "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - Business Combinations - NeuroQuest Acquisition (Details)", "role": "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "shortName": "Business Combinations - NeuroQuest Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.natus.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Revenue - Unbilled AR and Deferred Revenue (Details)", "role": "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails", "shortName": "Revenue - Unbilled AR and Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Inventories (Details)", "role": "http://www.natus.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Inventories - Narrative (Details)", "role": "http://www.natus.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Property and Equipment (Details)", "role": "http://www.natus.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://www.natus.com/role/PropertyAndEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "ntus:AmortizationofIntangibleAssetsProductionandNonproduction", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Intangible Assets - Narrative (Details)", "role": "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ntus:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details)", "role": "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "shortName": "Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ntus:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "ntus:AmortizationofIntangibleAssetsProductionandNonproduction", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Intangible Assets - Schedule of Amortization Expense (Details)", "role": "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails", "shortName": "Intangible Assets - Schedule of Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_SoftwareDevelopmentMember", "decimals": "-3", "lang": null, "name": "ntus:AmortizationofIntangibleAssetsProductionandNonproduction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Details)", "role": "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails", "shortName": "Intangible Assets - Expected Annual Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Goodwill (Details)", "role": "http://www.natus.com/role/GoodwillDetails", "shortName": "Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Leases - Narrative (Details)", "role": "http://www.natus.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": null, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.natus.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Leases - Supplemental Cash Flow (Details)", "role": "http://www.natus.com/role/LeasesSupplementalCashFlowDetails", "shortName": "Leases - Supplemental Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Leases - Supplemental Balance Sheet (Details)", "role": "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails", "shortName": "Leases - Supplemental Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "ntus:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Leases - Lease Maturities (Details)", "role": "http://www.natus.com/role/LeasesLeaseMaturitiesDetails", "shortName": "Leases - Lease Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Accrued Liabilities (Details)", "role": "http://www.natus.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LiabilityForUncertainTaxPositionsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Long-Term Other Liabilities (Details)", "role": "http://www.natus.com/role/LongTermOtherLiabilitiesDetails", "shortName": "Long-Term Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LiabilityForUncertainTaxPositionsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2017Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Debt and Credit Arrangements - Narrative (Details)", "role": "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails", "shortName": "Debt and Credit Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2017Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Debt and Credit Arrangements - Schedule of Long Term Debt (Details)", "role": "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails", "shortName": "Debt and Credit Arrangements - Schedule of Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details)", "role": "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails", "shortName": "Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Financial Instruments and Derivatives (Details)", "role": "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails", "shortName": "Financial Instruments and Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ntus:StandardProductWarrantyPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Reserve for Product Warranties (Details)", "role": "http://www.natus.com/role/ReserveForProductWarrantiesDetails", "shortName": "Reserve for Product Warranties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ntus:StandardProductWarrantyPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.natus.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Earnings Per Share - Components of Basic and Diluted EPS (Detail)", "role": "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail", "shortName": "Earnings Per Share - Components of Basic and Diluted EPS (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Share-Based Compensation - Share-based Compensation Expense Allocation (Details)", "role": "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails", "shortName": "Share-Based Compensation - Share-based Compensation Expense Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - Share-Based Compensation - Narrative (Details)", "role": "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Business Combinations", "role": "http://www.natus.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418404 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)", "role": "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails", "shortName": "Share-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418405 - Disclosure - Share-Based Compensation - Valuation Inputs (Details)", "role": "http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails", "shortName": "Share-Based Compensation - Valuation Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - Share-Based Compensation - Restricted Stock Award Activity (Details)", "role": "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "shortName": "Share-Based Compensation - Restricted Stock Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Share-Based Compensation - Restricted Unit Activity (Details)", "role": "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails", "shortName": "Share-Based Compensation - Restricted Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Other Income (Expense), Net (Details)", "role": "http://www.natus.com/role/OtherIncomeExpenseNetDetails", "shortName": "Other Income (Expense), Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details)", "role": "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails", "shortName": "Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421403 - Disclosure - Income Taxes - Component of Income Tax Expense (Details)", "role": "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails", "shortName": "Income Taxes - Component of Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421404 - Disclosure - Income Taxes - Components of Deferred Tax Asset and Liabilities (Details)", "role": "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails", "shortName": "Income Taxes - Components of Deferred Tax Asset and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421405 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421406 - Disclosure - Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details)", "role": "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails", "shortName": "Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Organization and Significant Accounting Policies", "role": "http://www.natus.com/role/OrganizationAndSignificantAccountingPolicies", "shortName": "Organization and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421407 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423401 - Disclosure - Employee Benefit Plan (Details)", "role": "http://www.natus.com/role/EmployeeBenefitPlanDetails", "shortName": "Employee Benefit Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423402 - Disclosure - Segment, Customer and Geographic Information - Narrative (Details)", "role": "http://www.natus.com/role/SegmentCustomerAndGeographicInformationNarrativeDetails", "shortName": "Segment, Customer and Geographic Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423403 - Disclosure - Segment, Customer and Geographic Information (Details)", "role": "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails", "shortName": "Segment, Customer and Geographic Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425403 - Disclosure - Commitments And Contingencies - Narrative (Details)", "role": "http://www.natus.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "Commitments And Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "I2019Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ntus_MedixMedicalDevicesSRLMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NotesReceivableRelatedParties", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426402 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ntus_MedixMedicalDevicesSRLMember", "decimals": "-3", "lang": null, "name": "us-gaap:NotesReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427401 - Disclosure - Sale of Certain Subsidiary (Details)", "role": "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails", "shortName": "Sale of Certain Subsidiary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "D2019Q2Apr2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ntus_MedixMedicalDevicesSRLMember", "decimals": "-2", "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2428401 - Schedule - Schedule II: Valuation And Qualifying Accounts (Details)", "role": "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails", "shortName": "Schedule II: Valuation And Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ntus12311910-k.htm", "contextRef": "FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - ntus12311910-k.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - ntus12311910-k.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 75, "tag": { "country_AR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ARGENTINA", "terseLabel": "Argentina [Member]" } } }, "localname": "AR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA", "terseLabel": "Canada [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GERMANY", "terseLabel": "GERMANY" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_DK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "DENMARK", "terseLabel": "DENMARK", "verboseLabel": "Denmark [Member]" } } }, "localname": "DK", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FRANCE", "terseLabel": "France [Member]" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "IRELAND", "terseLabel": "Ireland [Member]" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r509" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r508" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r506" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r507" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.natus.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ntus_AccruedSellingExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Selling Expense, Current", "label": "Accrued Selling Expense, Current", "terseLabel": "Accrued selling expenses" } } }, "localname": "AccruedSellingExpenseCurrent", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_AccruedTravelCurrent": { "auth_ref": [], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Travel, Current", "label": "Accrued Travel, Current", "terseLabel": "Accrued travel" } } }, "localname": "AccruedTravelCurrent", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_AmortizationofIntangibleAssetsProductionandNonproduction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Intangible Assets, Production and Nonproduction", "label": "Amortization of Intangible Assets, Production and Nonproduction", "terseLabel": "Total amortization" } } }, "localname": "AmortizationofIntangibleAssetsProductionandNonproduction", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ntus_AssetsAndLiabilitiesHeldForSalePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities Held For Sale Policy [Policy Text Block]", "label": "Assets And Liabilities Held For Sale Policy [Policy Text Block]", "terseLabel": "Assets and Liabilities Held for Sale" } } }, "localname": "AssetsAndLiabilitiesHeldForSalePolicyPolicyTextBlock", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ntus_AssetsandLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets and Liabilities, Lessee [Table Text Block]", "label": "Assets and Liabilities, Lessee [Table Text Block]", "terseLabel": "Assets and Liabilities, Lessee" } } }, "localname": "AssetsandLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ntus_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets", "terseLabel": "Tangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssets", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "ntus_CitibankNationalAssociationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Citibank, National Association [Member]", "label": "Citibank, National Association [Member]", "terseLabel": "Citibank, National Association [Member]" } } }, "localname": "CitibankNationalAssociationMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ntus_ContractWithCustomerAssetIncreaseFromPerformanceObligationSatisfied": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Asset, Increase From Performance Obligation Satisfied", "label": "Contract With Customer, Asset, Increase From Performance Obligation Satisfied", "terseLabel": "Additions" } } }, "localname": "ContractWithCustomerAssetIncreaseFromPerformanceObligationSatisfied", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ntus_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "terseLabel": "Additions" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ntus_ContractWithCustomerServicePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Service Period", "label": "Contract With Customer, Service Period", "terseLabel": "Contract With Customer, Service Period" } } }, "localname": "ContractWithCustomerServicePeriod", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "ntus_CostsIncurredForDevelopmentOfInternalUseComputerSoftware": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred for development of internal use computer software.", "label": "Costs Incurred for Development of Internal Use Computer Software", "terseLabel": "Costs incurred for development of internal use computer software" } } }, "localname": "CostsIncurredForDevelopmentOfInternalUseComputerSoftware", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ntus_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ntus_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Operating leases" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_DeferredTaxLiabilitiesBasisDifferenceInFixedAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred tax liabilities basis difference in fixed and intangible assets.", "label": "Deferred Tax Liabilities Basis Difference In Fixed And Intangible Assets", "negatedLabel": "Basis difference in fixed and intangible assets" } } }, "localname": "DeferredTaxLiabilitiesBasisDifferenceInFixedAndIntangibleAssets", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Right-Of-Use Assets", "negatedTerseLabel": "Operating leases" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_DemonstrationAndLoanedEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Demonstration and loaned equipment.", "label": "Demonstration and Loaned Equipment [Member]", "terseLabel": "Demonstration and loaned equipment [Member]" } } }, "localname": "DemonstrationAndLoanedEquipmentMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ntus_DerivativeInstrumentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Instrument [Abstract]", "label": "Derivative Instrument [Abstract]" } } }, "localname": "DerivativeInstrumentAbstract", "nsuri": "http://www.natus.com/20191231", "xbrltype": "stringItemType" }, "ntus_DerivativeLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Liability, Additions", "label": "Derivative Liability, Additions", "terseLabel": "Derivative Liability, Additions" } } }, "localname": "DerivativeLiabilityAdditions", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsDetails", "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ntus_DerivativeLiabilityAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Liability, Adjustments", "label": "Derivative Liability, Adjustments", "terseLabel": "Derivative Liability, Adjustments" } } }, "localname": "DerivativeLiabilityAdjustments", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsDetails", "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ntus_DerivativeLiabilityPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derivative Liability, Payments", "label": "Derivative Liability, Payments", "terseLabel": "Derivative Liability, Payments" } } }, "localname": "DerivativeLiabilityPayments", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsDetails", "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ntus_DevicesAndSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Devices and systems.", "label": "Devices and Systems [Member]", "terseLabel": "Devices and Systems [Member]" } } }, "localname": "DevicesAndSystemsMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxOnAcquisitions": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 17.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective, Income Tax Rate Reconciliation, Alternative Minimum Tax On Acquisitions", "label": "Effective, Income Tax Rate Reconciliation, Alternative Minimum Tax On Acquisitions", "terseLabel": "AMT on acquisition" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxOnAcquisitions", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeNetofForeignTaxCreditsAmount": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 15.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low-Taxed Income Net of Foreign Tax Credits, Amount", "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low-Taxed Income Net of Foreign Tax Credits, Amount", "terseLabel": "Global intangible low-taxed income net of foreign tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeNetofForeignTaxCreditsAmount", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsEarnoutAdjustment": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Earnout Adjustment", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Earnout Adjustment", "terseLabel": "Earnout adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsEarnoutAdjustment", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_EffectiveIncomeTaxRateReconciliationReturnToProvision": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 16.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision", "label": "Effective Income Tax Rate Reconciliation, Return To Provision", "terseLabel": "Return to provision" } } }, "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_EffectiveIncomeTaxRateReconciliationSAB118AdjustmentsAmount": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 18.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, SAB 118 Adjustments, Amount", "label": "Effective Income Tax Rate Reconciliation, SAB 118 Adjustments, Amount", "terseLabel": "SAB 118 adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationSAB118AdjustmentsAmount", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_EffectiveIncomeTaxRateReconciliationTaxAudit": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 13.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Audit", "label": "Effective Income Tax Rate Reconciliation, Tax Audit", "terseLabel": "Withholding taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxAudit", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_EmployeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees [Member]", "label": "Employees [Member]", "terseLabel": "Employees [Member]" } } }, "localname": "EmployeesMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ntus_FinanceLeaseRightOfUseAssetAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": 2.0, "parentTag": "ntus_FinanceLeaseRightofUseAssetNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation", "label": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation", "negatedTerseLabel": "Finance leases, accumulated amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedDepreciation", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "ntus_FinanceLeaseRightOfUseAssetGross": { "auth_ref": [], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": 1.0, "parentTag": "ntus_FinanceLeaseRightofUseAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Gross", "label": "Finance Lease, Right-Of-Use Asset, Gross", "terseLabel": "Finance Leases, property and equipment" } } }, "localname": "FinanceLeaseRightOfUseAssetGross", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "ntus_FinanceLeaseRightofUseAssetNet": { "auth_ref": [], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Right-of-Use Asset, Net", "label": "Finance Lease, Right-of-Use Asset, Net", "totalLabel": "Finance leases, property and equipment, net" } } }, "localname": "FinanceLeaseRightofUseAssetNet", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "ntus_ForeignCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign countries.", "label": "Foreign Countries [Member]", "terseLabel": "Other Foreign countries [Member]" } } }, "localname": "ForeignCountriesMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_ImpairmentofIntangibleAssetsDefinedLivedexcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Impairment of Intangible Assets Defined Lived (excluding Goodwill)", "label": "Impairment of Intangible Assets Defined Lived (excluding Goodwill)", "negatedTerseLabel": "Impairment of Intangible Assets Defined Lived (excluding Goodwill)" } } }, "localname": "ImpairmentofIntangibleAssetsDefinedLivedexcludingGoodwill", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_IncomeTaxProvisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Tax Provision [Member]", "label": "Income Tax Provision [Member]", "terseLabel": "Income Tax Provision [Member]" } } }, "localname": "IncomeTaxProvisionMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ntus_IncomeTaxReconciliationChangeOfValuationAllowanceOnForeignTaxCredit": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income tax reconciliation change of valuation allowance on foreign tax credit.", "label": "Income Tax Reconciliation Change Of Valuation Allowance On Foreign Tax Credit", "terseLabel": "Change of valuation allowance on foreign tax credit" } } }, "localname": "IncomeTaxReconciliationChangeOfValuationAllowanceOnForeignTaxCredit", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_IncomeTaxReconciliationLapseOfStatuteAndAuditSettlementOnUncertainTaxPosition": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income tax reconciliation lapse of statute and audit settlement on uncertain tax position.", "label": "Income Tax Reconciliation Lapse Of Statute And Audit Settlement On Uncertain Tax Position", "terseLabel": "Lapse of statute" } } }, "localname": "IncomeTaxReconciliationLapseOfStatuteAndAuditSettlementOnUncertainTaxPosition", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "ntus_IntegraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Integra [Member]", "label": "Integra [Member]", "terseLabel": "Integra [Member]" } } }, "localname": "IntegraMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails" ], "xbrltype": "domainItemType" }, "ntus_InventoryCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.natus.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventory current and noncurrent.", "label": "Inventory Current and Noncurrent", "totalLabel": "Total Inventories" } } }, "localname": "InventoryCurrentAndNoncurrent", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ntus_MaximumEligibleCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Maximum eligible compensation.", "label": "Maximum Eligible Compensation", "terseLabel": "Eligible compensation of employees" } } }, "localname": "MaximumEligibleCompensation", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ntus_MedixMedicalDevicesSRLMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medix Medical Devices, SRL [Member]", "label": "Medix Medical Devices, SRL [Member]", "terseLabel": "Medix Medical Devices, SRL [Member]" } } }, "localname": "MedixMedicalDevicesSRLMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails", "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "ntus_MovementinUnbilledReceivablesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Movement in Unbilled Receivables [Roll Forward]", "label": "Movement in Unbilled Receivables [Roll Forward]", "terseLabel": "Movement in Unbilled AR [Roll Forward]" } } }, "localname": "MovementinUnbilledReceivablesRollForward", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "ntus_NeurologyProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Neurology Products [Member]", "label": "Neurology Products [Member]", "terseLabel": "Neurology Products [Member]" } } }, "localname": "NeurologyProductsMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_NewbornCareProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Newborn Care Products [Member]", "label": "Newborn Care Products [Member]", "terseLabel": "Newborn Care Products [Member]" } } }, "localname": "NewbornCareProductsMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesLineItems", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ntus_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTable", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ntus_OtherComprehensiveIncomeLossNetOfTaxAndASUAdoptionImpact": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Of Tax And ASU Adoption Impact", "label": "Other Comprehensive Income (Loss), Net Of Tax And ASU Adoption Impact", "terseLabel": "Other comprehensive income, net of ASU adoption impact" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxAndASUAdoptionImpact", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ntus_OtometricsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Otometrics [Member]", "label": "Otometrics [Member]", "terseLabel": "Otometrics [Member]" } } }, "localname": "OtometricsMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "ntus_OtometricsProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "OtometricsProducts [Member]", "label": "OtometricsProducts [Member]", "terseLabel": "OtometricsProducts [Member]" } } }, "localname": "OtometricsProductsMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_RatioofInterestCoverage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ratio of Interest Coverage", "label": "Ratio of Interest Coverage", "terseLabel": "Ratio of Interest Coverage" } } }, "localname": "RatioofInterestCoverage", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ntus_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of finite and indefinite lived intangible assets.", "label": "Schedule of Finite and Indefinite Lived Intangible Assets [Table Text Block]", "terseLabel": "Components of Gross and Net Intangible Asset Balances" } } }, "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ntus_ScheduleOfIncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Income Taxes [Line Items]", "label": "Schedule Of Income Taxes [Line Items]", "terseLabel": "Schedule Of Income Taxes [Line Items]" } } }, "localname": "ScheduleOfIncomeTaxesLineItems", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ntus_ScheduleOfIncomeTaxesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Income Taxes [Table]", "label": "Schedule Of Income Taxes [Table]", "terseLabel": "Schedule Of Income Taxes [Table]" } } }, "localname": "ScheduleOfIncomeTaxesTable", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ntus_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsActivityTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table]", "label": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsActivityTable", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "ntus_ServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Services [Member]", "label": "Services [Member]", "terseLabel": "Services [Member]" } } }, "localname": "ServicesMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Fair Value", "terseLabel": "Fair market value of outstanding awards" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingFairValue", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ntus_StandardProductWarrantyPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Standard product warranty period.", "label": "Standard Product Warranty Period", "terseLabel": "Product warranty period" } } }, "localname": "StandardProductWarrantyPeriod", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ReserveForProductWarrantiesDetails" ], "xbrltype": "durationItemType" }, "ntus_SuppliesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplies [Member]", "label": "Supplies [Member]", "terseLabel": "Supplies [Member]" } } }, "localname": "SuppliesMember", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "ntus_VestingOfRestrictedStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Vesting of restricted stock units.", "label": "Vesting Of Restricted Stock Units", "terseLabel": "Vesting of restricted stock units" } } }, "localname": "VestingOfRestrictedStockUnits", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ntus_VestingOfRestrictedStockUnitsShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vesting of restricted stock units shares.", "label": "Vesting Of Restricted Stock Units Shares", "terseLabel": "Vesting of restricted stock units (shares)" } } }, "localname": "VestingOfRestrictedStockUnitsShares", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ntus_WithholdingTaxPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Withholding Tax, Percent", "label": "Withholding Tax, Percent", "terseLabel": "Withholding Tax, Percent" } } }, "localname": "WithholdingTaxPercent", "nsuri": "http://www.natus.com/20191231", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "srt_DirectorMember": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Person with designation of executive officer.", "label": "Executive Officer [Member]", "terseLabel": "Executives RSAs and RSUs [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails", "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/LeasesNarrativeDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails", "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/LeasesNarrativeDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r174", "r264", "r267", "r497", "r498" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails", "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/LeasesNarrativeDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails", "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/LeasesNarrativeDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by revision of previously issued financial statements.", "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revision of previously issued financial statements.", "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r139", "r514" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II: of Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]", "verboseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r176", "r264", "r268", "r499", "r500", "r502", "r512", "r513" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r178", "r447" ], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r139", "r514" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r355", "r356" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16 [Member]" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201802Member": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.", "label": "Accounting Standards Update 2018-02 [Member]", "terseLabel": "Accounting Standards Update 2018-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201802Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Information by billing status of receivables.", "label": "Billing Status, Type [Axis]", "terseLabel": "Billing Status, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r23", "r179", "r180", "r265" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $7,384 and $6,960" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails", "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r51" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r223" ], "calculation": { "http://www.natus.com/role/PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r71", "r73", "r74" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r70", "r74", "r78", "r379" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Identifiable intangible assets acquired, average useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r279", "r312", "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r28", "r181", "r185" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r117", "r203", "r211" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Intangibles amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from calculations of diluted EPS" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r170", "r470", "r487" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r64" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.", "label": "Assets, Fair Value Adjustment", "terseLabel": "Assets, Fair Value Adjustment" } } }, "localname": "AssetsFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r281", "r314" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r366", "r367" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r364", "r365" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r116", "r376" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration earn-out" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r368", "r369" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "terseLabel": "Liabilities assumed in acquisition" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers": { "auth_ref": [ "r14", "r469", "r486", "r503" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unamortized costs incurred for development of computer software, which is to be sold, leased or otherwise marketed, after establishing technological feasibility through to the general release of the software products. Excludes capitalized costs of developing software for internal use.", "label": "Capitalized Software Development Costs for Software Sold to Customers", "terseLabel": "Costs incurred for development of software to be sold" } } }, "localname": "CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r40", "r119" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r120", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r235", "r478", "r493" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 21)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r234", "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments And Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r58" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.natus.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.natus.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r250" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 34,148,700 in 2019 and 33,804,379 in 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r271", "r272", "r277", "r319" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/EmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r81", "r83", "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer software and hardware [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r204", "r209", "r373" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Internally developed software [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r125", "r378", "r380", "r381" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract with Customer, Asset and Liability [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r257", "r259", "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Unbilled AR, December 31, 2019", "periodStartLabel": "Unbilled AR, December 31, 2018" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r260" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "Contract with Customer, Asset, Reclassified to Receivable", "negatedTerseLabel": "Transferred to Trade Receivable" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r257", "r258", "r265" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred Revenue, December 31, 2019", "periodStartLabel": "Deferred Revenue, December 31, 2018" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r257", "r258", "r265" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract with Customer, Liability, Current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r257", "r258", "r265" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Contract with Customer, Liability, Noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedTerseLabel": "Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of assets, liabilities, and operations which are strategic or central to an entity's ongoing business.", "label": "Core [Member]", "terseLabel": "Core [Member]" } } }, "localname": "CoreMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r97" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r94" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Amortization", "terseLabel": "Intangibles amortization" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect of new accounting principle in period of adoption" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r130", "r351", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r135", "r353" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Non-U.S." } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r351", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current tax expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r130", "r351", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "U.S. State and local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Accrued amounts due to customers" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer related [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Credit Arrangements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r471", "r474", "r485" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r246", "r474", "r485" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "verboseLabel": "Revolving credit facility" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r54", "r248", "r417" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r55", "r132", "r251", "r252", "r253", "r254", "r416", "r417", "r419", "r483" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r352", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r45", "r418" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Debt Issuance Costs, Net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r352", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Non-U.S." } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r345" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income tax" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r130", "r352", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r19", "r20", "r341", "r472", "r484" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r328", "r345" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income tax" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditCurrent": { "auth_ref": [ "r51", "r420" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.", "label": "Deferred Rent Credit, Current", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.natus.com/role/LongTermOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Non-current deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LongTermOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r352", "r358" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "U.S. State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r342" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r345" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred Tax Assets, Net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r343" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r322", "r349", "r350" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r347", "r349", "r350" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r322", "r349", "r350" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "terseLabel": "Employee benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r323", "r349", "r350" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accruals deductible in different periods" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r344" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowances" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails", "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r349" ], "calculation": { "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "negatedTerseLabel": "Foreign earnings to be repatriated" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Contribution Plan [Abstract]" } } }, "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer matching contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/EmployeeBenefitPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r117", "r221" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r117", "r168" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Derivative, Fixed Interest Rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r388", "r389", "r391", "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial Instruments and Derivatives" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r387", "r388", "r391" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r65", "r66", "r407" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTerseLabel": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails", "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r383", "r384", "r385" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Derivative Liability, Notional Amount" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Technology [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r91", "r142", "r145", "r146", "r147", "r148", "r152", "r481", "r496" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Basic earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r91", "r142", "r145", "r146", "r147", "r148", "r152", "r481", "r496" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r125", "r149", "r150", "r151" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Income per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r411" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Exchange rate effect on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r329", "r330", "r357" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount": { "auth_ref": [ "r329" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount", "terseLabel": "Net deferred tax asset re-measurement" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period of recognition of unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation of unvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to unvested portion of stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "auth_ref": [ "r318" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of plan compensation cost recognized during the period.", "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "terseLabel": "Compensation expense associated with the ESPP" } } }, "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r397", "r398", "r399", "r403" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r273", "r274", "r276", "r398", "r453" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r397", "r398", "r400", "r401", "r404" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r273", "r274", "r276", "r398", "r454" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r273", "r274", "r276", "r398", "r455" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r402", "r404" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r125", "r405", "r406" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r425", "r431", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r427", "r436" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r424", "r441" ], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails", "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r424" ], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance leases, accrued liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Finance Lease, Liability, Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r424" ], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://www.natus.com/role/LongTermOtherLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance Lease, Liability, Noncurrent", "verboseLabel": "Finance leases, other liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails", "http://www.natus.com/role/LongTermOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r426", "r436" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows", "http://www.natus.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance Lease, Right-of-Use Asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r425", "r431", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets (principal payments)" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r439", "r442" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate, finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r438", "r442" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term, finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted average life of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r210" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r212" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r212" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r212" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r212" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r212" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r204", "r206", "r210", "r213", "r456" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r210", "r456" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r204", "r209" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r210" ], "calculation": { "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total expected amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Significant foreign jurisdictions [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r408", "r409", "r410" ], "calculation": { "http://www.natus.com/role/OtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Net foreign currency transaction gains (losses)", "verboseLabel": "Foreign currency gain (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r125", "r410", "r414" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Office furniture and equipment [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r117" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "(Gain) loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "Gain (Loss) on Sale of Assets and Asset Impairment Charges" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r192", "r194" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r125", "r198", "r207" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Carrying value of intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/Goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r117", "r193", "r195", "r199" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Goodwill impairment charge", "terseLabel": "Goodwill impairment charge" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows", "http://www.natus.com/role/GoodwillDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/GoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r196", "r197", "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Acquisitions/Purchase Accounting Adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r96" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r387", "r394" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentChargeOnReclassifiedAssets": { "auth_ref": [ "r219", "r220" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date.", "label": "Impairment Charge on Reclassified Assets", "terseLabel": "Impairment charge for sale of entity" } } }, "localname": "ImpairmentChargeOnReclassifiedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r117", "r214" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible asset impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r117", "r214" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "verboseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r125", "r218", "r227" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r134" ], "calculation": { "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r134" ], "calculation": { "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r134" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before provision (benefit) for income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r169", "r360" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income tax", "totalLabel": "Total expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails", "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r85", "r125", "r326", "r327", "r339", "r340", "r346", "r361", "r501" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfAssets": { "auth_ref": [ "r329" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount", "terseLabel": "Deferred charges on sales of U.S. intellectual property" } } }, "localname": "IncomeTaxReconciliationDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r128", "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign taxes at rates less than U.S. rates" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r129", "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Federal statutory tax expense" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Equity compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r329" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 14.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Withholding taxes" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 19.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Repatriation tax net of foreign tax credits" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r129", "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State tax expense" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "terseLabel": "Uncertain tax position" } } }, "localname": "IncomeTaxReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r114", "r121" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r202", "r208" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r88", "r167", "r415", "r418", "r482" ], "calculation": { "http://www.natus.com/role/OtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r111", "r113", "r121" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r190" ], "calculation": { "http://www.natus.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "ntus_InventoryCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r61", "r187" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "negatedLabel": "Less: Non-current Inventories", "terseLabel": "Non-current Inventories" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/InventoriesDetails", "http://www.natus.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r62", "r125", "r154", "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r33", "r34", "r190" ], "calculation": { "http://www.natus.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "ntus_InventoryCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "terseLabel": "Raw materials and subassemblies" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r190" ], "calculation": { "http://www.natus.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "ntus_InventoryCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r99", "r166" ], "calculation": { "http://www.natus.com/role/OtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Short-term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r440", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r441" ], "calculation": { "http://www.natus.com/role/LeasesLeaseMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest", "terseLabel": "Undiscounted future minimum operating lease commitments" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r50" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r475", "r491" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.natus.com/role/LongTermOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "terseLabel": "Contingent tax obligations" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LongTermOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r17", "r474", "r485" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Available amount under credit facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r48", "r132" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Line of Credit Facility, Increase (Decrease), Net" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Revolving credit facility with Wells Fargo Bank" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions": { "auth_ref": [ "r445", "r479" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reflects the amount of new advances made to related parties in the form of loan and lease receivables.", "label": "Loans and Leases Receivable, Related Parties, Additions", "terseLabel": "Loans and Leases Receivable, Related Parties, Additions" } } }, "localname": "LoansAndLeasesReceivableRelatedPartiesAdditions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease": { "auth_ref": [ "r445", "r479" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in loans and leases receivable due from related parties.", "label": "Loans and Leases Receivable, Related Parties, Period Increase (Decrease)", "terseLabel": "Loans and Leases Receivable, Related Parties, Period Increase (Decrease)" } } }, "localname": "LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesProceeds": { "auth_ref": [ "r102", "r476" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from related parties which reduce the amount of loans and leases receivable due from related parties.", "label": "Loans and Leases Receivable, Related Parties, Proceeds", "terseLabel": "Loans and Leases Receivable, Related Parties, Proceeds" } } }, "localname": "LoansAndLeasesReceivableRelatedPartiesProceeds", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r247", "r474", "r489" ], "calculation": { "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less: current portion of long-term debt", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r137", "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r137", "r244" ], "calculation": { "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2019" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r137", "r244" ], "calculation": { "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r137", "r244" ], "calculation": { "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Purchase commitments for inventory, total" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r55", "r245" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInDeferredRevenueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Deferred Revenue [Roll Forward]", "terseLabel": "Movement in Deferred Revenue [Roll Forward]" } } }, "localname": "MovementInDeferredRevenueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r112", "r115", "r118" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r79", "r82", "r90", "r118", "r150", "r480", "r495" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows", "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonCoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of assets, liabilities, and operations that are part of businesses or portfolios not strategic or central to an entity's ongoing business operations. Includes but is not limited to, higher risk, nonstrategic legacy businesses or portfolios intended to be wound down or disposed of other than by sale.", "label": "Non-core [Member]", "terseLabel": "Non-core [Member]" } } }, "localname": "NonCoreMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Foreign countries [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r122", "r123", "r124" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Property and equipment included in accounts payable" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.natus.com/role/OtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NotesReceivableRelatedParties": { "auth_ref": [ "r136", "r445", "r494" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.", "label": "Notes Receivable, Related Parties", "terseLabel": "Notes Receivable, Related Parties" } } }, "localname": "NotesReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails", "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedLabel": "Income from operations", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails", "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r432", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r424" ], "calculation": { "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseMaturitiesDetails", "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r424" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r424" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r428", "r436" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r423" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r439", "r442" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate, operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r438", "r442" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term", "verboseLabel": "Weighted average remaining lease term, operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesNarrativeDetails", "http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Tax net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r140", "r162", "r382" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r51" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r68", "r69", "r71" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Unrealized losses on available-for-sale investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r71", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Interest rate swap designated as a cash flow hedge" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67", "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Recorded foreign currency translation gains (losses)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r71", "r75", "r76", "r77", "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "terseLabel": "Reclassification of deferred foreign currency related adjustments related to the sale of Medix (See FN 23)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r80", "r83", "r86", "r250" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r270", "r320" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income (Expense), Net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Long-Term Other Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LongTermOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.natus.com/role/LongTermOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/LongTermOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing activities:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Long-Term Other Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LongTermOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.natus.com/role/OtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPaymentsToAcquireBusinesses": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.", "label": "Other Payments to Acquire Businesses", "terseLabel": "Inventory purchase commitment" } } }, "localname": "OtherPaymentsToAcquireBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r18", "r473", "r488" ], "calculation": { "http://www.natus.com/role/LongTermOtherLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LongTermOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r108" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of company stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r110" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Deferred debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r108" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r104", "r375" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Purchase price paid in cash to acquire entity" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r104" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r105" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquisition of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r105" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.natus.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.natus.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued", "verboseLabel": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.natus.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding", "verboseLabel": "Preferred stock, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.natus.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and in 2018" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r38", "r39" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r107" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from long-term borrowings" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r106", "r315" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from stock option exercises and ESPP" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r103" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-term Investments", "terseLabel": "Sales of short-term investments" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product Warranties Disclosures [Abstract]" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r241", "r242", "r477" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "terseLabel": "Product reserve warranty" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ReserveForProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r51", "r237", "r238" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "terseLabel": "Accrued federal, state, and local taxes" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "terseLabel": "Reserve for Product Warranties" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ReserveForProductWarranties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProductWarrantyExpense": { "auth_ref": [ "r116", "r239" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.", "label": "Product Warranty Expense", "terseLabel": "Warranty reserve" } } }, "localname": "ProductWarrantyExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r224" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r222" ], "calculation": { "http://www.natus.com/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Gross, Period Increase (Decrease)", "terseLabel": "Inventory transferred to property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r224", "r492" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.natus.com/role/PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r125", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r222" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r93", "r186" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for losses on accounts receivable" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RatioOfIndebtednessToNetCapital1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indebtedness divided by net capital.", "label": "Ratio of Indebtedness to Net Capital", "terseLabel": "Ratio of Indebtedness to Net Capital" } } }, "localname": "RatioOfIndebtednessToNetCapital1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_ReceivablesBillingStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.", "label": "Receivables Billing Status [Domain]", "terseLabel": "Receivables Billing Status [Domain]" } } }, "localname": "ReceivablesBillingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r29", "r125", "r182" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Allowance for Doubtful Accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r74", "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Reclassification of stranded tax effects upon adoption of ASU 2018-02" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails", "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r444", "r448", "r449" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r275", "r446", "r448", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FairValueMeasurementsNarrativeDetails", "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Sale of Certain Subsidiary Assets" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SaleOfCertainSubsidiaryAssetsSaleOfCertainSubsidiaryAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r109" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Payments on borrowings" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r321", "r504" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r44", "r125", "r215", "r216", "r504" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research & Development Costs" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r117", "r229", "r231", "r232" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r255", "r490" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r126", "r127" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r262" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r89", "r164", "r165", "r173" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails", "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r437", "r442" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations: finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r437", "r442" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations: operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r366", "r367" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails", "http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Summary of components of income tax expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r55", "r132", "r251", "r252", "r253", "r254", "r416", "r417", "r419", "r483" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/FinancialInstrumentsAndDerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Components of Basic and Diluted EPS" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r279", "r311", "r317" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r279", "r311", "r317" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r204", "r209" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r204", "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Amortization expense related to intangible assets with definite lives" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Operating lease, right-of-use asset" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r198", "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/GoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Income (loss) before provision (benefit) for income tax" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r35", "r36", "r37" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r43", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r131", "r446", "r448", "r449", "r450", "r451" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SaleOfCertainSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r95", "r176" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Revenue and long-lived asset information by geographic region" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r163", "r170", "r171", "r172", "r198" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Restricted Stock Units Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r287", "r299", "r302" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Restricted Stock Awards Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r338", "r354" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Uncertain Tax Positions" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Expected annual amortization expense related to amortizable intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment, Customer and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Self-funded insurance expense" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Marketing and selling" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Marketing and sales [Member]" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceAgreementsMember": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.", "label": "Service Agreements [Member]", "terseLabel": "Service Agreements [Member]" } } }, "localname": "ServiceAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r116" ], "calculation": { "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Share based compensation, vesting period", "verboseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Offering price, percentage of fair market value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited, Shares", "negatedTerseLabel": "Forfeited, units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted - average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Awarded, units", "verboseLabel": "Granted, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted - average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, end of period, Shares", "periodStartLabel": "Unvested, beginning of period, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, end of period, Weighted - average grant date fair value", "periodStartLabel": "Unvested, beginning of period, Weighted - average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Release, units", "negatedTerseLabel": "Vested, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value, vested in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted - average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Employee maximum withholding rate (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r288", "r290" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodStartLabel": "Unvested, beginning of period, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares available for future awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Weighted average shares exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Cancelled (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r289", "r314" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (shares)", "periodStartLabel": "Outstanding, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Intrinsic value of options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Intrinsic value of options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Weighted average vested options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price of vested stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r278", "r285" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails", "http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "On each of the third and fourth anniversaries of the vesting date[Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r125", "r281", "r286" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate intrinsic value of outstanding restricted stock units" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Share based compensation, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r306", "r316" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price for shares acquired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Beginning balance (shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Taxes paid related to net share settlement of equity awards (shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r433", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Internally Developed Software [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r125", "r240" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Liability for product warranties" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r170", "r198", "r226", "r230", "r233", "r497" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r59", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r21", "r22", "r250", "r255" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Employee stock purchase plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r21", "r22", "r250", "r255" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Net issuance of restricted stock awards (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r250", "r255" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation expense (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r250", "r255", "r292" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (shares)", "terseLabel": "Exercise of stock options (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r21", "r22", "r250", "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r250", "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Net issuance of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r255", "r280", "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r59", "r250", "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r21", "r22", "r250", "r255" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of company stock (shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r21", "r22", "r250", "r255" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of company stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r25", "r26", "r183" ], "calculation": { "http://www.natus.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets", "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r435", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": 6.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credits carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of reasonable estimate for tax liability for which accounting for tax effect from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated is incomplete pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability", "terseLabel": "Deferred tax liabilities related to foreign earnings" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "terseLabel": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect" } } }, "localname": "TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.natus.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Warranty reserve" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]", "verboseLabel": "Trade names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails", "http://www.natus.com/role/IntangibleAssetsNarrativeDetails", "http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledRevenuesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.", "label": "Unbilled Revenues [Member]", "terseLabel": "Unbilled Revenues [Member]" } } }, "localname": "UnbilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r324", "r333" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending-Unrecognized Tax Benefits", "periodStartLabel": "Beginning-Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "terseLabel": "Foreign exchange difference" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r331" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Interest and penalties related to uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r331" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "negatedTerseLabel": "Total Interest and penalties related to uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases for tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation", "negatedTerseLabel": "Foreign exchange difference" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Decreases for tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Increase in unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Lapse of statutes of limitations", "terseLabel": "Lapse of statutes of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails", "http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r155", "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additions Charged to Expense" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r434", "r442" ], "calculation": { "http://www.natus.com/role/LeasesLeaseCostDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantyReservesMember": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Reserve for expected cost from warranty provided on specific product or service.", "label": "SEC Schedule, 12-09, Reserve, Warranty [Member]", "terseLabel": "SEC Schedule, 12-09, Reserve, Warranty [Member]" } } }, "localname": "WarrantyReservesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r148" ], "calculation": { "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive effect of stock based awards" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r144", "r148" ], "calculation": { "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (shares)", "totalLabel": "Diluted Shares (in dollars per share)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares used in the calculation of net loss per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r148" ], "calculation": { "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)", "verboseLabel": "Weighted average common shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.natus.com/role/ConsolidatedStatementsOfOperations", "http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5144-111524" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/subtopic&trid=2144439" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2459-110228" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3,4))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(b))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r377": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.7(e))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r506": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r507": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r508": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r509": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r511": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r512": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r513": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r514": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL116659650-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e709-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } XML 30 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Debt Disclosure [Abstract]    
2019 $ 0 $ 0
2020 0 0
2021 55,000 105,000
Thereafter 0 0
Long-term Debt $ 55,000 $ 105,000
XML 31 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Other Income (Expense), Net (Tables)
 12 Months Ended
Dec. 31, 2019
Other Income and Expenses [Abstract]  
Other income (expense), net
Other income (expense), net consists of (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Interest income
$
250

 
$
334

 
$
425

Interest expense
(4,941
)
 
(6,794
)
 
(5,081
)
Foreign currency gain (loss)
(765
)
 
(800
)
 
1,013

Other
(135
)
 
(438
)
 
76

Total other expense, net
$
(5,591
)
 
$
(7,698
)
 
$
(3,567
)
XML 32 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt and Credit Arrangements (Tables)
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
Long-term debt consists of (in thousands):
 
December 31,
 
2019
 
2018
Revolving credit facility
$
55,000

 
$
105,000

Debt issuance costs
(335
)
 
(526
)
Less: current portion of long-term debt
35,000

 
35,000

Total long-term debt
$
19,665

 
$
69,474
Schedule of Maturities of Long-term Debt
Maturities of long-term debt as of December 31, 2019 are as follows (in thousands):
 
December 31,
 
2019
 
2018
2019
$
—

 
$
—

2020
—

 
—

2021
55,000

 
105,000

Thereafter
—

 
—

Total
$
55,000

 
$
105,000
XML 33 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Combinations - Integra Acquisition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 06, 2017
Dec. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Business Acquisition [Line Items]        
Goodwill   $ 172,998 $ 146,367 $ 147,644
Integra [Member]        
Business Acquisition [Line Items]        
Purchase price paid in cash to acquire entity $ 46,200      
Tangible assets acquired 13,700      
Intangible assets acquired $ 25,700      
Identifiable intangible assets acquired, average useful life 9 years      
Goodwill $ 8,100      
Liabilities assumed in acquisition $ 1,300      
Revenue   $ 539,100    
XML 34 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Expected Annual Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
2019 $ 21,616  
2020 20,724  
2021 17,329  
2022 16,375  
2023 14,483  
Thereafter 24,272  
Total expected amortization expense $ 114,799 $ 139,453
XML 35 R92.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment, Customer and Geographic Information - Narrative (Details)
 12 Months Ended
Dec. 31, 2019
Segment
Segment Reporting [Abstract]  
Number of reporting segments 1
XML 36 R96.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Sale of Certain Subsidiary (Details) - USD ($)
Apr. 02, 2019
Dec. 31, 2019
Aug. 02, 2019
Dec. 31, 2018
Related Party Transaction [Line Items]        
Accumulated other comprehensive loss   $ (16,275,000)   $ (38,032,000)
Medix Medical Devices, SRL [Member]        
Related Party Transaction [Line Items]        
Related Party Transaction, Amounts of Transaction $ 2,500      
Notes Receivable, Related Parties 2,200,000      
Gain (Loss) on Sale of Assets and Asset Impairment Charges 24,600,000      
Accumulated other comprehensive loss     $ 24,800,000  
Assets, Fair Value Adjustment $ 4,600,000      
XML 37 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Supplemental Cash Flow (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Leases [Abstract]      
Operating cash flows from operating leases $ 13,612    
Operating cash flows from finance leases 42    
Financing cash flows from finance leases 478 $ 0 $ 0
Right-of-use assets obtained in exchange for lease obligations: operating leases 2,697    
Right-of-use assets obtained in exchange for lease obligations: finance leases $ 300    
EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $R 8E ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 3(!B4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !,@&)016GI^>X K @ $0 &1O8U!R;W!S+V-O M&ULS9)-:L,P$$:O4K2W1[8A"^%HT]!5"X4&6KH3TB01M7Z0IMBY?64W M<2CM 0K::.;3FS>@7D>A0\+G%"(FLICO)C?X+'3$+\U# M2$Y1N:8C1*4_U!&AY7P##DD910IF8!57(I.]T4(G5!32!6_TBH^?:5A@1@,. MZ-!3AJ9N@,EY8CQ/0P\WP PC3"Y_%]"LQ*7Z)W;I +LDIVS7U#B.]=@MN;)# M V]/CR_+NI7UF9376%YE*^@<<621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( $R 8E %2YG7>P, "T1 8 >&PO=V]R:W-H965T&UL?5AM;YLP&/PKB!\P\ LDJ9)(3:)IDS:IZK3M,TVZC72WTU15ZIASIHKF69 MU7\WJM"W52Z"FIU7(7W M[&XGTI;0(7[EZM9,SH-V*$]:/[<77P^K,&Y[I JU-VV)S!Y>U%8515O)]N// M4#0<-5OB]/RM^N=N\'8P3UFCMKKXG1_,>17.P^"@CMFU,(_Z]D4- TK"8!C] M-_6B"@MO>V(U]KIHNM]@?VV,+H?PA M00P$,1+8QPIR($B'$/5#Z9[-+C/9>EGK6U#W]EZR=A:Q.VF?_KYM[!YV=\\^ MGL:VOJSC9?32EAD0FQ[!)P@V(B);>Q3@2&##"9V_%]A2A'B/V%&$Q%T0<(RB MHXL)/<%T">FRH\L)/74>$47,L$ "!1)"GSL"%+' BD42 F=N2X#B,?F&928 M4;[C\P9 !):80XDYY4M' D \5B^@Q(+R7:\!Q&,VBW'B8EK!]1MA/(XS3ZX9 MJ$;CS!>N"L6(V*.",\]HH@5S50"&>U1P[!D-M1"N"L!X M7A$,)Y_17(O$50&8%*MPG'U.L^POC2N \P/O=Q]CG-M23N M4TSB%5P]@58 MWSLKI=V 23I,U2_19U(N1!)[EF4"_P4(&N_4B >][M1?_#^P\)W[/ZE%=- M\*2-W=%V^\ZCUD;9KL2?[+#/*CN,%X4ZFO9T9L_K?@/?7QA]&3Y.1.,7DO4_ M4$L#!!0 ( $R 8E"KF]'X5P0 ,P4 8 >&PO=V]R:W-H965T&ULA9AKC^HV$(;_"N)[3^SQ?05(A:IJI59:G:KMYRR8!9V$T"2[ MG/[[.B&+8&:\_4(NO&._OCV>>'%IVF_=(<9^]KVN3MUR?NC[\U-1=-M#K,ON M2W..I_3/OFGKLD^/[6O1G=M8[L:@NBI "%O4Y?$T7RW&=\_M:M&\]=7Q%)_; M6?=6UV7[[SI6S64YE_./%U^/KX=^>%&L%N?R-?X1^S_/SVUZ*FZE[(YU/'7' MYC1KXWXY_U$^;909 D;%7\=XZ>[N9T-37IKFV_#PZVXY%X.C6,5M/Q11ILM[ MW,2J&DI*/OZ9"IW?ZAP"[^\_2O]Y;'QJS$O9Q4U3_7W<]8?EW,]GN[@OWZK^ M:W/Y)4X-,O/9U/K?XGNLDGQPDNK8-E4W_LZV;UW?U%,IR4I=?K]>CZ?Q>IG* M_PCC V *@%N U)\&J"E H8#BZFQLZD]E7ZX6;7.9M=?1.I?#I)!/*G7F=G@Y M]MWX7VIME]Z^KZQ>%.]#.9-D?97 G00>%1NJL.8F*5+]-Q/ FH Q7MW'6SY> ML?%JC-?W\0XUXBHQH^1TE2@(2+6A*F.54[P7S7K1U(M'7JX2>U>+E,;[@,PP M,G!"2]Z-8=T8Z@95LS:D&B<5]KQA5,&IS"A9UHLE7IQ 7BQM-(\ M5)3F#QDR*I/!R0QQ) ]C26GL,(TEY:P%,$!&C-$I+W5N5O- EH;L=2[7QSQ& M)>6HQQR5#"(=&(6;Q,B\%QEV21ZEDK+48Y9*2DEEA!#8S__)'OWP,)64IA[3 M5%)0&H]W@ VCREGA62HI3#V&J:2<-%H;XH61@;G;IA_3+!ZI0)'J,5*!HA($ M$+HS,NE$+E4"'JA @>HQ4($#)7C '<3IE-(Z PS(9*(T%?6Y$G@$ D6@QP@$ MAFW.2M+'' *]SJ76/ *!(M!C! *3:@9K\1;!R&S0+K-E 0] H"DISGS70+-- M"8*L"4:669_ HQ28E!1OG\#DI!JH%T9F@\HDZ\"C%"A* T8[, FGL%IH;(C1 MJ6!#;C;S, 4*TX#ASFEP8OJYYM$)SU((9&6&#&T43S]%Z1??#44S2-#'@=*)H?>A< #S0CDR(E MDIF%H#(?]!2B^%M]K2@=?Y 6<$:^X73*"Y69?HK'J*(8#1BCBO)12RL!IUV, M3B6NYW)_Q8-449#B[Y[UI'DX]N!R6T['Y;;%W;'2<,[W>]F^'D_=[*7I^Z8> MSY'V3=/'5*;XDDH[Q')W>ZCBOA]N7;IOK^=KUX>^.4]GA\7M '/U'U!+ P04 M " !,@&)0LC='_5<" !-" & 'AL+W=O9ZQJZ1E3?;<$=>JPOSOEE#6;ESD?DR\ ME)="Z@F09PV^D)]$_FKV7(W X'(J*U*+DM4.)^>-^PFM=\@$&,5K25HQZCLZ ME0-C;WKP[;1QH28BE!REML"JN9$=H50[*8X_O:D[[*D#Q_T/]R\F>97, 0NR M8_1W>9+%QDUB?4$ZC("A59H,(9 M5+38R@]0D,0+)HO03V#@QZD=*;8BQ1:D:(84/XMD$=Y%2JQ(B04IGB$E3YVC M1ZH)3&J%22TPR0PF79X.^S%Z0CA!0M!>NJ %*IW7+KC8;(YS5S(%^4\-14L0 MM"BBZ#'(/4D' D9U75^T/S"_E+5P#DRJ*\(4\C-CDB@[N%*O:Z'N]F% R5GJ M;JSZO+O@NH%D37]Y@^$?1/X/4$L#!!0 ( $R 8E!?@B*1( 0 &H2 8 M >&PO=V]R:W-H965T&ULC9C;;N,V$(9?Q=!](G%X#FP# MD85%"[1 L,6VUXI-'[ ZN)(2;]^^U"%>>SC:W5Q$!W\S_(#O=>FO6R?NN*4^5>FD7[5I9Y\U_JBOJRBECT<>/SZ7#L^AOQ>GG. M#^XOUWTYOS3^*KYFV9U*5[6GNEHT;K^*GME3!J(/&(B_3^[2WIPO^E)>Z_IK M?_'[;A4EO2)7N&W7I\C]X=UM7%'TF;R.?Z>DT;7-/O#V_"/[IZ%X7\QKWKI- M7?QSVG7'562BQ<[M\[>B^UQ??G-303):3-7_X=Y=X?%>B6]C6Q?M\'^Q?6N[ MNIRR>"EE_FT\GJKA>)GR?X31 3 %P#6 J1\&\"F ?P\0/PP04X! ?%8RM W M6=[EZV537Q;-^'C/>3^*V)/PO;_M;PZ=/?SFNZ?U=]_7C+%E_-XGFIAT9."6 MN1*QSWYM J@F4@C"X;Z!34@H>8]D(<(8T"HX62@?$HB[!!P5.C)R8*J!$58R MC;1L0DSRQ%C4;1F!)8G5":U:D*H%H5H@U2.C;MIA5DF)Y&Q"#)BV$CV+C,(X MUXI6+4G5DE"-.C&503O*,H4TAY"Q@.K/B$S3@=ZHUG<"0"0Q1-JHG->'@\G4G%I5-8%RI MFZ99-0 M-"1XF4W"EJP2N*L)3"?2(BRC,"%@9H2Q&7=@OS"3)^CNJ4HF!-8=8@#2X)E! M9?,3;<9Q&&DYSPR(_@YL#8*6A- \Z.\0XQHX7NT)S,[-9T9;%",\"@"KYL0* MH[D.NIO@P$BML>Z0 PW"SJPDC/8I1A@58'MEH;<\,*D47O4I#H14>&82G-%S M2R"CK8H17H4=)F6AQ3Q(B0U_0V%:68-E$QB7:DXW;5F,\"P(9F9H,P_@,8V% M$QP'4'CY)CC)Y(S5,MJUF":$8[.=(-3A)A@H!&8Y[H:,P$ *P6=TTV;)"+<$ MC76;X)VO'^$Z&"D$!V!YH)SB$@_.2*<=D]GP30$,G0)H P/*P+#K3I"Y59L\ M"CS::$P9>_>'W__IH!D;!MK.@+ SCFUX@GY:!8G]K HZ:*X*VMP PL?)Y[[( M:*YIQ%^;/O#F< MJG;Q6G==70X?[?NZ[IQ7F3SZ)>+H\MWUHG#[KC_5_KP9=S_&BZX^3SL[\75[ M:?T_4$L#!!0 ( $R 8E"6*1?>N0( +() 8 >&PO=V]R:W-H965T M&ULA99M;]HP$,>_2I3W;>*'/% !4@%-F[1)5:=NKUTP$#6) MF6V@^_:SG30-9\/>$-O\[^YWE]B^Z5G(-[7G7$?O3=VJ6;S7^O"0)&J]YPU3 M]^+ 6_//5LB&:3.5NT0=)&<;9]34"4[3/&E8U<;SJ5M[DO.I..JZ:OF3C-2Q M:9C\N^"U.,]B%'\L/%>[O;8+R7QZ8#O^D^N7PY,TLV3PLJD:WJI*M)'DVUG\ MB!Y6R!DXQ:^*G]5H'-E47H5XLY-OFUF<6B)>\[6V+IAYG/B2U[7U9#C^]$[C M(:8U'(\_O']QR9MD7IGB2U'_KC9Z/XO+.-KP+3O6^EF/:O6/<^]_P^SL 'N#?!@@/*;!J0W()\& M]*8![0TH,$BZ5%QM5DRS^52*YHC0 M:7*RCGK-HM/@L690),;[$ *'0BRP9XXO RQ]19Y=2E:^!"$8TK=/82,!=>&%3"\OJ: J2^\B572,L@:1D@G0#2TBDMQ03H) MDDY\4@I"+";^&\:TI&#_+'T99+VEN&!%:?CT3 .T"!Z?:>!+*S+PAIL0(O ,3T875\/E MSC4%*EJ+8ZOM^3]:'1J/1VPO/K"^L V)NQ _W73=S \F=U6KHE>AS;7J+K^M M$)H;R/3>X.U- S5,:K[5=EB8L>RZB&ZBQ:'OD)*A39O_ U!+ P04 " !, M@&)0HJ:F3.P% !>'P & 'AL+W=O3MWTVP]_+!^?^L,/\ZN+;?/8_MGV?VT_[>+1_-3+_7+= M;O;+;C/9M0^7TY_>HH]_QTZGIYJ'AN??O_7^\S#X.)C/S;Y==*M_EO?]T^6T MFD[NVX?F>=7_T;W^THX#\M/)./K?VI=V%>4')['&7;?:#W\G=\_[OEN/O40K MZ^;K\7.Y&3Y?Q_Z_-<,-:&Q IP;._; !CPWX>P/^80,9&\CW!M4/&_BQ@3\U MX&&^YL>Q#R?SINF;JXM=]SK9'=?#MCDL._?1Q^FZ._PXS,[POW@^]_'7ERLG M?#%_.70T:JZ/&DHTDFH62.-3S0W2E*GF%FG"23./8SD-B." :.A D@XJ-:"C MQ@^:S: 1%SCH,5D9.ZHK9?G&RIS44JBBMU8V$U]0@0?'<' ,!E>Z: M:BKH[%0GE016DJ$7/J_D,U8][,!;J]ZI>?#&:J9$"4N4H 2ILU':L^%KJG&9 M ,L$4$9?(N&](ZE@B0J4T*NQ,B5(:BXSLUK#.C6HHZ[2Z]K4<;Y2,[>H[9H_ M%R567(')4P SI<9*8=Q()2%S M(VH4G=N9$965]@.HDLA20Y@J#F#%:ZPXRY59651%;BHP5IS84F6AQRZV5"C, MI3W*?%:6&L*8>4 L$K2@[?$4PLV-Q M10;ZA%%, ,6E@OXU613/N':9FS9ELIV*4^:PL-80QPRCQF8T2P$SQRS;.S9P(*^NW;,&I=*DE#$X&X#0Y MBRTXX\ZB9OU0YVU=:@G#DP$\]6;GFBT\N:[$/(L:=4G.8B&=GVY ?ZZ(NR>G MSSJ(DEP5G$G_C*G-*$H:)EEJGWX$,U000W7Z$IH!S56H'@TY0\M/Y1RS /%><6]R87X*"G^:76"Y5K!&P$!O\ M$E5J![-+ +N"CC5B&9);6!@?@O"A8X: '6'DJ*:,V-"7RM+GNQ@Q'NT;=GW=OBE+#65>( "\F93BT9,Y7VKC M-V_K4DL8<1X@+IAU:+.5W3S,SUY#'MX\_][L'I>;_>1SU_?=>GCO^-!U?1M[+3Y$ZT]M M%KB-]WQS>^QX.^VXYOL^>G5^I7_P-02P,$% @ 3(!B4)R/ MEJXZ!@ 0"$ !@ !X;"]W;W)K>N4SZ$MO* MY>A2)N=P2%^_MKLO^Z>FZ2;?-NOM_F;ZU'7/5_/Y_NZIV=3[#^USL^W_\]#N M-G77?]P]SO?/NZ:^'QMMUG-V+LXW]6H[O;T>KWW:W5ZW+]UZM6T^[2;[E\VF MWOV[:-;MZ\V4IM\O_+YZ?.J&"_/;Z^?ZL?FCZ?Y\_K3K/\U/4>Y7FV:[7[7; MR:YYN)E^I*M*TM!@5/RU:E[W9^\G0U<^M^V7X<,O]S=3-SAJULU=-X2H^Y>O MS;)9KX=(O8]_CD&GIWL.#<_??X_^T]CYOC.?ZWVS;-=_K^Z[IYMIFD[NFX?Z M9=W]WK[^W!P[%*:38^]_;;XVZUX^..GO<=>N]^/?R=W+OFLWQRB]E4W][?"Z MVHZOK\?XWYOA!GQLP*<&%-]LX(\-_(\&\F8#.380U6!^Z,KX;*JZJV^O=^WK M9'?X>I_K8131E?1/_VZX.#[L\7_]X]GW5[_>4B'7\Z]#H*-F<=#PN>:DF/?1 M3[=@=(L%F^9\>8.E5<1P*:FLA(BQ"P\[ZL< _J*C 0<0&$#& '(>@ OUI Z: M,&JVHV9&(1:D^@MDS*77?48RU^NPZP!=!]#MB -$&"#:;A>ZVP=-/#-*(:E1 MM+2B6+I2=1E$?;Y 0I+,:'@STJ5? MF-P_$@._7OME^WQ3BMHR4%%,VK%5!5_D3&,6D >F#?6\':(^Z!P!5%2X0-JU ME94B&?X0!A ! J6@78N=W\%'G8R1C'Q!HGU;G3B? 2]A!!%@4,HPB#"$"% H M:0J1A4>9J- ]MZI9H%*#",F\DR(#7\(L(@NCJ!,[68 4YGM= M6L$-$P0L%" MRN1WPC0BBR-#?$(8$3NE@2P0F3EM94'*W"C#6"++)8,ELD#I1WTT0\3*A)Q> MG>%@*3.G&>.)+9Y,]F3+E)DXTAD?R3CH)6H%9$%R*P#&D&(+*9,^V9+%>TWX M)5"Q*S2E@&I6<"X-,285(U+IA2%;NL2^AC;/VLJ\=ZQ7 T!&9<&9W,<85@PJ MEU1F0F!R,"!'J2<'VU1ONFTE9% '1+/^;BEEEL2,J<$!>-8+MZ-(T8YU&D*R M(A6FQ@0R<3'W=6%4,4"5'O8+!G0AKUT#4;2%L55E%D.,&<6@8"I-#K)<,8/C M74D%)+[/9+G!C/'$H%HJ3?9!X.GSC_8,9,DGO1A ,HKNO&*_=(X1Q:6=R64F MA,>\\*"<*=5P7WB;XGW4NPM+H"(2T6Q&P20W)SSFA0=%3="IU[]?U #)+$2O MAQF2,<=,_O$8%Q[@0G-@X6V"[P>&'C]+) NF3*J0K*\EOGF M;3EBGO6[D@I(>EBZ3/KQF$T>L6Y 8 MNX U)'JQAE1<9FKD$Y"?G!@-GG+)G9Z$>!! M:20I>+W6A+HRD-YU KJ0>[ M?4?35M7/(SU!@"H4DONR,+3$[L"QRZRZ!4-$ $3T%L1"T!F/[C4XXM$[,!42 M26;])A@= M!!&AT"#V^T8RLB$ZI"*I>=$9@: JBA\;0XBBZ.!46?<"V!RB2P MMR0'N_.S8^1-LWL]/'];-0S>\+?KWN\.9_N%# MUSX??Z\P/_UHXO8_4$L#!!0 ( $R 8E WXRH#M $ -(# 8 >&PO M=V]R:W-H965T&UL?5/;;M0P$/T5RQ]0;YP4JE42J=L*@032 MJ@AX]B:3B^I+L)U-^7O&3AH"1'VQ/>,Y9\Z,Q_ED[+/K #QY45*[@G;>#T?& M7-6!$N[&#*#QIC%6"8^F;9D;+(@Z@I1D_'!XQY3H-2WSZ#O;,C>CE[V&LR5N M5$K87R>09BIH0E\=3WW;^>!@93Z(%KZ"_S:<+5IL9:E[!=KU1A,+34'OD^,I M"_$QX'L/D]N<2:CD8LQS,#[5!3T$02"A\H%!X':%!Y R$*&,GPLG75,&X/;\ MROXAUHZU7(2#!R-_]+7O"GI'20V-&*5_,M-'6.JYI60I_C-<06)X4((Y*B-= M7$DU.F_4PH)2E'B9]U['?9IOTG2![0/X N KX"[F87.BJ/Q1>%'FUDS$SKT? M1'CBY,BQ-U5PQE;$.Q3OT'LM>9+F[!J(EIC3',,W,]B_"MKUVY&(\OFSL?V.,!Y1RN,$1ZO"#K8:$QH?C>SS;>IVF3-NG4:=MG M+G$25(@S()?NWP](FF5MM"^ C=_SLS'9B.;)M@"./&O5V9RVSO5'QFS9@A;V M!GOH_$V-1@OG3=,PVQL0501IQ?AN=\NTD!TMLN@[FR+#P2G9P=D0.V@MS.\3 M*!QSFM 7QZ-L6A<7#@Q*?HT1EXTK*P3K4 M,XN7HL7SM,LN[N-TD[Z?8=L /@/X CC$/&Q*%)5_$$X4F<&1F*GWO0A/G!RY M[TT9G+$5\;1.DFP1I)$C_6^)6S.%5$K;JJ0;3Q&FRI,2ABY.\\BX#>\_CF_P- MGZ;]JS"-["RYH/,O&_M?(SKP4G8W?H1:_\$60T'MPO'.G\TT9I/AL)]_$%N^ M&PO=V]R:W-H965T M92YP$ M%4(&Y-+]^QF29E&;+X"-W_.S,?ED[+/K #QYT:IW!>V\'XZ,N:H#+=R-&:#' MF\98+3R:MF5NL"#J"-**\23YR+20/2WSZ#O;,C>C5[*'LR5NU%K8OR=09BIH M2E\=C[+M?'"P,A]$"S_!_QK.%BVVLM120^^DZ8F%IJ#WZ?&4A?@8\"1AZH$D0! HJ'Q@$;E=X *4"$N38FRHX M8ROB'8IWZ+V6//V4LVL@6F).GA3XOL8SM\6R38]U6#;.$V.5&;LXR1OO.O WO/X)O_# MYVG_(6PK>T&PO=V]R:W-H965T M/8FD\2J M+\%V-N7O&3MIB&C@Q?:,SSES\3@?K7OR'4 @SUH97] NA/[(F*\ZT,+?V!X, MWC36:1'0="WSO0-1)Y)6C.]VMTP+:6B9)]_9E;D=@I(&SH[X06OA?IU V;&@ M>_KB>)1M%Z*#E7DO6O@*X5M_=FBQ1:66&HR7UA '34'O]\?3(>(3X+N$T:_. M)%9RL?8I&I_J@NYB0J"@"E%!X':%!U J"F$:/V=-NH2,Q/7Y1?U#JAUKN0@/ M#U;]D'7H"GI'20V-&%1XM.-'F.MY0\E<_&>X@D)XS 1C5%;YM))J\,'J6053 MT>)YVJ5)^SC=9'RF;1/X3. +X2[%85.@E/E[$429.SL2-_6^%_&)]T>.O:FB M,[4BW6'R'KW7\O9=SJY19X:<)@A?0?8+@J'X$H%O13CQ5W2^3<\V$\P2/5O3 M^3\$#IL"AR1P^%^%KR&<9W_%8*N.:G!MFB5/*CN8-,1B [YKZGYC;0!,97># ]3A]UH,!4V(Q[=X=M.034:P_?Q_V/*)R]]0 M2P,$% @ 3(!B4'R)JZVT 0 T@, !D !X;"]W;W)K&UL?5/;;MP@$/T5Q >$->NDT6;M\44!Q@6\ M3OZ^@!W72:V^ #/,.7-F&+(1S;-M 1QY45+;G+;.]0?&;-F"$O8*>]#^ID:C MA/.F:9CM#8@J@I1D?+>[84ITFA99])U,D>'@9*?A9(@=E!+F]0@2QYPF],WQ MV#6M"PY69+UHX >XG_W)>(LM+%6G0-L.-3%0Y_0N.1S3$!\#?G4PVM69A$K. MB,_!^%;E=!<$@832!0;AMPO<@Y2!R,OX/7/2)64 KL]O[%]B[;Z6L[!PC_*I MJUR;TUM**JC%(-TCCE]AKN>:DKGX[W !Z<.#$I^C1&GC2LK!.E0SBY>BQ,NT M=SKNXW23)C-L&\!G %\ MS$/FQ)%Y9^%$T5F<"1FZGTOPA,G!^Y[4P9G;$6\ M\^*M]UX*SM.,70+1''.<8O@J)EDBF&=?4O"M%$?^#YQOP_>;"O<1OG^G\'J; M(-TD2"-!^M\2MV)N/B1AJYXJ,$V<)DM*''2_(M0"#/6AF?TS:$[LB8+UO0PM_8#@S>U-9I$=!T M#?.= U$ED%:,;S;OF!;2T")+OK,K,ML')0V<'?&]UL+]/H&R0TZW],7Q*)LV M1 0*E(A#)^39QT3AF!R_,+^\=4.]9R$1X>K/HIJ]#F M]$!)!;7H57BTPR>8ZKFE9"K^"UQ!87A4@CE*JWQ:2=G[8/7$@E*T>!YW:=(^ MC#>WNPFV#N 3@,^ 0\K#QD1)^0<11)$Y.Q W]KX3\8FW1XZ]*:,SM2+=H7B/ MWFO!^5W&KI%HBCF-,7P1LYTC&++/*?A:BA-_ ^?K\-VJPEV"[_Y1>%@GV*\2 M[!/!_K\EKL6\?Y6$+7JJP35IFCPI;6_2)"^\\\#>\_0F?\/':?\J7".-)Q<; M\&53_VMK Z"4S0V.4(L?;#84U"$>[_#LQC$;C6"[Z0>Q^1L7?P!02P,$% M @ 3(!B4##@!DRU 0 T , !D !X;"]W;W)K&UL?5/;;MP@$/T5Q <$+]YM5BO;4C95U4JMM$K5]IFUQS8*>%S Z_3O"]AQ MK,;J"S##.6^C\38U&"^=-TS#; M&Q!5)&G%>))\8%K(CA99]%U,D>'@E.S@8H@=M!;FSQD4CCG=T5?'DVQ:%QRL MR'K1P'=P/_J+\19;5"JIH;,2.V*@SNG#[G3>!WP$_)0PVM69A$JNB,_!^%+E M- D)@8+2!07AMQL\@E)!R*?Q>]:D2\A 7)]?U3_%VGTM5V'A$=4O6;DVIT=* M*JC%H-P3CI]AKN= R5S\5[B!\O"0B8]1HK)Q)>5@'>I9Q:>BQA"?>G;CO31F&UL MC53M;ML@%'T5Q .4!"=;%-F6FE;5)FU2U&G;;V)?VZA\>(#C[NT'V'7=CDG[ M8^!R[CGG M?YJ,V3[0 <>I9"V0)WSO5'0FS5@63V1O>@_$ZCC63.+TU+;&^ MU3%)"D(WFP]$,JYPF="@)1Y MSUKX!NY[?S9^11:6FDM0EFN%##0%OMT>3_N CX ?'$:[FJ-0R47KI[#X7!=X M$PR!@,H%!N:'*]R!$('(V_@U<^)%,B2NYR_L#[%V7\N%6;C3XB>O75?@ T8U M-&P0[E&/GV"N9X_17/P7N(+P\.#$:U1:V/A%U6"=EC.+MR+9\S1R%<=QWCG, M:>D$.B?0)>$0=<@D%)W?,\?*W.@1F>GL>Q:N>'ND_FRJ$(Q'$?>\>>NCUY)F MVYQ< ]&,.4T8NL*\(HAG7R1H2N)$_TJGZ?0LZ3"+Z=D;A_\@V"4)=I%@]X8@ M>U=B"K-+B^R3(OO_$$EAWHN0U<5),&U\LA95>E"Q75;1I2MN:;SX5_C44E^9 M:;FRZ**=?S[QDANM'7@KFQOOI?-=O"P$-"Y,/_JYF=[RM'"ZG]N4+/^*\@]0 M2P,$% @ 3(!B4!2E3&.W 0 TP, !D !X;"]W;W)K&UL?5-;;MLP$+P*P0.$-F4[@2$)B%,4+= 1H*VW[2T>B!\J"1E M);?/DE)4M17Z(W)7,[.SY#(=C'UQ#8 GKTIJE]'&^^[(F"L:4,+=F XT_JF, M5<)C:&OF.@NBC"0E&=]L#DR)5M,\C;FSS5/3>]EJ.%OB>J6$?3N!-$-&M_0C M\=36C0\)EJ>=J.$9_/?N;#%BLTK9*M"N-9I8J#)ZOSV>=@$? 3]:&-QB3T(G M%V->0O"US.@F& ()A0\* I)U M7%L=UV'\DR03;9W )P*?"7>Q#AL+1>>?A!=Y:LU ['CVG0A7O#UR/)LB).-1 MQ']HWF'VFO-DG[)K$)HPIQ'#%YCMC&"H/I?@:R5._!_Z8;_.3U8M)I&?_&'Q ML"ZP6Q7818'=?WM,X.5*87L=17F3GB;WG\5)^P\=Q?Q2V M;K4C%^/Q:N,%5,9X0"N;&YRA!E_8'$BH?-C>XMZ.LM\#J2E&1IDCPPQ86F91YS9UOF9O!2:#A;X@:EN/UY FG&@N[H+?$L MVLZ'!"OSGK?P!?S7_FPQ8HM*+11H)XPF%IJ"/NZ.IRS@(^";@-&M]B1TL29>2@;C>W]3?Q]ZQEPMW\&3D=U'[ MKJ '2FIH^"#]LQD_P-S//25S\Y_@"A+AP0G6J(QT\4NJP7FC9A6THOCKM H= MUW'ZD]UHVX1T)J0+X1 );"H4G;_CGI>Y-2.QT]GW/%SQ[ICBV50A&8\B_D/S M#K/7,MT?9L"KSIYR?$EG=<_@)02P,$ M% @ 3(!B4(AX6&UL?5-AC]0@$/TKA!]P[+)5STW;Y/:,T423S1GU,]M.6W+ 5*#;\]\+ MM->K6OT"S##OS9MAR$>TCZX#\.1)*^,*VGG?'QES50=:N!OLP82;!JT6/IBV M9:ZW(.H$THKQW>XUTT(:6N;)=[9ECH-7TL#9$C=H+>S/$R@<"[JGSXX'V78^ M.EB9]Z*%+^"_]F<;++:PU%*#<1(-L= 4]&Y_/&4Q/@5\DS"ZU9G$2BZ(C]'X M6!=T%P6!@LI'!A&V*]R#4I$HR/@Q<](E902NS\_L[U/MH9:+<'"/ZKNL?5?0 M6TIJ:,2@_ ..'V"NYQ4E<_&?X HJA$%RJ655(/SJ&>6($6+IVF7)NWC M=,/?SK!M )\!? 'E+G%D=BI][V(3[P_\M";*CI3*])=$.^" M]UKR;)^S:R2:8TY3#%_%O$2PP+ZDX%LI3OPO.-^&'S85'A+\\)O"?Q!DFP19 M(LC^6^)6S.&/)&S54PVV3=/D2(6#29.\\BX#>\?3F[R$3]/^6=A6&D'P3SG8:L\GPV,\_B"W?N/P%4$L#!!0 ( M $R 8E"W_QISMP$ -(# 9 >&PO=V]R:W-H965TZ:%;&F>1M_)YJGIO9(MG"QQO=;"_CN",D-&M_3=\2CKQ@<'R]-. MU/ $_G=WLFBQF:64&EHG34LL5!F]VQZ.28B/ 7\D#&YQ)J&2LS'/P?A19G03 M!(&"P@<&@=L%[D&I0(0R7B9..J<,P.7YG?U[K!UK.0L']T;]E:5O,GI+20F5 MZ)5_-,,#3/5<4S(5_Q,NH# \*,$$NPG>?%%ZO$R2K!$DD2#X1 M[+^4N!9S\R4)6_14@ZWC-#E2F+Z-D[SPS@-[Q^.;?(2/T_Y+V%JVCIR-QY>- M_:^,\8!2-E&UL M?5/;;M0P$/T5RQ]09[TI+*LD4K<(@032JHCR[$TF%]678#N;\O>,G30$&O7% M]HSGG#DS'F>CL4^N!?#D64GM09LSICKXX'KJF]<'!BJP7 M#7P'_Z,_6[38PE)U"K3KC"86ZIS>[8ZG-,3'@,<.1KY R$*&,7S,G75(&X/K\POXIUHZU7(2#>R-_=I5OZ?C/DXW*9]A MVP ^ _@".,0\;$H4E7\47A29-2.Q4^][$9YX=^38FS(X8ROB'8IWZ+T6/#UD M[!J(YIC3%,-7,;LE@B'[DH)OI3CQ5W"^#=]O*MQ'^/X?A1^V"=)-@C02I&^6 MN!%SF_R7A*UZJL V<9H<*]/,/8LLW+OX 4$L#!!0 ( $R M8E!UO\J/LP$ -(# 9 >&PO=V]R:W-H965T6_>#$,^HGUR'8 GSUH95]#.^_[(F*LZT,+=8 \FW#1HM?#!M"USO051)Y!6 MC.]V;Y@6TM R3[ZS+7,A@9=Z+%KZ M_]J?;;#8PE)+#<9)-,1"4]#[['@ZQ/@4\$W"Z%9G$BNY(#Y%XV-=T%T4! HJ M'QE$V*[P $I%HB#CQ\Q)EY01N#Z_L+]/M8=:+L+! ZKOLO9=0>\HJ:$1@_*/ M.'Z N9Y;2N;B/\$55 B/2D*."I5+*ZD&YU'/+$&*%L_3+DW:Q^F&9S-L&\!G M %\ =RD/FQ(EY>^$%V5N<21VZGTOXA-G1QYZ4T5G:D6Z"^)=\%Y+?IOE[!J) MYIC3%,-7,:\1++ O*?A6BA/_"\ZWX?M-A?L$W_^F\!\$ATV"0R(X_+?$K9C] M'TG8JJ<:;)NFR9$*!Y,F>>5=!O:>IS=Y#9^F_;.PK32.7-"'ETW];Q ]!"F[ MFS!"7?A@BZ&@\?'X-ISM-&:3X;&??Q!;OG'Y"U!+ P04 " !,@&)0NI@0 M-[0! #2 P &0 'AL+W=O:6 M*=%JFJ?1=S)YBKV3K8:3(;972IB/(T@<,KJE5\=S6S=J*&[^!^="?C M+3:SE*T";5O4Q$"5T?OMX9B$^!CPLX7!+LXD5')&? W&8YG131 $$@H7&(3? M+O 4@8B+^-MXJ1SR@!L /@'X#+B+ M #8FBLH_"R?RU.! S-C[3H0GWAZX[TT1G+$5\&PO=V]R:W-H965T-\=&'-% UJX*]-!BS>5L5IX-&W-7&=!E!&D%>.;S2>FA6QI MGD;?R>:IZ;V2+9PL<;W6PKX>09DAHUOZYGB2=>.#@^5I)VKX#OY'=[)HL9FE ME!I:)TU++%09O=T>CDF(CP$_)0QN<2:ADK,QS\&X+S.Z"8) 0>$#@\#M G>@ M5"!"&;\G3CJG#,#E^8W]:ZP=:SD+!W=&_9*E;S*ZIZ2$2O3*/YGA&TSU7%,R M%?\ %U 8'I1@CL(H%U=2],X;/;&@%"U>QEVV<1_&FV0WP=8!? +P&;"/>=B8 M*"K_(KS(4VL&8L?>=R(\\?; L3=%<,96Q#L4[]![R?GU3O(V7A\V=C_RA@/*&5SA2/4X >; M#065#\<;/-MQS$;#FV[Z06S^QOD?4$L#!!0 ( $R 8E!ENULGM $ -(# M 9 >&PO=V]R:W-H965T] M2UNMDDC=(@022*LBX-F;3!*KO@3;V92_9^RD(4#@Q?:,YYPY,Q[GHW7/O@,( MY$4KXPO:A= ?&?-5!UKX&]N#P9O&.BT"FJYEOG<@Z@32BO$LNV5:2$/+//G. MKLSM$)0T<';$#UH+]^,$RHX%W=%7QY-LNQ =K,Q[T<)G"%_ZLT.++2RUU&"\ MM(8X: KZL#N>#C$^!7R5,/K5F<1*+M8^1^-#7= L"@(%58@, KK9Q:4HL7+M$N3]G&ZV=_-L&T GP%\ =RG/&Q*E)2_ M%4&4N;,C<5/O>Q&?>'?DV)LJ.E,KTAV*]^B]EOPVR]DU$LTQIRF&KV)V2P1# M]B4%WTIQXG_!^39\OZEPG^#[WQ3^(_]AD^"0" [_+7$KYD^5;-53#:Y-T^1) M90>3)GGE70;V@:&UL?5-A;]P@#/TKB!]0[DC:5:M.IL M3EOG^@-CMFQ!"WN%/73^ID:CA?.F:9CM#8@J@K1B?+>[85K(CA99])U,D>'@ ME.S@9(@=M!;F]0@*QYSNZ9OC43:M"PY69+UHX >XG_W)>(LM+)74T%F)'3%0 MY_1N?SBF(3X&_)(PVM69A$K.B,_!^%;E=!<$@8+2!0;AMPO<@U*!R,OX/7/2 M)64 KL]O[%]B[;Z6L[!PC^I)5J[-Z2TE%=1B4.X1QZ\PUW--R5S\=[B \N%! MB<]1HK)Q)>5@'>J9Q4O1XF7:91?W<;I)DAFV#> S@"^ VYB'38FB\L_"B2(S M.!(S];X7X8GW!^Y[4P9G;$6\\^*M]UX*?I-D[!*(YICC%,-7,?LE@GGV)07? M2G'D_\#Y-CS95)A$>/).8;I-D&X2I)$@_6^)6S'7'Y*P54\UF"9.DR4E#EV< MY)5W&=@['M_D;_@T[0_"-+*SY(S.OVSL?XWHP$O97?D1:OT'6PP%M0O'3_YL MIC&;#(?]_(/8\HV+/U!+ P04 " !,@&)0#-7$XK4! #2 P &0 'AL M+W=OPT.*2GICGUT-X,FKDMJEM/:^ M/3+F\AJ4<#>F!8TWI;%*>#1MQ5QK0101I"3CJ]6.*=%HFB71=[998CHO&PUG M2URGE+!_3B!-G](U?7,\-E7M@X-E22LJ^ G^5WNV:+&)I6@4:-<832R4*;U= M'T_;$!\#?C?0N]F9A$HNQCP'XUN1TE40!!)R'Q@$;E>X RD#$H7B'WFO&=[N$70/1&',:8O@L9CU%,&2?4O"E%"?^ M#YPOPS>+"C<1OOF@<+],L%TDV$:"[7]+7(HY?$K"9CU58*LX38[DIM-QDF?> M:6!O>7R3]_!AVG\(6S7:D8OQ^+*Q_Z4Q'E#*Z@9'J,8/-AD22A^.>SS;8,C$QRA1V;B2 M2W/@1:OT'6PP%M0O'@S^;:E-:K9)(W2($$DBK(NBS M-YDD5GT)MK,I?\_824. B!?;,YYSYLQXG(_6O?@.()!7K8PO:!="?V3,5QUH MX6]L#P9O&NNT"&BZEOG>@:@32"O&=[MW3 MI:)DGW]F5N1V"D@;.COA!:^%^ MGD#9L:![^N9XDFT7HH.5>2]:^ KA6W]V:+&%I98:C)?6$ =-01_VQU,6XU/ M=PFC7YU)K.1B[4LT/M4%W45!H* *D4'@=H5'4"H2H8P?,R==4D;@^OS&_B'5 MCK5FXIF8O_#%=0&!Z58([**I]64@T^ M6#VSH!0M7J==FK2/T\TMGV'; #X#^ *X3WG8E"@I?R^"*'-G1^*FWORWY'<_9-1+-,:+_P/DV_+"I M\)#@AS\4'K8)LDV"+!%D_RUQ*R;[*PE;]52#:],T>5+9P:1)7GF7@7U(C\A^ MAT_3_D6X5AI/+C;@RZ;^-]8&0"F[&QRA#C_88BAH0CS>X=E-8S89P?;S#V++ M-RY_ 5!+ P04 " !,@&)0TXS!XK4! #2 P &0 'AL+W=O:&:2%;FJ?1=S)YBKU3LH63(;;76IA?1U X M9'1+/QW/LFY<<+ \[40-+^"^=R?C+3:SE%)#:R6VQ$"5T;OMX9B$^!CP0\)@ M%V<2*CDCO@;C2YG131 $"@H7&(3?+G /2@4B+^-MXJ1SR@!D#@\#M"H^@5"!"&;]G3KJD#,#U^97]4ZP=:[D(!X]& M_9*5;W.:4E)!+0;EG\SX&>9Z;BF9B_\*5U 8'I1@CM(H%U=2#LX;/;.@%"U> MIEUV<1^GF[MTAFT#^ S@"R"->=B4*"K_*+PH,FM&8J?>]R(\\>[(L3=E<,96 MQ#L4[]![+?A]FK%K()IC3E,,7\7LE@B&[$L*OI7BQ-_!^39\OZEP'^'[_Q1^ MV"8X;!(<(L%A39 F;TK&PO=V]R:W-H965T<" MCMM_/\"NYW;^ MQQ[]V[XT@'-,^V 7#D5:O69K1QKCLR9HL&M+ WV$'K;RHT M6CAOFIK9SH H(T@KQC>;/=-"MC1/H^]L\A1[IV0+9T-LK[4P;R=0.&1T2]\= M3[)N7'"P/.U$#3_!_>K.QEML9BFEAM9*;(F!*J-WV^,I"?$QX+>$P2[.)%1R M07P.QD.9T4T0! H*%QB$WZYP#TH%(B_C9>*D<\H 7)[?V;_%VGTM%V'A'M4? M6;HFHP=*2JA$K]P3#M]AJN>6DJGX'W %Y<.#$I^C0&7C2HK>.M03BY>BQ>NX MRS;NPWBSWT^P=0"? 'P&'&(>-B:*RK\*)_+4X$#,V/M.A"?>'KGO31&RN?$CU/@/-AL**A>.7_S9C&,V&@Z[Z0>Q^1OG?P%0 M2P,$% @ 3(!B4(#Q^UG* @ Y L !D !X;"]W;W)K&UL?5;M;ML@%'T5RP]0&\B'4R61FD[3)FU2U6G=;YJ0Q*IM/"!) M]_8#['@I/NQ/#/C<]%$(D[S75:-7Z=&8]C[+]/8H:J[O9"L: M^V8O53%4VXDDE^E377/W9 MB$I>5BE)KPO/Y>%HW$*V7K;\('X(\[-]4G:6#2R[LA:-+F63*+%?I0_D?D,G M+L C7DIQT3?CQ!WE5UA7KD6C[+Z5>[,<946:;(3>WZJS+.\?!']@:9ITI_^FSB+RL+= M3JS&5E;:_R;;DS:R[EGL5FK^WCW+QC\OW9O9-0P'T#Z #@&%#\@Z(;_S3]SP M]5+)2Z*ZRV^Y^X_)/;5WLW6+_BK\.[MY;5?/:UK,EMG9$?6838>A-Q@R(#++ M/DA0)+&AHW"*PQG<(?/A[#:& (M(@E&(DXE@"),,0!B>23'"+3K Z& (LPR"(JD&<&^ M)@Q0C.X-@281'6Q_,O8VRZ>A#@+%=' %(&-[LWQ42A$HEF^X")"QPUE>A#H( MM(CHX#I QB9G) ]U$"CR=2"X%!#@4; D7R@.)Z M0('59Z$. #$2*6X4UP,*K$["?(.@2+Y17 \HL#H)\PV"(OE&<3V@P.HTS#<( MBG4CN!Y08'5*0QT$"K]PV4V350MU\.VE3K;RU/C>]F9U:&$?J&_2_L&[_O<[ M5X>RT&PO=V]R:W-H965T MI%"VP)US_8$06W4@F;W2/2A_ MTV@CF?.F:8GM#; ZDJ0@-$GV1#*N<)E'W\F4N1ZCR#T6. = M_G \\[9SP4'*O&82E.5:(0--@6]WAV,6\!'PF\-H5V<4 M*CEK_1*,Q[K 24@(!%0N*#"_7> .A A"/HW761,O(0-Q??Y0OX^U^UK.S,*= M%G]X[;H"WV!40\,&X9[U^ !S/=<8S<7_@ L(#P^9^!B5%C:NJ!JLTW)6\:E( M]C;M7,5]G&[VZ4S;)M"90!?"38Q#ID Q\^_,L3(W>D1FZGW/PA/O#M3WI@K. MV(IXYY.WWGLI4YKEY!*$9LQQPM 59K<@B%=?0M"M$$?Z'YUNT]/-#--(3]=T MFFP+9)L"613(_BGQ^DN)6YC]ER!DU5,)IHW39%&E!Q4G>>5=!O:6QC?YA$_3 M_L1,RY5%9^W\R\;^-UH[\*DD5WZ$.O_!%D- X\+QFS^;:^5;.%DB>NU%O;O$909,KJE M;XX'63<^.%B>=J*&W^#_=">+%IM52JFA==*TQ$*5T=OMX;@+^ AXE#"XQ9F$ M2L[&/ ?C1YG134@(%!0^* C<+G '2@4A3.-ETJ1SR$!^\T9,*IJ+% MZ[C+-N[#>)/PB;9.X!.!SX1]C,/&0#'S;\*+/+5F(';L?2?"$V\/''M3!&=L M1;S#Y!UZ+WG";U)V"4(3YCAB^ *SG1$,U><0?"W$D7^B\W5ZLIIA$NG)DL[_ M([!;%=A%@=U"X/KKAPH_0Q*^_Q"#+5JJP=9QF!PI3-_&05YXYWF]C6_(WN'C ML/\2MI:M(V?C\6%C^RMC/& JFRN&UL;5/;;IPP$/T5RQ\0@R%IN@*D;*JJE1IIE:KMLQ<&L.(+ ML+$]XW/.7#PN)FV>; _@T(L4RI:X=VXX$&+K'B2S5WH Y6]: M;21SWC0=L8,!UD22%(0FR0V1C"M<%=%W,E6A1R>X@I-!=I22F=]2XX2%4,K(.?X'X-)^,MLJHT7(*R7"MDH"WQ77HXY@$? ;\Y3'9S1J&2 ML]9/P?C>E#@)"8& V@4%YK<+W(,00:XR6XG_ !82'ATQ\C%H+&U=4C]9IN:CX5"1[ MF7>NXC[--WFZT/8)="'0E7 ;XY Y4,S\"W.L*HR>D)E[/[#PQ.F!^M[4P1E; M$>]\\M9[+U5&/Q?D$H06S''&T TF71'$JZ\AZ%Z((_U I_OT;#?#+-*S+9U> M[PODNP)Y%,C_$\C?E?@1DV7)NR!DTU,)IHO39%&M1Q4G>>-=!_:.QC?Y!Y^G M_8&9CBN+SMKYEXW];[5VX%-)KOP(]?Z#K8: UH7C)W\V\YC-AM/#\H/(^HVK MOU!+ P04 " !,@&)0 8^6_-$! "MG8I]M5# > MX+A[^P%V72_CB^&.WY\[#&2CTJ^F!;#H38K.Y+BUMC\18LH6)#,/JH?.K=1* M2V9=J!MB>@VL"B0I"-UL4B(9[W"1A=Q%%YD:K. =7#0R@Y1,_SF#4&..M_@] M\-? #[,_^HEU$%I6*2^@,5QW24.?X<7LZIQX? +\XC&8U1[Z3 MJU*O/OA:Y7CC"P(!I?4*S TW> (AO) KX_>LB1=+3US/W]4_A]Y=+U=FX$F) M%U[9-L='C"JHV2#LLQJ_P-S/'J.Y^6]P ^'@OA+G42IAPA>5@[%*SBJN%,G> MII%W81RGE<-QIL4)=";0A7 ,/F0R"I5_8I85F58CTM/>]\S_XNV)NKTI?3)L M15ASQ1N7O15)LLW(S0O-F/.$H2O,!X(X]<6"QBS.]#\ZC=.3:(5)H"=K.CW& M!791@5T0V/W3(KUK,89)XB;[J,D^(K"[,XEA]G&3-&J21@32.Y,8YG!G0E:G M0X)NPKTPJ%1#%^[D*KM&?055EW1L-)JI6RX$K9/+B& M6_=4+(& VOKIP&UL;5/M;ML@%'T5 MQ .4!"=K%MF6FDY3)ZU2U&G;;V)?VZC@ZP*.V[S6O\![N6<:V'>3J!PR.B6OCN>9-VXX&!YVHD:?H'[W9V-M]BL M4DH-K978$@-51N^VQ],NX"/@CX3!+LXD5')!? [&CS*CFY 0*"A<4!!^N\(] M*!6$?!HODR:=0P;B\ORN_CW6[FNY" OWJ/[*TC49/5!20B5ZY9YP>("IGCTE M4_$_X0K*PT,F/D:!RL:5%+UUJ"<5GXH6K^,NV[@/X\T^F6CK!#X1^$PXQ#AL M#!0S_R:)(>478/0A#F-&+[ M;&<$\^IS"+X6XL0_T?DZ/5G-,(GT9$GGAW6!W:K +@KL%@*W^P\5?H8DR=.M/YMQRD;#83=](#;_XOP?4$L#!!0 ( $R 8E"([N,C MW $ $% 9 >&PO=V]R:W-H965T#$A"4^"'\'C*+-X!?O0PJ53;JM<&NF>&6RMS).@IS@<0))/^T&.Y:]&$^,$F] M)JE'(-Z9^#")W^3@-3EX!-*=B0]S\)MD7I/,(Y#M3'R8O0G9'$$.LG673Z%* M7 =W\3?9]7X_1.X(_X7/C\-7*MM^4.@BM+D([K@V0F@PI01W9E<[\QZM 8-& MVVEFYG*^E7.@Q;@\.&1]]&PO=V]R:W-H965TG> M":[@;)#MI63F]01"#SG>XC?' V]:%QRDR#K6P&]P?[JS\1:952HN05FN%3)0 MY_AV>SRE 1\!CQP&NSBC4,E%Z^=@_*QRO D)@8#2!07FMRO<@1!!R*?Q=]+$ M<\A 7)[?U+_'VGTM%V;A3HLG7KDVQP>,*JA9+]R#'G[ 5,\.HZGX7W %X>$A M$Q^CU,+&%96]=5I.*CX5R5[&G:NX#^--DDRT=0*="'0F'&(<,@:*F7]CCA69 MT0,R8^\[%IYX>Z2^-V5PQE;$.Y^\]=YKD:2'C%R#T(0YC1BZP&QG!/'J8>/XW[/3,.511?M_-/&!ZBU=N!3V=SX&6K]#YL- M ;4+QR_^;,8Y&PVGN^D+D?D?%_\ 4$L#!!0 ( $R 8E"1U*?;N0$ -,# M 9 >&PO=V]R:W-H965T)W^?0%[73?Q"S##.6X9OCB;>="PY2YCUKX0>XG_W9>(LL*C67H"S7 M"AEH"ORP.YZR@(^ 9PZC79U1J.2B]4LPOM8%3D)"(*!R08'Y[0J/($00\FG\ MGC7Q$C(0U^>;^N=8NZ_EPBP\:O&+UZXK\ &C&AHV"/>DQR\PU[/':"[^&UQ! M>'C(Q,>HM+!Q1=5@G9:SBD]%LM=IYRKNXW23W6C;!#H3Z$(X1 *9 L7,/S'' MRMSH$9FI]ST+3[P[4M^;*CAC*^*=3]YZ[[5,]TE.KD%HQIPF#%UA=@N">/4E M!-T*<:+OZ/?[;7ZZF6(:^>F*3]./VP+9ID 6!;+_! YO:GR/2?=OJR2KIDHP M;1PGBRH]J#C**^\RL0\T/LH_^#3NWYEIN;+HHIU_VO@ C=8.?"K)G9^ASO^P MQ1#0N'#\X,]FFK/)<+J?OQ!9_G'Y%U!+ P04 " !,@&)0GX1!XL,! W M! &0 'AL+W=OM5OZ16#X_9D!QF)6^L7T !:] M2C&8$O?6CD="3-V#9.9.C3"XG59IR:Q;ZHZ840-K DD*0@^'>R(9'W!5A-A9 M5X6:K. #G#4RDY1,_SJ!4'.)$_P6>.9=;WV 5,7(.O@*]MMXUFY%-I6&2Q@, M5P/2T);X,3F> (AO)!+ MX^>JB3=+3]S/W]0_A-I=+1=FX$F)'[RQ?8D?,&J@99.PSVK^"&L].49K\9_A M"L+!?2;.HU;"A"^J)V.57%5<*I*]+B,?PC@O.UFRTN($NA+H1G@(/F0Q"IF_ M9Y95A58STLO9C\Q?<7*D[FQJ'PQ'$?9<\L9%KU6:TX)O8?@2PJD 6![*\2TYL28Y@L;I)'3?*(0'YC M$L/%@-;ZZ3LWU\M;7A96C6N;DNU?4?T&4$L#!!0 ( $R M8E 0#QJ@M $ -(# 9 >&PO=V]R:W-H965T?,X&-&^V!7#D74EM<]HZUQT8LV4+BML[[$#[/S4:Q9UW3<-L9X!7D:0D M2S:;>Z:XT+3(8NQDB@Q[)X6&DR&V5XJ;WT>0..1T2Z^!5]&T+@18D76\@6_@ MOGSBF 1\!/P0,=F&3T,D9\2TXGZN<;D)!(*%T M08'[XP+/(&40\F7\FC3IG#(0E_95_27V[GLY,Y3/I7VCHAF0C) M#8&-B6+E'[GC169P(&:?4R1K*8[)?_1DG;Y;K7 7Z;LE/=VO"Z2K FD42/]I\?&FQ37, MAYLD;#%3!::)VV1)B;V.F[R(S@O[E,0[^0L?M_TK-XW0EIS1^9N-\Z\1'?A2 M-G=^A5K_P&9'0NV"^>!M,Z[9Z#CLIA?$YF=<_ %02P,$% @ 3(!B4(9> MK0:W 0 T@, !D !X;"]W;W)K&UL;5/;;MP@ M$/T5Q <$&^]NHY5M*9NJ:J166J5J\\S:8QN%BP-XG?Y] 3N.D_H%F&'.F3/# MD(_:/-L.P*%7*90M<.=-J%^!CPA\-H5V<4*KEH_1R,A[K 21 $ BH7&)C? MKG /0@0B+^-EYL1+R@!BR=>NZ[ MQC5T+!!N$<]?H>Y MGCU&<_$_X K"APEA8TKJ@;KM)Q9O!3)7J>=J[B/TTUVF&'; #H#Z *X MC7G(E"@J_\H<*W.C1V2FWOA6BA/]#TZWX=FFPBS"LS5\O]\FV&T2["+![D.)Z:<2MV(^ MJR2KGDHP;9PFBRH]J#C)*^\RL'H\Q]L,00T+AR_^+.9QFPRG.[G'T26;US^ U!+ P04 " !,@&)03;F. M-.X! !F!0 &0 'AL+W=OI. 3O[(,%I%(8) M%:QI29E[WU&5N>P-;UHXJD#W0C#U^P!<#@79D'?'QO7IO7K,)ZDR12&!T13 M0#0'9%Z'CD(^\T=F6)DK.01JO/N.N2?>["-[-Y5S^JOP9S9Y;;VW,D[BG-X< MT80YC)AH@=G,"&K99XD(DSA$'\(C/#Q&,XQ]>+P,WV4XP18EV'J"[3\E;EN$AIP*82WMFGJ^W0FPT.%^.VJ=VKL?5'P\ANFFIT'JWE'U!+ P04 M" !,@&)0.K7@EK; O@T)L4RN:X=:X[$&++%B2S5[H#Y6]J;21SWC0-L9T! M5D62%(1N-CLB&5>XR*+O9(I,]TYP!2>#;"\E,W^.(/20XRW^<#SQIG7!08JL M8PT\@_O9G8RWR*Q2<0G*; MD! (*%U08'Z[P!T($81\&J^3)IY#!N+R_*'^$&OWM9R9A3LM?O/*M3F^P:B" MFO7"/>GA$:9ZKC&:BO\.%Q >'C+Q,4HM;%Q1V5NGY:3B4Y'L;=RYBOLPWB3[ MB;9.H!.!SH2;&(>,@6+F]\RQ(C-Z0&;L?F#,[8BGCGD[?>>RF2 M?9J12Q":,,<10Q>8[8P@7GT.0=="'.D_=+I.3U8S3"(]6=)W_XF?K@JD42#] MJ\3K+R6N879?@I!%3R68)DZ31:7N59SDA7<>V%L:W^03/D[[#V8:KBPZ:^=? M-O:_UMJ!3V5SY4>H]1]L-@34+ASW_FS&,1L-I[OI!Y'Y&Q?O4$L#!!0 ( M $R 8E#-3*MS\ $ &8% 9 >&PO=V]R:W-H965T0/B+DLEZY8I&RBJ)5::96JZ;,7AHMB8VJ;)?W[VH901)P7 M[!F?.6?&9B:?N'B5+8#RWACMY0FU2@U'C&79 B/RC@_0ZY.:"T:4-D6#Y2" M5#:(41SZ?H(9Z7I4Y-9W$47.1T6['B["DR-C1/P] ^73"07HW?'<-:TR#ESD M VG@)ZA?PT5H"Z\L5<>@EQWO/0'U"=T'QW-F\!;PTL$D-WO/5'+E_-48WZH3 M\DU"0*%4AH'HY08/0*DATFG\63C1*FD"M_MW]B=;NZ[E2B0\$2T"X!F16!\]"-O-'HDB1"SYY8K[[@9@G#HZAOIO2..U5V#.=O-3> M6Q&E:8YOAFC!G&=,N,$$*P)K]E4B=$F\629PBB8,@V(FX,)_<=^H421T$ MT4[$A?GD33*G2.8@V+^)"Y/L1/#F/V<@&MOATBOYV-OILO&N0^0^M'WR'SY/ MH!]$-%TOO2M7NMML3]2<*]"I^'?ZZ5H]]%:#0JW,-M5[,;?^;"@^+%,-KZ.U M^ =02P,$% @ 3(!B4$#V!2ZX 0 T@, !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0L^PVNUD!4C95U4J-M$K5]MD+ UCQ MA=IF2?X^8T,H37FQ/>-SSEP\S@9CGUT+X,F+DMKEM/6^.S+FRA84=S>F XTW MM;&*>S1MPUQG@5>1I"1+D^26*2XT+;+H.]LB,[V70L/9$MWK":09+%IM5*J% .V$TL5#G]'YS/.T"/@)^"1CH?)O3 R45U+R7_LD,7V&JYQ,E4_'?X0H2X2$3C%$:Z>)*RMYYHR853$7Q MEW$7.N[#>'.;3K1U0CH1TIEPB''8&"AF_IE[7F36#,2.O>]X>.+-,<7>E,$9 M6Q'O,'F'WFNQ/>PS=@U"$^8T8M(%9C,C&*K/(=*U$*?T/WJZ3M^N9KB-].V2 MOD_6!7:K KLHL/NGQ,.'$MEUG.2%=Q[8^_B(["]\ MG/9';ANA';D8CR\;^U\;XP%326YPA%K\8+,AH?;AN,>S'<=L-+SIIA_$YF]< MO %02P,$% @ 3(!B4-EB&Q2R 0 K@, !D !X;"]W;W)K&UL;5/;;MP@$/T5Q <$7S9)N[(M95-5K=1*JU1-GUE[;*, MXP)>IW]?P([KMGX!9IASYLPP%!.:%]L#./*JI+8E[9T;CHS9N@?%[0T.H/U- MBT9QYTW3,3L8X$T$*EN/EU HE325/Z MYG@27>^"@U7%P#OX!N[[<#;>8BM+(Q1H*U 3 VU)']+CZ1#B8\"S@,ENSB14 M4 ;@]O[%_C+7[6B[F#L[8 MBGCGQ5OOO5;Y^Z1@UT"TQ)SFF&P3DZX1S+.O*;*]%*?L/WBV#\]W%>81GF_A M]_D^P6&7X! )#G^5^&\!;-,O!::+DV))C:..4[KQKL/X$!^(_0F?)_DK-YW0 MEES0^5>+O6T1'7@IR8T?C]Y_GM60T+IPO/=G,X_0;#@&ULC57;;ILP&'X5Q /4V)PK@K2DG39IDZ).W:Z=Q FH!C/;"=W;SS8N M2L!LN<$'OL/_&6,7/>-OHB)$>N\-;<7*KZ3L'@$0^XHT6#RPCK3JS9'Q!DLU MY"<@.D[PP9 :"E 0)*#!=>N7A9G;\K)@9TGKEFRY)\Y-@_F?-:&L7_G0_YAX MJ4^5U!.@+#I\(C^(?.VV7(W J'*H&]**FK4>)\>5_PD^/D.D"0;QLR:]N.I[ M.LJ.L3<]^'I8^8&NB%"REUH"J^9"-H12K:3J^&U%_=%3$Z_['^J?37@59H<% MV3#ZJS[(:N5GOG<@1WRF\H7U7X@-%/N>3?^-7 A5<%V)\M@S*LS3VY^%9(U5 M4:4T^'UHZ]:T_? FS2W-34"6@$8"C/Y)""TAO)<064)T+R&VA'A" $-VLYA/ M6.*RX*SW^+ ?.JRW'7R,U>?:ZTGS=C(670T*SK,%Y8M=@K$]R];XA1('!4D MDUV4S))&B3K0W#:ITR9UV$P6=#U@DNL%#=,EF\QIDSEL)I]WG[AHY/['(9H9 M03@[CM#,* [S>29P=4[JJ_$[YJ>Z%=Z.277DFH/QR)@D2C-X4&J5NHW' 25' MJ;NIZO/A2AH&DG7VN@7CG5_^!5!+ P04 " !,@&)0U+;EK"H" "J!@ M&0 'AL+W=ONOFR <_5>,WW?Q 3X: M:[(^EBW9DN8NVS[3EE9S41S0>O??#]"Z5LC2+_+PG/,[!Q2*GO$W41$BO?>& MMF+I5U)V"P#$H2(-%B^L(ZUZ%FPBZ1U2W;<$Y>FP?S/BE#6+_W0OTV\UN=*Z@E0%AT^D^]$_NAV7(W I'*L M&]**FK4>)Z>E_S%<;#.--X"?->G%7=_32?:,O>G!E^/2#[0A0LE!:@6LFBM9 M$TJUD++Q>]3TIY*:>-^_J7\RV566/19DS>BO^BBKI9_YWI&<\(7*5]9_)F,> MY'MC^*_D2JB":R>JQH%189[>X2(D:T859:7![T-;MZ;M1_T;S4V(1D(T$4+X M7T(\$N)G"7 DP&<):"2@&0$,V0LU>2QA$!;AJH1&S&C#1 R9^Q*QMS$QE8R,2] C9VI P_"<#5) I3>1, M$QF!^$X@SJ%;('8*Q$8 /CB81QTPR&#:83ER%*:S,!L;AN(@R\-99@=U,ON3LJN NW]:G^+?,#_7 MK?#V3*KCP?S$)\8D48+!B]*JU,4Q#2@Y2=U-59\/Q^UO/*]<;DR6 ME%_SO=G5_UGG1994]6GQXI7[PB2KUBA+/>G[@9CJ^%3>+P&\,6L6_6W,L+XY'32G/>?ZS.?ES-1W[348F-35K+FTSJ&,L\+=N_H^6AK/*L\U*GDB6_3[_;7?M[ M[/R_F6$#V1G(LT$=^R,#U1FH:PVH,Z!W@^!# ]T9Z'<#^M @Z R":PW"SB"T M#+S3Z+:W:YY4R6Q2Y,=1<9IQ^Z29V.(FK"?$LKG8WO_V?_4=*^NKKS/RPXGW MVCCJ-'QIHK[F'FGBOF;N:L19X=59GE.5*-4[Z9@'VLKB<\G&M4Z4#T'S( 1=$"M ^HYL+*\.VETJ]FUFJCN8SB* MAE&T$T5$5I2Y=J+XUJ"["D$1!=:X?^2GEVH 4PW @"@KU9,FN @AB22.$L(H M(8A"5I30B?)%Z- J]P&I2 76V#VZ,BDH9$8F@CE'(&<;KL@9_-BW4IE';L:A M3<\#$$6VITP:P( LP%JYQ%)[J"1 &;^:V0($K(N,#]40QH MD )W2(%:9&2/*A+%3!S<(X7;)$ER X9[EP@&5(L;DT"=R:D6B"07!S<3 ;H) M.PDQNR*^OEJ)B9$N,23M;@]%Q,3!O$C B]2,"PR#E .JQ3!(=4VU2!0P<3 Q M$L @&6XEAD'J =5B&"18R=UJD2ABXF!B)(*!05]B&&0TH%H,@W17,E M$"GN M>1,3HP ,BDE581B4N+Y:A6%08&50]@,E%#%/!XIYO 8P*'M%A2(&;H6)48 8 MQ4"G,#%J #$*$Z, #.ZH(A$WJI@8!8AQ1Q6)F":B,%8*K#&*@5MAK-2 -88P M,82(L4<5B;@UAC!6!-88Q?0APEC1@#6&,#&$8'"J12)F#A&S;P7$$-/*"!-# M X@A3 P!&$C8U2(1\ZA#F!@",! W8!@&&K#&$(:!T/+AW%L@(F8F:TR,!C X MHPI%3-?5F!@-B"&FZVI,C!Y C,;$:!<&>P^ZZ#2]#62LV7= MJ/>B0"HV$O.Z!VQEB.G=&I.E!VQE-(9&(VBLKO M#;>R>;5L79^+F\?3-X-W-Z=/&'\GQ\ZK*L_;U\CK/*U,GZ7^MT]N8 M9'4^2]O#)&Q)\]4#[D?NC?$\_MI5$F@8JL)Q?X#NI' M?Q(Z0I-*U3+H9,L[3T"=^T_A[A@;O 7\;&&0L[EG*CES_F*"+U7N!\804"B5 M42!ZN,$!*#5"VL9OI^E/6QKB?'Y7_V1KU[6Z[XKW #JN'&B=ZCY%3:KU=>I>+,J6@KC+R.8]O9<7#Z=]HZ(7*$ M:"*$^+^$V!'BCQ*P(^ % 8VEV-XV(N4;C#NONE2=IFVS7= M'JFSMP)O@@S=C)##[$=,-,-$;Q&']XAD\Q9R? \)PW\R2)N%XA7!6(K@&<"Z<+D?H1L+*0;3>(D3M)%N6NP-,%X4?(*+(VVV\>%:30[ M*_/8OA%Q:3OIG;G2QVX/I^9<@98,'K1:H]_W%%"HE9FF>B[&6SX&BO?N :/I M+U+\!5!+ P04 " !,@&)00C2MGXL" !D"@ &0 'AL+W=O1\T:N?9+I=J7()#[DM9$ M+GA+&_WDR$5-E!Z*4R!;0B1G)EZX]U7.FPH]KUA]]_IA3(- M-Y5HC3UGTOYZ^[-4O!Y8="DU^>BO56.OW>:(WOR7F':,7K+W9FTEKA7VFBY=Z]E)$,@^\P>,0$FG\4 MP: (M@3+&P*,0YA@"1(L+4%T5\%R4F6/R2RFZ47"A:/,"%2) )5HHM)C4'@C M$RT26"4&56) )88)$I @F;D9Q8X*4I @!2I()_M,GW!S!:JL )751 7 1!$L MDH$B&2"2P03FG4$!"!^W$SDRA!XP= #=.>HR%,$Q0O@!2R%0X@@;@M.&@+@E MR$$!1PE%3[@*YP1!09FY&L]<14Y7X3BAY!%7 1!V_%,1G#H$Q"YQE0I'"JV> MXJ)PG$[SX\GI*H83 M@Z$#:NHJGI]0X<+QY<=PK#!T1,U&UL MC97;CILP$(9?!7'?!9MC(H*4;%6U4BM%6[6]=L@DH#68VD[8OGUMPU("1NI- M?&#F_V8M>0*WT'^:(]\_#.,R\NQ8:; Z]#9[8H-'"4^HC ML0![QP#R-L%PBL,09&('B( M,;(+A%:!T B$#P+Q+,G>)C(VC;'!*$2^'1-9,9$%D\PPO4T\P:#-:C:Q%1-; M,.D,$R\P'U#L3Z)YX"163F+A;&:<9,'!8>JG=DQJQ:1+3+)R[!NKP&9Y/9*5 M"XI\>Q'XEACPO K\1:Z!CU8N,EJI-O0?5V0P>@!%X0K'6G)[A"T)!7,.7EZ2 M>+-9 =E+$P46T*)_!,O:BA=WT9NTK!KXU31KX13LUIB78K([/@A[;%K>/_/^ M-?E&^+5JA'-B4C5.T]XNC$E0P?A/*HQ2/6#C@L)%ZFFBYKSOXOU"LG9XH;SQ MFI<; MO17\K&DO9_W 5'+@_-4,OIXV862 **-'91R(;FYT1QDS1AKC]^@93BE-X+S_ M[O[9UJYK.1!)=YS]JD^JVH1Y&)SHF5R9>N;]%SK6DX7!6/PW>J-,RPV)SG'D M3-IO<+Q*Q9O11:,TY&UHZ]:V_;"2XC','P#' #@%Q.E_ Y(Q('$"P$!F2_U$ M%"D+P?M ##^K(^9,Q.M$;^;13-J]LVNZ6JEG;V6*LP+\5N MJ4#_3( &F"B@EP+:^&2> 4*_0>(U2*Q!>E<&Y@4B],ZH'!#LR@0;,T,&.2!<;9_BQ9I\E6&W(U9JE8XCQ\<.>R%P4L8=_^W>)'F0YS'*_?T M>V41?G!FT8/6FS2C\1TX#1LS)=K/MBN"B'@>+=^ : Z2$J_P)02P,$% M @ 3(!B4#ZFLHVT 0 U , !D !X;"]W;W)K&UL?5/M;ML@%'T5Q ,4?R1M$MF6EDS5)FU2U&G;;V)?QZA\N$#B]NT+F%IN M9NV/X5[..9R#H1B4?C8=@$6O@DM3XL[:?D>(J3L0U-RI'J1;:946U+I2GXGI M-= FD 0G69+<$T&9Q%41>D==%>IB.9-PU,AHB:>MO3$^?Q#_3%D=UE.U,!!\;^LL5V)-Q@U MT-(+MT]J^ 8QSQJC&/X'7($[N'?B]J@5-^&+ZHNQ2D059T70UW%D,HS#N++> M1MHR(8N$;"*DJ_\2\DC(;PAD=!:B?J665H56 ]+CS^JIOQ/I+G>'6?MF.+NP MYM(:U[U6JTU:D*L7BIC]B,EFF.PSXO OXGX]08@S,+G(%EUD@9_/=\BR98%\ M42 / JM/,6Y,[D?,.F!DP*2;='L;90F5/&QOS)#9^?K[_I/J,Y,&G91UORH< M:*N4!:>8W#FQSCVQJ>#06C]]<',]7K2QL*J/;XA,#[EZ!U!+ P04 " !, M@&)044CA N$" #U"P &0 'AL+W=OWUW\SEY=5?W2G*34WFN1E\W:/VE=W0=!LSO)0C1WJI*E^7)0=2&T&=;' MH*EJ*?9M4)$') QY4(BL]#>K=NZQWJS46>=9*1]KKSD7A:C_/LA<7=<^^&\3 M3]GQI.U$L%E5XBA_2/VS>JS-*!A8]EDARR93I5?+P]K_"/=;PFQ B_B5R6LS M>O=L*L]*O=C!U_W:#ZTBF #I \@0 .R_ ;0/H$Y T"EK4_TDM-BL M:G7UZN[?JH3=%'!/33%W=K*M7?O-9-N8V([13! MHP$2& &#"H*J(&T\O5'!< **$M"6@-T01$X:'29J,64GDL>1D^P601'.."Z& MH6(8(H8[8CH,'RU#:!P[6J:@$-<1H3HB1(>SQ$,T6>(#(V$$CA($1M.84EP. M1^7PB1Q@S)'#IV5A<>AN-P1%4I@1$Z-B8J0V"4Z0H 3)\BV;H@3I@BV;3A*% M&%*G&@@H(3.Y0(AW@1 1D\Y0S#026%X0P+L D 4EZ4'C='G*7!"<#,#XN:4X!0$]R )EY>%X!XDL* L M/>BF7Q .H5,6%):$,TV6S)SKB*/3.0K MZ^XBV@VTJOI+=C#<]#?_ %!+ P04 " !,@&)0Q35.)N\! #9! &0 M 'AL+W=O*]H MT\)%>+)GC(A_1Z!\2/W ?W,\-U6MC -E24&,#=X"?C,Y5<.7\QQKC[1U0C@2PHD0Q!\2HI$0O1/P MAP0\$O""@%PIMC=GHDB6"#YXPOW=CIA+%!RP[GYNG+;9]DRW1VKO+<-[G*"; M$1HQ1X<)9YA@0B"M/H4(UT(!_@](B(=_>0\R,D",+U+*+50B,K$-T5 MNEL7P*L"V K@.X%XT2F'V5M,ZPK9+# GA]G-,8M:'U7P9MEQ-/O!#$1EAT=Z M.>];9?HT\T[S^12:"[+P'_7@4MQN= M?ZW?F&ULE5CK;N)&&'T5 MRP^P]EP\QA$@)<"JE5HIVJK=WPX,8*WMH?80MF]?WY88?V>2\ ?;P_GN<[ZY MS"^F^E$?M;;>SR(OZX5_M/;T$ 3U]JB+M/YB3KIL_MF;JDAM\UD=@OI4Z737 M"15YP,-0!46:E?YRWHT]5\NY.=L\*_5SY=7GHDBK_YYT;BX+G_F_!KYEAZ-M M!X+E_)0>]%_:_GUZKIJOX*IEEQ6ZK#-3>I7>+_Q']K"182O0(?[)]*4>O7MM M*"_&_&@_?M\M_+#U2.=Z:UL5:?-XU2N=YZVFQH]_!Z7^U68K.'[_I?UK%WP3 MS$M:ZY7)OV<[>USX,]_;Z7UZSNTW<_E-#P%%OC=$_X=^U7D#;SUI;&Q-7G>_ MWO9<6U,,6AI7BO1G_\S*[GGI_U'1((8%^"# KP+L?0$Q"(@W ?6N@!P$Y)N M?%<@&@2BB4#0Q]XE!Z^MH@'SU&/X&!/.;C$KBF%71-!X<'6#(S>>.!%7T<0"A?!;Q/IC)1L* M88QC1P7,E^@4B)M\S; ""17(3H&\49!,0NTQ48$QL1CE'FT5T%0[+"#J<<0]QRIY9A[_ [N M<@QI%=#%0BNQO(EHCSLF*CV!A(EU%PKV#H_68%(F" MI'#9P0V&@P69N;:.F/-\=D>1,)TYI3,H4D*)Q$:^#D5*2/95+-2T1@ E8\?\ M%KB!B/ 3)4(@YXX7=QE!NTS$A$,%IKS@GR^1<&R\ 9MIM!0DA:.S"TQY01?X MB#D6(8$I+Z([HL7T$X!99$(*NA\6?-HT!M!-QXXF)[P- #D:I< T%FA?3:H# M-A/*90=S78"EFSDZCL!<%\D=1SC,/$E)!0YQ(3VMB&E.U@B5D&7W(U3O=# Z M]!>Z.G0W,+6W->?2MH?>T>CUEN>1MY<&D_$5>]CT=S5O:OJKHS_3ZI"5M?=B MK#5%=W&P-\;JQLGP2^/>4:>[ZT>N][9]C9OWJK^RZ3^L.0W74<'U3FSY/U!+ M P04 " !,@&)0RF4G54@$ <%@ &0 'AL+W=ON/!SM M0[-H7ZJJ:/Z[MV5]7B4\>;OQ[?"\[_H;Z7IY*I[MG[;[Z_30N*OT&F5[J.RQ M/=3'16-WJ^07?K>1U \8$'\?[+F].5_TJ3S6]??^XK?M*F$](UO:IZX/4;C# MJ]W8LNPC.1[_CD&3ZYS]P-OSM^A?A^1=,H]%:S=U^<]AV^U7298LMG97O)3= MM_K\JQT34LEBS/YW^VI+!^^9N#F>ZK(=_B^>7MJNKL8HCDI5_+@<#\?A>![C MOPW# V@<0-B%P6_$VXQG_J; MP]H-O[EL6W?W=:VX7J:O?: 1TM#<9)F7"X"9C)'!="2D(P$=;Y[["T;?S/,I METIY; "*"U(Y9J,@&P78Y!X;A>8Q2DB/#\*1$CSRN#4DI$-"Q#Q".IB( 1-M*"9\!4,84;'"$5LBL_0\ B:S*249/X;#G&,21VAA#V+TPP5CZ#; MJ:3.E?$9A3 E128CA+ '7!H8/-A@.W"95LPIDD4Q3H!N!$IDQ,.-B^ M>#9'R5FHY-P8__L 8"K+6>3SP+$=1 M!F]6AQ=:".GP([C)S3W\G0/'PN[T*F1+"YR#E]G03]&F?&%RZ"&17;M\%.)>G--EV_;_I'T3P?CNWBL>ZZNAKVY79UW5D7D'UVH?:VV%XO M2KOK^E/CSIO+?N7EHJM/XUYL>MT07O\/4$L#!!0 ( $R 8E"CH9EF_ ( M # , 9 >&PO=V]R:W-H965T>[QW1/?<5E< M9?52GX10SFN>%?72/2E5WGM>O3N)G-=WLA2%_N8@JYPKO:V.7EU6@N^-4YYY ME)#0RWE:N*N%L3U6JX4\JRPMQ&/EU.<\Y]6_MF"^V9X2H\GU1B\U:+D M1_%3J%_E8Z5W7L^R3W-1U*DLG$HBXW,_J1[ M=5JZL>OLQ8&?,_4DKU]%EU#@.EWVW\5%9!K>1*+/V,FL-I_.[EPKF7I=)#G1F]#E(J MH2,D=SJVDQ[?^TTF#JI91GI=M3-LNU&R[.9SK_^3L/H/4$L#!!0 ( $R M8E"<0IG$' ( #\& 9 >&PO=V]R:W-H965TKJI5:*=JJ[;633 ):@ZGMA.W;US:$LN#M37S@ MG_^;L6%2]%R\R@I >6\-:^76KY3J-@C)8P4-E0^\@U8_.7/14*67XH)D)X"> M;%##$ Z"!#6T;OVRL'M[41;\JEC=PEYX\MHT5/QY L;[K1_Z]XV7^E(ILX'* MHJ,7^ [J1[<7>H4FEU/=0"MKWGH"SEO_,=SL++ M:>L')B%@<%3&@>KA!CM@S!CI-'Z/GOZ$-('S^=W]DZU=UW*@$G:<_:I/JMKZ MF>^=X$RO3+WP_C.,]<2^-Q;_%6[ M-QDHAE'SJ3]]8Y7J7@SNNA4&OHVC'5K MQW[TOX>Y _ 8@*> ,/IO !D#R"( #9G94I^IHF4A>.^)X;(Z:MZ)<$/T81[- MICT[^TQ7*_7NK8QQ7*";,1HU3X,&SS3XO6*W5B3_3)!.8,H".[/ -IZ\RR)Q M&Q"G ;$&T3Q%LJABD,16T@Z2, D_H$1.2K2BQ#A=8 9-,L<$*8[0D3R*EU6CV:=L6NLW*BYU M*[T#5[HKV&_WS+D";1D\:+=*=_-IP>"LS#35#>V:S3]9Y1_ 5!+ M P04 " !,@&)0&/G%E5$" 3!P &0 'AL+W=O>>>W&N\X'Q5U$3(KVWEG9BZ]=2]AL 1%63%HM[UI-.O3DQ MWF*IMOP,1,\)/AI22T$4! BTN.G\(C>Q)U[D[")ITY$G[HE+VV+^MR24#5L_ M]-\#S\VYECH BKS'9_*3R)?^B:L=F%6.34LZT;#.X^2T]1_#S3[3> /XU9!! M+-:>KN3 V*O>?#MN_4 ;(I144BM@];B2':%4"RD;?R9-?TZIBNMGOGHB M)&LG%66EQ6_CL^G,GC(W'82IYW$8<=JVF[$H$6>NS2.H#L-%G,W:%5[%+)_4_;!&=)_MC MI$>+%2_5Q!\'](?,>%W\P/S<=,([,*D&EQDO)\8D42Z#>V6P5C?4O*'D)/4R M56L^SNEQ(UD_74%@O@>+?U!+ P04 " !,@&)0FQ[VG^,! "/!0 &0 M 'AL+W=O'1@"6AM3VPG;MZ]M6$03'W*)/>.9[Y\Q\>2CD&^J!=#!.V>] M*E"K];#'6%4M<*J>Q "].6F$Y%0;4YZQ&B30VB5QADD8;C"G78_*W/F.LLS% M1;.NAZ,,U(5S*O\>@(FQ0!'Z<+QTYU9;!R[S@9[A)^A?PU$:"R^4NN/0JT[T M@82F0)^B_2$*;8*+>.U@5*M]8%LY"?%FC6]U@4);$3"HM$50LUSA&1BS)%/' MGQF*%DV;N-Y_T+^XYDTS)ZK@6;#?7:W; FU14$-#+TR_B/$KS VE*)B[_PY7 M8";<5F(T*L&4^PVJB]*"SQ13"J?OT]KU;AVGDSB;T_P)9$X@2T+D$O DY"K_ M3#4M["G=FBE?&>RW3>)OCJP7-,80$(_8.<%[!YOTXP$[_\Z M?*!1;U!\HX-73\F.JA]4GKM>!2>AS:MT;Z<10H,!AD_F [=F.BX&@T;;;6;V M&UL=951;YLP$,>_"N)]!0P&$A&DIM6T M29L4==KZ[)!+0+4QLYW0??O9AC(&S@NVSW?_WYW!1]%S\29K .6],]K*G5\K MU6V#0%8U,"(?> >MWCESP8C22W$)9"> G&P0HP$*PS1@I&G]LK"V@R@+?E6T M:>$@/'EEC(@_>Z"\W_F1_V%X:2ZU,H:@+#IR@1^@?G8'H5?!I')J&+2RX:TG MX+SS'Z/M/@I-@/7XU4 O9W//E'+D_,TLOIYV?F@R @J5,A)$#S=X DJ-DL[C M]RCJ3TP3.)]_J'^VQ>MBCD3"$Z>OS4G5.S_WO1.$\/A=\2\XVB+]-E4QFB/PN[IY*6VWDJ<)$5P,T*CSW[P03.?:/(( MM/J$0"[$'JW"$XS< K$SQ]@*Q#,!%-\12)P"B15(_BL2+XHC@1,M;%*Z^L"@, M,5Z0@MG-92 NMF=)K^+7UC;,F77JBX_(WOQ_[D-3_4[$I6FE=^1*]P][R\^< M*]#9A \ZCUKW\6E!X:S,---S,32S8:%X-S;J8/I;E'\!4$L#!!0 ( $R M8E!.5=XT+0( &T& 9 >&PO=V]R:W-H965T^\ A#.1T-:OG(K(;IGA'A908/Y$^V@E4^.E#58R",[(=XQP >= MU! 4>%Z"&ERW;I'KV(X5.3T+4K>P8PX_-PUF_]9 :+]R??<:>*U/E5 !5.0= M/L$O$+^['9,G-+( UXJZ'GD[VC*ME3^JX.WP\K MUU.&@$ I% .6RP4V0(@BDC;^#ISN**D2I_LK^U==NZQECSEL*/E3'T2UT&5BDE09_F+5N]=H/ M_-T(P) 1C@I\\3 B'A/ S(7J8$ T)T2P!F5)T;[98X")GM'>8>;L=5A^1 M_QS)[IS]@J M$UMDHIF,P203F>B.1F+52"P:LX:ODZ5&FLW>6[(HUYN]MD>(&Z.IU6AJ,9K, MC*8+HT'R);6K9%:5S**2SE2R12&A-R\%32Y= ^RD!QIW2GINA?IV)]%Q9KX$ MZM+.XFLY2\WH^Z0Q@_@G9J>ZY"CD2],4]4BI 6O2>I+M*SO[Q0. HU#:5 M>V8FH#D(V@W#'8W_,,5_4$L#!!0 ( $R 8E"R2*^2EP( ',) 9 M>&PO=V]R:W-H965TTDW=_/-A11^S+M!6QS[CWG&OO8JYN0+^K,N8Y>VZ93 MZ_BL=7^?)&I_YBU3=Z+GG?ER%+)EVG3E*5&]Y.S@@MHFP6E*DY;57;Q9N;$' MN5F)BV[JCC_(2%W:ELD_6]Z(VSI&\=O 8WTZ:SN0;%8]._$?7#_U#]+TDBG+ MH6YYIVK119(?U_%'=+]#U 8XQ,^:W]2L'=E2GH5XL9VOAW6<6D6\X7MM4S#S MNO(=;QJ;R>CX/2:-)TX;.&^_9?_LBC?%/#/%=Z+Y51_T>1V7<73@1W9I]*.X M?>%C022.QNJ_\2MO#-PJ,1Q[T2CWC/87I44[9C%26O8ZO.O.O6_#EP*-87 M'@/P%(#S?P9D8T V!2 7D S*7*F?F&:;E12W2 Y_JV=V4:#[S$SFW@ZZN7/? M3+7*C%XWA)2KY&H3C9CM@,$S#'Z/V(4(2B9(8@1,*C"H KOX;,Z083A!!B;( M7()\EJ#(O"H&"'&0SD$027/J51*B4EA'#NK( QVE-U?; 4)G#*0LD"/.U+0.6#RA')4Q3@3050..OH2J@J6;S^HX$I?"^3P$:?\N, MH#E/5BTL +3@+PC@R7T>%.Z)JO(]!OWOUD2PR2 ,2"&^%!RP5.72U,)>A$(S M(I3Z/ H1PL\L->@T&P(+7P>"+2P'A%L)BAT$T+]70R!BJ7_ YL% MS"-\8M M"/+-(IF=?O8Z\IW)4]VIZ%EH];F+U!+ P04 " !,@&)0"H=V.Z$" !["@ &0 'AL M+W=OVZ>0V M/"O5WT>1W)]92^4=[UFGWQRY:*G24W&*9"\8/=A-;1.1.,ZCEM9=N-O8M2>Q MV_"+:NJ./8E 7MJ6BK\/K.&W;0CA^\)S?3HKLQ#M-CT]L1],_>R?A)Y%D\JA M;EDG:]X%@AVWX4>X?R!V@XWX5;.;G(T#4\H+YZ]F\O6P#6.3$6O87AD)JA]7 M]LB:QBCI//Z,HN'$-!OGXW?US[9X7R1-[_K@SIOPS(,#NQ(+XUZYKI>#NJZ%1:^C8\Z\X^;\.;#,9M^ 8R M;B#3AN%PH@%D,_]$%=UM!+\%8CC\GIIO#/=$G\W>+-JCL.]T\E*O7G=9D6RB MJQ$:8QZ&&#*+23,RQ41:?X(0%$*L0/(?),4%$E0@L0+I7( 4BRR'F,S&=#8F M+\H2IZ0H)44HY8(RQ.0S2I;$GL/(4$J&4*H%)7,H29X5."5'*;E+2>(%)7!^GJ(B/A+N;\ ,[KE(@#L< MUEA\#)HGF\;@X> >AS4F!]?E29I[.+C+88W-P?4Y%#X.[G-88W1PG5YY' BX MT6&-T\&U>N:AX$:'-4X'U^JQAX(['=98'5RO0TP\Y1#YD\,*5[D!LGW#D7#$M&-]IJ;/N!*=) MPX[*# L]%D,[-$P4[\=6+YKZS=T_4$L#!!0 ( $R 8E!TUEX[F@( $H) M 9 >&PO=V]R:W-H965T\>!YORC@][WW>0@/5G>I7O1% M"!.]-G6KU_'%F.XQ2?3A(AJN'V0G6OOE)%7#C>VJ>U&8EKZ:N6O&D(GUM&J[^;44M[^L8QV\#S]7Y8MQ LEEU_"Q^"O.K M>U*VETQ>CE4C6EW)-E+BM(X_X<<=3IU!K_A=B;N>M2.7RE[*%]?Y=ES'R!&) M6AR,<\'MZR9VHJZ=)\OQ=W0:3S&=X;S]YOU+G[Q-9L^UV,GZ3W4TEW7,XN@H M3OQ:FV=Y_RK&A&@%=M_[X/ M7R@=S6 #,AJ0R0!G'QJDHT'J&20#69_J9V[X9J7D/5+#W^JX6Q3X,;63>7"# M_=SUWVRVVH[>-K0H5\G-.1HUVT%#9AKR7K$+%3F=)(D%F"@(2$%Z^W0>( MH)O($!%$"$+.'#%Q6')Q9F_<'%8 M36F64;_F0C)"<^8!);-#S=TR?G!UKEH=[:6QYV-_BIVD-,*Z1 _6V<5>;*9. M+4[&-0O;5L/I/G2,[,:;2S)=GS;_ 5!+ P04 " !,@&)0MP5)HA," #[ M!0 &0 'AL+W=OX-/__SSC;%=C(R_B@9 M>F\=[47I-U(.>X3$N8&.B"\ZPG\?@+*Q]$/_?>*YO3523Z"J&,@-OH/\,1RY&J'% MY=)VT(N6]1Z':^E_"/=UIO5&\-+"*%9]3U=R8NQ5#[Y<2C_00$#A++4#4O^N_LG4[NJY40$U(S^;"^R*?W<]RYP)79Z M$M^;B_\*#Z!*KDE4CC.CPGR]\UU(ULTN"J4C;U/;]J8=IY44SV'N@&@.B): M,/YO )X#L!6 )C)3ZD<61KI)$4:QA;'5Y)&;(W-R9!N.,+9R M'++M KSZ3V:!I(-\U.+EO>^^@-02P,$% @ 3(!B4)E +4:T @ MT@H !D !X;"]W;W)K&ULE5;;CMHP$/V5*!^P MR3@W@@")BZI6:B6T5=MG P:B3>+4-K#]^]I.2"&94)8'8ILS9^9,.,E,+ER\ MR2-CRGDO\E).W:-2U=CSY/;("BI?>,5*_BX(JO14'3U:"T9T-*G*/^'[L M%30KW=G$GJW%;,)/*L]*MA:./!4%%7\6+.>7J0ON]> U.QR5.?!FDXH>V'>F M?E1KH7=>R[++"E;*C)>.8/NI.X?QB@0FP")^9NPB;]:.D;+A_,ULONRFKF\J M8CG;*D-!]>7,EBS/#9.NXW=#ZK8Y3>#M^LK^R8K78C94LB7/?V4[=9RZ(]?9 ML3T]Y>J57SZS1E#D.HWZK^S,<@TWE>@<6YY+^^UL3U+QHF'1I13TO;YFI;U> M&OYK&!Y F@#2!A!X&! T <&S 6$3$'8"O%J*[WYM VV_ZFVR/UZ7D6I<'$.QNB!K.H,>0&$_JC>\RRCX$6X>D*VC((5L:" M],*C-.RDZ&/"B-QC5AA/A!<2H/T(+$%X1Q#C!"%*$%J"X(X@P0DBE"!"*NAT M>U5C(HLIZVY'?OW!4\5HJAA)E7:Z'O=21=&C3 F:*>EEBH<(1BC!Z/FVIBA! M^O^V+M*>5D(>B@4?-Y6/R(6NJ_Q>MN1QL@$' Y*,=.V)@8*!/*A%YT 0BG" M C<7!,_?1<#M!2%21=156X, ;N_D2S+P( #\;%8>LE,Z&*SUVV.%@S[EBNA;_19OBJ ?,=I.SO3++1*]%/675&\6K9H+T MVC%V]A=02P,$% @ 3(!B4)[*DF/Y 0 >@4 !D !X;"]W;W)K&ULA93;CILP$(9?!7'?-4>G&P'2+E752JT4;=7VVH$A MH#68VD[8OGUM0Q 'JWL3>X9__OG& 2<#XZ^B!I#.6TL[D;JUE/T1(5'4T!+Q MP'KHU).*\99(%?(+$CT'4IJBEJ+ \S!J2=.Y66)R)YXE["IIT\&).^+:MH3_ M?0;*AM3UW7OBI;G44B=0EO3D C] _NQ/7$5H=BF;%CK1L,[A4*7NDW_,L=8; MP:\&!K'8.WJ2,V.O.OA:IJZG@8!"(;4#4CZY10D2N5+VSX M,\L>M,PW^#&U EUR2J1\&H,+]. M<162M9.+0FG)V[@VG5F'R?]>9B\(IH)@+O"C_Q:$4T&X*4 CF1GU$Y$D2S@; M'#[^63W1[X1_#-5A%CIISLX\4],*E;UEV \3=--&D^9YU 0+3;!6Y'L%CF<) M4@ S16"E"$Q]N.P0!7:#T&H0&H-H-4:T&6/4Q$;3&4T<>YZW&66O\KV5;$43 M66DB"TV\H1DU>-'G0QAN1+E%% ?8CA);46(+"MZ@Q+LNH>5@WE.M8+ 5!EM@ M#AL8O#__1XRW![-7X<,Y/J@S*O?<68!.7H/2BS M6EV$0$76XPO\ /FS/W&U M0K-+U5+H1,LZAT.=NQ_]PS'5>B/XU<(@%G-'9W)F[$TOOE:YZVD@(%!*[8#5 M<(,C$**-%,:?R=.=C]2!R_G=_;/)7>5RQ@*.C/QN*]GD[K/K5%#C*Y&O;/@" M4SZQZTS)?X,;$"77).J,DA%A?IWR*B2CDXM"H?A]'-O.C,/D?P^S!P130# ' M^-'#@' *"#T42SQ*D &:*P$H1F/AP>4(4V U"JT%H#**E0;C) M8I3$1M(9B;?)XI%BQ1!9&:(=0QRD&XA1DSR >*180<16B-@"L;W/>'=$''O> M%F2O\KV5;$636&F2/4WH;VB2_Y;DD6(%D5HATAU$XG_80*2[J[>59*^RE@0M M'I]NAM\QO[2=<,Y,JG=L7EO-F 1EZ3TIMT;UWWE!H)9ZFJHY'[O0N)"LGQHL MFKM\\0]02P,$% @ 3(!B4 !#G"_? 0 %P4 !D !X;"]W;W)K&ULC91=;YLP%(;_"O+]:C ?01$@+:VJ35JEJ-6V:P<. M =7&S'9"^^]K&X+2U!?C ON8]SSO.09<3$*^J@Y !V^<#:I$G=;C%F-5=\"I MNA,C#.9)*R2GVH3RB-4H@38NB3-,PC##G/8#J@JWMI=5(4Z:]0/L9:!.G%/Y MO@,FIA)%Z++PW!\[;1=P58ST""^@?X][:2*\4IJ>PZ!Z,002VA)]C[:[W.J= MX$\/D[J:![:3@Q"O-OC9E"BT!0EL"-<,9[H$Q"S)E_%N8:+6TB=?S"_W1 M]6YZ.5 %]X+][1O=E2A'00,M/3']+*8?L/23HF!I_A><@1FYK<1XU((I=P_J MD]*"+Q13"J=O\]@/;IP6_B7-GT"6!+(FD+F7VS]2^XJC M+3%[4]M%MQ7NF2E>F=5SE9&PP&<+6C2[64.N-$E*5@TV_-6$>$V( \2?3"(_ M(/8"8@=(/@'(396S)G6:P6F^14D>%X>OOFE[9#Q1 M>>P'%1R$-K^'^XA;(3089'AG:)TYI=: 0:OM=&/F&UL;53;CILP$/T5RQ\0$P>VFPB0-EM5K=1*T59MGQT8+EI?J.V$ M[=_7%Y;2A!?L&9\Y9\;C(1^5?C4=@$5O@DM3X,[:X4"(J3H0S&S4 -*=-$H+ M9IVI6V(&#:P.08(3FB0/1+!>XC(/OI,N^. ME[[MK'>0,A]8"]_!_AA.VEED9JE[ =+T2B(-38&?MH=CYO$!\+.'T2SVR%=R M5NK5&U_J B<^(>!06<_ W'*%9^#<$[DT?D^<>);T@#*.I^*]P!>[@/A.G42ENPA=5%V.5F%A<*H*] MQ;6781WC299-8>L!= J@]^8+[%VP-U=U-Y9[B* M<.:2-\Y[+1_H8TZNGFC"'".&+C#;&4$<^RQ!UR2.]"X\S>@ZP6XUQUT@V"T( M:+I?)TA7"=) D/Y7Y/ZFR'M,FJ;K(MFJ2'8OLDMN1")F'S R8C:W(F31.@&Z M#8_6H$I=9!B8A7>>BR<:6O\/'H?J&]-M+PTZ*^L>4&ASHY0%ETJR<;ET;HYG M@T-C_?:#V^OXFJ-AU3 -*IG_%N5?4$L#!!0 ( $R 8E *S_.<%0( ),& M 9 >&PO=V]R:W-H965T^TDDX".P=1VPNG;UPM!0*PDN0A>_OG]S=BRLYZR=UX! M".>C(2W/W4J(;H,0/U308+ZB';1RYD19@X7LLC/B'0-\U$$-08'GQ:C!=>L6 MF1[;L2*C%T'J%G;,X9>FP>S?%@CM<]=W;P-O];D2:@ 568?/\!/$KV['9 ^- M+L>Z@9;7M'48G'+WD[\I4Z77@M\U]'S2=E0F>TK?5>?;,7<]!00$#D(Y8/FY M0@F$*".)\7?P=,"T?7/_HG.7N>PQAY*2/_515+F;NLX13OA"Q!OMO\*0 M3^0Z0_+?X0I$RA6)7.- "=?_SN'"!6T&%XG2X _SK5O][$0$"X"D"'3J7[& A<9H[W#S&9U6)T)?Q/*8A[4H*Z=GI/9+0 MS]!5&0V:K=$$$TTP5Y3WBC@:)4@"C!2!E2+0\>%TA2BP&X16@U ;K"<&OK=> MI&$TL=:T1B-/N_XMTGE%.8-:6Z'6%JAP 64TR60I;^5YBQTHGZEF,)$5)KJ# MBN6.WLJY$VC[X,3I0*DF[>2FUW) M%V+L$#@)U4QDFYE[TG0$[88G (WO4/$?4$L#!!0 ( $R 8E#,6T1)F ( M "8) 9 >&PO=V]R:W-H965TM2@8HVU:=_?MM"S)8KL[X(&TYY]YS+M#;[,+% MJSPRIKRWLJCDS#\J54^#0&Z/K*1RQ&M6Z3M[+DJJ]%0< ED+1G>65!8!#D,2 ME#2O_'EFU]9BGO&3*O**K84G3V5)Q;\%*_AEYB/_NO"<'X[*+ 3SK*8']HNI MEWHM]"SHHNSRDE4RYY4GV'[F/Z'I"H6&8!&_:UF0V5;,F+/_E.'6?^Q/=V M;$]/A7KFEV^L-93X7NO^!SNS0L.-$IUCRPMI_[WM22I>ME&TE)*^-=>\LM=+ M&_]*@PFX)>".@,A#0M02HG="_) 0MX38(02-%5N;%55TG@E^\43S>&MJWB(T MC77UMV;1%MO>T^61>O4\)U&2!6<3J,4L&@SN85"'"'3T+@6&4BSP@(YO$RR' M".)H6 TA"&%8100:C6R J*\B2> ,1@@M@'BO@(\=BK58!*+J2SF"TK(&#E^ M 1C&J5OW%00+-0Y6G8"JDX%J$A%'=8,AO3Q11%('M810"#G65@ *)R2&)1-0 M,@$DNX4F@S2A(_=#Q.H1XD;F&)0Y!F1.')GC3U460@TK"Z#N5W8"2IX DE-' MVYO MM6OV3]@T&V=]80X!M@F]AVE.$#^I..25]#9<\6TQG"D]XRC/K1T MDX+ME1F.]5@TG;N9*%ZWIY*@.QK-_P-02P,$% @ 3(!B4 U=$0*B @ MN@D !D !X;"]W;W)K&ULE59M;YLP$/XKB!]0 M\ N05"12DVK:I$VJ.JW[["9.@@J8V4[2_?O9AE!BCBG]$MO'46@>'>"GX60WF@4WE58@WN_BV782Q MC8B7?*,M!3/#B:]Y65HF$\>?CC3L][2.P_F%_8M+WB3SRA1?B_)WL=6'13@+ M@RW?L6.IG\7Y*^\22L*@R_X[/_'2P&TD9H^-*)7[#39'I475L9A0*O;>CD7M MQG/'?W&#'7#G@'N'5IQ)!](YD \'^E\'VCE0SR%J4W':/#+-EKD4YT"V?V_# M["E"]]2HO[%&)[;[9N11QGI:IA3GT1Q#$,)P% 1,E#@"G@.X[26Z1+1X]1BG'F2S=&(3JG_DL.P#)"_8H2#0I8Q>7> M-0V,7&%\8.F[6I^,+DO:A6\"FW*JRN".R$T M-T'&=R:\@VFD^D7)=]I.,S.7;3?1+K1HNDXIZMNUY3]02P,$% @ 3(!B M4/RQB\E^! 2Q< !D !X;"]W;W)K&ULE9AK MCZ,V%(;_"N('!'S!AE$2:9)HU4JM--JJV\],XERT@+- )MM_7VY+P7Z=S3AX>=?EU^JL5.U]S[.B6OGGNKZ^!$&U/ZL\K1;ZJHKFEZ,N\[1N M+LM34%U+E1ZZ07D6T# 409Y>"G^][.Z]E>NEOM79I5!OI5?=\CPM_]VH3-]7 M/O%_W/A\.9WK]D:P7E[3D_I+U7]?W\KF*ABM'"ZY*JJ++KQ2'5?^*WG9<=D. MZ!1?+NI>3;Y[;2KO6G]M+WX_K/RPC4AE:E^W)M+FXT-M59:UEIHXO@U&_=%G M.W#Z_8?U3UWR33+O::6V.OOGL_JSOOZDAHP M80 ;!Q#^< ?!G!C0-"GTLW-+JW3];+4=Z_LE_>:MKN(O/!F]O?MS6ZRN]^: MZ:F:NQ]KP>-E\-$:&C2;7D,G&C(J@L;ZZ((B%QMJ#:=S!UM;(:*Y9&=+"*$X M"@8399T!-DLTP08X-, [ WP69&C,5*\1G:;H4Y6"BY!A1Q%T% %'Q'#4:Z*) MHRAL_[ ? ?T(X,=8F8VP_! ^=]2O(- Q 80[6\C(@\@EC%R"R)D1N;260H9) MXG 30S_D@YQ M((4 3Q93B+41'&M#(%5>"05>$M,+$KGF#7.#,-N$,.L>BAR0)!@O!/!%F.4X MB*:S1E$Y$AM$#%7CSW7ST#&PB$TLSES98Q81\3R>"88"L:G F5FN4.3:WI@* M!&!!F/0!(LX<3P&"L4! S0LKG^39,J(8"Q1@03@FA.)ZI^3YM:.XF"FH4R&, M7 ?1=+-RB78_$!*:H/T/E?)!!5 ,"8KJWURK031=J_Y9:L5O"YMF!\8/E/Q1 M!5,,'XK@8SXN0J>8%11T-\)\.%"[O1'\4588*A1T.!:ZHS%Y M*.A'I.5'_GQ1Y\XP?BC CS3;0PK:$K(P>Z0MDLD%I>8N S*^2+@C;HPS"G F M71T\9A4+GP<-PZQBH#>Q0,/LW@1WO4@(JA3)'JT\PY!D")(F9!@@&GKT;P?A M-*A8VJ';*M/\1BAEG&$,O,:@0B+EQ^,,D8()E5B(-H M5CKQPNSKMD@F%E*:JP%DT8(X&EJ&J<@ \*39OS#[/2UZN!:8C R1T<$-AGG' MXE\H>HP>AM!COF%!D6-F.>83![V4N8:;031GAG"]8G&,,0XP)LUZ@B+7D0=& M#@?(B:U##]"7)8GS#8!C1'" B-@L)R1RIN0XQ@%XB!W/(8XKGT?/;TF.BY#; M16B_K$"1=/C!!CZV \/U__!U!+ P04 " !,@&)0\\KI)J," !& M"0 &0 'AL+W=O+ M#?@Q2B(UF:9-VJ2J4[?7-"&)5=MX0)+NVX\'UW7->>H;&_#=_>Z/X6!UX^)9 MGAE3P4M3MW(=GI7JEE$D]V?64+G@'6OUER,7#56Z*TZ1[ 2C!^O4U!&.XRQJ M:-6&FY4=NQ>;%;^HNFK9O0CDI6FH^+ME-;^M0Q2^#CQ4I[,R ]%FU=$3^\G4 M8WN6ON^ MN2\Y[MU@!]P[X,'!3O2ZR0JRBJXF4&^S=39X9(,&BTA''Q 80FRQYX[? W:^19;" M! **(-:?O!.1P $2,$!B R3O J2367 VF;5IG8P8I0F&.2G(20%.-IF,U./$ M,"(#$1F R">(S$-\0C@A,8%!.0C* 5 Q >4?U5* B ) E!-$X6LA*)W!E""F M]#%E//G[I8?)D]A+QK?ZWQI!,;PE8W\YES,[#LWL:@1(PM-M[8R*<;;)(BEF M2.#FOD,8('D%!']T'2!X@R,"4)(IQ1DA-,*@8D%F2@F"2P$":D$YK07(+P9S M@N!"@(!*4&932@H((O."X(* @(I0YE-4YJT%DB[P1/<.,(.63#0Z?1HF3O:@ MEL&>7UIEZOQH=+@,W-GS<3*^-9<$>ZJ]A7$WC!]4G*I6!D]&UL=53; MCILP$/T5Q ?$X'!+1) V6ZU:J96BK=H^.S!K_(K>\BBIS?%.UZN A/WA@CXN\9*!]/?NB_.YZ[IE7&@8I\( W\ M!/5KN AMH86EZACTLN.])Z ^^0_A\9P9O 7\[F"4J[UG*KER_F*,;]7)#TQ" M0*%4AH'HY0Z/0*DATFF\SIS^(FD"U_MW]B=;NZ[E2B0\^?@5YGIBWYN+_PYWH!IN,M$:):?2?KWR)A5G,XM.A9&W:>UZNX[321S- M8>X / ?@)0#; #0)V'@)M@[<]Q;@OV* ,>9FR!R$D26 M(%H1I$&P*7+"9!;33T6&NV#OEHF=,K%#)MS(?,1$^T]$$J=(XA#!&Q$7YA.1 MU"F2.@BBC8@+$[M%,J=(YB!(-B(N3+H10:M_G8%H;)=+K^2WWDZ8E7<9) _8 M]LI_^#2%?A#1=+WTKESICK-]47.N0*<2[/33M7KP+0:%6IEMJO=B:O_)4'R8 M)QM:QFOQ#U!+ P04 " !,@&)09]- 8*H" J"0 &0 'AL+W=O1;BQ4Z^[Y=A8CWB-=]I2\',Z\(WO*XMD_'C M[T :CIK6<#I^8__J@C?!/#/%-Z+^4^WU:1D68;#G!W:N]:.X?N-#0&D8#-'_ MX!=>&[CUQ&CL1*W<,]B=E1;-P&)<:=AK_ZY:][X._&]FL $>#/!H@+)/#958O MJSPI%O'%$@V8=8_!$PP:$;%A'R4P)+'&,W/\46 S1V3I1\AV#D$(PUX0,%#B M",B'0$N8@(($U!'0*0%*O$SUF,QAVC[4DJ1% >NDH$X*Z"!/)YWIH#(GA, Z M&:B3 3K>QJRSF5S(8S2)(%U"E"G '2HIU/,= @I M\\P_D'/89_M8@NZ4\P.'4I@ )?"_F0 19?[/V8.*:4AYE- ;2C>J )HI9;E_ MZ 800E,I%*7>7FX&G.<1]G*\A6 T*F\Y#M:6>X2!%.6^XQAP/(MH=D,*+B"( M %*S4DD J33*;TG!I09!M:;TI2B4/__$;R 8<#[B2<-HN#RZ9JR"G3BWVM;= MR>K8\.^Q;3C>^MI>!%PC>J?I;Q$_F3Q6K0J>A3;MS#6=@Q":&R^3R%2TD[FX MC).:'[0=YF8L^^[=3[3HAIM)/%Z/5O\!4$L#!!0 ( $R 8E#%U0XBH0( M /\( 9 >&PO=V]R:W-H965T_!/ORW//ZJI1Z_"D=;N,8[4[\9JI2+2\,?\RN-)6T.\6;7LR']Q M_=P^2C.+!Y9]6?-&E:())#^LPSNT?$#$.CC$[Y)?U6@A'BUD^_[=9C8 MB'C%=]I2,/.Y\'M>59;)Q/&W)PT'3>LX'M_8O[KD33(O3/%[4?TI]_JT#HLP MV/,#.U?Z25R_\3ZA+ SZ['_P"Z\,W$9B-':B4NXWV)V5%G7/8D*IV5OW+1OW MO?;\-S?8 ?<.>'! ]%.'M'=(WQW(IPZD=R">0]REXFKSP#3;K*2X!K);WI;9 M7826Q%1_9XVNV.X_4QYEK)=-CI-5?+%$/6;;8? (@P9$;-@'"0Q);/'$'7\4 MN)\B:/81\C"%((3A*%(PT=01I.-$DP5,0$ "X@C(F #YE>HPU&&:6Y1%DL$Z M&:B3374P\G0R0*?(20+K4%"' CK>PFSI1.<+P2B=T>P<5@F41FBDQ J^,.X2!"N5^X!@( MG$1HYG)"\+V 4D"J\*520"J/YI*"+Q $W2 +7XE,RP&ULA5;; MCML@%/P5R^^[OH*=R+&TN52MU$K15FV?B4-B:VWC HFW?U_ 7L;.>U.W;.66G'=+SV-%B1O$GDF'6_'E1&B#N%C2L\@VJ6C?/5&Q/\XQ<>%VU>$\==FD:1/^L<4WZE1NX'X'7ZEQR&?#R MK$-G_!WS']V>BI4WJ1RK!K>L(JU#\6GEO@3+72KQ"O"SPCV;S1V9R8&0-[GX M MKMS4=8[XA"XU?R7]9SSF UQG3/XKON):P*43L4=!:J9^G>+".&E&%6&E0>_# M6+5J[($>"3$-T+\D !& M (WI"[*N86 M<91GE/0.':Y#A^2M"Y9 '%= M0&P5B)5 ?%=P/=4! Q2F'5(%OI:LB8DB[>!V)B:>[75G%EC- HM9J)D=,'"V MR5.\B /-K@4%DX5NV(("?OJ/FP2MEJ'%%K]=U TTJB7Z>M!93J M2CL3%/A!9,\IL>:4&#F!--7\)J:5(-+]6D!QI"GM3% "[6Y3J]O4<@*ZV]0X M@2< %OJEL: 2N-#]6E 1@(EFV9N]B VF9]6>F%.02\OEBS"+3AWP)90OJA;? MB,XX-+*;S-!6OR%ZKEKF' @7[[5Z54^$<"Q,^L_"7RDZ^;2H\8G+:2+F=.AG MPX*3;FS5WO1_(?\+4$L#!!0 ( $R 8E#>/,$O-P( $H& 9 >&PO M=V]R:W-H965TBJI5: M*;JJ[;-#-@&=P=1VPO7?US:$X\"]E]A>9F9G-WA).RY>9 F@O->:-7+KETJU M&X1D44)-Y0-OH=%/SES45.FCN"#9"J G2ZH9(D&0H)I6C9^E-G806?J4BH30%G:T@O\ /6S/0A]0J/*J:JAD15O/ 'G MK?^$-_O$X"W@5P6=G.P]4\F1\Q=S^'K:^H$Q! P*912H7FZP \:,D+;Q9]#T MQY2&.-W?U3_;VG4M1RIAQ]GOZJ3*K;_VO1.V/>&XK_!#9B& M&R<96*UX.*ME+3UWZM&KMV@_Z=YB:0@4!& DX^)(0#(7PC1!\2 MHH$0S0BH+\7V9D\5S5+!.T_T_VY+S4N$-Y'N?F&"MMGVF6Z/U-%;MB*/*;H9 MH0&3]Q@RP> 1@;3ZF(*X4N1D02?O$^R6B"1^#]DO(1@3MXO066AH!<*IBR1R M"T1.@<@*1--.A<&L4STFMIC&8CX1LH[QK%X'+(["U4QM[X#A=1 _NEW'3M>Q MP_7,3MYCDDD>'#]&,\]+$"$8SRT[4"$)_N,X<3I.%HXQF;T->>+HLT:M9IX= ML)"09&YZ"8MQ',P\H\F-JD%<[+227L&OC3(OYB0Z#L0G8F[D+)[K0=G/M3>9 M?LI^I^)2-=([ ;:U17$8[C)*IYV82+F9U[ZA8S>5!5V8BG M+N@/=O]C@=3 OO!O1BY92\[?A63;V>1K]G\U@ SP:X,D )1\: MD-& O!O0#PWH:$ =@V@(Q>:FX(HO9IT\!=WP>5MN=A%ZH#K[:S-IDVW_T^GI M]>QQD1(\BX[&T<@L!P9?,&@B(NU]6@)#2RRQ9^XLL/*)A%TCA8\@A&$5! R4 M6 ?D*E ".Z"@ VH=T"L'U,G4P##+-):YRVGF1 M *$N=G!0^A6*$8E@Q Q4S M0+&3U^7 )!?+L 0Y@GWFCN6.7)]!<9K#:A-0;0*H31RUB;=*1C('6OD0\_9T MX4,(IPF%!:>@X!00G#J"4V^9-,^=W*U\B&2Q\Q$*'\(D9S=V< 8*SH CD,$. MW^!.'8(2NY2!W7T$42IG[ MH4",W*HUZ$991I\X#2-T?3!QZM8;""-ZM[NZ(8SA&T46@;7^$6% =^[JQE"& M6,9L6D%G/FE:=%LB_#N9NCO?O!N5S9]\"*5 M;C1L.["54@FM,K[7^O:ZI9P&E=@J\YKJ]V[HJX:!DNW8,T93X[KX#U!+ P04 M " !,@&)0R(P9"] " "\"@ &0 'AL+W=O>Q,G00N8@I-LW[ZV M82-B#[T)V#DS\XWMG'AU5?WK<))21V]-W0[K^*1U]Y0DP^XD&S$\JDZVYIN# MZANAS; _)D/72[%W04V=$(1XTHBJC3)[]7QI.U$LEEUXBA_2/VS>^[-*+EEV5>-;(=*M5$O#^OX WXJ,;K6#+_MUC"R1K.5.VQ3"/"ZRE'5M,QF./U/2^%;3!L[? MW[-_MFBF+06G$V_BL6O>\3OG?P^ ,@606P!._QM IP#J!20CF6OU MH]!BL^K5->K'W>J$/13XB9K%W-E)MW;N.]/M8&8OFRS%J^1B$TV:[:@A,PVY M5Y2A@K.;)#$ -PH"4A 73^\H")R @@FH2Y#>):!>&Z.&.4WK-!11YG4"B'"Q M@)*"*"F DGHHHX;/JI 4^RB *,\74!B(P@ 4K\J6A54HS_P-#E68X2*#83@( MPP$8[L%PH SS%J\$1(0OK$L&HF0 2N:A9$&5E/M'J@Q%".;(08X M]TWTQZH=HA>ES8W$W1L.2FEI,J)'D^MDKI*W02T/VKYFYKT?[U/C0*MNNBLF MMPOKYA]02P,$% @ 3(!B4.2.Y@%F! .Q< !D !X;"]W;W)K&ULE5A;C^(V&/TK4=Z[B>_)")"&8:I6:J71KMI]SH"! M:'-ADS!L_WUS6S;8QQ',PT#"^2[']OD^VXM+67VKCUHWWH\\*^JE?VR:TU,0 MU-NCSI/Z4WG21?O+OJSRI&D?JT-0GRJ=['JC/ MH&,H@3]+"7RWZ=V_5:E&> MFRPM]%OEU><\3ZK_UCHK+TN?^#]??$X/QZ9[$:P6I^2@O^CFG]-;U3X%5R^[ M--=%G9:%5^G]TG\F3Z^B-^@1_Z;Z4D^^>QV5][+\UCW\N5OZ89>1SO2VZ5PD M[<>'?M%9UGEJ\_@^.O6O,3O#Z?>?WG_OR;=DWI-:OY39UW37')=^Y'L[O4_. M6?.YO/RA1T+"]T;V?^D/G;7P+I,VQK;,ZOZ_MSW739F/7MI4\N3'\)D6_>=E M^$7RT0P;T-& 7@V(G#5@HP'[93 ?@8\&_%X#,1H(PR 8N/>#N4F:9+6HRHM7 M#>OAE'3+CCR)=KJVW;(04MY"-#2'$Q M,9H (T-C0.[ ; F%#A9 9,5( @QDATPHL<4P]PQ%79_.)*$D22(9$S>>L#( M2209RFF<862DE9#L$\+I*)B. NDP(QUEI<.(,TP$PT0@##?"1%:8:&9T8Q@G M!G$,^:QCFPZ;"41"7"Q"$,JJ%J$5B\?"GDF DW%LX38C;CKE1!'JSMU1Z C( M79FY$WN<8J) \C9046H#-P@8 H^O(W!*4T1QY*8)B^TSH8!F9-*D-DUYNQQ& MFC90"@#< " /YQ88+L"$@>S- CJ";K)O!0RRMX&QM%?B!N (BYD[>5S\":C( M*C23YXZ!,G.W<7C@;9R<&W?<"@CH!X'Q!U?]\GN-835.RMRFA7>R;F)@O7>V(7?$X<^QR*"SD-[V=,<3VE MJ)Z:4J5V]7-PI;B<4;N<<>IR@6L*?6!71[&R*=J/65QM)5(^,[L42Y$B*3*' M"RP)*A]@C"5!T1[)+ C4WB21.<)8.A1(1W&'"ZP(&M]/F&%%,+2U,0DS>\M" MYKH,/L#8<=A!O=9B;+?&N37-L'X8ZHS2X0++@HD'"&-9 M,'0,L0C;YY!9PE@^#,A'N8ZB6!8L>H PE@4#)P-E[@5'D+A3Q!S+AP/YN)8T MQZK@Y('3-U8%!YM?99V_ 2ARL<72X4 ZD>-.A#MN"O@#;+$D..H4%EL "ATK MD6/=<*";R+'#XE@/_($=%L=ZX*A-F(MY!-TL9CJWFK%P.!!.Y.C! @M"/+## M$E@0 K4)D[&PCXUP_Q],+@1S71WZV]G:VY;GHNGNS"9OKS? S[2[4#3>K\G3 M9KC'_>5FN%;^.ZD.:5%[[V73E'E_J;@ORT:W:8:?V@2/.ME='S*];[JOJOU> M#=>YPT-3GL:KZN!Z7[[Z'U!+ P04 " !,@&)0',VL:N@# .$@ &0 M 'AL+W=O>WV:,JL_5*?3&7_V==-F77VL3EX[:DQV6X(*@L/?5][ M9997[FHQE+TVJT5][HJ\,J^-TY[+,FO^6YNBOBQ=<#\*ON6'8]<7>*O%*3N8 MOTSW]^FUL4_>-WDW&U,4?2;+\>^4U+W6V0?>WG]D_SHTWC;F+6O-IBZ^ MY[ONN'1CU]F9?78NNF_UY364 MQ:*4V<_QFE?#]3+E_PB3 W *P&L Z$\#U!2@?@4$GP8$4T! KRQ*4/?I%F7 MK19-?7&:\?6>LGX4P7-@>W_;%PZ=/?QGNZ>UI>^K* X6WGN?:-*L1PW>:."J M\&SV:Q4H5;%&%H[W%6RX0H?WDI1+ %"F4&)#U9! W5+H0$X0B F"(4%PUU.$ M"2D<1;3%70>S/-#D4B4.!6!/B4:-O693O$V!!!*") M*I5202P#:Q%8"\ 1 =:\%D2?=-Y&4($? 2$65 K\F<$=BBI[P "MR*A0DVAN6J.6'8] MD&R/>C1PKPKI4FPCB*RA042)N2R"N;6]['K(72^FZ\BQ(\EJ2#1<[:! MLMTAM[N8ONTU\N;TNNAQ@OVFVI2OH;G=#R:^)5F/"GY,VL.>=4Z;W5GM^S#QGI? MUYVQE/X7RW[Z4)A]U]]&]KX93RC&AZX^3:&PO=V]R:W-H965T+4-K#]^]I.R 9[V+X0 M>W+FS)G!GDEYI>R5GS 6SEM+.KYT3T+T"\_CNQ-N$7^B/>[DFP-E+1)RRXX> M[QE&>^W4$B_T_=1K4=.Y5:EM&U:5]"Q(T^$-<_BY;1'[6V-"KTLW<&^&E^9X M$LK@566/CO@'%C_[#9,[;V+9-RWN>$,[A^'#TGT.%NO 5PX:\:O!5SY;.RJ5 M+:6O:O-UOW1]I0@3O!.* LG'!:\P(8I)ZO@SDKI33.4X7]_8/^OD93);Q/&* MDM_-7IR6;NXZ>WQ 9R)>Z/4+'A-*7&?,_AN^8"+A2HF,L:.$ZU]G=^:"MB.+ ME-*BM^'9=/IY'?EO;K!#.#J$DT.0?N@0C0[1NT/\H4,\.L2&@S>DHFNS1@)5 M):-7APU_;X_4*0H6L:S^3AEUL?4[61XNK9+"2&EE8]*B,-3:F"![=)HR4&T&J#6BU)E=DRA+ M(T,O@"JLTP^ @JAX<'QS4'$.' >SOKE=.T.(C4@>J"A %<7_5:P*X,#Y8'?7 X\Z.GCNA>MO, M.@W5YU U=<->JV&KF_T[S3"IOR-V;#KN;*F0(T,W]@.E DN1_I.4=Y(?!].& MX(-0RTRNV3 AAXV@_3C]O>D3I/H'4$L#!!0 ( $R 8E R'D72\@$ -L$ M 9 >&PO=V]R:W-H965T\;GG+G@<=PS_BHJ &F] M4=*(Q*ZD;(\(B:P"BH7#6FC42<$XQ5*9O$2BY8!S0Z($^:X;(8KKQDYCX[OR M-&:=)'4#5VZ)CE+,_YV L#ZQ/?O=\5*7E=0.E,8M+N$GR%_ME2L+32IY3:$1 M-6LL#D5B/WO'2ZCQ!O"[AE[,]I:NY,;8JS:^Y8GMZH2 0":U E;+'TII";.]^_J7TSMJI8;%G!FY$^=RRJQ#[:50X$[(E]8_Q7&>G:V-1;_ M'>Y %%QGHF)DC CSM;).2$9'%94*Q6_#6C=F[8>37332M@G^2/ G@OBSKZ_(PG]2DSL,VH?,,/8_,"_K1E@W)M4%-->D M8$R"2M%UU"Q5ZJ69# *%U-N]VO-AW@9#LG9\2M#TGJ7_ 5!+ P04 " !, M@&)0QI8 +[L! #2 P &0 'AL+W=O2^2 M2!T>'E)4-BK];%H BUX%ER;'K;7]D1!3MB"8N5$]2'=3*RV8=:9NB.DUL"H$ M"4YHDNR(8)W$119\9UUD:K"\DW#6R Q",/WG!%R-.4[QF^.Q:UKK':3(>M; M3["_^K-V%IE9JDZ -)V22$.=X]OT>-IZ? #\[F TBS/RE5R4>O;&MRK'B1<$ M'$KK&9C;KG 'G'LB)^-EXL1S2A^X/+^Q?PVUNUHNS,"=XD]=9=L<'S"JH&8# MMX]J?("IGB\83<5_ARMP!_=*7(Y2<1-65 [&*C&Q."F"O<:]DV$?X\UN/X6M M!] I@,X!--82$P7E]\RR(M-J1#KVOF?^B=,C=;TIO3.T(MPY\<9YK\4A33)R M]403YA0Q=(%)9P1Q[',*NI;B1/\)/Z3_(=BL:MP$@LV"@.Z3=8+M*L$V$&P_ M**"?BHR87<#(U2+)HJ<"=!.FR:!2#3),\L([#^PM#6_R#H_3_H/III,&791U M+QOZ7RMEP0E);MP(M>Z#S0:'VOKCWIUU'+-H6-5//XC,W[CX"U!+ P04 M" !,@&)0=9]6FDP% #"' &0 'AL+W=O5M_KEQ":V8_][E!?SU^:YGBU6-2;E[ OZB_E,1SB M?Y[*:E\T\;9Z7M3'*A2/7:/];B$8,XM]L3W,5\ONV7VU6I:OS6Y["/?5K'[= M[XOJW]NP*]^OYWS^\>#K]OFE:1\L5LMC\1S^#,U?Q_LJWBW.41ZW^W"HM^5A M5H6GZ_D-O[HSLFW0(;YMPWM]<3UK2WDHR^_MS6^/UW/69A1V8=.T(8KX\Q;6 M8;=K(\4\_NF#SL_O;!M>7G]$_Z4K/A;S4-1A7>[^WCXV+]=S-Y\]AJ?B===\ M+=]_#7U!>C[KJ_\]O(5=A+>9Q'=LREW=_9UM7NNFW/=18BK[XL?I=WOH?M_[ M^!_-< /1-Q#G!MQ\VD#V#>3/!NK3!JIOH)(&BU,I'3=W15.LEE7Y/JM.G_=8 MM+V(7ZG(_J9]V)'=_2_24\>G;RO'Y7+QU@;J,;U Q@C'G+<-8:9JU)UHXGZ=R>,.;B/4)9EGXD@!+^@H%!,@8F M8T R!@>P,( =_Q$=#.!&?$1'"W562)/P 6#66V>3CPA@2G*=*=O#K#W@S>( MG&&9L_',\8Q3\!'<]:!A+V&2I>0A'&/6))WN#N"XY?*B"P]3APYTPP4@T&5" M8/O@$_R#8P/A8QRD!UT6; S3/N4/P*)D4]<$,.V]SK&'+80C#_&9$%CXW$Q@ M#TN?VS'L65*OLSSECH)X['PLY0[ N',9X7+L-YP:CA,9 ^=8_-R/YTY@]0LV M@KL>-*R7>4X&:X"3,CID.F(#G-;"9:H7V'4$=1TGUK^@HS]@SU.Q>>YD MRAZ%Q='9FY0] !-29(8-B4U'4M-Q(E.ZQ.*7?#Q[$HM?TJ&?LM>#+NN-TVR1 M2'(-8)S'F6'J? @7QV:9RSRS8*&>X[*? ,M?J@G\8?E+.O@#_NC:P NF6^C*&-D M.N,#*&&9R1B?Q)8CP8(C-_(HK'XU8<&AL/K5F 6'H@N$M-O]/^3N4\@P5VPS MBMJ,=9F!5F&]JRD[%)DMBE%[%'1-(+Q0Z?QW#7"2,6<(=R">'>"&J6.?46,V M*A0R$'?1N?O, 8RQW))%8?]0R#\R,E+8/]0$_U#8/]08_U! \W'THMM. !<_ MJ23[3B><'N*B56=2QR:BJ(E8B,8FHL'Z@6Z 4?DKKE)!()1F MN72P3VBP$R$R'5-CG] 3?$)CG]!@64!)H;HFC%"(][EJ,ON35/?69=9W&BM5 M3]A MIK.LQ<5!SCY4S]TA63W;E*^'ICT/N7AZ/HB[$>U!4/+\EE_=G8[3?H8YG>[] M453/VT,]>RB;IMQWAT%/9=F$F"/[$K-["<7C^687GIKVTL;KZG2J=KIIRF-_ M8K@X'UNN_@-02P,$% @ 3(!B4#S5Q>Z] 0 TP, !D !X;"]W;W)K M&UL;5/;;MLP#/T501]0);*3%H%MH.DP;, &!!VV M/2LV;0O5Q9/DN/O[Z>)Z7N<72:0.#P\IJIBT>;$]@$.O4BA;XMZYX42(K7N0 MS-[I 92_:;61S'G3=,0.!E@3@Z0@=+<[$LFXPE41?1=3%7IT@BNX&&1'*9GY M?0:AIQ+O\9OCF7>]"PY2%0/KX!NX[\/%>(LL+ V7H"S7"AEH2_RX/YWS@(^ M'QPFNSJC4,E5ZY=@?&Y*O N"0$#M @/SVPV>0(A Y&7\FCGQDC($KL]O[!]C M[;Z6*[/PI,5/WKB^Q \8-="R4;AG/7V"N9X#1G/Q7^ &PL.#$I^CUL+&%=6C M=5K.+%Z*9*]IYRKN4[HY'N>P[0 Z!] E@*9:4J*H_ -SK"J,GI!)O1]8>.+] MB?K>U,$96Q'OO'CKO;?J(:,%N06B&7-.&+K"[!<$\>Q+"KJ5XDS_"\\/=)L@ MV]2818)L14#OLVV"?),@CP3Y/T5F[XI,F$/$J%GENQQDU50)IHOC9%&M1Q5' M>>5=)O:1QD?Y"T_C_I69CBN+KMKYIXT/T&KMP"O9W7D1O?]ABR&@=>%X[\\F MS5DRG![F+T26?US] 5!+ P04 " !,@&)041T23(L" !#"0 &0 'AL M+W=OQ<,YI(H0)_8YK8AX8@VMU3]'QBLBU92?/-%P2@Z&5)5>X/NQ5Y&B=K.%67OFV8*= M95G4])D[XEQ5A/]=TY*U2Q>YUX67XI1+O>!EBX:505+06 M!:L=3H]+=X7F6Y1H@D'\*F@K;L:.3F7'V*N>?#TL75]'1$NZEUJ"J,>%;FA9 M:B45QY]>U!T\-?%V?%7_;))7R>R(H!M6_BX.,E^ZJ>L-YIJ! ^O\\UZF5)YKY\>B5VZ")2LS .&9V'-@?Q=%AXH?JC7RX@WS M!XU;R+>,IEPF^A0!+L'8!5DNGX(9GC "NW6% L HG)" 6PV%CV\A!#<;PE84 M<9",T\56NB$*1YNH!]WNHF0J%KAO$="XV/I&1@^_8+AO$="X.!J[Q ^[P,V- M$L E'KLD]E?(^E9Z-R=,1?G)G-["V;-S;:X.-ZO##6$5F!/J'=Y=+[X3?BIJ MX>R85.><.8V.C$FJ8O&?5!2YNM$,DY(>I1XF:LR[8[V;2-;T5Q9ON#=E_P!0 M2P,$% @ 3(!B4)L)X@&ULC57;;ILP&'X5Q/UJ3B80$:0EZ;1)FU1UVG;M)'\"JL',=D+W M]K,-903<+#?XP'?X/V/LK&7\110 TGFM:"U6;B%ELT1([ NHB'A@#=3JS9'Q MBD@UY"WFF9E[XGG&SI*6-3QQ1YRKBO _:Z"L7;F^ M^S;Q7)X*J2=0GC7D!-]!_FB>N!JA0>505E"+DM4.A^/*_>@O'WU/$PSB9PFM M&/4='67'V(L>?#FL7$]7!!3V4DL0U5Q@ Y1J)57'[U[4'3PU<=Q_4_]DPJLP M.R)@P^BO\B"+E9NXS@&.Y$SE,VL_0Q\(NTZ?_BM<@"JXKD1Y[!D5YNGLST*R MJE=1I53DM6O+VK1M]P:G/1)M,C010OUF'6'"<:8 M$%]C-G-,<(W86E2BY!KS.,?$_XR0"C*D":QI L,/KSQ2NT!H%0B-0#022">K ML>D@V$!J _G@Q\$">YXW26-!AHD7!F/D54V1M:9H5E,2QG8!;!7 ]Z]*;!6( MYQ7@2=AU/ L;X/=R+JPN"TO.R099=YAX[**7\SVCQ&J46.+X$Z-D;A3%-YQ2 MJU/ZW^VT3>?K%B4WC-2I;/V//4NH8/HC>S,S>R@T.C[TC?&-\%-9"V?'I#J) MS'EQ9$R"$O4>E%RA+JEA0.$H=7>A^KP[J;N!9$U_"Z'A*LS_ E!+ P04 M" !,@&)0QESPAU # #@#0 &0 'AL+W=OVO%MW<8[-:B+,LBYH_-EY[KJJ\^;/FI;@N M?>R_3GPK#D>I)X+5XI0?^'&S4*!I9=4?&Z+43M-7R_]!_P?4:0-N@0 M/PM^;4?OGE[*DQ#/>O!YM_215L1+OI6:(E>/"]_PLM1,2L=O0^H//K7A^/V5 M_6.W>+68I[SE&U'^*G;RN/03W]OQ?7XNY3=Q_<3-@B+?,ZO_PB^\5'"M1/G8 MBK+M?KWMN96B,BQ*2I6_],^B[IY7P_]J!AL08T & \S>-0B-0?AF0-\UH,: M6@9!OY0N-EDN\]6B$5>OZ;?WE.LLPO=417^K)[M@=_^I\+1J]K)*HG 17#21 MP:Q[#!EA\( (%/O@@D NUL0Q)U,'&Q?!HBDDT(P@E!!!-$($$$*&!6J'M,U&'J/A(I0U:X7%"2QHD5,!=$<3(3,0;J98#> MV-+;8]C("XX2:NEU08P2*\DR@ DA',."8U!P# BVPK*.'3E-7[\C+A CN.&@ MV^L(S_0L?$,E&= D(J&5OAL %"7,:D\9@ ICQ&8T@TWP 9,;JLF QH[LS/PW M) ,@!$=S2 4T*(,2V8 "DJL3N[P!L+J_@]HSI#:5D0).D0,Q6 M#(#LS,D T"1SII+A#P(&O@ALIGU@N$=C]A_5!'=-#+5-IYK<7I>&J;/7+@JC M-'7V&H*Q>&Z_XB8 M6_'FT%TA6F\KSK74I\71['!->2#ZF&S-K]7UI;]LO-'T=Y^O>7,HZM9[$E(= MPKNC\EX(R95*=*?T'=5U:QB4?"_U:ZS>F_[.T0^D.)G[5#! =OY*-6;;@%,\"YXKPO2&C/L*=55"X+I)SE CV\:J00S6*HS MU8,"5CN2X#0.PPT5K.M)F;O>496YO!C>]7!4@;X(P=3?9^!R+$A$;HV7[MP: MVZ!E/K S_ 3S.AP55G11J3L!O>YD'RAH"O(IVA\RBW> 7QV,^FX>V"0G*=]L M\:TN2&@- 8?*6 6&PQ4.P+D50AM_9DVR+&F)]_.;^A>7';.8\V0DF,-_ARMPA%LGN$8EN7;/H+IH(\6L@E8$>Y_&KG?C M..O?:'Y"/!/BA;#9_I>0S(1D(42Q"S\Y,C#E1MZMV'L ?[!U+GK=7"2!O>>^_N-E 90-'Q"O1;O MC*7@T!@[W>)<32=G*HPQZD B,C?#U^_*S?^?>RW$:[=?:W77J2[];;__C==-+[7?3]8;4N_^-W]]OM MYN<__*&=:-"+HWZW-ZO^^"&][42] M&?[8[U9__/-N#5]VF[\\R1_3(MHD=VFGUJ/.Y.9YD]9&VSWZS]8/CM?K7;** MKM)-7FRK;VV+7:TU]^5E6F0YKMLB>I]LZ^_)(OQ?_^V_-4W&C[A(UF5&Z]T\ MB&6R*FNMRVY]R%9I=+Y[N$V+ZAO=;O=H,.AV>RV?7J5W6;F%SK?1>?)0Z^#\ M^.;+=?3Y]/W9R?&GZ.S\I*69$YA# 0MX!H3P/?K/]+EA'-WI9#KJCVO[N2L* M7($/63F'%OZ:)D7K:AX=]?I'@]I+(JT+&/](_J4K=/H8ET;RWC2[47_F:]6 MM-%P_"Z3XMM3\@Q3V64PE5[]#%>[.,%_P91O\J=U]=W+59J40()Y[9=J*V[E M+HO\,5O/:R,].7ZIB<*.D^ M7[<=S'Y_< 3+6ENWFVP+ASE?PIH>WKZ)KM/YKH#>ZUSPX0$V_GJ;S[_%T4&W M T<.7? 5G M)2F8VQ6UU\[S-M8D_(79*LT=B*A^M-U1!?I.YMOL,446E.CW>U@OG&.@RKN\ MJ.W2IZ2 ]3J>SU-X"]Y9\/LM;5T_)'#"WNU*.(5EV_A.']+B#F?QL[RN; OO*D;98AM5TC8971Q6X+)VF-Y-3&4DO# M^6#RMWC?+%-8SMK!17'FYW*3S-/_^!W(*V5:/*:_^^-)6FQ!5(EHY_)UB>=B M>Y^:6^OW9?0^76;KC#8,N,+W9V82Q))!B*'W4<^7RV MGI"I).LH<>Q\F\.G61F*!A&LP@>0C"*4)F)\YS:-EK"GB^@I@]W SN3 9+!$ M)%'IL<%%S,J2;@!8P"BK+$VA2P._0,/ 8K?1V=D9SWGO0#I1G3VLRWR5+:CM M=\DJP6:O400LO3P7'4!/T#<3P;U]CIV?H1NLV+K,Y8+HMTDV2+*/T.,G,INY7##A;1 M/)A=C8?F>('L?P_0:*BJ55?O=@@;T"2Q&LPC8KL[GY[E"^/ M=O"/YM:!20%)9;!8\D)CPQ_S?/&4K6I<_CT26@&$@13XD$;;Y'MM3+0,^Z;? M_)N2Q2I+;K,5'8(:;;@MWR3/N-]M;Y>N[(^#+#]$BO:W-L^&#O+*F M9CP-PP'Y?K'O%;=@10K45%<&0H+8T] G-X]]"\2+_ZIFFI:C2D][&N*![WF! M>-:663D=9]#WH&7@4LC>#L]SD,;ZO:IFV,S,:TS*LM]_^[^G_=[D+1V5[7.= MG_ %5#:+.V]1 (U!P\#_L=P#P]UM[^'<_SU=O-5'&ED%@ M]*SAFR8"WSWL5G05"'L#>:!([X'KX:6YRNO"!A-&V;I!+Q(2C?CUW^^[KP[A M)@0"O(=K&X3J-Z^^O[P8 SA0[:&-C,4RG/1L__K^!9EB/GV_ZFMV/Z+9S]Q M>B'\$$:W *4I >G"">0U*THH6]6(Y%6O,_6\ZM6\76JKD?./3J76P(NSJ7W1 M/)/::WMF$9"2HP&2%H0SHB#IB4B7T%!2_ .2T:1^'AOOB!-0.W$,+5>(O]%A MN1[P(OL[C;1VIQ=P6J--D2^S/8Q?19H:'_T,>CN+OW0^03EH6,$KX-A),64DO=3&DJY3-/K@:\GB 81P/$\HB#>TN"UV\RW(Q?7NF'?DM<'7EXBD ME4/D5V^B99$_Z$>PH+_(9X0+ND M=/G#7YR#=-O$<_6Y/V"U[7N7E-F\1HW9:H>T_KHS^C5%\1*OFD=8.U!+A/Y! MV*0K!C488+-SO#!$F%J_N C3)UU[ 0T .4?IW2H*GKY $F4&&T_S4P)7>I7?9 M&EN+;D4L2[:1O0!KQM+Z%WKN7_P4#E9!.LLAO$9_O<$E:ES&_[I">S0D M6-1.X"]P!L3*@\>AR.9;E1[0EU8_;R]^T,J]D&^CV$)3;?H\P1$VLOM7?-;: M[>G#9I4_ ]WSVYL=W-BX=!M8\Q]YM[4#6O6CVP0O!CPY0"1\=N56K9.?:Q>F M,V>;(_?X Z^V#N::M^.[VDQ MSWA"/!%FC"V221,KJAM?%WO.74WPK+S>=NAJWZ$_Z60G"OZ?\]LR.IYOXZC& MLDGB.KXX.,;>O%[1V7S;().GD'_7&T7]]3M$S M4CN[K4O9OOA[5ZJF,K]RI6K?O70B6L?7ON?.V(F7I[M,,S@0\P9C_+Y9UOR: MKYQE@X.]71I#T>$#B ZOMR)[I82<*BTF07/1 W$5Z3P'91UN>"=ZRODDV86$ M] 4;S?/7-.]E=)3,C416-S[753W8LGDF8A\(#A]456;O(2 MI8\ECKG!'ER[_V#?LT(93U:U\NYY'9@INIIP?BH:I>2[:3,*$XT%']^UI:+6>;I'MUJB-G".D?YN]I.G26AF;DG<,-/X,VPGKRG9M_IL- M/7LLT.W[?OY:8FMR.)0OTKL?'<[G5EQ^9HK4MT[HA<]?1UN5CUXDKNL$;1'( M@N^!XMGMWGF:PO5!%Y"]$(#O\DTAGK;KR\O] M'WL_PFU>%/E3DY#LR!5MZUY"F^=ED^5/S.%;M(R70">%7 AP*Q[EN]HF7";/ MPDS7>X;02'R'LK!OHF7#JM7O4/$ZDA[(*AMV.G^M8X[$4R>.+ZPX_NHV6KV M<73KE 2@L&=8KA_X-D4C>?-7U[O-AB4W8+O ?^? BW=%ZDX4J;V9#VYK=ER2 M9,A&'-:F7WI+33WU?3C/UT?4<]-Q:"+UAI.,':QV"V5L^[UGZO 4@X&RWOR5 M7()/)*B"N-MQ=%E W]D&S>9"N35M3W@7JI*W\'&CS-OX4KO]I-E_].[+]=GY MZ?5U='+Q^=W9^?'-V<7Y-0@>J;L/E/_7+@8XQ _X?$NV Q)"\1HQ'!'%?A0[ MBH4W@P6"D'<@&)%(&H0A;E(.&5G"GE7[XT.^=W/+BKWXX:75^P.42 M.+_/9 4NMT#>67D/H\%?>>S;='Y/D;#(0DCR0&G9!*MN[V%/S.ANTU66PLF3 M4 U0]]+'Q$1W!$M#HTM691[MMAF:[Z#I10J"S8(F>I\5"_2)T%) Z@=E5NE M%C](6$A=?W'<5:Y:WA58Q]V*Y6IOQ^9[RDHO&BOB.,#K2)/:L=1>H<,.13K= M%4ETL8XNYML<-+%HS!IB'#T9*IM+$,XZW17(3>]28"XJLBBE4'?:XJ=LF5[/ M,XQE 9T-/7_][EOYD?[5>XOA-O+#N6E7?F43^L%PW.E'#[",I!/QQ=.)CDO: MA(8YA>-.HKM5#MH/7^:X0@Z/M679]2_;(RF&'/X$ZTS6%O,RUH8/> MH#-Q\\?I5H,^#OJC\(T:J7%8$@8VE66.>@Q&*E5= "O8+_QZ1GTNU]OH@Y]F;:Z=EA*/G'\(\E# -/]D&O,[#OD&KG>4LG M>I>B $7.K8@.M/K*8O-HZ6C=GGJ-\U("M/P6#ODZWT9TCZS%"*XDK>^K_K[ M@+]UBFP9(PWIUJ3/S C6+!CAC8]3]S^H_]V[2;1O9_GO8(1:.#GFCDJ.=N#Y MG SBM/Q_!C+%$8D))WK*=ZL%,K2#T6!FUEX7 O<1Y23X&G1],K,X^T\GNMC" MZ-'86.+AU[8'38AJZ)@Z'Y'1?Z*2^^X=K,DTU&44?.4!#,(L./_5&&R4)W][ & M^.TB2^[6(+WCB[ACSGZ""E=)MX0)T!*EG1VQZ"/-E]LGV,N@/Y'+2])[=W"# MB!J< &/)5_D=!BH [6]SXIGT@!HC$?!VMTI0:$27*$FJSK90@F2WB(H\?Z#[ M12=@!SU/V$NY3"F2$"XK7*,5G+9%.,1[]O7 ^%9PQ3E.1&T51+APNI=PA^01 M1^:2) L,H\PW<#%BK,66E""\U_G>Q8D\ZPW4-#BSH@_D:"[KD8D7Q5VR%OL) M?7QMY 9C-;R$H:D^I7%FQ7F? M_:N/=J6[UYZ2,@S\A.4\28 !Y\ \$OS7YP2.^6PZH<4ITNK+[^&B>6*1(#K> MW<%I@%/;[;+H H\3O+CH>A,BI;/P('-8I(]X&$%VV(FX@5D.GL7+6@ M\VW5&C67%(\U2./Y3@X'<$U4-VL6O"1QJ>"W&9A='\SQ?R>YPIXT?PQ$E$\JONX).G#16 MDOBRNX4I%<0B,!X/%H :D'WX=+P0A(D'BA16\Y(O;MRBJ MK!BUO "-OY,2.1<_%';SLGSM;BV4]IQ23NJ.B4_&'Y_N\]7J^0AX++KV=K<@ MY61)02+/,=IAT<:@+K"@(5+@T5J !_4>A#66$4&C(86%^<'<3J03:<1\4?'> ME.HXA]L8-Y)RG&RK#\DB%8I"^41?UZ!6_D#%(>GL"_MH3IVV=T,=I" F.TW( M"VRE73SM!X5M%E$]7]_XG;KC$*,5K4RZV7H-Z,LZ<_X)6NKC!QCB/(D.22S_ M>'Q\^6:OOMJJH[(.F;#)C-5[O"M3LOWKQK:9H/G$6+.3-Q&V?/-Z:X/H'97Q MF*@RMNUH//N"E1K_"2TN;60GND9>Y]= F;"+N9<#GV_1C4 [L(.;:+5".P>I M%TV!^X$.G*DE*JZK);%1$4A4;O CQ#Y"Q%K88O5'\ B?U$N1 VNZ8UJ/W5)M M L^/;::#7D[,IU U?$XB]2+#>TFUY[PT=-*))+2/+"UW:\W6Y&=B@(''>'T] MW<.1,B."Q5N(/0?M#4Q"S+WA@,L)@,-6H@!7T$6.BU N,PP3]J> ;!:D&)0^ MX40-?4IN>"%0? W=3K# :!0E'HW>(5@Z?-RQ(W\ %K]CNP^K(8ZP0K/V4TK4 M-=^*ERYE1R9:LMC:3)>9VAV1W'";*;>&I1&Z2]T(/LC5]Y#\FE.*F1\U7P)N MX$]FECI%EH]DR=T)H)7W-_I]MO&F$+P T4^9>N[&"T[2DU_E12XJ(PE0JN+3 M,0/M8DV^O89APH0*4JW%H0;J$A XZ_+:4]V<8X_NDK\_4FN"3TV!C[A1;BT, M)NV 5(A6*C*GKT,JH^W$(\+LCY;R 41,,G/1 1,&X4F::-,D4]!*!70@6X\: MZ#S!]7Q*^2J!L3'=0@?1(Z/_ UU%6IFLQ73VCZ8T7 M@?@L4"RLD@P&7U_ "LRW*V1I>%:8M:IL2O0-RRTTBFNAG([E:G?$38\Q)Z9Q M%VY=%Q%J\W=-]M-G=R&P(H?[OU![I$N3\N.#UT'X8_,N#Q:-->9B5\GV-GW.A?WCI0)Z!TCQ M+K; '43>9C_.J'622*_2VF[Z4RN,AV8#N+W$;JN24IP'R5D127!JO#, M@XRR))"3],HMZ=BAO8K#?NE$D$LCYEN:7F&K:NWT MD0\D*\KM408B#_^5[[9B7V4JQ:Y)+W&>&E0LG(#%G!.FPL&T$6H2+,A0.NEM MNGU"$9]&01*B<_\TC5D)U35?<=HT?G/['*4B_2$M:O:27T'BE^SP^ML.-X@C M.H"%Y+";@]6'HR+[.)=()!HD&]A1T]XV?!?I(0LG1W(=RA>26H0$,-V%K>9E7 M,M@]E;+@@5+-;87@KO0??.R%0?&@CU8DB=8GEI5BD$8Y-3%&3K_6:)DK28_% MA1'VP W15D\+V(6D)W'C;DC_@[B'?07Z\A R?A4EV)\,LY#*]YV'JU1AA]<24Q'%X]XK MMV]9JS?.$_P7JF?^(W?:MJ0LD-8B*G?MM D[YR-7ACOD%MD%*."1"TC$SAZ^ MWXI,8:=GS6+8*N9' .T^IBM2;3!TFM:=794I<7SRBH>?J$VY@'/# MU=0W#J MEL.FJ.4T*>#&H(QH=%*NUT!O<_%29@\:^>656+PI<^/1(2LD)R*FLC=S:W;# M,6[OBY1]W=L4C=7.Y4E#CB,*5\#_L'G_1&7H/XF%^M^2A\U;E\-,4![B!KI M,"!T*8DWB$(9$N4L3IZM#%BYJ@KS&!K-Q@-]@CJQ#TTMTSN'YH:_5+;I!Y9< ML\]IZ='>5RQH3E5[;>D"_)]2I5F8%XAYP*TI']02-\HX*'6XCBO4Q09JM59S M:X&<#/VE&V4R3C?]'88G MO':' 8FP;.4)9?N4']&>5GK%^SH,9'O=_O.(R:T):YMF;G)"J>CRCRH_TJ$H+J#"G[!>3V][&H#SFHU'5KU_Z!.)&B'AM8&3%J M7!C]W+@5;NV:O\V"PX(7H5X2WKY>8J;&(MB1ZB;*):J6/36[N.^(MO37RGX0 M==:B%!O&ZJ;BC.*-0DFRK1+4_@VGB]A$9"5^L5J<.=H-?7[H*0.UA=W:> AJ M@LT;E RRQMGA_E4RUD2XVQ3O%V:.R59,"^3_]8)^RPUD055< MQ%-@(ZLNGRHL$X.4=F,%*,NFF)+2D@><-GWP\?U_9$N7YV*$&4.*;)-"$8DY, M+]DEJ>@1[F9R4 %RA37Q8]8K2&"#.?\]52]F5:?#(5.&!HO^: MX8.88'W'3'_U/1#IOQJ3-U6YF>3:=.6T3A9XZ>K_[9>^J'U&?B"Q1\4V'U!0 MMO'TUAMZD9;S(KO%9;_-'T7;6K$^J["#- ]9T18MLLI2V*5H@N-?Y&8)DP.: MU"18.&3T+=(3#(:O-A*DD[4S,O+.!\I!8R0#Q109F?SV%?S'JW7*B9Q5_E5< MNY$!\0G]Y["A3QSQ$UA],S;3>$\B*Z$,,<;VP]#/0;]THBN+9J=1W(,/*+4O$LO9A]V)JGM?5S K:3$G&&-!:R_R#B M>;8R!EHR(R(CJ"(#NGUDDXOQ"SQ7AT0A4AQA(R_Q"TCZZRW;DR]T*\0#;UVI MFL5._% >\1H0]S7SI3EDXA%'P%QR"6K4NG(+C)PBP4K2Y>DY=R)GV/%=RGNN M$GI I2@ZN@C_(XKP%UMO$_%53D,]JJ%UF3$XIXZX**Z?=N1":K/*D340D+#M M.Y'FKK4,J3D!;M]PMA4<1H>/M&<07\4H(XS1^YY),Y&GQ(/71XZXQ>>J$AJ. M/(A\4Z,QNL/M,=P^;U(7C<:N8?3,D;=HR_UL49K U%=:% GNIP:5AP9#",(4 ML#V?A:@M:"1"OERBYN!?X+!.F,&JN:,79L]W.#+?E3GW_"/06"M+JT/">A6];P*?57U?REVK8JG5^IL)JSGU*V[U<7S%,T]K M^PJ/"H6 L3&%Q#X2+IK$ZEO/ W&HP%A$FFXR"CL_S%V1[S;WPP]U] MZ,IP7I*:3\/;*?B7X+,?<7V$+@4:G9^\CZ$(54B"80AOK4"FK/6Q)^-2TO8^ M9;JN2Q^%H2&(&8M,[NKUH8E+&[*A@4'^@*.5EA)V4*U+UW?;>U('2E0ZYGSF MBO1. -GX2A%["5R!DMK+@6H(:%Q$Q 4P8H8%'1,/ _R"7-MN9!I4E\^<2-?@0+0Q&A_M\P:%!%$Q)(^#0%C\$2I[O1-<<20ZHEI0]#;Z%H[- PRI=9R[4AFXR3I$@9F_DE\HF M/O-85?R MQB&!C$U'"V9( $D_H(R'4$B\XU(B"KNU976$-? M,+&/-X]O_IVFOM_G:XH^R=BMX7:)R=0-T<3K=ACDO@GKYZL1FUICEYW@9=,N M40!(0R0N%0E]>##??T>BK3:E7'I&16M:HN,^#!(S?DC6L5AR$R%(.IL$FE.=B:T21T?D:^7ZM2D^NX9,- MGI:&5LMJ&QSWELYW MI"!RD]*4.8_E9 [5.T&1VHTB.GR7HVD/ M;8T430P<^TW0.0H=8=^];O)^.M_3O41O=+G^^-A8GIA>T7HM&;79O?VS*9USM"HR(Y2P) M541+,2I@E:.90V%TV<]G ,2P=4POL8 AOXVQ,T52YC[OTMXA<'2;&$_R?7/E MQ903V3YQDZ!::56,W+)+QVN]+2PHZ.IHF"YK8KG=JFMKVR^=K7L,O&>6I8T?P>H4E@ MBG_*GS"XAX>^IG)1)/C=BR,4_8DKWB?8;SK%R(@?,6O?P*ZLGKW[,PBNYG$@ M1@V[^G5$14:@-HT@6\@'PJ)B;%0A^N M.=WNRS1#,9?Z:1&*Z+3P646)SO.PGNMI^!@^*H\-RS\\T,YB(U* MFGXCV\3ZFKK^_!$E$4AD/C44VT >31TYDI,TMYDSWBYVFZR_%;O-=OZ,E:$H MQ3WW'\OZXY*BZK5*'TJQ_22:#(SKGBZAY6V0]OO]/MF56TT HQFIQ<A?')**5_2EPGF(>D"Z_9E#Y,9OH\\^GX8A+-FAR)MD*GKK6K_Q@1NUM\B?Y<)&.2B-+1B"-IZQ1TV=-8Z?^^:/ MUY%4CH.1 U>B+&H.'Z%PC>>T,.2DF=W6H.+P.HAA8Z^> )@;;3$AU,Y'X3[W M+ !);(9)W*:NHX4> S5"-2Q6XO[K>T8#JD,VICM_;.SVV .^9B)<5RJ4GM- Z@%D?O(:$B%5+B MG8*]XJ7\94-IGHR=7PWJ;EB2I-*JB4K8_UTEG:@>819)0DN3BA4S%_8_>;-1 MLDI#4PZG4R-D3&* X''OM^WPQ%Y_E$_PQQ>*$I#::>2PNJ69XP!"DJK'F&(2 M/Z=HD"V7HSV,<]:'J/O\4>O0:@K>T$@!&^]1JSVBPQ<%SUT+^"PDG2HG(W*] M YW"1=([ZC)CP\#952!BNMTRIOQ*<%H3Y?(5O%:KI3)#TA^K.?]X.7"L2EFY ML2NG@6X,*C*(+0=!%69(">=.N4UW9[AQLYM&#W(@-O>+ONB)859V%8R&%2)#5Q_M)4.VD^DN"9_TDOC M:AP6WX;?G8R4%8'FN-@Y/F?@>D5XRP1WQSNI3IV3J@5QE%(IMRIL4[(9DYIA M' L#C4T9Z!XHVPBT @MCLQU#+[,U:IK,G"#;RME_-][$E8;^4A9.$7X/?V<< M.TKY9"_EL2?"N>G\5ML;GP.(+FAV+&!0@\')=(XFN7.4)E5LS'F1X.NAB MY\.NZ?IVEZV09C55DGS^B0I M>;6[[(3-XA5#&L=Z*JJ.9.63I5"7@F4%BJ1V<+AKAB_D! ).<"-L-M:'C8'C MY9@"9[>(,,5+BDYQ_L1[7W9*1L__[\SZ'+376*>JBI9@T#43WT)'R_AP-8BO MH;O:0H48Z[S/:7+N$@>$R+08&&DKJ H+@X3>)DBWN8/P$[S)28F=B][,CF+) MJO1R8H@5VA2W!N*-S"DKW01>,[RD"$)E ^N?#^PK@_RPQL"Y!N]S.Z0.B1(P MJ%M%=V*EN TFGEE-NDY8X(4/U3JE2-@!3F)PO=M)5)5KS-$O2@6($$SM99"* MY3O+UZ]:T%J$LU!>*(%HBBZ''1%]X.S">"@1-M'JT-2SW \$N+ 53;$YE% - M;2Y#5., ^)23=_HA(; P4GJ#--A8 B)%7<3H!*=5<8*DQ(FNTSN6)E.T[U'^ MMQIYQ5%D17)7!QY,BIH#6D+#8V&SWTX3U,(R)'V)(./J(/>BO]L!L; M;BKV#.W49<62C16C IK)#@;%.F4)JT#%99P*Y6>Q(F"=K?4,FWFYV H;!COJ MXBFB794N74_&JNH*MI&=TU< BAMF#?,]ZG6/NB.R9%+MLA/5B&XHW$51,+RF M)$$+%O^-JEABW 9Z2N#.O'<89A7[?DI&A+ QCD.#-0#J9P09<=YQ\X0)(9DK M';*T%7BN$ JF5FZM18D3[1S/&Y.]?0_=G-*.Z;.9:FPLE&-OB;(%3G<6 MQ96$U]@(JAA%]Y$:9ES[-^U!K]/U3\+%J94Y MO*NNEJ3';@HXJ07&]-+R+5>HO2)62)-_WJT4BWD:1\<%POO!]OT>B 1N MOOSAN9(\)]91-L!GZR63&YX8%BT=9"&&?Z _:TOXO=Y8C6DM&FDMG,&W$Z9+ ML!O7!>TF6X;X %G;NGL5/M]Y=8QUQS?,D@RA?A(0_^US=)*B$D!'XQBNZJTD MV3Y'AR?'?WD379^>@"CO@]6X@/@V31T0P!DK$4+%EQAH0C%?-TGY#I7]I?2UEMX,.F#E@D3MJK;OEBJ29YU3J"]XXYW'N-C'R00 M<%,4<%IH-D@CJ#!/'(9VC+1H=90B#+*[-5S/08-IL(8M4AI(*A*I^><=*%V# MKBZ62ZY6,");&K2!/N.7;XE2TEF0A_'O21E'+:OGD]%> M*D_)$L;;Z)[=I=:G!S,*J8*=,6:8M=$H7'O'W]WAY>>+@3AD=R0@II'VOGW" M"9U:I U*.^MV9NX>8D0EM&THZ@"#Q$85D-AG(6\#Y:Y:J9CX;^.6*KFU$9*1HM@/O M%0GD9O,J+Z;8$SMSQZU"BAB_[9WC%7LG!F4"FSCTH6K]073$KB]2[Q14]]KM MRYM./T6@1P8%)QXX $ M/LS&VP4L8T]%7%^4PF#DB4W0+7-SRV65&QV_0L;C^U*<%W6AS'!7UG=>(WO& M/BWIU?6044*I8B>[^;:4.XY5=:P5.0[40V7BO_&8Z/S=GFP9 ILQ MMK7N-M;R$@+%VA04P\">(;)]VI(6OG9%*ZV-@=9.;:T+:D_[;6PK*ZOB1JT& MB0][T:@3"4,!'0D35>FZJAZ(CIOBO[);!G5>[=CU96-BC+_AI8&>M'V' ]6( M%XID0;W7Q^!4RP(SJ?G?@Y W"N)9V&AB6TD831X&+LZ#FAIPXH+\:5J+5S$( M9?!^V#H .AAP&4A(T*(A@J=>UYBL:G)7&4Z"M"@PPV(^4*0C8@\"5R!F-\*] MVV9'NB^$;2P!5RY R54>(6E !U6U#]"Y%G*0U70?^C5475#W\XKL1'"LCY$E MP$QL80I0&"A3GYDA*%T?TMN"BJQ@[5N663\<7[_3#1-6,B96(MFWDL ]'?8I M@=LF;#L;LR14&M)-AIV(:75YK$2H-ODVOM*(NL8RY7%Q@C$(_\ M@@=$KPBWM\_D54I3'7Q92EV#![RU<22Y"T9& R &#I#=ID0DY;P%79Y+Q$E74_;@XM%\93:>,0-XOX!),2#UW3K>[7<8>>>E0*"2!=A -,X0%4@--9 8C#=W)B#9/N,%N9=IAJ=&P99ZIEU)H<3<2E' M0 $X+(N2DF,:IJ:>TJ:?-KSQ8ME1' MYAN5).^FVA)A2>\+;WCXL13P&@4C%GQP'CA5IEZ^;,:!+G)O5O?=! H\$#]+ M\<+;%KES_ILS)L$#3K/SG1-#4MQ*AU' "R[[R,>&XKQ4K@\]#@O+6W",P7V+ MJJ$/REAAA;N9L363G.4_K]_,]>_[?5,B3S3MZLK=W*=^J12]I)Z2$RAF*!Q[ M<\<[I4Q9Y1]>L[@%\NX^*25^/U6U14(")-S+20%. F@^^O[84U,N$W1I*MD,C].NHF%)W*L'4[#%*UC_;%R+_T M=GN$N=1K"E9$HTI&*\?+0)%_$@'I@0/X-I5),EQ5B_CXVY"!,*"2KV\Y;J5J M]@CH0B3@X*K102U[*(#S;#_\ M+GD$!BB^!02T$V TU41N@H#7M+@%12FJ,-TV1HO BZ>W$ $]X!Y]+J/7C+_U M+\61ZE25Q&GK*6=[DYASW%T.1_W*44.C:?+0F0HKQ]X)?Y%6(>/B/BR]/1,M M8JQND4M-&/S(!QO(WCCY^08>G>R$7GH MR:(*'J()O=(,K%Z:XXN3,]<638&C"+SY_A"/=[K0_E'4(?.XF87W\ERLM8!$ MPVM-'AZ:'\Z5#!RKC&$_EH3&$(K"3$JXGVA*MSYH^-$KX0M MRAN;MXES+%*N"4 YF;"Z&W8E/6T;5/E? ?S71=X6HN MQ9,VE,")(UNS*59-EW2HF,NPN0 Z_7B9BKE'BF#M-D>PF6OEHSX6=5$=>A#] M8E:Y5AJG-F!QDTAY@F#0P9@CK76#3BU!@G7)25M2\,K= ZZ0HE7.PR3Y>86P M^)*39SXT5)2V,HPW;//)';+U9U=":^6;GZ,O:UFZXZNX#AD9'42#N LZH\<" M&8R&T8U67^,]O4$0 C)62G#YX7@VB][L;WL&;??C\7CBR>I*2W$WC:/?BX>] MKAE(;Q8/QR-7R>?*[^%A;QQWH>$WKVB:AC&,I]UI=+QM#+QIV@KD:GU3%9W" M5"H@++60^U< >^T9@@FYKY=-J]($C:]KZESKB2>,J6HC!\/.N'TJM:-C8,M< M:R$8H@^^B5\UZT:\4IQXM19@I8Y5-=B\-M0&]=>N"D%CHEL3-K/Z% 8!%U?U M*4A%!UVS\?QT(#%(7:^:5V\+7_SIO2_=V7ZYG)W#Y7)S<87EHFV-*/%?XL2J M)[F^?G1RKI(GI[IK*<%;)..'6ZPGB"=\$O='> [@PR'\\34OO@F6'<7[].+) MM MG==@?8J(,1^EPS<51-Q[U>]%X$,\&_>B&7,UVN--9/!IWH]DDGO9&T2=H M[6=0B=='JH':=P]!'NW-^G!J\:_N!#F(_?T@FO3BP1AYP6063P;CZIHU9Y^T MO15'ERM-Z?:I*NT[?88?:]J?1.\WNB,;Q;#B()G%W,&Y+])@"-QU&PW@\G(4PA8QTJOBHPL+Z\6 R M(2FUUW\;7>S-8 &!'C80!CJ(A],)B?[MZ2Q1#]@Z<&KXS[0[@.F^E-L2]7KQ M&*@(/X YCL?Q9 3_@5:&X\"K;Y.!HL-A/^Z.>D@N R2' ?S%!$@,?=+MXQ_] M>-8;-.<-,2Y5T^:A\'(P-CPQQG]VJU&?PT[/\H$@B!/O^!^.XJSS# ?LQRFE MU1<"PTOM[==RFIOC\X]G[SZ=@K)P?7ISO5]24<.-BS634+_X/U+;E@KLWQAT\"[/O[WVM9MT?K^F2NUXQ+K3>-CM@K0"IVH$Y',0 M'8Y&\&A*?P_AR(TF^![09V\VQ?QB-X_B8:3>-9=R1"U3IY@(4; MCN(I_'8XB/L#;..P/X*V<<@]X-W3?C2$_Z#B"T.9T0L@'/6I8SBRHTE7 R*I M\*R#F7+'MP<-3WN.&1SB">[B[,:3403"5!_XBO]Q&/?&.-!^W(/5NTRV1 ?P M"3#OPQX=Q,-^/!HA ]>O^L#6IO;7/K8 ,Q>XONC8@YCB:G=-?W(7P#94?YJ, M:$6A43[Y[],7ZCKUQWB9P4!@]6G]8$23>#084OO -4!N[4_@]H&M.L15H4G M>L!Z]VB]!_CE@.Y!J6765B&KGG.7%?78$$H^M#F&O:')[MLZ>HVA:_/#AE<= MGMID0 <>H33H1P:O3FS#GKKB:&Q^R/81"IQ)\ZHJ1-Z,S(P1]HE?JDT6SS]N M5.<%>K116@>]GN&S-EU@'B;K+B-25CUZEJ@W-,@_%T%.T0DDW2P-!L^"[+C^"';&YJG*X7KKP#.3&P M> /B^RJ.);KM%.I2K,"^F6J')OB63 IS!E82W<-_=RVE=4_R8L-R-; @YPJG MVKV)*YUAVM=H]M(V[6N$8;DHZ'Y-,?*D)5 IJZ7:3%EU>DC6.P2=A+N2@T.$ M#&@ YD?QQWS?BO6 G0=^,":95: \ZNO+M@#=*=L994JBM\>TR.:R5 N3V)J) MO* *HT,HSK(;U3U @AH% HV/NW5T*A91PS/"XH\O5JRX,#;%D<;M_L,UU.+H M=ZZH6>=W]7)FLF3MGP=6;PI+E9?F'(SY3EOI!G.X2R(HPE8L\)?%^-&,5G MU;YMNNZSK:C&=16:JE+YPK45FI,^;L(E$[Z);*W&ET),JV9(CGU%6#K1<1.A M[^71M9*F-K.T-NZR6L6$J]]0R6@N95(5CO]*5^AIBQF/6!OI$(%("R(K,$T0 M68D& C(># M*0J$_0'^/PQ+Q4+0_D$XQFX:)+U!OQ^A#*<"'4MQ =,Y(*5S1N8)D-.A'7@R M@2==K3-:WS?%P2CO\Z>U%(WQ1??VS8.\:T'@?MU_ ?^<555!^Z@IH:\U'RY, M5&N=T8N26JT7PO#BA!=&16V1_3.G!-)SI55J(.TA=.C_[.5M#& M&KJMYP -=&S^'??&9)B#_XLGH#^@.0X5H$%_1D8XU%0&H+# WT,\ V/XS[$S52.6;8./0#509J"O?%Q?NO9Y\^A073&^(/G(?%FO0Q=LHIPQ+^ MWC;M9ILHJ:.3?CP#=?12 /5L[(FM\WV(*X.*S5F-B:(.-R7UM98::;,"0-_L M3;&%YL%,B=%,XC$%)=;PU3;O;?R:_MM@U^H?;T M]/CZ]-I%_GGZQDU;AO4]/+H+*FF46K8KM7:'0W95RQ&?8/E44HFU;I:D@U1RV?!(8@+:A1;EDJ>.%ZD]N- M2*!:^H@:P0MMVA]4K)GXT\_AC8TY# TVSL,-W/+S;(,Q9!*M^"8:CL=\FTGU MSWK0W&@:77MOBQG/J!?]DA090]G[Q_UX"O?D]>[6E>JAD($>F2V8WP23@@NW M.QK!!QN5A%=&+C)XCY:':ESGRU*#75;"F:*ZBQ2")A=C%;W% IRY;30K\K/9 M'B,V-H?['Z Y:=SK[_FFL6[DVE8[DN%YUO1#CE/F5/=?$4BX_W^ MN5Y8"&U7DVIIGP$(4,$6A>E^_] VU5F@'Y-PM>J!:*+O ]2ST YY(OX4X]3; M5^?H($*#8J_6AWVGQ^9U)M_]C<$=/.OWW?K)!)H]([%8BP_$ 6'-M,%=?(C^ M7K2VMK6#MN:#:#::81NUBA<@+H*(R,&(P=D&49+G%!!6Y=O9= ;W@UBOCL5Z M=>5X.=>]ND'N4*.E00=$$.;#%8+J=V9J/JNU_5XTI.@*C3JU1D<@@?Y4;6_4 MZ<'#=N>IZ'DHS#WLE(^9J.T?XP$:>=+NR(V=Z.N]!P24%F2OB&0D4EG\NHNB MR:-2.S$5^A/!<4P&WX-HV.VQ]#B*!]U^-!B.68 $7@4:2&\R9AFR#ZK%- )N MP%(D"2XC*T9.@5N%^DIE84$Z'8SQTVZ?79YX;^[$&LNWSB'T,B1/YV!LW%9R MCHC\JD*+TK@!T*UY*!G%CY?XF!..]TE'QR?SH[?G7TZNT%?<]-1 M^G%?9E"=@_/S^(0+A@X=?]!59SV)OH _OE;+VH#>V1U&LW@ /^JPEBG61E_% MK+Y(-4:"K6$0-?34C,:@WO:G(_>1WGJ"7ZA&\A)#6[I3H(=1=^)>WA3Y,J70 M;&01*5T.75 DT!_;=6]IU)4H#.@(!XH!DKI.5\NCY6[-!PL.%%&DZA6SD7=> M:%.P-Z#,17U2:'HVQ@H.HG.?@!+/O Q$\CYJVDBZ2C[!+T[X] ML*B4'F LTG0XJB[+^_26XPM.H.]L&QV;:+K&=U^UV.]/W]U0$,+)U>G[,_CS MZNKX_.,I1B-XI29Q?:JUA0U6?[Z,/I.E-(Y.8)(((TXC_ H$#1P4M,.F0H;FI,RF@]DW&>K/CW6;&H M^$XF$O6CR;YDU=1*K3XHU"5=&N0WG^BA/:&J)/;A:MH\5^ M#_I]VTC+$DE!L]*H3-9?12Z,=*WE$F[S_)N#@\N+16E37GS4/;G5F3UD6Y^1)4I@EE81;5WE%#(HWV[CNC@MP+@$ MS\F,;J'%!P0I5.D!]N(Q*[9<25%R$"C*WAA\]Y.=%BTDE,N$$'L,FA^0P8X= M=< 5(BXUI^J?VL_P]J6PS04& ]I/V&2-+^:W? &Y78PMW#ZU!!+0(YDY3"%( M\L7,Q0 BN1>^:MF"4!TE9-JF'0I;#!#& P(D9-VSM(\EA='8[:!A MCSDUBJW-VZ;%I5Q91[6>^GPCD@)B"P&J)PYC^<4 LDI%C"5O@]A1OJ<+M3=Q MM4C]/6;HZ!#[H6E\'K'_DW9PQ0WX;V-QN<%"(K20YMOW40J'7WJ=;K?CH=V5 M!$[RE]I+..UT"RWXEO I$BX6!2E?B%N4.,K::<6)AM-QU-,R/+,=+Z_9"Z,B MHCL8&;0Z@RCA^6>]U4M3.HD=L&+(:GJ=R>A-RCDY#Z@'HM#'8SGV*;-7+!:^N$P(1+L1K4(4FPH1;U8[CG42 MLB(9Y0W?+BR%(OS7HI21K2BG(CVZ3U9+M>\I(J0;]EMH0MK X'@!D?.(L;D4 M9TVB1?+,50G@ _GBT]F[BZNP-^V!@"D.;U]8,Q@5MW'EVFAA$&,RFM#<5M% M#!#=1Z",D/C:Y;](('3W+\>Z' XH3NUPU$>UD<-IYW73SRH#Q"?7D6#R?#Z+.#=6]HL=DS/7O)I]'NQD07@$K:!T;KZ7M]R3SLZ6KI M6AGUO/JZTY&JZ]O")JO2=G.] (^@IO],>&*>RT."O^*^7J/:/^JSFH?G9T? MGY^<'7^*SLZO;ZZ^L"* "L+[TZNS7XYOSGYA;P=7E&R JG*#M,4/Z*;'.CDF MZ6IM_?<@Z[&J4DG_,BZOH+?2!2[4QE!2YC>5#R6Q(7R#( .L97-7>/\=<;2C M#,XS?@@#(]9WQ.B<.8*-<$+Z5T%D"\U3C4-I(>XJ-?\)@;P6T1DP(V=_!3)@ MR\$QZR;O36F7]]B%A_>D?]YX2&M^\('F[P0!XM0?9%+\KU.'[VP*6_2.B,%& M7Z[?"X_'(&NR>A&Q?P:!V'GM"%A/_U'GIL#AQ[W>3PUM8H: AEI6&+XY"R'T M607XS ^)&T.(0O\^Q]*T$&2]L;):S,3=1VM?@GM/@T[U:LJ^JJ91-S;R$LX; M/MRM'>PSH\RA4X)!UEZ=?QIKF;@]18EP[]+!=YRG@,4BR> ;(R!%7 <9>^]#/#9LO] M:KXP%=8U&=@H]TVCM2F0P6!XR3E:AXG3180HX'SVD+XRWX@*WU6@-X8#QP'J MN:2L-**:>BEADE]=S?:&))3*&\;VL\]F>W5Z?7KURVGT 8[CY=7%^R\G-]%7 ML@"1L>V?5!I>3 :OJ@X/6_'P3ZT/[R"2_G]=)OY_XSKNO_\_MX+[_]+J[2\K MVKJ%!^/.,(@/TT!JY6%/C@^(8J7%0+6*+J?C_2J(.K+KVHH;+<\-#P>EA8DI M@XKG%F1VPC)G\G%03R.2,A.5]F0%>;E(9Q)LUKF@<%"P:>:3]4N-RR=:3-09 MY^_)Z M!]U.M]OST*%8+TL=$\T=-O6W<=^\V.6RH@6\FCF'@%K2A4/6Y"U':S(9 MH06R22LRDTT:/ZM7 Z?0/C\^-\@RA;1W64MV%( M4# "W'EJ&-J]8%#)^-C.7PHB)#D7I573]I^.K4P%BMB%9MPZH=R$HMJ>7UWL5]9@P MC39;"]/+)I2]*OR$LNQ6'-MQV!O%XTF/<^4P"5/SZ^ (]6>8 _:UFAL40N,. M!O%X-L;_8"#R /V:0\;AI6(^KBP2GX&@9''5 J#_513?ZST],+PP3<+/'H;= M[0PG/(%N9SQS?Z$+7YO]H8]D#"%"K0-^XAO4[E>O.XP&('V.QC4G(Q>+?D_Q2EURK()U2.YCETA:1^^.KT_?1R<7GR]/SZ^/;\XNSJ.VKBD^&,5N MS\]LV3-;9CHH;]U0G=/4_T&X(MN+-,Z<,^A^3P5M37CQI=7U##3A% 00M1K6 M]VJCUH3*R;%8PFYGC'J@ '9&M!CT03%'+&#U\VE8P10X_A3X]FC8]37KDDH! M.@PPH3"3P0S^?P"-?6P/XA['_?X$@Z(QTG\2#X8]$PC-(<]32G$DIW:W.\ H ME'@(+_/Z'O/9NB1T9UEYRLCYO9@1JF\%($SXP*$F!1X]?(D J3,NY1Z89WXV MCALT38#]C#JJU'4O?5%A=/WCUNU(9FO_(A:(T+QPX"HH@R0$T:F-7=6@ MI:5:?!/L-$*DF6\_6]SLRF^\8K?Y&N.)PPK$_!,JGRYIG2^D?3(GQ52QUZD? M3\;#> R;*-PT+#DM J#,PYO"N7CQ%_=OW+6XLGRB> E:& @]@.NOPOY!7[Q''/*\[^?HW*$!R\U4"U \5;SS2P*:NO#. ME":XGL,>YNB,' $&.X%2:BTUN(ZG?M";=OI]?Z6^P:;CT9!P'8:=(6(#$))] M@^?@U(6/P$B&\: [H.L76@1!Y$->+-.L[<,-&10P]8'RYS&:&3_:.^$909:, M!KU_:+Z#4:<_LO.=#./NE#*?Z)?VLX\F1G>G!?>=B4Q&\MBMI1R,L0:&!YP" MET.SET&U<8FC]6+OMBKV(UD$:G-6Y*PE.A$5=IS2_-; 1MCF&H>-Q@4"Q M!TU3O;\!-XWX#(AB7'01)^;6=Q_[89N*[(BZX\,MD;]QP2R M09"*2QED Y/D7DT+>PW3_YF\TY-N/)MU R8D>IS=+>)-#!#] X09,RI?;:=0 MQZS,IJ%9GPAC0><4E7K8D9AIY_1^$\F)JA "':G_/B=ZMDOFWH^OY?8Z6 MC[/U!B$JA;76+=.6U>._8JLTA@8OR M82,)$'6&K?S^2-]O&JJK'4())2GG=%?DNXVRHM"&9W.\<0HD3CVEF@$F@0(P>'%Q8%TC M%'89TUN9Z=9/ V5(-,<40$@@8;4SF[3^^0QXYPBQ?B6V<%'&]%CQ1#;0@IN M77-30?%&J\,P 5"T*9\UB;APL:S;ICTCDPY+1CZN1DH-4W"(E]>::/#%K3;O MPN61>" )?[D$T7W\*84-\EA]U::$DD<70O#D)PB;:=5BG5NK@G]7(UB4'T7, M]U5HJUM&KEDR8I\6&X 9O'\B=!8 &_HYJ(M MCWS59\MHG2+X')6GR]:V%)Z"C698UI4XL>]6BDDR+2L:;6[[<:[,YF^YHNV3 MAA%ZAFS_M>Q8-$$INC!K&8-CI#?^U(K>LLJ#-#?_Y,O; RMB-:KF-B6NC@L:%8K&V M%V 4?1 =M*TA%1Y>?5<[P 0!2\ O:A-FB8 $>2^S""K) 5,*B-Q 2J!+JJP] M[,R&C> +7"RQL4EQ+S;.3'98)F;2W=J 'VCYA@9'%+6"?@.N1#]XIU;6>.]Z MDT\O'-H/K+D!J=BZE:F*T#*/;C /2Q4ZCV$5 MS,H\;6OJ"E[$>Y6K,M+F1T M_W1.=F$K^#4QLQZA8(Z8-4V[S+&1F8%V,QE2%-0470)76EP482U[ ^%8P(-Z MEILAP$5/.-VD,^Z^U/\LZDT&<7LN+0 "H!5@#LYD+P &9&PTXN22?ECH(@32KOJ:1(O]2 MMLQT0Y0]"$[?/XDK=RU7]OE'33:0?=Q9R+N5.8_,V/?P"FZFE37_2Y@R42(R MY7%G,G%,>=3IC?\I3)FG]-MXS]+# M]'F3/BX)LI8I3Z?%CR*)*IB6M$A'1^["0"7Y5#9ZA9B[M\G\F^QVM$P3QN03?]#+*JWSZ4AY/+DIG MG5[H+ M);24!2:R.+K=D=$!-3"LFDVMO&!';I28FZS(+VR(,R@W4$3#Z^:BV4<-G=#G MO6_]:(N:8,E^%*&:0>L.N@$#A'\.JO*>?52+X>)4:JT8)+$"P C.TQI8>_ J M(;5KPGU[N *GH)^=GUQ\/H7F_P?&*YQB\ZEX+QN<" M]Z6+@PA1F$'X&J#;']/2SZJAR8?HDR<$Z'$\F0TIO2?N3GM-X%P4!BV5TP\G M8\H%FI)ZVXN[O8'67NMQEA!"\KV)0.<5#!?Z4;I5^!3H:S23.)U)/)X)O#5H MX%@_HPY(3K.ZP=3[]M]>BSM.&W1S_#^HQ($M"G^;8M%R#A0H-632%(/:#QCW MVKVB>X?#DZ8C60+$\IZP\$U%",BLH-O0@Z4:(J1\K]?%;(E^=_:# S\@@T1_ M)&%!@W[<'W-O(W(WUL.W; DL)1@!T7CS&X_T;UTOS7&A=?L@*9 PB]E0B*87 M3R=]=IEV:8WH3:H>9H Z1F/$1)\QS4YF%*Q!+T[CP70,"S$9$#+E9#P4PM4, M-[L(DW@VFT6#&*-D8"MFHX%'S@@&>(A8D72\IG&?1@HZU'#4/+;#:6],>-_Q MA"L+],CB],8/$LY+?S(EY):X1WCN>%;Z?8?BXJ FFK<,0<5'4T$>AQ;&M Z$ M9BG2W)[]YN,Z9=CYPUD\Z'-477\4#X=F 7PC=+$O69JZ3^G,5ZNI@>25%RA? M^5NP#-VI( \_.),! DN'8F(AUPPX'!,!0JX)22WIM;0LA%/ M>@.&]9S.QN&B!L!S[Z@XL)'08!$X29!S5*I@HGBLIEQR 6-0ISB:VK0/D6/8 M\@3*XEVJHVKVFP2T*Y*FY*(]9'-RPU)9VL/+8]SEV@'CN#=]S9K@B]TAW043 M^)3C(O9P RW1-I>*BASR8,LNR^>\>*4OSN?O)PTY97F:DC!5*"9VIYGN/IK. M#$F]/OW>3WC)T/_CI@Q :B7\]E=@WDKF#C8IER=SK84OTFK" 5][57VH#=LN MX0'*7$,J87% 4M>$V2B08K^5[W!_=GBU1ID#1J%U0Y@0L+36!3M,5\O =%6D7-+QJ>/-L MVI5\B%"QFO:'T0A6!\\G"F><>EX2OEY_RM4X,.N3QC8D ?#+6H$]B!_G@M:/ MM72Z&&H*NCY\,\2:11M6OWBA4SI88VFKWQOR'R-J_80A&>'EQP;VP;*2KJ?F MQU?G.( F,40>B\(G#NJV]MHA%@EY@[5*^?22*0!:E1S*>D>-)!>H]LE!YM2$"]Q[00B<[:EE_&(^FT03N^Z_>C*&@94 )$_S_*3/_;O1Q ME=^R:4>Y&ZS3$;[M+O=]8Q-A8;J]+!.T_7Q.[1?FQWPLP1B&D_&AK.*2C+L]D5+Z4:SP;@2?/QJ M$:>E/A[E6XG@1RR0EV??A8S6H'YHW\T5>)?*+/AT--\NK?DH?-V_=*[O41]BHE_$"Q'K=:[=BCOK?-]DD,5#!" M.(U*^-G>J<&0>A;]BZ=:/\OA0,@0.J=0718"MUB,88D'3(Q/U$[U7C5&?.VB MS'?%G!BVP(OC\=!RF_7#02L JU]L:]O8;YVJLD/7Y^ZVS!990CE*N B-\N@6 MF,_MCAU5T->+)&D#OX@X%VPVD/[_'VZ1J-0_8>39)TL$F>."2J5 M?4S1G^(H1F?UT@ Y+"/?^A(R?M/"Y2C)FTBI.%S'0!N ;J44#[HG$:H]$V/!7H+L1)]=PC/[KR0PQCGD M?)(9X0F1%(2Y9Q2N-4^EWMU=$CYM2$\FJLSN&R6O,!B=HX+><(B_[HJL7##@NQCF$5&A2!'>"O8? MCPYZKY[]#K/EGYAS7CHX?!+6>9&1IUD8D!P-=10 M=+4;%]DG6'NR;:%JJ8/MR*B1#S,21Y7)VR&R=:'E:BN1#R%7>X$1Z9J)L*,[ MTC@>6L_JM57C2C?4+Y?_W^F.\%.TEVPP'PSO/)2RV3#YD^_S]/5$1:MX1(^Z#^,SG"CUHK=[K%;$$=" MAT&Z<[HH?72EV?Q&1?Q9>/+4\V3/Q7V@(Q4K;9'&-N'S8.+IG<=+@1,6ZLGP^V=PNV/\F[\-M+GXF&@@CWAKNC-A, M7"?)C(I*HU%A**&8A0&;\?HGZE&70L@E" 0X[S6"; 3\T\L.E.D@X3 .%"*( M"3$'L$0/D,\E5Q!"Q'Q+@=Q0X'SS@J_AG8 9PNEVE<](.+7_=8)8FGYEZ#)^:0/'=GY-97<&\0S-9:\)C8OWG",534E(.1@8YZ_D-HVL MAFA,B'H5:H4\XP5P9HI ;JZ(PJ&$6]6XV#>_\1$":J:JK&6&->J:3%ZEI%)[ M.T=EW^RF&Q$B$!UXR.V+IUX\?/B#N64<3A6$C1Y,JB:#21">&1A?PSI#!X-J MR>M1V-*PO242<)X(%09KWXF_R:./.7MQMC3Q5B[]HY#T0O=KD;F^;R/@DP)+:JS-JZI)LT(K3O>D'N%V%BG:PXC #25E M5*DN9?H]T:295OM"->9"3"N"#,JY5%8J:!9%42 MSAX+:,Y,N0#MR&C>66GPNZ3^=)7LN4X8G0TR#Y_N[GG!WAI3+ S60\W!K\/JJV0.-3-OU+_V-U(+,7)NT'?"'S"$K([. MRA#1)YC4J>(\Q9KMP=SY?/GIXJ^GI]&[T_/3#V6GXW.D @KB0KR@(U+B M\=I G #ZU[#;._SV)BJ31Q+ ,6/?I6JQ'L!4[H(8*R&1&'P=AD0&>*BL*$F4 MI-.$!-#"B==Z8Q'(@ZP/D<_\WF6VRB)P,E8(EV!,#S0Y?"$KX1HF(BV>7VY3 M;ZO@C@ES(.BH]@U#"X//?B0!VYQ9CLI%7GR?45V"5$<:#K .V4 6C:R QU@L MF/M%A9F^)UST&E9.>L?PXJ[D*@[C8YK?%3)[3 MCXCS"_U\N;ZY^'QZ%1/B[\?3BX]7QY=_.CN)SLX_7%Q]9J">KV8WR1C H1F< M0I$*L!YL,L\5C2S;;$F>8 (W=,8)?=?9>];D-B8 5LHZOD^)*2'G"P,VMF1I M=GUAK-TVH_LU<263B2GS21#22DTTB:VWEEE($QP*&V"D>4NKC-U7D.;YF*5/ M;.3S,S*H<\*29=2=Z$_.B(:TU[P03-0NU9%#O#'1E8!W4JSZ[69'$> $P*:: M!@?K5^MC4^5,5Q^]TJ]6M59G_KZ^V-K+><,HO3.LJT0+<'3H'3D:5UC/<1&8 M6K9I\D B[;4#\7-013&:3J4@.OTS@"AZ[R&*XN@O<%N!3!3+*?#P1,?XD/&8EO7FR0C'B:%[A!B7'53RG380N8H3#H((84'GHI+V2,VH MO!1,X1L8K1X+-),E!&3\H8W0F6YY*$FU^AJ.B-K4 "MH\R'Y1B?7K8N6+!=M MQIU6?[9,C@V&%9LNVL^?A)UD?#W %)WE?!&\F]RBMUX0L(C+H+%*(IEQ0'>> M.<+W8@_6I'4#[FP3@>1@^)8H^ZC6$@53N-PB9XM6)&$2H\C>+DG6#RDF;1@3 MXX(C6>5DNDF04(W1_B]-Q4(><@O)@G%V^&K1Q35Q.W3\L10[!OR"J)U;%N#4 MR4HB'.HE!(WBH,8XJ'%]=X2UR1<2NV#WY54;<26M53/U%V18#(QPY3T79BP; MNRY#L%G:S_OGD@X?QE[:EC22Z[?&J5KZE0G\3#F%E&!(\3@'47_6CX<,0][M MQM,QU9B>\%\N[AHMB&3G['?[%";4'W3C[J!'_\4(UP,TUL2]"0;VC>#9E"K: MC:#%V:3K5@^6^M0QT)^Y;#WR2<87AE^NB4_0L+!Z()5P[T,CG(K)HQF.*3!Y/J,3@:!;/L)JL A9C84\LWHGU$7KQ=*K!%MSME8>BFT[B_H"Z MFLSBR71"N$H#*J!WGC[=Y@6Z]V#7FD#R>1=#RK#_UP^S-XMYT$.%\9V.,+,10#QVIZ=T/N(>%ZGNT(H,!Q1IC ML;=1W)]VHS\!<>!IH. '9_5J'OD,*YMVI<'1#(<^&<58%M@-?0C[-XG&\7@P MPFKSW;$9>!N^)(^]>2!^$K,)+1)VCLM/<^AB6*5&._M7]Y'6IQ>.=IT3_<-! M\WOJL-:/%U+>>"JUCJ$%]89P>/>(2BJ*[W@8]X9=K,C7'6HX UJQ9X1J"+1\ M7-P1YE/B0]W@-XXK6M9.*@;I#:+9@*DYGG0)+@Q#UP;1^Q_,N#-:_SI7 !8M M'RGIKJ;[YZJ^Y='C>MV?(H\#6=,:$'4X$POC\9HU4N@-KH &['C[ MT]*[E>'R%]%5#4^$3ZQM^07XMLZ?UMZ;+,8$9T3R=:A82VR Y(Z"&'^U:-5( MVB3)?_;ADO7B-?ZUUQ5 ^'!\=A7],)L[B$!D/:3K#FECKK4NTMZ&L*#%UW$#MHFU#B1.USB-08@J[ M%/?P;U0"G[V2E:%!W$'.9 R'1FI5MFY<^)^I,MXJZNGA_%9 M*30O"0D29!8-,\ >X\BAEM7>(SI4X]8/W-9?:)JX7&<$Q(:GS^E*#A7$X)5W6"'NE'6LB#OO?WX?A)S$..@:Y1ERR=!%R+4A2X5@1AWJ,18D^R M%#1IR@+!FSI?ZH@7C086OBAW--./;N9:T-+::LAW0 9W2%][*S)MM5RRSR<-WJA;"$*![%51W#QU5,NM<+[L7$(UY?LPDP8&%IEB+;. M'2:%=(,GA_W94')19MVQ*U[W(Y_?"*??ONEF&[ N]!ZP(R3?ZD;94M^_WBQ CPD,F9 M1B+4J/:%E\;W8@[@;R"'3S:;+2SL=HWE]T#YG#16/T2 ^'%0<^U5KWZM8/75 M5[&IZ!UP:U=^0%0DM2@%W]8*#VGQK=(A8&"#O+.VH(&O%R+&M"J4:EG?9#30 MU:Z0L*:@T1.T%I'3%.0&%K;,^#[\XIS:G '@N*4B\^H,KP7ICTY$M M79:M#,$'#)0!%-&M0)@(T7&==@JT*._S0@K.4IFKH%,?58@$0*]R751G]#15 M4IO[]E;0D$#1P"!U_;C +/1)>W]V?/57!A$6Z"76V!L'+8?WTA>@?LP27D8!?2(#3B"&"#B"%GO%FQ)_C2I#KST7I M:0"*%#5Z2H7\4_& V]P.=WB<),CRG\!@6Q&08Y72Q1&*061Z0!DIE-%*O,@E MXY>"R2.N\>2$M*6TGU")"PD_(>DN7[NHE-U&^(<*L^+?"%OCGN\5R9?>!=&# MS W"ZSX>'U^*M.H" =D1_;<=K!LKO+@#Q%M1\Z'EHKKJ*<.;JPWT 4OYB0\P M63VCE"+%K,F2D;IRX*1LF-?5%<<+$ S713YIR9BU_9 +4F(NX="F^MBX.AX@ M1^ZX;4?5!U5Q'%,E(\1%<"RK\"\NP@J/E-RK-CCQU>5$=<13$WOA"XP*][5M MTP?#2EB92Y@B*KQ%K")-X:%!X? M(:5.5&.A\_MTL8,WSLY^-A@-:% F/SQ'=!S+K5J/*#F)M(48](&C+JR407IH M;F4?1[?#@4UXL:U: R=_.GW_!1@ZS>?XTQ<.9D&#]5^^''\Z^_#7L_./T?') MR<47M #:*.8?0,,YLQ*_C9?VDOY[7[Y0?__K/F(]=@E(N&F+?'>[!8;CY9F# M:!S/R./8BT?3(6/G] 0):!(/X%$3Q 9":[@\ZP'FU&-._]=J&=%9/)CU,+)[ M.$-T \RV1M";87>X;]335XQZ&L\F4QK]L(_@'8?3>#ADY"2>4-.H1_%T['/K M$3^'4KIQ,K6AHX-O-HJ&\7 ZP;%W";F')[1G[)-7C'T8]Z9]]4=-.,^\W^?! M\[R:!C^()[#$??*)ZA1X0DUC'T^Z\"L"2"&$UQ"GR3.J0929F!9V3IKX1SD. M>#(N02XGK\ZA_E6#Y+H$C1PN$L&+\+[O>GQ9L\3$^"KPZ26K>WY,>UIFZ%(+ M/!(XW7TLR[6/:\@4>):2-W5C CE?I&J6S(XJDAD9_[!" @G!&L44-+2UHJ;G MMBG*1&L)3#'J#EG,5-[TI:_GXN<(0OP5;<>W^I L4L["),]K50 7Z+^-6=4Z MQ_[""HB6=*]QP.KOC"N)(EGA"^TV!9'P/'%<:*+D&]J3U<;OK(^J1:/YQHA( MH4<7.CI^2#$:+CJDZ%24VMZHYE=6,E,?DF\!M#^''6G]$;'/LJN)I48,U,+; M^D6$*?QWJ&;.U?VY;?M&)O0RB:I<4!F/\=RJ9X@Q" V"J\&Z$A#.:S31^S70 M) N3,4Z!6SFFS+$5?+>6C%[V7#2IQ3[)E0+GT7J07B]"M4'=T6%EXXYZ$3G:?5]IAKHBR8LNTO>K>5K# M=S:2R0CSY!NPKFMO?G$V*5.[6T1=%P* !A9RIP7YH:N\:! M1TWF*Y;WR3^.3AV./HFMVSR(P?*&'$E6=_2IQB^IJ5XI4;K1/&0[1 ML'/7LXK)X90Z I6L'I)?V>?A1\WACF[@3V:6.D76(F7)W4&BE7TF7S<.$R94$&"U@UP"5K%B&XKV MY"J$.Q7%/+I]B&[1!""F7'\,HL.T<][9;LPPNJL3[?A@&=KG..C["UYZ^O M"1H9YYJM?5GZL%(ZF2<\FEFR7N^(1ERWS;TY(QH2$EP/&+M+MRME]YRM>1&( M77.,N0P&7_?.6>.X5<\LT;*Z);.PL-DSQKHS4/*9TC&I+O^XBV:>%&I4Q/KNOT^Y;#12G)FU:1ZM1@ M]#(M,F6!A_'4>-V&1Q$WF8_SJAUG"9_T.4D,=-OYE^U/!$=C][_'YB9,G_#QB2/'C67 M!?*4,E]NGR@@24^EV7$7V0/,9$$)9<3!Y!.;7*&A\S#3.\Z^H#.)L8&%I;CR M]W!62A8VW$<4G>\\><:#0CEZMS24MF/:=,MN5&%1:X5)_G"+0;=FS?]?)@\" MQZDQ!TZDT2_K O29BD"U"+>:EZ .%4DQSR(E5;__*,\C]X<<>KARBRW)#NCY MH(JJOB3&6OA.DR72P'K+BCKSE,+(]\KM6Q8=..Q=N2W= ?XC9"VI["Z7EDK$ M54YR?U;,=P_*M)B]K?%4;B6 H>Y T45PU7UI])B>:V>_9=LYR7EF>E:$QU8Q M]21:H6>#^&B6?/\3UIQ+ MV8!Y_8T2@=AU;X@;Y3OT9[F.*]3%RK=JXMR:JESL(P":W"C+;AH^16QBU.5? MS @45\DP/$V:M2=/KE8X/G 9%<\2.*KWK)>S4&)_))FT.:?&7,5H^7U$*X]X M?DF:E-&P1ES7*'&K.FB.\4N1+')W61U??Z'#==0=QAA@(%RNC([\\<5N!(GQ M)M\ (0]&W3>ZI%'IXF/, M $\HVZ?\B/:TTBL*S#HB\7Z_:O]YQ HQJ*F-7N\V[\:<&U>D3>$GM>EA:W9. M$FO*1*,J%8_V*Y>I2) 8?^7P";1A4&C!PH=02#77FDB]?R"NH&$]T*,R8O3) MI%@XL6DKW-HU?YL%AP4O0KTDO"V@1'">1; CU4V42U35!Y7MW';JI.,V[P7U/%V.%H/9O.%W$E*O$M&0@KEH,3]H-?7[H*8.! 8P9 MHB:;O$')(&N<'=Z?9(!T5630 ^5O)I;;O!GW5:3Q) 8%5M4HQ!YGR#TTLB,A MNL:5K;Y-EO/)V]+OC"7%^K[&%2#&%YPL*#S5D.3B'*&1^,] M@Y*T2 !>WH$9K*BP,DI:E!496 GQRL$EXA1JMVUD^QFATF2-X>2*@@?[5QN\-)\QTQ_]3UH":^:JMQ, M>D/[J-+D-A?LQH33S1(J M5H1\CT%W:47)!5\OO51E*=5H@I>Y6<+D($Y;;"!D]"W2DRLRSEDQ:Q=MT!"T MW.AUX7+;7B:_?07_\6J=PH:IBC(F'D3V3+[Z X@\[ M:=@B]Y##V-$JYR5@$^C=H+ZRXT"56'G64)0$-ZG&,JQ$MFG,8.08][H#!95A MA[@I[(G"@="R1V8^C=XLVB= /H#857DVZ>P5EH % MU5N;))[*Z#B$L*B"9GOLKI<, M,1C)$+2JO%^A. >1IE5-7*PM[@PZ9I&7,O"N:4D*OFK6E;7F)7T#27U, M/CMC_"Z5@<]!,:SH3I='O 8D09CY&J!V!&[,UV0[=]!H2B/QU4H$5=U_K$3>,.(DWD:B&_D3V&V^=-ZJ(_V(<2A!2C/HL2,; R7A16);A!Y:'!$ )_ M'K;G[WUM05UV.8+'IQ7!X#&%&:R:.WIA]BR'"FQ Y7R>9?><:3!%PTH M "^]C_OFF*8/XEA:KY3Z/OW6H(V8XG!1J4S7=]M[4D:HA,*<5XL1M?C@(S/0 MY(]=:<%N,$8I(XP$9+\+028T+C_8:?(4NI&IW^R,\]>KKC/R@<^WI7.,D[SC MO=!P,#"NS*,FR@C8>^>'0&F/'47SB.UK,)SL5CSG#K4@*4P")D7,6P.+ G11 MJ-HRF=LP)1 .%VC65=PF]B82#V+<2#JFYN:I;.*SI&@JR.]:77@WG7L+W17M0A $UM.#!.[)%5"XA M&X-DQXSQ5PEP*)N*.%3M6S1'+6CA5IB43O;KR>8QS]X50J;W^1IYT/>,G2IN MEYA,W1!-2%(]8ZP!'= MP ^@U6 9C$<7SL*EIJKN<^,L-?<&^PV/B$$IM+TML0PR!O]8S2U$)Q>6LB8) M' $.V!XRZ4WCH(KR$51 M;=2/.5Y"S"1.PCQQTQ#W86-/$:I N032E(]"]0M?URN;-[+SRJ-4/4)7:&#, MYAQ>B^T='WMM" M,I0'O3U\EZ,]$@VDDE%7O@DZ1UDE[+O7[?ZDIX:]@[Y/2>1TZ"Q^MP,!M%KN MG6MY-!5]UV.9E M?\;5%I&BB;,DT6=@GBF&,JP0\^KA_RONRWO;2+(\OTK^H4+3@Q0[;R:K@05D M6:Y6KP^U)5=A4%@,*).R.263@DC:96 __+PKKHR(S*1>+%^_\ M/97 S_"3>6W2"WN\5;CN=8F3$7S"]U\+^OO]F?+8=N$]B[""603Z7$I%A6Q#6G MV_UNM=XK7-&(4$2G18K[/=HW3$>F9SID&? +#&S)I?96: 5=<'P_1U5EG2-J*S5L54].^I M'/D/=O"SL=C<+C9_/!X>]A\0NOQ>H_*I] S>9-PW5"WO5Y]WXKU9J#2R#6/> MP48X"6-_?EH0RIA=94]\-CH5AZV97X$L4._8WMW)^25H/BNS5ZF*WDX96[L% M$9/\4^7Z(B#"*#(?TY"K1X>M_.PT='.-OZK54JY7C3BBD_@9-FC_,P<;RSLU1 6L^,]Y@K9\[$1%"(+0"*K"X1IDMP5TI48[P*+%6[P=D42GZKA MPT=S9:>:[ZVH(&4MU ;\%:?%W&OW$YF2)?_12"Y69-%IU8HEZ?]. M7#L@!)'8X\<%$G[??A?4,5.^0LPC8VY3\!/ZZ'+"WN)^YV .:)2U$.R K4"; M@D(&ZB "<:"K;; @&D3=\4C*CPS&-%'8,O0]H9>78W0L=Z1):C.I1;8+)XK> MUHG2\:#\=&5OOEN7D[X04 MABB7Y8>-LO8J9D@*=#>K%"\=CC#J0O)U3@,#MR".$;;LA,+8,*>[#LJ'.L/! MS0Z#H_0 NL)WQC1V:4"9GO")4Q[!_%4Y(GO0I2P)[RBH*1(>B1Q5+C#7K/3Q MLUSHCB5+V3>?K"BT4+#*T+B"P[(AI;#O]:.C?5MES"QD*A%>UX$$6P?2^T+[ MO<)(WYRWLU?Z"^4V,O%:K$CS7S)KO+#^9>L(R*<()-M8,UU/K6TG-HP1-'X4 M9N_)#F4L\0_&:KAR?8XLJV.Q>'S.P""47\2>OKO#XX9TF:X'5<;W:!*N\ 65 MBH5YTY^Q@,VCB;)%;*65ZX6%OY89=EYE5M>WAS45@=V)1QMKPJ+#'^4DX\WNUXS@Z*CFV28WXY2GFI4D#)^*J6 M@J4/BJCGG&^1HW4B"2E#BX?U7J(E;)O1L%]>FX+\;'"I,L-)-5:=&9[*R-3P M_D;DIW;9<#BHJ6ZSM#[H)/M:$-D+TX+'(1 M( ]+BO\FYR;5J%>6N;V3.1PJN-[5"&+^0"I,#?,D<\0'L8!\$=S.Q=X1>%V, MIU#8)-;[Y3FM=WH"8X;7+5+F%"C1<:4['5@:&T HP"Z./D$R$5:>5, I;-X( M?Y$*AUMM%BRY2QU*TG\%;-TN1>C**?8DNF82S$-]W*DD:%.JWLH$-)UM-Z,6 MU NP%\IS12E)*92((:(/G)T;RB12,]J/0CW++45)Q?M1A=,UV)@*=50UT"\W MJN(1605T@)2N%V7T7@S U.KA4(EY(S4+U?.*H^R-Y*X\N# I+C>[^HPF9*S M9W8MM3)^S-D1U8F%;_@\M4JT5!(#:4!Y &:9ITJ0,X2TCI9J&3"6);A M?7=LD%@H[AG!C+%+\!;W=*G,D#@3B>,GT^9'*C-N[:)','J:1 M+ S /KQF^5NJ# /B%3<5@X_J5+7-UG(,"PF3'0R*E>,=K,(">]&ZH)G%/8%' M[.W0@&Y%6G1SV%'8=8:GB'95NM0]6?9Q1=QLL88MV]\+*(0_:YCO:9Z=9G5 M%!=4NW-1]8:>'/9XJ\I'!U?Y)PP-U/#L*']-NC$/. MN&0*HRJ(VU8A?D(;DF@U)=,E5M/XB/ ('E!?#*"/S1)X/OF8V.^A@[M;S/Y; MA,KLD#N_=.T0\!_JO":"3NL#)Y-\VCRSRV!.\FI:/?,J8>9NX>S>V9/&FDRP M2ZQ;?U2!6ZO0C5O>]A=JE 7<'54R)[7=QMD"=KFUX;5X;$0B>YVKLP]2EKK$ MG3C+/9<;H -LH2V9I)A04=[-:A]9'2F%T5D=KD4ZR::M7O34^S?M06Y*U707 MYV6WPX_=U9)L;E.AG);O[A[-%@N'QVED'@Y-MB060MM:8OSQ8\HED[!2@/K# M!>6?/T?]#O35!SA4DI#Y8K'!O_SQ",3Z.$TN="GL?QWN58W[-C7%E?X&1 (W MY?;SMTZNIYB%V6VRWMPQN>&)85%4HX$)?C&E*.XLZ_^22GN+'U)*0.IVW.P> M=N#K^-P%I15QN1'+T9^*J*?]>999RS3,DL_#@6N84.S>^0IU%3H:9P>$ 9?R ME,GD_.S?SQ)$P'QG13=RH:7]BND0E?]+UG6$BJ\PQ(B"!&\6NS^0'&#ZD\NK MFY?=E+1;N-/YAG=7O[._"N4TQ(-);;69,"&/ZNT3V.+DZSB^3=2\]$\ M8G(GSZR;@'/NSIV;@"62?R2?V%%N>W-A1BY5L'?+&J8W&C@+&[8AZ+O;O?QD MR:U7B8"81N)]F]P2.K4?J1;X'1:4GRLF&*A&YDUSS#LL%)*)DJI+__?VT0F= MWBR=\&FV0M-AU_K-9J4A_RPD/A40&)$/LKJ+FJGG&TBR;$^S(E6:3:\42$9C5_?44P]#L;^]2I]\RA MB(7Z@6_/]3W9)]\ B0F]PAYQ[,33OF(W#ID5B7#7YCGQECC!-D"P%^H4Z_8H MNQT>!]O2Y5KU_+\28!WN(V-V64$Z*D9&@F9 KL=<8&*QW5,UU5/\D=TRQN?] M@?U4=@2/9=D?&NAY[#NJ7B7Q.11W@[J=B1AZ-+&6 LU/P%OZN1.@1R%'2SOV MF?XLX2VHUILR.18XG04R^4C.KV_R(5N_].#-L-4 Z'3!M2@!3,M O%%W F(Y M$@G;8D=(BP(7*2JR I,B'J,*U;%IB>K][->G:E\(HW*M:L)(.!7[B=$5=M A MS3M/!R;F(.2@*M.I#\T:*OU%]M,W!I,2;6,E@Z1+B A!'U,46W1R0_63/5SE MY<&$,%/DC+-\L)*\2CKB@MZ M**/2%O^YQ *WVG$U:>;SY%E_VW,J9=4T,W@B3;/=G*KH#6?Z()/F\P(6 M%'_+9KBY]O.3!.M34[%?K"-=-B.]C+%EC7@?CU]A\GPAQOZ,-CI/VZ)-GBO_ M&T+65V4R2[.RB;GB6B#1*JG2IIJ[R9BP?!0V?(.$Y<;ZJ97Q$>7FDJV:C9":W%06< MYW'S7G:ZT_>;Z>>C[H<%%Q?LP7#18UF:50W] M7E=44T)=8EIVGF=I"?L-K^*>5\@SD&]6L/FS*ID#BZTR+$TQ;Y@HVK2>8:W! MNDWG62V7ALOZ*ZZ,6L MI2+R$UP5F@2L!ZQW3NM=XI?>"3UC![P;BJ&5J&U@)"3X+&6\''3Q%S5J-VD[ MVCR()KM2)6$*,1;5]]6Q)Y.Q<\P:JIP)QZ@B>L$:+#.@;^^\X'50(%,MJHHJ M>U3N(6A2I( &[T"LD0(T,4#4:56V2*1%B3]A6(I4X6Z& XO=!*BO+(H$Z4H1 M&5/6PMZ+$[I8YB0\ .^HL,9,,8._9-TMO% ^996E-;"EZKF4HW.W]X+K,A84FSR!O^5PX]T!J<8?B^0#94%4@"L-?"+$M@&_%[AGE=MR2!>BSN\ M@N&J*V9*:-(N]^#03]21C,('QZ[!&SO,SC@0/]K879Y6@'$&^JH2FT%L.<)E M*.FRF,$5#I?%E>0[V$J47+Y0&Q[#-P&>8LMA ?3 MTI&;@5!2#;23PX[,HNV0< =W8=G,(L _L5V@QRG%_/3+*0J]8;=GU]$ !Q(& MQ.6 .Q@@U CRG!8HT14J\1'LG$UI:)$(B)H3*>&"85>"?P*W3-.8 K/;30!S MI&X3*^O$&@]( ;^J(I/6GT%\!%9V?;C5N#!D],SIMN,#XDP*BRO!I76-A184 MZHZQ&=KX]=:A%W23$8S=7E:*SR2@2BI%)X&5W7@C.[98;^.]79'7;(^%C(44\+./ M8H,BSZR+(U-FWBT0SB%)23-<>19/9W]=Q\EW[7&@EK:>D)SD[FD*'0[8IYID MWW-5B\G4R.A#Y#G!TEZSW.O#?B=G%8EIO[\QN''F1:$77R80UFY3T5!.1(FT M50/GYIF@(00E_%@[J-^<)'.0"L\""!\@#H!TR@XJAS& J,!S_ M*8ONF9CPWFG$2T9HND'6XA%B.84+EV,1.M183$$HYR=>VR\$A8[+97N-UM,R M^:G;7CW-DY^\4!=[$U)CNDN3UY+:YY^(\%63JD NQ ;Y?%!<5*-0'D>N0\ B9S6DI8 .FN4L;('^ MD15)634L;P&G!!$UGS4L[8)\"(6NN@^KVVIJZV*CD#;65@0YLH&/\T* MMEBANG!@AZC<>:"U5149JJCFH;)=R$$D^O4E &1PWJS'D8@<,#OK+B9IA [C M\18M!YA$T@V98#CHC!@(:#/S7 R;\(M7J)!+07)1136LNQ5BV6.ML#U!Z;%1 M":F+HX[1OE WH 5;:T_4I>NI!V8TDEEFF4M$$2=S?3+#X_;.UAKCFJX6]'= ME('@C5:Y3+^E2@;I@DK81 $T=;VZOSN].VSX9,&)(I)48.'4K?$VJ321$[RGRC+CJ["" V,;=Y=F*=AZ7L'L2OA9@C;Z M,LK_\8[0QDT:? YKVQ;V.4/5ZP2-\VWE%;U\0371@;#.H>_U/CDST)OQ]=)% M9&%1S&RIJ9Z,HE=N(7;;73[6.K_ZLKW_PHFN-%H!]T)S00W2!9D)\HQ_H^%H M'!#.XYJ49+";U 6R(K:P?_#ED4[)^)(;E/\)'W1?H>5MFAIY\#RM9E7?DKW6 MN3_^ G:_<]_MUK*/7(<#6FC"5AR&EBY;X->A'#F2.< MD.>*!WXHQRZZ@]TM^R=&=BR32QBW%J#?;"4<[8PM%2^LG-H7V(4)+Z1_WI@0 M?/[#R_6?V*8:%HES+^^W?./2ORYT/+JU)/DIX2PD[Z]?)*\NG[]]QS7L4>J@ MO7V]^&:,"10NIOYQC;5,::)%F8HU:-KD^4^!-M'!INRS[LHM+4)P8V$ZD3!F M2-289P=3X1M7.AQDG'_$CRVYN+H.VI*]932D*\V%O!Z3P]=Y[ MBF?DN+AGU64"=TTSXY+*$_03*9<%B&[%',WJOW7#0=P@D!*$QGF#_T,[:HF7 M;L43I]0,G>3"$0(.E$B7":C_JV6[[NF!%YDF868/P\ZFU8PGD$V;N?X-!4S5 M[%$?R1C<6 Q=,T'2LJS]RD%,*ZLRJ1OO+F40%ZYOX0B%8]B5C0!S)57P"($L M%7BQMPIZS2HB;R#4@LXX)\]9 K\HNH:5?CLW<3Q^G0$#,JS-BRBRP-U\2FTU MR9VJ]T-#U9% 9-&=9F6B+=>81(F)[>H%R[FC$1YQR5V,)W7H0X"_3IBCLO&- MOLAG9#[ET"D6)U$'(8<#AVZ4!?!I#/-1L5U*R&^!7;8@FM=5EKR+)5FBOD=: M7SF'GR4T]HO$D%-@U1+5FM"Z$)A-Y,<749UJ=BSQ'EQ(OH>486[9]&/!#O) MVREH5)I%/L.FT[JB4()J6J'[G$^>+PQ>Z"@W& EH)UE)[!1:A ,E %R1#Q\H M !W]#^1B1LLM?M0[X3G%M]1E_EWS+>LIJ%O6?&<5Z+GDB,,G@:3F(!1DC.1& M1#YH6KLC].5N-""W;T5,]E+;SU%:HGT3ZV3 N@HX]V%I9TUO7W/ MX^GLUU^^(6_MP-K0GN04553S M"K<9$R#N"1R&644";8ORR[L5F026%":4E[+PL)2YO2GH6LUEPV;3)AOJ'YCZ MK$RS>:/[^8]+.[684!O5Y;SH)J0NR5C%R:B""6Z78S5@X$+UVT<7*:];C7M[ MV-/M)Y&H-@2AV'$UA"3>Y('75/AQE[S88")!X1.YSY^E)#['9+:W=BK<9*6_ MV:P\W;WGU5[KQ]AP":VY21? O&LBC1(O>C0PZ3?453O!6YCBAIIT-J_(%@*< M, \YC2G11'(I)K.&#"!X(5QJX[)8>Q-M76,AV, MYIKQ\:. 3.*/:DF!)\):%QA-DJ'J6V3SY+B!GQ!G+6K18D!'*AKNK<;;U/<% M(G_[IC)DC YJ-;D*BZ^^WNI_DTS$M/W4C-:GKKPR?= .O&3S.*['O!)2RM-V M5K!LD=%JTYO7NDX%F\_K!N/KYDS)LSG98>E%D$/;!I9T5E)$T0PD9B9G922T M%V&6SN=P@Z4H+<.FSNO2V+.= 4XPQH<.79L6-%+@QR +!\:1@/S M^)EN"%JU=+8[&F_8$CZ@=6ZJXLT[&5*FQ#PN0"$D)E_MNPB)M M8*ELVD.^WV0<^-FD>3MF3?#%K"(V/LL\/R@F4&S0PZ$M42MMTK5.*1HZ0FR\ M]R"+S0$AC:@&)".=V F0\CEO@Y5#:"XI*WL*B[ \/'#M-)U +0Y,:O= )30Z MH\9NBOPGO!_H)\%SU3\EZQY4 3O=7VK,8)-R@[++S<)PE/ M4(BJ*)+YA,2H&7- (.JL$';N+'G)-)2G.5W9DY)"113U\8 7>TF--X7\: 7Y MCQ.X[C-FV'!?Y<+ZL]Q.IU&QN6BX7=RSNXB:0'L8@>5BK*>N3M4UR)A.PIY*5H.RD8[/HVM(HGN?1 X)L$4A0RM1:"; MP#<5IH(\*+AO7.@5'=%&VBKRBG^IJ76N)H$OAY!OK(S:O1ZD-\<2FD2C_Q:K M3YBLU.YK$XP5?P:JE? !PE&%5@5VV^]HA]&;^G,XTFB_?A,\\T"]IW;PB3=$ MN =*6NC%@5I6#YJZ369P5?^VWG_"E!A!.5I1V'LVPY\M7R-9\LO]]I:])HI/ MPCJ=XMM+=5KZY@),#'>HA-Y4[^]6H)MM="DI.OR8JD2!3\CG9K"I9Z]O"$?N M \/HXSO=Z6'ZR_79*6C8!,QF<8]7 MR;,!144R<)!K_&NQ.:"D;R*):[A<6U0O'OG>(PG=07"R0@ 9OH&%]UDU&_O9 MWL(4)L,(IG,5WH%FG_7Z\WHO>>@HS)+/2=^]*G;2NNQ!CHY.D/+94E9^CYX@ M>OV?.D%,GQR>WIRTY+[)<5I/='YSFA_:R^&".G9^$](MGCK#:EZ/F&$)2M'0 M!C;V_$)QX<#FB,=J<:+#+'X_H'FU5DFD=<#?#DC-K/,/8'"K4_%' MF:*6*5?B30-AN!Y*@BHI?VYJN&&U3%"GCE/3"G4W+33TZ0 MLR+S5)S)&]"'_33)&N9,T:[M/GY_A]F34CGTYA)[NEM'TF;49ZEV6UCXL-VV MYF'LU5>.XKL[2+URZP(>N]]O\<"A&=S=CC<8I4C:QO&;_R]$A<_*\.:+\*%^O!!1S(O?7,P+E8-X10UWOP)IC*OA^ &% M?X9Z 6$^_/Y QKPZF,G_32+COX@BA8=+)?O'*,C\CAA7>,9UN%T#13 \M3([ MIHWP,*I(&\%X(!.GUVM-IXL>N8"#:PUJP#<(MYG_1/&"E M5&G!Z-R:*!9YT&UO-7VA*QG&VA[3B*F[Z-9+_)%MPCMOW0J.^T_K1[:(8L5' M*HYEU7)4;ZFB:>B5'4$K". #TDCWC:*>9IF7P#-B7MY>_LAYY$07/F5FH<%; MU]PU^L)IY.\?J' (W+K-:59$-W3PV[R)?HNVAO.#^"[^M;VE<(84P7)<\#42 MCL[>GE^B]/IN)?F&*F@U)9L%1_CZV])Y&=9\8,1MWVQC4N.;U>%Q^^\#FB^^ M3U%06EM8WJ)O7S/0H?S/]>[__$P3/LUR^._' M==PK]QW1#4>H_\@%"DM!/WP+BBR\!47LAOK1X\E_-$G$.B[^?W5<]G:,/,A@ MGDDBB8M UF4U43;U6B"H\"6OD=_?;>_OT2R&5Z!W5D8 JGEWC()5B\W,P*L= MWYNG4^I%DD_BPHR]"O;2]B] /ZB==T?VH]D=U;@W50=&[?B[JA\AKOMZ!QXN MD.YD(<1YR]"%B/,L0'T8<7WS_C[+QL@.8Q!S1_>G&@(V?Z]J\IKV^NZH\!!2 MQOT*;(:=CZYQ'][O!/HL( 8&0=N\;<+>X])55UGT=SF(@Q=[?:1F'# Z]Z'= MQ3X;@7L7M=B&Z6,4;<;DP5Y2X;B5T;KL78)/L?WG:4S,003 M6.1^=?J*/ 9^+WU4[F-->6RH&R1/&304Y#& %I7G85&F4Y(+?4UVA@@WS37( M#CN-LFRHZ_CV.K7.=G @_$9Z*)6X5M\+"N!$+YA!/'+9\KG*^P;F+!:\%@ M_.&^$%1P/JZ61U^!C(7 )@S(9,]1'0%Q%B:.-[W$85'!"TT%UT-4$-HG.VO1 M@<6Z4/$81V_)=_"^T BU)G'&"'?_3T9)ETL:["L%YDZH,(3OHI!+>BXB5"P# M?_/53-"[ G_S(EU,8KYW�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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments And Contingencies
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments And Contingencies COMMITMENTS AND CONTINGENCIES
Purchase commitments—We have various purchase obligations for goods or services totaling $45.0 million at December 31, 2019, which are expected to be paid within the next year.
Legal matters—We currently are, and may from time to time become, a party to various legal proceedings or claims that arise in the ordinary course of business. Our managements reviews these matters if and when they arise and believes that the resolution of any such matters currently known will not have a material effect on our results of operations or financial position.
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Reserve for Product Warranties
 12 Months Ended
Dec. 31, 2019
Product Warranties Disclosures [Abstract]  
Reserve for Product Warranties RESERVE FOR PRODUCT WARRANTIES
We provide a warranty for products that is generally one year in length and in some cases, regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, we may be required to
incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management's best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
As of December 31, 2019, we have accrued $6.4 million for product related warranties. The estimates we use in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Other Income (Expense), Net
 12 Months Ended
Dec. 31, 2019
Other Income and Expenses [Abstract]  
Other Income (Expense), Net OTHER INCOME (EXPENSE), NET
Other income (expense), net consists of (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Interest income
$
250

 
$
334

 
$
425

Interest expense
(4,941
)
 
(6,794
)
 
(5,081
)
Foreign currency gain (loss)
(765
)
 
(800
)
 
1,013

Other
(135
)
 
(438
)
 
76

Total other expense, net
$
(5,591
)
 
$
(7,698
)
 
$
(3,567
)
XML 42 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments And Contingencies (Tables)
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Operating lease, right-of-use asset  
XML 43 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions The fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:
 
December 31,
 
2018
Weighted-average fair value of options granted
$
11.03

Expected life in years
4.0

Risk-free interest rate
2.7
%
Expected volatility
35
%
Dividend yield
None
Share-Based Compensation Expense Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Cost of revenue
$
264

 
$
218

 
$
232

Marketing and selling
800

 
801

 
540

Research and development
1,024

 
1,039

 
1,332

General and administrative
6,227

 
14,945

 
7,341

Total expense
$
8,315

 
$
17,003

 
$
9,445
Stock Options Activity
Stock Option Activity—Stock option activity under the stock awards plans for the year ended December 31, 2019 is summarized as follows:  
 
Number of
Shares
 
Weighted
Average
Exercise Price
Outstanding, December 31, 2018 (127,453 shares exercisable at a weighted average exercise price of $18.22 per share)
201,542

 
$
24.48

Granted
—

 
$
—

Exercised
(124,303
)
 
$
18.35

Forfeited
—

 
$
—

Expired
(3,150
)
 
$
13.35

Outstanding, December 31, 2019 (18,531 shares exercisable at a weighted average exercise price of $35.25 per share)
74,089

 
$
35.25
Restricted Stock Awards Activity The following table summarizes the activity for restricted stock awards during the year ended December 31, 2019:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Unvested at December 31, 2018
293,588

 
$
37.04

Granted
197,333

 
$
31.53

Vested
(129,659
)
 
$
36.46

Forfeited
(21,500
)
 
$
35.76

Unvested at December 31, 2019
339,762

 
$
34.14
Restricted Stock Units Activity The following table summarizes restricted stock units activity for the year ended December 31, 2019:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Outstanding at December 31, 2018
112,805

 
$
36.80

Awarded
118,740

 
$
38.62

Released
(42,130
)
 
$
34.11

Forfeited
(16,319
)
 
$
37.60

Outstanding at December 31, 2019
173,096

 
$
38.62

*Includes the MSUs granted at the valuation date, which may be subject to additional awards or forfeitures depending on the outcome of the performance measures at the end of the performance period.
XML 44 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Other Liabilities (Tables)
 12 Months Ended
Dec. 31, 2018
Other Liabilities Disclosure [Abstract]  
Long-Term Other Liabilities
Long-term other liabilities consist of (in thousands): 
 
December 31,
 
2019
 
2018
Long-term taxes payable
$
12,330

 
$
15,425

Non-current deferred revenue
4,563

 
4,338

Finance lease liabilities
599

 
—

Other
124

 
82

Total
$
17,616

 
$
19,845
XML 46 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Goodwill [Roll Forward]      
Beginning Balance $ 147,644 $ 172,998  
Acquisitions/Purchase Accounting Adjustments   (7,324)  
Goodwill impairment charge 0 (14,846) $ 0
Foreign currency translation (1,277) (3,184)  
Ending Balance $ 146,367 $ 147,644 $ 172,998
XML 47 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment, Customer and Geographic Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]      
Revenue $ 495,175 $ 530,891 $ 500,970
Long-lived assets 24,702 22,913  
Neurology Products [Member]      
Segment Reporting Information [Line Items]      
Revenue 287,236 279,787 243,156
Neurology Products [Member] | Devices and Systems [Member]      
Segment Reporting Information [Line Items]      
Revenue 220,306 200,762 171,315
Neurology Products [Member] | Supplies [Member]      
Segment Reporting Information [Line Items]      
Revenue 66,059 67,025 59,955
Neurology Products [Member] | Services [Member]      
Segment Reporting Information [Line Items]      
Revenue 871 12,000 11,886
Newborn Care Products [Member]      
Segment Reporting Information [Line Items]      
Revenue 110,912 133,872 155,280
Newborn Care Products [Member] | Devices and Systems [Member]      
Segment Reporting Information [Line Items]      
Revenue 53,465 72,807 89,027
Newborn Care Products [Member] | Supplies [Member]      
Segment Reporting Information [Line Items]      
Revenue 38,264 40,669 43,928
Newborn Care Products [Member] | Services [Member]      
Segment Reporting Information [Line Items]      
Revenue 19,183 20,396 22,325
OtometricsProducts [Member]      
Segment Reporting Information [Line Items]      
Revenue 97,027 117,232 102,534
OtometricsProducts [Member] | Devices and Systems [Member]      
Segment Reporting Information [Line Items]      
Revenue 92,050 110,597 75,466
OtometricsProducts [Member] | Supplies [Member]      
Segment Reporting Information [Line Items]      
Revenue 4,977 6,635 27,068
OtometricsProducts [Member] | Services [Member]      
Segment Reporting Information [Line Items]      
Revenue 0 0 0
United States      
Segment Reporting Information [Line Items]      
Revenue 292,400 300,860 270,860
Long-lived assets 11,868 10,019  
Foreign countries [Member]      
Segment Reporting Information [Line Items]      
Revenue 202,775 230,031 $ 230,110
Canada [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 4,140 4,504  
Argentina [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 0 999  
Ireland [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 5,732 5,083  
Denmark [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 1,799 1,371  
Other Foreign countries [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets $ 1,163 $ 937  
XML 48 R97.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule II: Valuation And Qualifying Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
SEC Schedule, 12-09, Allowance, Credit Loss [Member]      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period $ 6,960 $ 8,978 $ 4,182
Additions Charged to Expense 1,584 6,423 10,017
Deductions (1,160) (8,441) (5,221)
Balance at End of Period 7,384 6,960 8,978
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 637 5,862 3,706
Additions Charged to Expense 0 0 2,156
Deductions (31) (5,225) 0
Balance at End of Period 606 637 5,862
SEC Schedule, 12-09, Reserve, Warranty [Member]      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 9,391 10,995 10,670
Additions Charged to Expense 3,949 4,487 5,370
Deductions (6,936) (6,091) (5,045)
Balance at End of Period $ 6,404 $ 9,391 $ 10,995
XML 49 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Supplemental Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Leases [Abstract]    
Operating lease right-of-use assets $ 15,046 $ 0
Current portion of operating lease liabilities 5,871 0
Operating lease liabilities 12,051 0
Total operating lease liabilities 17,922  
Finance Leases, property and equipment 2,377  
Finance leases, accumulated amortization (1,418)  
Finance leases, property and equipment, net 959  
Finance leases, accrued liabilities 390  
Finance leases, other liabilities 599 $ 0
Total finance lease liabilities $ 989  
Weighted average remaining lease term, operating leases 3 years 9 months  
Weighted average remaining lease term, finance leases 2 years 11 months 1 day  
Weighted average discount rate, operating leases 5.30%  
Weighted average discount rate, finance leases 5.10%  
XML 50 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Stockholders' Equity STOCKHOLDERS’ EQUITY
Common Stock—We have 120,000,000 shares of common stock authorized at a par value or $0.001 per share. 
Preferred Stock—We have 10,000,000 shares of preferred stock authorized at a par value of $0.001 per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of December 31, 2019, no shares of preferred stock were issued and outstanding.
XML 51 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
Income (loss) before provision for income tax is as follows (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
U.S.
$
(22,851
)
 
$
(54,370
)
 
$
(18,059
)
Foreign
1,594

 
22,110

 
23,209

Income (loss) before provision for income tax
$
(21,257
)
 
$
(32,260
)
 
$
5,150



The components of income tax expense (benefit) for the years ended December 31, 2019, 2018 and 2017 (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Current
 
 
 
 
 
U.S. Federal
$
(948
)
 
$
(1,872
)
 
$
10,110

U.S. State and local
561

 
(59
)
 
1,079

Non-U.S.
8,386

 
5,732

 
12,764

Total current tax expense
7,999

 
3,801

 
23,953

Deferred
 
 
 
 
 
U.S. Federal
(7,491
)
 
(8,248
)
 
6,345

U.S. State and local
(816
)
 
(1,751
)
 
(1,333
)
Non-U.S.
(5,278
)
 
(3,127
)
 
(3,522
)
Total deferred tax expense (benefit)
(13,585
)
 
(13,126
)
 
1,490

Total income tax expense (benefit)
$
(5,586
)
 
$
(9,325
)
 
$
25,443


Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands): 
 
December 31,
 
2019
 
2018
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
3,035

 
$
3,192

Credit carryforwards
2,415

 
2,882

Accruals deductible in different periods
23,672

 
15,197

Employee benefits
1,554

 
1,262

Operating leases
4,643

 
—

Total deferred tax assets
35,319

 
22,533

Valuation allowance
(606
)
 
(637
)
Total net deferred tax assets
$
34,713

 
$
21,896

Deferred tax liabilities:
 
Basis difference in fixed and intangible assets
(13,850
)
 
(15,687
)
Operating leases
(3,959
)
 
—

Foreign earnings to be repatriated
(800
)
 
(500
)
Total deferred tax liabilities
(18,609
)
 
(16,187
)
Total net deferred tax assets
$
16,104

 
$
5,709


The income tax expense (benefit) in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of 21%, 21%, and 35% in 2019, 2018, and 2017, respectively to income before taxes due to the following: 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Federal statutory tax expense
$
(4,464
)
 
$
(6,775
)
 
$
1,802

State tax expense
(300
)
 
(1,160
)
 
(318
)
Foreign taxes at rates less than U.S. rates
(2,205
)
 
(1,071
)
 
(3,101
)
Deferred charges on sales of U.S. intellectual property
—

 
—

 
980

Equity compensation
824

 
519

 
606

Tax credits
(1,428
)
 
(2,021
)
 
(1,498
)
Uncertain tax position
2,910

 
1,311

 
2,048

Lapse of statute
(3,961
)
 
(1,214
)
 
(1,521
)
Change of valuation allowance on foreign tax credit
—

 
—

 
314

Earnout adjustment
—

 
—

 
(190
)
Repatriation tax net of foreign tax credits
172

 
—

 
16,564

Net deferred tax asset re-measurement

—

 
—

 
3,883

Tax audits
—

 
658

 
726

Withholding taxes
1,107

 
1,185

 
2,880

Global intangible low-taxed income net of foreign tax credits
1,601

 
2,326

 
—

Return to provision
560

 
(1,417
)
 
711

AMT on acquisition
—

 
—

 
621

SAB 118 adjustments
—

 
(2,676
)
 
—

Other
(402
)
 
1,010

 
936

Total expense (benefit)
$
(5,586
)
 
$
(9,325
)
 
$
25,443


At December 31, 2019, we had U.S. state net operating loss carryforwards of $23.7 million, of which an immaterial amount will begin to expire in 2020. At December 31, 2019, we had U.S. federal and state R&D credit carryforwards of $1.2 million and $0.6 million, respectively. These R&D credit carryforwards will begin to expire in 2039 and 2021, respectively. At December 31, 2019, we had $0.1 million of U.S. foreign tax credit carryforwards that can be used to offset future U.S. tax liabilities related to foreign source taxable income. The foreign tax credits will start to expire in 2022.
At December 31, 2019, certain foreign subsidiaries had deferred tax assets attributable to net operating loss carryforwards as follows: $1.0 million in France, $0.4 million in Denmark, $0.4 million in Canada, and $0.1 million in Germany. These foreign net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028.
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of $0.6 million and $0.6 million were recorded at December 31, 2019 and 2018, respectively. The decrease of $31.0 thousand in valuation allowance was primarily due to a valuation allowance recorded against our net operating loss carryforward in Canada due to utilization in the current year.
The realizability of the deferred tax assets is primarily dependent on our ability to generate sufficient taxable income in future periods. Management weighs the aggregate effect of all positive evidence and negative evidence in determining the likelihood of realization of the deferred tax assets. The factors used by management to collect evidence included historical earnings of the applicable taxing jurisdiction, the cash refund opportunity to utilize the tax losses, and the future forecast of profitability in the jurisdiction. Weighing all the positive and negative evidence, we have recorded a valuation allowance related primarily to net operating losses in certain foreign jurisdictions and U.S. foreign tax credits where it is more likely than not that the tax benefit of the net operating losses and tax credits will not be realized.
There are no changes to the position on our permanent reinvestment of earnings from foreign operations. As of December 31, 2019, we intend to distribute all of the earnings from Excel-Tech and Natus Ireland in excess of their operational needs. We have recorded a deferred tax liability of $0.8 million accordingly for 5% Canadian withholding tax on the expected Excel-Tech distribution to Natus Ireland. Natus Ireland has 0% withholding tax under domestic exemption and therefore, no liability has been recorded. We intend on permanently reinvesting the earnings of remaining foreign subsidiaries. The other remaining foreign subsidiaries have both the intent and ability to indefinitely reinvest its undistributed earnings.
Uncertain Tax Positions
A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands): 
Balance at January 1, 2017
$
5,898

Increases for tax positions related to prior years
747

Increases for tax positions related to the current year
1,712

Lapse of statutes of limitations
(1,393
)
Foreign exchange difference
53

Balance at January 1, 2018
$
7,017

Increases for tax positions related to prior years
526

Increases for tax positions related to the current year
699

Lapse of statutes of limitations
(965
)
Foreign exchange difference
(50
)
Balance at January 1, 2019
$
7,227

Decreases for tax positions related to prior years
(48
)
Increases for tax positions related to the current year
495

Lapse of statutes of limitations
(3,763
)
Foreign exchange difference
6

Balance at December 31, 2019
$
3,917


For the year ended December 31, 2019, unrecognized tax benefits decreased by $3.3 million and $3.5 million of income tax benefit in the income tax provision were recorded. The decrease was primarily attributable to the lapse of the statute of limitations in uncertain tax positions and adjustments related to the prior years in certain jurisdictions.
The unrecognized tax benefits for the tax years ended December 31, 2019, 2018 and 2017 were $3.9 million, $7.2 million and $7.0 million, respectively which include $3.6 million, $6.5 million and $4.0 million, respectively that would impact the effective tax rate if recognized.
We expect a range from zero to $2.4 million of unrecognized tax benefit that will impact the effective tax rate in the next 12 months due to the lapse of statute of limitations provided that no taxing authority conducts a new examination.
At December 31, 2019, 2018 and 2017, we had cumulatively accrued $0.4 million, $0.5 million, and $0.6 million for estimated interest and penalties related to uncertain tax positions. We record interest and penalties related to unrecognized tax positions as a component of income tax expense (benefit), which totaled approximately $(80.0) thousand, $(80.0) thousand, and $(10.0) thousand for the years ended December 31, 2019, 2018, and 2017, respectively.
We are currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next 12 months.
Our tax returns remain open to examination as follows: U.S. federal, 2015 through 2018; U.S. states, generally 2014 through 2018; and significant foreign jurisdictions, generally 2014 through 2018.
XML 52 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:
Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
On April 1, 2019, as part of the sale of our Argentinian subsidiary, Medix, we provided a loan to Medix for $2.2 million. This asset was measured at fair value less costs to sell as of December 31, 2019 and is classified as Level 3 asset. The loan is classified within other assets on our consolidated balance sheet. Subsequent changes in the fair value of the loan receivable are recorded within our income statement as an operating expense.
 
December 31, 2018
 
Additions
 
Payments
 
Adjustments
 
December 31, 2019
Other assets:
 
 
 
 
 
 
 
 
 
Loan receivable
$
—

 
$
2,200

 
$
—

 
$
(294
)
 
$
1,906

Total
$
—

 
$
2,200

 
$
—

 
$
(294
)
 
$
1,906

The derivative financial instruments described in Note 12 are measured at fair value on a recurring basis and are presented on the consolidated balance sheets at fair value. The table below presents the fair value of the derivative financial instruments as well as the classification on the consolidated balance sheet (in thousands):
 
December 31, 2018
 
Additions
 
Payments
 
Adjustments
 
December 31, 2019
Liabilities:
 
 
 
 
 
 
 
 
 
Interest Rate Swap
$
77

 
$
—

 
$
—

 
$
236

 
$
313

Total
$
77

 
$
—

 
$
—

 
$
236

 
$
313

We estimate the fair value of the interest rate swaps by calculating the present value of the expected future cash flows of each swap. The calculation incorporated the contractual terms of the derivatives, observable market interest rates which are considered to be Level 2 inputs, and credit risk adjustments, if any, to reflect the counterpart's as well as our nonperformance risk. As of December 31, 2019, there have been no events of default under the interest rate swap agreement.
The following financial instruments are not measured at fair value on the consolidated balance sheet as of December 31, 2019 and 2018, but require disclosure of fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of the relatively short maturity.
The carrying amount of our short-term and long-term debt approximates fair value based on Level 2 inputs since the debt carries a variable interest rate that is tied to the current LIBOR rate plus a spread.
XML 53 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2016 $ 417,374 $ 312,986 $ 149,408 $ (45,020)
Beginning balance (shares) at Dec. 31, 2016   32,920,246    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Vesting of restricted stock units 0      
Vesting of restricted stock units (shares)   35,929    
Net issuance of restricted stock awards 0      
Net issuance of restricted stock awards (shares)   249,366    
Employee stock purchase plan 1,581 $ 1,581    
Employee stock purchase plan (shares)   48,470    
Stock-based compensation expense 9,445 $ 9,445    
Repurchase of company stock (2,268) $ (2,268)    
Repurchase of company stock (shares)   (60,800)    
Taxes paid related to net share settlement of equity awards (7,052) $ (7,052)    
Taxes paid related to net share settlement of equity awards (shares)   (193,212)    
Exercise of stock options 1,885 $ 1,885    
Other comprehensive income 21,425     21,425
Net loss (20,293)   (20,293)  
Ending balance at Dec. 31, 2017 422,097 $ 316,577 129,115 (23,595)
Ending balance (shares) at Dec. 31, 2017   33,134,101    
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect | Accounting Standards Update 2016-16 [Member] (3,919)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Vesting of restricted stock units 0      
Vesting of restricted stock units (shares)   266    
Net issuance of restricted stock awards 0      
Net issuance of restricted stock awards (shares)   272,941    
Employee stock purchase plan 1,700 $ 1,700    
Employee stock purchase plan (shares)   63,649    
Stock-based compensation expense 17,003 $ 17,003    
Repurchase of company stock (5,630) $ (5,630)    
Repurchase of company stock (shares)   (173,545)    
Taxes paid related to net share settlement of equity awards (5,183) $ (5,183)    
Taxes paid related to net share settlement of equity awards (shares)   (160,700)    
Exercise of stock options $ 9,748 $ 9,748    
Exercise of stock options (shares) 124,303 667,667    
Other comprehensive income $ (14,437)     (14,437)
Net loss (22,935)   (22,935)  
Ending balance at Dec. 31, 2018 398,444 $ 334,215 102,261 (38,032)
Ending balance (shares) at Dec. 31, 2018   33,804,379    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Vesting of restricted stock units 0      
Vesting of restricted stock units (shares)   42,130    
Net issuance of restricted stock awards 0      
Net issuance of restricted stock awards (shares)   175,833    
Employee stock purchase plan 1,354 $ 1,354    
Employee stock purchase plan (shares)   53,839    
Stock-based compensation expense 8,315 $ 8,315    
Stock-based compensation expense (shares)   0    
Taxes paid related to net share settlement of equity awards (1,689) $ (1,689)    
Taxes paid related to net share settlement of equity awards (shares)   (51,784)    
Exercise of stock options 2,281 $ 2,281    
Exercise of stock options (shares)   124,303    
Other comprehensive income 21,757      
Other comprehensive income, net of ASU adoption impact 23,089     23,089
Net loss (15,671)   (15,671)  
Ending balance at Dec. 31, 2019 $ 416,123 $ 344,476 $ 87,922 $ (16,275)
Ending balance (shares) at Dec. 31, 2019   34,148,700    
XML 54 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets INTANGIBLE ASSETS
The following table summarizes the components of gross and net intangible asset balances (in thousands): 
 
December 31, 2019
 
December 31, 2018
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Technology
$
108,400

 
(6,035
)
 
$
(55,408
)
 
$
46,957

 
$
111,198

 
(6,768
)
 
$
(50,046
)
 
$
54,384

Customer related
90,351

 
(50
)
 
(40,527
)
 
49,774

 
99,440

 
(1,961
)
 
(38,574
)
 
58,905

Trade names
45,874

 
(3,237
)
 
(25,355
)
 
17,282

 
47,217

 
(4,397
)
 
(19,250
)
 
23,570

Internally developed software
13,281

 
—

 
(12,606
)
 
675

 
16,264

 
—

 
(14,164
)
 
2,100

Patents
2,692

 
(133
)
 
(2,559
)
 
—

 
2,718

 
(133
)
 
(2,524
)
 
61

Service Agreements
1,190

 
—

 
(1,079
)
 
111

 
1,190

 
—

 
(757
)
 
433

Total Definite-lived intangible assets
261,788

 
(9,455
)
 
(137,534
)
 
114,799

 
278,027

 
(13,259
)
 
(125,315
)
 
139,453


Finite lived intangible assets are amortized over their weighted average lives, which are 14 years for technology, 13 years for patents, 10 years for customer-related intangibles, 7 years for trade names, 6 years for internally developed software, 2 years for service agreements, and 11 years weighted average in total.
Internally developed software consists of $11.1 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold.
During the fourth quarter of 2018 we recorded an impairment charge related to intangible assets of $8.2 million. These impairments relate to end of life decisions for the core technology utilized in our Bio-logic products and our GND and Neurocom product lines. We acquired Bio-logic core technology as part of the acquisition of Bio-logic Systems Corp in 2006 and have maintained the technology since its acquisition. In 2018 we partnered with one of our contract manufacturers to develop and manufacture the next generation technology to be used in its Bio-logic products. The decision to develop this new technology resulted in an impairment of the originally acquired core technology of $5.6 million, which was recorded within intangibles amortization expense on our income statement.
On January 15, 2019, we announced the implementation of a new organizational structure, "One Natus." As a result of this new organizational structure, we announced we exited two of our non-core businesses, GND and Neurocom. The decision to exit these non-core businesses resulted in the impairment of intangible assets of $2.6 million as of December 31, 2018. These impairments were the result of deterioration of expected future cash flows as compared to the carrying value of the assets. Impairments were determined by performing an undiscounted cash flow analysis on intangibles assets. The impairment charge for GND and Neurocom is recorded on our income statement within restructuring expense.
Amortization expense related to intangible assets with finite lives, including impairment charges described above, was as follows (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Technology
$
6,906

 
$
14,100

 
$
7,705

Customer related
8,662

 
12,244

 
10,945

Trade names
6,111

 
6,736

 
6,479

Internally developed software
1,438

 
2,123

 
2,117

Patents
60

 
84

 
244

Service Agreements
322

 
757

 
—

Total amortization
$
23,499

 
$
36,044

 
$
27,490


The amortization expense amounts shown above include internally developed software not held for sale of $1.3 million, $1.9 million, and $1.9 million for the years ended 2019, 2018, and 2017, respectively. The amortization expense for internally developed software not held for sale is recorded within our income statement as a general and administrative operating expense.
Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): 
2020
$
21,616

2021
20,724

2022
17,329

2023
16,375

2024
14,483

Thereafter
24,272

Total expected amortization expense
$
114,799
XML 55 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Other Liabilities
 12 Months Ended
Dec. 31, 2018
Other Liabilities Disclosure [Abstract]  
Long-Term Other Liabilities LONG-TERM OTHER LIABILITIES
Long-term other liabilities consist of (in thousands): 
 
December 31,
 
2019
 
2018
Long-term taxes payable
$
12,330

 
$
15,425

Non-current deferred revenue
4,563

 
4,338

Finance lease liabilities
599

 
—

Other
124

 
82

Total
$
17,616

 
$
19,845
XML 56 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 63,297 $ 56,373
Accounts receivable, net of allowance for doubtful accounts of $7,384 and $6,960 115,889 127,041
Inventories 71,368 79,736
Prepaid expenses and other current assets 19,195 22,625
Total current assets 269,749 285,775
Property and equipment, net 24,702 22,913
Operating lease right-of-use assets 15,046 0
Intangible assets, net 114,799 139,453
Goodwill 146,367 147,644
Deferred income tax 30,355 22,639
Other assets 21,509 19,716
Total assets 622,527 638,140
Current liabilities:    
Accounts payable 27,253 28,805
Current portion of long-term debt 35,000 35,000
Current portion of operating lease liabilities 5,871 0
Accrued liabilities 54,451 52,568
Deferred revenue 20,246 17,073
Total current liabilities 142,821 133,446
Long-term liabilities:    
Other liabilities 17,616 19,845
Long-term debt 19,665 69,474
Operating lease liabilities 12,051 0
Deferred income tax 14,251 16,931
Total liabilities 206,404 239,696
Commitments and contingencies (Note 21)
Stockholders’ equity:    
Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 34,148,700 in 2019 and 33,804,379 in 2018 344,476 334,215
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and in 2018 0 0
Retained earnings 87,922 102,261
Accumulated other comprehensive loss (16,275) (38,032)
Total stockholders’ equity 416,123 398,444
Total liabilities and stockholders’ equity $ 622,527 $ 638,140
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Lease, Cost
Components of lease cost were as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Operating lease cost
$
6,823

Finance lease cost:
 
Amortization of right-of-use assets (principal payments)
466

Interest on lease liabilities
58

Short-term lease cost
51

Variable lease cost
2,836

Sublease income
(179
)
Total lease cost
$
10,055

Supplemental cash flow information related to leases was as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
13,612

Operating cash flows from finance leases
42

Financing cash flows from finance leases
478

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
2,697

Finance leases
300
Assets and Liabilities, Lessee
Supplemental balance sheet information related to leases was as follows (in thousands):
 
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
15,046

 
 
Current portion of operating lease liabilities
$
5,871

Operating lease liabilities
12,051

Total operating lease liabilities
$
17,922

 
 
Finance Leases
 
Property and equipment, gross
$
2,377

Accumulated amortization
(1,418
)
Property and equipment, net
$
959

 
 
Accrued liabilities
$
390

Other liabilities
599

Total finance lease liabilities
$
989

 
 
Weighted Average Remaining Lease Term
 
Operating leases
3.75 years

Finance leases
2.92 years

Weighted Average Discount Rate
 
Operating leases
5.3
%
Finance leases
5.1
%
Finance Lease, Liability, Maturity
As of December 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
Year ending December 31,
Operating Leases
 
Finance Leases
2020
$
6,788

 
$
401

2021
5,302

 
346

2022
3,657

 
176

2023
2,498

 
97

2024
1,277

 
5

Thereafter
842

 
—

Total lease payments
20,364

 
1,025

Less imputed interest
(2,442
)
 
(36
)
Total
$
17,922

 
$
989
Lessee, Operating Lease, Liability, Maturity
As of December 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
Year ending December 31,
Operating Leases
 
Finance Leases
2020
$
6,788

 
$
401

2021
5,302

 
346

2022
3,657

 
176

2023
2,498

 
97

2024
1,277

 
5

Thereafter
842

 
—

Total lease payments
20,364

 
1,025

Less imputed interest
(2,442
)
 
(36
)
Total
$
17,922

 
$
989
XML 58 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories (Tables)
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Inventories
Inventories consist of (in thousands): 
 
December 31,
 
2019
 
2018
Raw materials and subassemblies
$
37,259

 
$
31,459

Work in process
1,780

 
2,424

Finished goods
50,521

 
63,932

Total Inventories
89,560

 
97,815

Less: Non-current Inventories
(18,192
)
 
(18,079
)
Inventories
$
71,368

 
$
79,736
XML 59 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets
 12 Months Ended
Dec. 31, 2019
Related Party Transactions [Abstract]  
Sale of Certain Subsidiary Assets SALE OF CERTAIN SUBSIDIARY
We divested our wholly owned subsidiary, Medix, on April 2, 2019 via a stock sale to the local managing director, a related party. In exchange for the stock, we received $2.5 thousand in cash and provided Medix with a $2.2 million limited-recourse loan. The loan is secured by a real estate assets of Medix and repayment is conditional upon the sale of the real estate asset.

The held for sale criteria under GAAP was met in the first quarter of 2019. As such, we completed an asset impairment analysis which resulted in the full impairment of all assets held for sale. We recognized an impairment loss of $24.6 million which included an accrual for the anticipated realization of deferred foreign currency related translation adjustments in accumulated other comprehensive income of $24.8 million, net of tax, and an adjustment of $4.6 million for assets with a book value in excess of their fair market value. Included in the year ended December 31, 2019 is the impact of the sale of Medix, which was completed as of June 30, 2019, and the deferred foreign currency related translation adjustments previously in accumulated other comprehensive income have been released from the balance sheet along with the held for sale accrual.

XML 60 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2019
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Intangible asset impairment $ 8,200          
Goodwill impairment charge     $ 0 $ 14,846 $ 0  
Undiscounted future minimum operating lease commitments     2,442      
Recorded foreign currency translation gains (losses)     (1,576) (14,360) 21,470  
Net foreign currency transaction gains (losses)   $ 900 (765) (800) $ 1,013  
Operating lease right-of-use assets $ 0 $ 0 15,046 0    
Total     $ 17,922      
Cumulative effect of new accounting principle in period of adoption           $ 0
Minimum            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Contract With Customer, Service Period     12 months      
Maximum            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Contract With Customer, Service Period     60 months      
Office furniture and equipment [Member] | Minimum            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Estimated useful lives of property and equipment     3 years      
Office furniture and equipment [Member] | Maximum            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Estimated useful lives of property and equipment     5 years      
Buildings [Member] | Minimum            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Estimated useful lives of property and equipment     30 years      
Buildings [Member] | Maximum            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Estimated useful lives of property and equipment     40 years      
Share-based Payment Arrangement, Option [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Vesting period     4 years      
Share based compensation, expiration period     10 years      
Share-based Payment Arrangement, Option [Member] | Director [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Vesting period     4 years      
Share based compensation, expiration period     6 years      
Restricted Stock Awards [Member] | Employees [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Vesting period     3 years      
Restricted Stock Awards [Member] | Executives RSAs and RSUs [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Vesting period     4 years      
Restricted Stock Awards [Member] | Executives RSAs and RSUs [Member] | On each of the third and fourth anniversaries of the vesting date[Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Vesting percentage     25.00%      
Restricted Stock Awards [Member] | Director [Member] | On each of the third and fourth anniversaries of the vesting date[Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Vesting period     1 year      
Vesting percentage     100.00%      
Accounting Standards Update 2016-02 [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Operating lease right-of-use assets           19,500
Total           22,300
Accounting Standards Update 2016-16 [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect       $ (3,919)    
Retained Earnings | Accounting Standards Update 2018-02 [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]            
Cumulative effect of new accounting principle in period of adoption           $ 1,332
XML 62 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Inventory Disclosure [Abstract]    
Raw materials and subassemblies $ 37,259 $ 31,459
Work in process 1,780 2,424
Finished goods 50,521 63,932
Total Inventories 89,560 97,815
Less: Non-current Inventories (18,192) (18,079)
Inventories $ 71,368 $ 79,736
XML 63 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 23,499 $ 36,044 $ 27,490
Weighted average life of intangible assets   11 years    
Costs incurred for development of internal use computer software   $ 11,100    
Costs incurred for development of software to be sold   2,200    
Intangible asset impairment $ 8,200      
Core [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairment     5,600  
Non-core [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairment     2,600  
Patents [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 60 84 244
Weighted average life of intangible assets   13 years    
Technology [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 6,906 14,100 7,705
Weighted average life of intangible assets   14 years    
Customer related [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 8,662 12,244 10,945
Weighted average life of intangible assets   10 years    
Trade names [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 6,111 6,736 6,479
Weighted average life of intangible assets   7 years    
Internally developed software [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Weighted average life of intangible assets   6 years    
Service Agreements [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 322 757 0
Weighted average life of intangible assets   2 years    
General and administrative [Member]        
Acquired Finite-Lived Intangible Assets [Line Items]        
Total amortization   $ 1,300 $ 1,900 $ 1,900
XML 64 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity (Details) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Equity [Abstract]    
Common Stock, shares authorized 120,000,000 120,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock authorized 10,000,000 10,000,000
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock issued 0 0
Preferred stock outstanding 0 0
XML 65 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Component of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Current      
U.S. Federal $ (948) $ (1,872) $ 10,110
U.S. State and local 561 (59) 1,079
Non-U.S. 8,386 5,732 12,764
Total current tax expense 7,999 3,801 23,953
Deferred      
U.S. Federal (7,491) (8,248) 6,345
U.S. State and local (816) (1,751) (1,333)
Non-U.S. (5,278) (3,127) (3,522)
Total deferred tax expense (benefit) (13,585) (13,126) 1,490
Total expense (benefit) $ (5,586) $ (9,325) $ 25,443
XML 66 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock Awards [Member] - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Shares      
Unvested, beginning of period, Shares 293,588    
Granted, Shares 197,333    
Vested, Shares (129,659)    
Forfeited, Shares (21,500)    
Unvested, end of period, Shares 339,762 293,588  
Weighted Average Grant Date Fair Value      
Unvested, beginning of period, Weighted - average grant date fair value $ 37.04    
Granted, Weighted - average grant date fair value 31.53 $ 37.22 $ 34.94
Vested, Weighted - average grant date fair value 36.46    
Forfeited, Weighted - average grant date fair value 35.76    
Unvested, end of period, Weighted - average grant date fair value $ 34.14 $ 37.04  
XML 67 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt and Credit Arrangements - Schedule of Long Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Debt Disclosure [Abstract]    
Revolving credit facility $ 55,000 $ 105,000
Debt Issuance Costs, Net (335) (526)
Less: current portion of long-term debt 35,000 35,000
Total long-term debt $ 19,665 $ 69,474
XML 68 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Compensation and related benefits $ 26,991 $ 24,891
Warranty reserve 6,404 9,391
Accrued federal, state, and local taxes 11,156 8,285
Accrued amounts due to customers 3,008 5,507
Accrued professional fees 2,083 1,820
Accrued selling expenses 507 246
Self-funded insurance expense 950 0
Accrued travel 224 201
Deferred rent 0 205
Other 3,128 2,022
Total $ 54,451 $ 52,568
XML 69 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]      
Total amortization $ 23,499 $ 36,044 $ 27,490
Technology [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 6,906 14,100 7,705
Customer related [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 8,662 12,244 10,945
Trade names [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 6,111 6,736 6,479
Internally Developed Software [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 1,438 2,123 2,117
Patents [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 60 84 244
Service Agreements [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization $ 322 $ 757 $ 0
XML 70 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Benefit Plan (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Defined Contribution Plan [Abstract]      
Employer matching contributions $ 3.6 $ 4.7 $ 2.5
XML 71 R95.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Apr. 02, 2019
Dec. 31, 2018
Medix Medical Devices, SRL [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Notes Receivable, Related Parties   $ 2,200  
Medix Medical Devices, SRL [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Notes Receivable, Related Parties $ 1,906   $ 0
Loans and Leases Receivable, Related Parties, Additions 2,200    
Loans and Leases Receivable, Related Parties, Proceeds 0    
Loans and Leases Receivable, Related Parties, Period Increase (Decrease) (294)    
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Derivative Liability 313   $ 77
Derivative Liability, Additions 0    
Derivative Liability, Payments 0    
Derivative Liability, Adjustments $ 236    
XML 72 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Lease Cost (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Operating lease cost $ 6,823
Amortization of right-of-use assets (principal payments) 466
Interest on lease liabilities 58
Short-term lease cost 51
Variable lease cost 2,836
Sublease income (179)
Total lease cost $ 10,055
XML 73 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income (loss) before provision (benefit) for income tax
Income (loss) before provision for income tax is as follows (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
U.S.
$
(22,851
)
 
$
(54,370
)
 
$
(18,059
)
Foreign
1,594

 
22,110

 
23,209

Income (loss) before provision for income tax
$
(21,257
)
 
$
(32,260
)
 
$
5,150
Summary of components of income tax expense
The components of income tax expense (benefit) for the years ended December 31, 2019, 2018 and 2017 (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Current
 
 
 
 
 
U.S. Federal
$
(948
)
 
$
(1,872
)
 
$
10,110

U.S. State and local
561

 
(59
)
 
1,079

Non-U.S.
8,386

 
5,732

 
12,764

Total current tax expense
7,999

 
3,801

 
23,953

Deferred
 
 
 
 
 
U.S. Federal
(7,491
)
 
(8,248
)
 
6,345

U.S. State and local
(816
)
 
(1,751
)
 
(1,333
)
Non-U.S.
(5,278
)
 
(3,127
)
 
(3,522
)
Total deferred tax expense (benefit)
(13,585
)
 
(13,126
)
 
1,490

Total income tax expense (benefit)
$
(5,586
)
 
$
(9,325
)
 
$
25,443
Deferred tax assets and liabilities Significant components of deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands): 
 
December 31,
 
2019
 
2018
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
3,035

 
$
3,192

Credit carryforwards
2,415

 
2,882

Accruals deductible in different periods
23,672

 
15,197

Employee benefits
1,554

 
1,262

Operating leases
4,643

 
—

Total deferred tax assets
35,319

 
22,533

Valuation allowance
(606
)
 
(637
)
Total net deferred tax assets
$
34,713

 
$
21,896

Deferred tax liabilities:
 
Basis difference in fixed and intangible assets
(13,850
)
 
(15,687
)
Operating leases
(3,959
)
 
—

Foreign earnings to be repatriated
(800
)
 
(500
)
Total deferred tax liabilities
(18,609
)
 
(16,187
)
Total net deferred tax assets
$
16,104

 
$
5,709
Reconciliation of effective income tax rate
The income tax expense (benefit) in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of 21%, 21%, and 35% in 2019, 2018, and 2017, respectively to income before taxes due to the following: 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Federal statutory tax expense
$
(4,464
)
 
$
(6,775
)
 
$
1,802

State tax expense
(300
)
 
(1,160
)
 
(318
)
Foreign taxes at rates less than U.S. rates
(2,205
)
 
(1,071
)
 
(3,101
)
Deferred charges on sales of U.S. intellectual property
—

 
—

 
980

Equity compensation
824

 
519

 
606

Tax credits
(1,428
)
 
(2,021
)
 
(1,498
)
Uncertain tax position
2,910

 
1,311

 
2,048

Lapse of statute
(3,961
)
 
(1,214
)
 
(1,521
)
Change of valuation allowance on foreign tax credit
—

 
—

 
314

Earnout adjustment
—

 
—

 
(190
)
Repatriation tax net of foreign tax credits
172

 
—

 
16,564

Net deferred tax asset re-measurement

—

 
—

 
3,883

Tax audits
—

 
658

 
726

Withholding taxes
1,107

 
1,185

 
2,880

Global intangible low-taxed income net of foreign tax credits
1,601

 
2,326

 
—

Return to provision
560

 
(1,417
)
 
711

AMT on acquisition
—

 
—

 
621

SAB 118 adjustments
—

 
(2,676
)
 
—

Other
(402
)
 
1,010

 
936

Total expense (benefit)
$
(5,586
)
 
$
(9,325
)
 
$
25,443
Uncertain Tax Positions
A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands): 
Balance at January 1, 2017
$
5,898

Increases for tax positions related to prior years
747

Increases for tax positions related to the current year
1,712

Lapse of statutes of limitations
(1,393
)
Foreign exchange difference
53

Balance at January 1, 2018
$
7,017

Increases for tax positions related to prior years
526

Increases for tax positions related to the current year
699

Lapse of statutes of limitations
(965
)
Foreign exchange difference
(50
)
Balance at January 1, 2019
$
7,227

Decreases for tax positions related to prior years
(48
)
Increases for tax positions related to the current year
495

Lapse of statutes of limitations
(3,763
)
Foreign exchange difference
6

Balance at December 31, 2019
$
3,917
XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Derivatives (Tables)
 12 Months Ended
Dec. 31, 2019
Derivative Instrument [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] held the following interest rate swaps as of December 31, 2019 (in thousands):


Hedged Item
Current Notional Amount
Designation Date
Effective Date
Termination Date
Fixed Interest Rate
Floating Rate
Estimated Fair Value
1-month USD LIBOR loan
$
40,000

May 31, 2018
June 1, 2018
September 23, 2021
2.611%
1-month USD LIBOR
$
313

Total interest rate derivatives designated as cash flow hedge
$
40,000

 
 
 
 
 
$
313
XML 76 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation SHARE-BASED COMPENSATION
Share-Based Compensation Expense—We account for share-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation. Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Cost of revenue
$
264

 
$
218

 
$
232

Marketing and selling
800

 
801

 
540

Research and development
1,024

 
1,039

 
1,332

General and administrative
6,227

 
14,945

 
7,341

Total expense
$
8,315

 
$
17,003

 
$
9,445


Stock Awards Plans—Natus' 2018 Stock Awards Plan (the “Plan”) provides for the granting of the following:
•
Incentive stock options to employees;
•
Non-statutory stock options to employees, directors and consultants;
•
Restricted stock awards and restricted stock units;
•
Market stock units;
•
Stock bonuses; and
•
Stock appreciation rights.
As of December 31, 2019, there were 2,764,603 shares available for future awards under the plan.
Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than six years after the date of grant. Most options vest ratably over four years.
Stock Option Activity—Stock option activity under the stock awards plans for the year ended December 31, 2019 is summarized as follows:  
 
Number of
Shares
 
Weighted
Average
Exercise Price
Outstanding, December 31, 2018 (127,453 shares exercisable at a weighted average exercise price of $18.22 per share)
201,542

 
$
24.48

Granted
—

 
$
—

Exercised
(124,303
)
 
$
18.35

Forfeited
—

 
$
—

Expired
(3,150
)
 
$
13.35

Outstanding, December 31, 2019 (18,531 shares exercisable at a weighted average exercise price of $35.25 per share)
74,089

 
$
35.25


As of December 31, 2019, unrecognized compensation related to the unvested portion of stock options was approximately $0.5 million, which is expected to be recognized over a weighted average period of 2.7 years. The intrinsic value of options exercised, representing the difference between the closing stock price of common stock on the date of the exercise and the exercise price, in the years ended December 31, 2019, 2018 and 2017 was $1.4 million, $13.6 million, and $3.1 million, respectively.
As of December 31, 2019, there were: (i) 70,990 options vested and expected to vest with a weighted average exercise price of $35.25, an intrinsic value of $0.0 million, and a weighted average remaining contractual term of 4.5 years; and (ii) 18,531 options exercisable with a weighted average exercise price of $35.25, an intrinsic value of $0.0 million, and a weighted average remaining contractual term of 4.5 years.
Black-Scholes Inputs—The fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:
 
December 31,
 
2018
Weighted-average fair value of options granted
$
11.03

Expected life in years
4.0

Risk-free interest rate
2.7
%
Expected volatility
35
%
Dividend yield
None

We did not grant any stock options during the years ended December 31, 2019 and December 31, 2017.
The expected life of options is based primarily on historical share option exercise experience of the employees for options granted. All options are treated as a single group in the determination of expected life, as we do not currently expect substantially different exercise or post-vesting termination behavior among the employee population. The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based primarily on historical volatility data of our common stock. We have no history or expectation of paying dividends on common stock.
Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, we estimate the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated we will record additional expense and if the actual forfeiture is higher than estimated we will record a recovery of prior expense.
Restricted Stock Awards Activity—The following table summarizes the activity for restricted stock awards during the year ended December 31, 2019:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Unvested at December 31, 2018
293,588

 
$
37.04

Granted
197,333

 
$
31.53

Vested
(129,659
)
 
$
36.46

Forfeited
(21,500
)
 
$
35.76

Unvested at December 31, 2019
339,762

 
$
34.14


As of December 31, 2019, unrecognized compensation related to the unvested portion of stock awards was $6.4 million, which is expected to be recognized over a weighted average period of 2.3 years. The fair market value of outstanding restricted stock awards at December 31, 2019 was $11.2 million. For the restricted stock awards granted during the years ended December 31, 2019, 2018, 2017, the weighted average grant date fair values were $31.53, $37.22, and $34.94, respectively. The total grant date fair value of restricted stock awards vested during fiscal year 2019, 2018, and 2017 was $4.7 million, $12.9 million, and $12.7 million, respectively. For the restricted stock awards that vested during the years ended December 31, 2019, 2018, and 2017, the total intrinsic value was $4.0 million, $11.2 million, and $14.3 million, respectively.
Restricted Stock Units Activity—The following table summarizes restricted stock units activity for the year ended December 31, 2019:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Outstanding at December 31, 2018
112,805

 
$
36.80

Awarded
118,740

 
$
38.62

Released
(42,130
)
 
$
34.11

Forfeited
(16,319
)
 
$
37.60

Outstanding at December 31, 2019
173,096

 
$
38.62

*Includes the MSUs granted at the valuation date, which may be subject to additional awards or forfeitures depending on the outcome of the performance measures at the end of the performance period.
As of December 31, 2019, unrecognized compensation related to the unvested portion of stock units was $3.7 million, which is expected to be recognized over a weighted average period of 2.0 years. The aggregate intrinsic value of outstanding restricted stock units at December 31, 2019 was $5.7 million. For the restricted stock units granted during the years December 31, 2019, 2018, 2017, the weighted average grant date fair values were $38.62, $36.77, and $35.16, respectively. The total grant date fair value of restricted stock units vested during fiscal year 2019, 2018, and 2017 was $1.4 million, $10.0 thousand, and $1.2 million, respectively. For the restricted stock units that vested during the years ended December 31, 2019, 2018, and 2017, the total intrinsic value was $1.3 million, $8.7 thousand, and $1.3 million, respectively.
Employee Stock Purchase Plan—Under Natus' 2011 Employee Stock Purchase Plan (the “ESPP”), U.S. employees can elect to have salary withholdings of up to 15% of eligible compensation to a maximum of $10,625 per offering period, to purchase shares of common stock on April 30 and October 31 of each year. The purchase price for shares acquired under the ESPP is 85% of the fair market value on the last day of the offering period. As of December 31, 2019, there were 499,431 shares reserved for future issuance under the ESPP.
Because the ESPP does not have a “look back” feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of common stock on the last day of the offering period and the purchase price for the offering period, which is 85% of the fair market value. Compensation expense associated with the ESPP for the years ended December 31, 2019, 2018 and 2017, respectively, was $0.2 million, $0.3 million, and $0.3 million.
XML 77 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment, Customer and Geographic Information
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment, Customer and Geographic Information SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION
We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, our operating segments were based on its three strategic business units. In January 2019 we announced the transition of our operating structure from three strategic business units to a single, unified company with globally led operational teams in Sales and Marketing, Manufacturing, Research and Development, Quality, and General and Administrative functions.
Following the reorganization, we operate as one operating segment and one reportable segment, which provides medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Financial information is reviewed on a consolidated basis for purposes of making operating decisions and assessing financial performance. Consolidated financial information is accompanied by disaggregated information about revenues by end market and geographic region. We do not assess the performance of our end markets or geographic regions on measures of profit or loss, or asset-based metrics. We have disclosed the revenues for each end market and geographic region to provide the reader of the financial statements transparency into our operations.
The following tables present revenue and long-lived asset information by end market and geographic region. Revenue is based on the destination of the shipments and long-lived assets are based on the physical location of the assets (in thousands):
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Consolidated Revenue:
 
United States
$
292,400

 
$
300,860

 
$
270,860

Foreign countries
202,775

 
230,031

 
230,110

 
$
495,175

 
$
530,891

 
$
500,970

Revenue by End Market:
 
Neuro
 
Devices and Systems
$
220,306

 
$
200,762

 
$
171,315

Supplies
66,059

 
67,025

 
59,955

Services
871

 
12,000

 
11,886

Total Neuro Revenue
$
287,236

 
$
279,787

 
$
243,156

Newborn Care
 
Devices and Systems
$
53,465

 
$
72,807

 
$
89,027

Supplies
38,264

 
40,669

 
43,928

Services
19,183

 
20,396

 
22,325

Total Newborn Care Revenue
$
110,912

 
$
133,872

 
$
155,280

Hearing & Balance
 
Devices and Systems
$
92,050

 
$
110,597

 
$
75,466

Supplies
4,977

 
6,635

 
27,068

Services
—

 
—

 
—

Total Hearing & Balance Revenue
$
97,027

 
$
117,232

 
$
102,534

Total Revenue
$
495,175

 
$
530,891

 
$
500,970

Long-lived asset information by geographic region is as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
Property and equipment, net:
 
 
 
United States
$
11,868

 
$
10,019

Ireland
5,732

 
5,083

Canada
4,140

 
4,504

Denmark
1,799

 
1,371

Argentina
—

 
999

Other foreign countries
1,163

 
937

 
$
24,702

 
$
22,913

During the years ended December 31, 2019, 2018 and 2017, no single customer or foreign country contributed to more than 10% of revenue.
XML 78 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Components of Gross and Net Intangible Asset Balances
The following table summarizes the components of gross and net intangible asset balances (in thousands): 
 
December 31, 2019
 
December 31, 2018
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Technology
$
108,400

 
(6,035
)
 
$
(55,408
)
 
$
46,957

 
$
111,198

 
(6,768
)
 
$
(50,046
)
 
$
54,384

Customer related
90,351

 
(50
)
 
(40,527
)
 
49,774

 
99,440

 
(1,961
)
 
(38,574
)
 
58,905

Trade names
45,874

 
(3,237
)
 
(25,355
)
 
17,282

 
47,217

 
(4,397
)
 
(19,250
)
 
23,570

Internally developed software
13,281

 
—

 
(12,606
)
 
675

 
16,264

 
—

 
(14,164
)
 
2,100

Patents
2,692

 
(133
)
 
(2,559
)
 
—

 
2,718

 
(133
)
 
(2,524
)
 
61

Service Agreements
1,190

 
—

 
(1,079
)
 
111

 
1,190

 
—

 
(757
)
 
433

Total Definite-lived intangible assets
261,788

 
(9,455
)
 
(137,534
)
 
114,799

 
278,027

 
(13,259
)
 
(125,315
)
 
139,453
Amortization expense related to intangible assets with definite lives
Amortization expense related to intangible assets with finite lives, including impairment charges described above, was as follows (in thousands): 
 
Years Ended December 31,
 
2019
 
2018
 
2017
Technology
$
6,906

 
$
14,100

 
$
7,705

Customer related
8,662

 
12,244

 
10,945

Trade names
6,111

 
6,736

 
6,479

Internally developed software
1,438

 
2,123

 
2,117

Patents
60

 
84

 
244

Service Agreements
322

 
757

 
—

Total amortization
$
23,499

 
$
36,044

 
$
27,490
Expected annual amortization expense related to amortizable intangible assets
Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): 
2020
$
21,616

2021
20,724

2022
17,329

2023
16,375

2024
14,483

Thereafter
24,272

Total expected amortization expense
$
114,799
XML 79 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Principles of Consolidation
Basis of Presentation and Principles of Consolidation
The accompanying Consolidated Financial Statements includes our accounts and accounts of our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.
Revenue recognition
Revenue recognition
Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services.
For the majority of devices and supplies, we transfer control and recognize revenue when products ship from the warehouse to the customer. We generally do not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue.
Depending on the terms of the arrangement, we may also defer the recognition of a portion of the consideration received because we have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price for each distinct performance obligation. Our estimate of SSP is a point estimate.  The estimate is calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs.
We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond the base agreements to customers. The separately priced service contracts range from 12 months to 60 months. We receive payment at the inception of the contract and recognize revenue ratably over the service period.
For products containing embedded software, we have determined that the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products.
Inventory Inventory
Carrying value of intangible assets and goodwill
Goodwill
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired.
Goodwill is tested for impairment at the reporting unit level. In 2018 and 2017 we had four reporting units for purposes of goodwill impairment testing. In early 2019 we announced the implementation of a new organizational structure which consolidated our three strategic business units, Neuro, Newborn Care and Hearing & Balance into “One Natus”. As a result of these organizational changes we have concluded we have one operating segment and one reporting unit for purposes of goodwill impairment testing in 2019.
In accordance with accounting standards we perform a qualitative assessment to test goodwill for impairment prior to the performing the first step of the goodwill impairment process. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting the reporting unit.
Prior to the adoption of ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) in 2019, which simplified the goodwill impairment test, if the fair value of a reporting unit was less than its carrying amount, we would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Based on the qualitative assessment in 2019 and 2017, we determined the fair value of goodwill was more likely than not greater than its carrying amount, and no further analysis was needed.
Due to organizational changes announced in late 2018 our evaluation of our GND reporting unit, which was part of our Neuro business unit, was determined to be impaired. Prior to calculating the goodwill impairment loss, we analyzed the recoverability of GND long-lived assets (other than goodwill). As a result, we recorded a goodwill impairment charge of $14.8 million within restructuring expense on our income statement. There was no remaining goodwill in the GND reporting unit as of December 31, 2018.
In 2019 we elected to early adopt ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The adoption of this standard eliminates the second step of the two-step impairment test described above and allows a Company to expense the difference between carrying amount in excess of the fair value of the reporting unit as a reduction in goodwill. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements as we concluded based on the qualitative assessment performed in 2019 that the fair value of the reporting unit was more likely than not to be greater than its carrying amount, and no further analysis was needed.
Long lived assets
Long lived assets
We continually monitor events and changes in circumstances that could indicate that carrying amounts of our long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, we will assess the recoverability by determining whether the carrying value of an asset group will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of the asset group, we will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Leases
Leases
We determine if an arrangement is a lease at inception of the lease. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the
lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit borrowing rate, generally we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the lease commencement date. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term.
Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet.
We have lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, we account for these components separately. For equipment leases, such as office equipment and vehicles, we account for the lease and non-lease components as a single lease component.
Liability for product warranties
Liability for product warranties
We provide a warranty for products that is generally one year in length. In some cases, regulations may require us to provide repair or remediation beyond the typical warranty period. If any products contain defects, we may be required to incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis.
We accrue estimated product warranty costs at the time of sale based on historical experience. A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Share-based compensation
Share-based compensation
We recognize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 16 of the Consolidated Financial Statements.
For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.
We recognize share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 25% on each of the annual anniversaries. RSAs and RSUs for non-employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
We grant market stock unit (“MSU”) awards to certain employees. We estimate the fair value of MSUs at the date of grant using a Monte Carlo simulation model and amortize those fair values over the requisite service period, which is generally three years. The Monte Carlo simulation model that we use to estimate the fair value of market-based MSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the market-based MSUs, which is determined at the date of grant, must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.
We issue new shares of common stock upon the exercise of stock options and the vesting of RSAs, RSUs, and MSUs.
Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.
Cash Equivalents
Cash Equivalents
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents.
Short-term Investments
Cash Equivalents
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents.
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts
We estimate the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which we operate and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.
Assets and Liabilities Held for Sale
Assets and Liabilities Held for Sale
We consider assets and liabilities to be held for sale when all of the following criteria are met:
•Management approves and commits to a formal plan to sell the asset or disposal group;
•The assets or disposal group is available for immediate sale in its present condition;
•An active program to locate a buyer and other actions required to complete the sale have been initiated;
•The sale of the asset or disposal group is expected to be completed within one year;
•The asset or disposal group is being actively marketed for sale at the price that is reasonable in relation to the current fair value; and
•It is unlikely that significant changes will be made to the plan.
Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, we record the asset or disposal group at the lower of its carrying value or its estimated fair value, less estimated costs of sale. We consider deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on our income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. We assess the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and report any reduction in fair value as an adjustment to the carrying value of the assets held for sale.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate their fair values due to the short-term maturities.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to five years for office furniture and equipment, computer software and hardware, demonstration and loaned equipment, and 30 to 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over three years.
Research & Development Costs
Research & Development Costs
Costs incurred in research and development are charged to operations as incurred.
Income Taxes
Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements carrying value of assets and liabilities and the tax basis of those assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, we adjust the valuation allowance which reduces the provision for income taxes.
We recognize the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05. 
Foreign Currency
Foreign Currency
The functional currency of our subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. We have recorded $(1.6) million, $(14.4) million, and $21.5 million of foreign currency translation gains (losses) for the years ended December 31, 2019, 2018 and 2017, respectively.
Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2019, 2018, and 2017, net foreign currency transaction gains (losses) were $(0.8) million, $(0.8) million, and $1.0 million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. dollar, Canadian dollar, Euro, British pound, and Danish kroner.
Effective July 1, 2018, Argentina's economy is considered to be highly inflationary under U.S. GAAP since it has experienced a rate of general inflation in excess of 100% over the latest three-year period, based upon the cumulative inflation rates published by Center for Audit Quality (CAQ) SEC Regulations Committee and its International Practices Task Force (IPTF). As a result, beginning July 1, 2018, the U.S. dollar is the functional currency for our subsidiary in Argentina, Medix I.C.S.A. (“Medix”). Accordingly, all gains and losses resulting from the translation of our Argentinian operations are required to be recorded directly in the statement of operations. Through June 30, 2018, prior to being designated as highly inflationary, currency translation adjustments of Medix's balance sheet are reflected in shareholders' equity as part of Accumulated Other Comprehensive Income; however subsequent to July 1, 2018, such adjustments are reflected in earnings. Currency adjustments recorded in earnings for Medix subsequent to July 1, 2018 represented a gain of $0.9 million.
Comprehensive Income
Comprehensive Income
We report by major components and as a single total the change in net assets during the period as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income (loss) has been separately stated from the consolidated statements of operations. Accumulated other comprehensive loss consists of translation gains and losses on foreign subsidiary financial statements, interest rate swap designated as a cash flow hedge, reclassifications from the adoption of ASU 2018-02, and reclassification of previously recorded deferred foreign currency related translation adjustment losses upon the divestiture of Medix.
Basic and Diluted Net Income per Share
Basic and Diluted Net Income per Share
We compute net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted, shares of restricted stock, and shares of market stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.
Recent Accounting Pronouncements .
XML 80 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Combinations
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Business Combinations BUSINESS COMBINATIONS
The assets acquired and liabilities assumed at the date of acquisition are recorded in the Consolidated Financial Statements at the respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets is recorded as goodwill. 
The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. We determine the fair value by applying established valuation techniques, based on information that management believes to be relevant to this determination. We also utilize independent third parties to assist in the valuation of goodwill and intangible assets.
The results of operations from acquisitions are included in the Consolidated Financial Statements from the date of the acquisition.
Integra
On October 6, 2017, we acquired certain neurosurgery business assets from Integra LifeSciences (“Integra” or “Neurosurgery”) for $46.2 million in cash. As part of the acquisition, we acquired a global product line, including the manufacturing facility it leases from a third party and the U.S. rights related to four other product lines. The total purchase price has been allocated to $13.7 million of tangible assets, $25.7 million of intangible assets with an associated weighted average life of 9 years being
amortized on the straight line method, and $8.1 million of goodwill, offset by $1.3 million of net liabilities. Besides pro forma revenue, pro forma financial information for the Integra acquisition is not presented as certain Integra expense data necessary to present pro forma net income and pro forma earnings per share is not available. Pro forma revenue assuming the acquisition occurred on January 1, 2017 would be $539.1 million for the year ended December 31, 2017.
Otometrics
On January 3, 2017, we acquired the Otometrics business from GN Store Nord A/S for a cash purchase price of $149.2 million, which includes a $4.2 million net working capital adjustment. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software. Otometrics provides computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms to hearing and balance care professionals worldwide. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets.
Management worked with an independent valuation firm to determine fair values of the identifiable intangible assets. We used a combination of income approaches including relief from royalty and multi-period excess earnings methods. The valuation models were based on estimates of future operating projections of the acquired business and rights to sell products as well as judgments on the discount rates used and other variables. We determined the forecasts based on a number of factors, including our best estimate of near-term net sales expectations and long-term projections, which included a review of internal and independent market analyses.
XML 81 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Derivatives (Notes)
 12 Months Ended
Dec. 31, 2019
Derivative Instrument [Abstract]  
Financial Instruments and Derivatives FINANCIAL INSTRUMENTS AND DERIVATIVES
We use interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of our expected LIBOR-indexed floating-rate borrowings. We held the following interest rate swaps as of December 31, 2019 (in thousands):


Hedged Item
Current Notional Amount
Designation Date
Effective Date
Termination Date
Fixed Interest Rate
Floating Rate
Estimated Fair Value
1-month USD LIBOR loan
$
40,000

May 31, 2018
June 1, 2018
September 23, 2021
2.611%
1-month USD LIBOR
$
313

Total interest rate derivatives designated as cash flow hedge
$
40,000

 
 
 
 
 
$
313



We designated these derivative instruments as cash flow hedges. We assess the effectiveness of these derivative instruments and record the changes in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income, net of tax. Once the hedged item affects earnings, the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, we will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.

As of December 31, 2019, we expect that approximately $143 thousand of losses associated with the cash flow hedge, net of tax, could be reclassified from AOCI into earnings within the next twelve months.
XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 238 537 1 false 75 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.natus.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.natus.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.natus.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Consolidated Statement of Comprehensive Income (Loss) Sheet http://www.natus.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidatedStatementOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Consolidated Statement of Comprehensive Income (Loss) Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.natus.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Business Combinations Sheet http://www.natus.com/role/BusinessCombinations Business Combinations Notes 8 false false R9.htm 2101100 - Disclosure - Organization and Significant Accounting Policies Sheet http://www.natus.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Revenue (Notes) Notes http://www.natus.com/role/RevenueNotes Revenue (Notes) Notes 10 false false R11.htm 2104100 - Disclosure - Inventories Sheet http://www.natus.com/role/Inventories Inventories Notes 11 false false R12.htm 2105100 - Disclosure - Property and Equipment Sheet http://www.natus.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 2106100 - Disclosure - Intangible Assets Sheet http://www.natus.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 2107100 - Disclosure - Goodwill Sheet http://www.natus.com/role/Goodwill Goodwill Notes 14 false false R15.htm 2108100 - Disclosure - Leases (Notes) Notes http://www.natus.com/role/LeasesNotes Leases (Notes) Notes 15 false false R16.htm 2109100 - Disclosure - Accrued Liabilities Sheet http://www.natus.com/role/AccruedLiabilities Accrued Liabilities Notes 16 false false R17.htm 2111100 - Disclosure - Long-Term Other Liabilities Sheet http://www.natus.com/role/LongTermOtherLiabilities Long-Term Other Liabilities Notes 17 false false R18.htm 2112100 - Disclosure - Debt and Credit Arrangements Sheet http://www.natus.com/role/DebtAndCreditArrangements Debt and Credit Arrangements Notes 18 false false R19.htm 2114100 - Disclosure - Financial Instruments and Derivatives (Notes) Notes http://www.natus.com/role/FinancialInstrumentsAndDerivativesNotes Financial Instruments and Derivatives (Notes) Notes 19 false false R20.htm 2115100 - Disclosure - Reserve for Product Warranties Sheet http://www.natus.com/role/ReserveForProductWarranties Reserve for Product Warranties Notes 20 false false R21.htm 2116100 - Disclosure - Stockholders' Equity Sheet http://www.natus.com/role/StockholdersEquity Stockholders' Equity Notes 21 false false R22.htm 2117100 - Disclosure - Earnings Per Share Sheet http://www.natus.com/role/EarningsPerShare Earnings Per Share Notes 22 false false R23.htm 2118100 - Disclosure - Share-Based Compensation Sheet http://www.natus.com/role/ShareBasedCompensation Share-Based Compensation Notes 23 false false R24.htm 2120100 - Disclosure - Other Income (Expense), Net Sheet http://www.natus.com/role/OtherIncomeExpenseNet Other Income (Expense), Net Notes 24 false false R25.htm 2121100 - Disclosure - Income Taxes Sheet http://www.natus.com/role/IncomeTaxes Income Taxes Notes 25 false false R26.htm 2123100 - Disclosure - Employee Benefit Plan Sheet http://www.natus.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 26 false false R27.htm 2123100 - Disclosure - Segment, Customer and Geographic Information Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformation Segment, Customer and Geographic Information Notes 27 false false R28.htm 2125100 - Disclosure - Commitments And Contingencies Sheet http://www.natus.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 28 false false R29.htm 2126100 - Disclosure - Fair Value Measurements Sheet http://www.natus.com/role/FairValueMeasurements Fair Value Measurements Notes 29 false false R30.htm 2127100 - Disclosure - Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets Sheet http://www.natus.com/role/SaleOfCertainSubsidiaryAssetsSaleOfCertainSubsidiaryAssets Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets Notes 30 false false R31.htm 2128100 - Schedule - Schedule II: Valuation And Qualifying Accounts Sheet http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II: Valuation And Qualifying Accounts Uncategorized 31 false false R32.htm 2201201 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Notes 32 false false R33.htm 2302301 - Disclosure - Revenue (Tables) Sheet http://www.natus.com/role/RevenueTables Revenue (Tables) Tables http://www.natus.com/role/RevenueNotes 33 false false R34.htm 2304301 - Disclosure - Inventories (Tables) Sheet http://www.natus.com/role/InventoriesTables Inventories (Tables) Tables http://www.natus.com/role/Inventories 34 false false R35.htm 2305301 - Disclosure - Property and Equipment (Tables) Sheet http://www.natus.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.natus.com/role/PropertyAndEquipment 35 false false R36.htm 2306301 - Disclosure - Intangible Assets (Tables) Sheet http://www.natus.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.natus.com/role/IntangibleAssets 36 false false R37.htm 2307301 - Disclosure - Goodwill (Tables) Sheet http://www.natus.com/role/GoodwillTables Goodwill (Tables) Tables http://www.natus.com/role/Goodwill 37 false false R38.htm 2308301 - Disclosure - Leases (Tables) Sheet http://www.natus.com/role/LeasesTables Leases (Tables) Tables http://www.natus.com/role/LeasesNotes 38 false false R39.htm 2309301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.natus.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.natus.com/role/AccruedLiabilities 39 false false R40.htm 2311301 - Disclosure - Long-Term Other Liabilities (Tables) Sheet http://www.natus.com/role/LongTermOtherLiabilitiesTables Long-Term Other Liabilities (Tables) Tables http://www.natus.com/role/LongTermOtherLiabilities 40 false false R41.htm 2312301 - Disclosure - Debt and Credit Arrangements (Tables) Sheet http://www.natus.com/role/DebtAndCreditArrangementsTables Debt and Credit Arrangements (Tables) Tables http://www.natus.com/role/DebtAndCreditArrangements 41 false false R42.htm 2314301 - Disclosure - Financial Instruments and Derivatives (Tables) Sheet http://www.natus.com/role/FinancialInstrumentsAndDerivativesTables Financial Instruments and Derivatives (Tables) Tables http://www.natus.com/role/FinancialInstrumentsAndDerivativesNotes 42 false false R43.htm 2317301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.natus.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.natus.com/role/EarningsPerShare 43 false false R44.htm 2318301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.natus.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.natus.com/role/ShareBasedCompensation 44 false false R45.htm 2320301 - Disclosure - Other Income (Expense), Net (Tables) Sheet http://www.natus.com/role/OtherIncomeExpenseNetTables Other Income (Expense), Net (Tables) Tables http://www.natus.com/role/OtherIncomeExpenseNet 45 false false R46.htm 2321301 - Disclosure - Income Taxes (Tables) Sheet http://www.natus.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.natus.com/role/IncomeTaxes 46 false false R47.htm 2323301 - Disclosure - Segment, Customer and Geographic Information (Tables) Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformationTables Segment, Customer and Geographic Information (Tables) Tables http://www.natus.com/role/SegmentCustomerAndGeographicInformation 47 false false R48.htm 2325301 - Disclosure - Commitments And Contingencies (Tables) Sheet http://www.natus.com/role/CommitmentsAndContingenciesTables Commitments And Contingencies (Tables) Tables http://www.natus.com/role/CommitmentsAndContingencies 48 false false R49.htm 2401401 - Disclosure - Business Combinations - Integra Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails Business Combinations - Integra Acquisition (Details) Details 49 false false R50.htm 2401402 - Disclosure - Business Combinations - Otometrics Acquisition Narrative (Details) Sheet http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails Business Combinations - Otometrics Acquisition Narrative (Details) Details 50 false false R51.htm 2401402 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details) Sheet http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails Organization and Significant Accounting Policies - Narrative (Details) Details http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 51 false false R52.htm 2401406 - Disclosure - Business Combinations - NeuroQuest Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails Business Combinations - NeuroQuest Acquisition (Details) Details 52 false false R53.htm 2402402 - Disclosure - Revenue - Narrative (Details) Sheet http://www.natus.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 53 false false R54.htm 2402403 - Disclosure - Revenue - Unbilled AR and Deferred Revenue (Details) Sheet http://www.natus.com/role/RevenueUnbilledArAndDeferredRevenueDetails Revenue - Unbilled AR and Deferred Revenue (Details) Details 54 false false R55.htm 2404402 - Disclosure - Inventories (Details) Sheet http://www.natus.com/role/InventoriesDetails Inventories (Details) Details http://www.natus.com/role/InventoriesTables 55 false false R56.htm 2404403 - Disclosure - Inventories - Narrative (Details) Sheet http://www.natus.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 56 false false R57.htm 2405402 - Disclosure - Property and Equipment (Details) Sheet http://www.natus.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.natus.com/role/PropertyAndEquipmentTables 57 false false R58.htm 2405403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.natus.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 58 false false R59.htm 2406402 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.natus.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 59 false false R60.htm 2406403 - Disclosure - Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) Sheet http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) Details 60 false false R61.htm 2406404 - Disclosure - Intangible Assets - Schedule of Amortization Expense (Details) Sheet http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails Intangible Assets - Schedule of Amortization Expense (Details) Details 61 false false R62.htm 2406405 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Details) Sheet http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails Intangible Assets - Expected Annual Amortization Expense (Details) Details 62 false false R63.htm 2407402 - Disclosure - Goodwill (Details) Sheet http://www.natus.com/role/GoodwillDetails Goodwill (Details) Details http://www.natus.com/role/GoodwillTables 63 false false R64.htm 2408402 - Disclosure - Leases - Narrative (Details) Sheet http://www.natus.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 64 false false R65.htm 2408403 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.natus.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 65 false false R66.htm 2408404 - Disclosure - Leases - Supplemental Cash Flow (Details) Sheet http://www.natus.com/role/LeasesSupplementalCashFlowDetails Leases - Supplemental Cash Flow (Details) Details 66 false false R67.htm 2408405 - Disclosure - Leases - Supplemental Balance Sheet (Details) Sheet http://www.natus.com/role/LeasesSupplementalBalanceSheetDetails Leases - Supplemental Balance Sheet (Details) Details 67 false false R68.htm 2408406 - Disclosure - Leases - Lease Maturities (Details) Sheet http://www.natus.com/role/LeasesLeaseMaturitiesDetails Leases - Lease Maturities (Details) Details 68 false false R69.htm 2409402 - Disclosure - Accrued Liabilities (Details) Sheet http://www.natus.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.natus.com/role/AccruedLiabilitiesTables 69 false false R70.htm 2411402 - Disclosure - Long-Term Other Liabilities (Details) Sheet http://www.natus.com/role/LongTermOtherLiabilitiesDetails Long-Term Other Liabilities (Details) Details http://www.natus.com/role/LongTermOtherLiabilitiesTables 70 false false R71.htm 2412402 - Disclosure - Debt and Credit Arrangements - Narrative (Details) Sheet http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails Debt and Credit Arrangements - Narrative (Details) Details 71 false false R72.htm 2412403 - Disclosure - Debt and Credit Arrangements - Schedule of Long Term Debt (Details) Sheet http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails Debt and Credit Arrangements - Schedule of Long Term Debt (Details) Details 72 false false R73.htm 2412404 - Disclosure - Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) Sheet http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) Details 73 false false R74.htm 2414402 - Disclosure - Financial Instruments and Derivatives (Details) Sheet http://www.natus.com/role/FinancialInstrumentsAndDerivativesDetails Financial Instruments and Derivatives (Details) Details http://www.natus.com/role/FinancialInstrumentsAndDerivativesTables 74 false false R75.htm 2415402 - Disclosure - Reserve for Product Warranties (Details) Sheet http://www.natus.com/role/ReserveForProductWarrantiesDetails Reserve for Product Warranties (Details) Details http://www.natus.com/role/ReserveForProductWarranties 75 false false R76.htm 2416401 - Disclosure - Stockholders' Equity (Details) Sheet http://www.natus.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.natus.com/role/StockholdersEquity 76 false false R77.htm 2417402 - Disclosure - Earnings Per Share - Components of Basic and Diluted EPS (Detail) Sheet http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail Earnings Per Share - Components of Basic and Diluted EPS (Detail) Details 77 false false R78.htm 2418402 - Disclosure - Share-Based Compensation - Share-based Compensation Expense Allocation (Details) Sheet http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails Share-Based Compensation - Share-based Compensation Expense Allocation (Details) Details 78 false false R79.htm 2418403 - Disclosure - Share-Based Compensation - Narrative (Details) Sheet http://www.natus.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation - Narrative (Details) Details 79 false false R80.htm 2418404 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) Sheet http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails Share-Based Compensation - Stock Option Activity (Details) Details 80 false false R81.htm 2418405 - Disclosure - Share-Based Compensation - Valuation Inputs (Details) Sheet http://www.natus.com/role/ShareBasedCompensationValuationInputsDetails Share-Based Compensation - Valuation Inputs (Details) Details 81 false false R82.htm 2418406 - Disclosure - Share-Based Compensation - Restricted Stock Award Activity (Details) Sheet http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails Share-Based Compensation - Restricted Stock Award Activity (Details) Details 82 false false R83.htm 2418407 - Disclosure - Share-Based Compensation - Restricted Unit Activity (Details) Sheet http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails Share-Based Compensation - Restricted Unit Activity (Details) Details 83 false false R84.htm 2420402 - Disclosure - Other Income (Expense), Net (Details) Sheet http://www.natus.com/role/OtherIncomeExpenseNetDetails Other Income (Expense), Net (Details) Details http://www.natus.com/role/OtherIncomeExpenseNetTables 84 false false R85.htm 2421402 - Disclosure - Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) Sheet http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) Details 85 false false R86.htm 2421403 - Disclosure - Income Taxes - Component of Income Tax Expense (Details) Sheet http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails Income Taxes - Component of Income Tax Expense (Details) Details 86 false false R87.htm 2421404 - Disclosure - Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) Sheet http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) Details 87 false false R88.htm 2421405 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.natus.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 88 false false R89.htm 2421406 - Disclosure - Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) Sheet http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) Details 89 false false R90.htm 2421407 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 90 false false R91.htm 2423401 - Disclosure - Employee Benefit Plan (Details) Sheet http://www.natus.com/role/EmployeeBenefitPlanDetails Employee Benefit Plan (Details) Details http://www.natus.com/role/EmployeeBenefitPlan 91 false false R92.htm 2423402 - Disclosure - Segment, Customer and Geographic Information - Narrative (Details) Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformationNarrativeDetails Segment, Customer and Geographic Information - Narrative (Details) Details 92 false false R93.htm 2423403 - Disclosure - Segment, Customer and Geographic Information (Details) Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails Segment, Customer and Geographic Information (Details) Details http://www.natus.com/role/SegmentCustomerAndGeographicInformationTables 93 false false R94.htm 2425403 - Disclosure - Commitments And Contingencies - Narrative (Details) Sheet http://www.natus.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments And Contingencies - Narrative (Details) Details 94 false false R95.htm 2426402 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.natus.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 95 false false R96.htm 2427401 - Disclosure - Sale of Certain Subsidiary (Details) Sheet http://www.natus.com/role/SaleOfCertainSubsidiaryDetails Sale of Certain Subsidiary (Details) Details http://www.natus.com/role/SaleOfCertainSubsidiaryAssetsSaleOfCertainSubsidiaryAssets 96 false false R97.htm 2428401 - Schedule - Schedule II: Valuation And Qualifying Accounts (Details) Sheet http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II: Valuation And Qualifying Accounts (Details) Details 97 false false R9999.htm Uncategorized Items - ntus12311910-k.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - ntus12311910-k.htm Cover 98 false false All Reports Book All Reports ntus12311910-k.htm exhibit211123119.htm exhibit231123119.htm exhibit311123119.htm exhibit312123119.htm exhibit321123119.htm exhibit43-descriptiono.htm ntus-20191231.xsd ntus-20191231_cal.xml ntus-20191231_def.xml ntus-20191231_lab.xml ntus-20191231_pre.xml chart-5bdaf063b6f2531ead0.jpg http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 83 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue $ 495,175 $ 530,891 $ 500,970
Cost of revenue 196,551 217,952 213,376
Intangibles amortization 6,916 8,924 6,380
Gross profit 291,708 304,015 281,214
Operating expenses:      
Marketing and selling 129,109 136,680 126,166
Research and development 58,733 61,482 51,822
General and administrative 59,649 70,599 74,424
Intangibles amortization 15,144 22,585 19,171
Restructuring 44,739 37,231 914
Total operating expenses 307,374 328,577 272,497
Income (loss) from operations (15,666) (24,562) 8,717
Other expense, net (5,591) (7,698) (3,567)
Income (loss) before provision (benefit) for income tax (21,257) (32,260) 5,150
Provision (benefit) for income tax (5,586) (9,325) 25,443
Net loss $ (15,671) $ (22,935) $ (20,293)
Net loss per share:      
Basic $ (0.47) $ (0.69) $ (0.62)
Diluted (in dollars per share) $ (0.47) $ (0.69) $ (0.62)
Weighted average shares used in the calculation of net loss per share:      
Basic (shares) 33,696 33,111 32,564
Diluted (shares) 33,696 33,111 32,564
XML 84 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Inventories INVENTORIES
Inventories consist of (in thousands): 
 
December 31,
 
2019
 
2018
Raw materials and subassemblies
$
37,259

 
$
31,459

Work in process
1,780

 
2,424

Finished goods
50,521

 
63,932

Total Inventories
89,560

 
97,815

Less: Non-current Inventories
(18,192
)
 
(18,079
)
Inventories
$
71,368

 
$
79,736


Non-current inventory consists of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products that we no longer sell, inventory purchased for lifetime buys, inventory built as a last-time build, and inventory that is turning at a slow rate. We believe that these inventories will be utilized for their intended purpose.
XML 85 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Notes)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases LEASES
We have operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to eight years, some of which include options to extend the leases for up to ten years. Our leases do not have any residual value guarantees or any restrictions or covenants imposed by leases.

Components of lease cost were as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Operating lease cost
$
6,823

Finance lease cost:
 
Amortization of right-of-use assets (principal payments)
466

Interest on lease liabilities
58

Short-term lease cost
51

Variable lease cost
2,836

Sublease income
(179
)
Total lease cost
$
10,055

Supplemental cash flow information related to leases was as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
13,612

Operating cash flows from finance leases
42

Financing cash flows from finance leases
478

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
2,697

Finance leases
300



Supplemental balance sheet information related to leases was as follows (in thousands):
 
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
15,046

 
 
Current portion of operating lease liabilities
$
5,871

Operating lease liabilities
12,051

Total operating lease liabilities
$
17,922

 
 
Finance Leases
 
Property and equipment, gross
$
2,377

Accumulated amortization
(1,418
)
Property and equipment, net
$
959

 
 
Accrued liabilities
$
390

Other liabilities
599

Total finance lease liabilities
$
989

 
 
Weighted Average Remaining Lease Term
 
Operating leases
3.75 years

Finance leases
2.92 years

Weighted Average Discount Rate
 
Operating leases
5.3
%
Finance leases
5.1
%


As of December 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
Year ending December 31,
Operating Leases
 
Finance Leases
2020
$
6,788

 
$
401

2021
5,302

 
346

2022
3,657

 
176

2023
2,498

 
97

2024
1,277

 
5

Thereafter
842

 
—

Total lease payments
20,364

 
1,025

Less imputed interest
(2,442
)
 
(36
)
Total
$
17,922

 
$
989
Leases LEASES
We have operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to eight years, some of which include options to extend the leases for up to ten years. Our leases do not have any residual value guarantees or any restrictions or covenants imposed by leases.

Components of lease cost were as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Operating lease cost
$
6,823

Finance lease cost:
 
Amortization of right-of-use assets (principal payments)
466

Interest on lease liabilities
58

Short-term lease cost
51

Variable lease cost
2,836

Sublease income
(179
)
Total lease cost
$
10,055

Supplemental cash flow information related to leases was as follows (in thousands):
 
Year Ended 
 December 31,
 
2019
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
13,612

Operating cash flows from finance leases
42

Financing cash flows from finance leases
478

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
2,697

Finance leases
300



Supplemental balance sheet information related to leases was as follows (in thousands):
 
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
15,046

 
 
Current portion of operating lease liabilities
$
5,871

Operating lease liabilities
12,051

Total operating lease liabilities
$
17,922

 
 
Finance Leases
 
Property and equipment, gross
$
2,377

Accumulated amortization
(1,418
)
Property and equipment, net
$
959

 
 
Accrued liabilities
$
390

Other liabilities
599

Total finance lease liabilities
$
989

 
 
Weighted Average Remaining Lease Term
 
Operating leases
3.75 years

Finance leases
2.92 years

Weighted Average Discount Rate
 
Operating leases
5.3
%
Finance leases
5.1
%


As of December 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
Year ending December 31,
Operating Leases
 
Finance Leases
2020
$
6,788

 
$
401

2021
5,302

 
346

2022
3,657

 
176

2023
2,498

 
97

2024
1,277

 
5

Thereafter
842

 
—

Total lease payments
20,364

 
1,025

Less imputed interest
(2,442
)
 
(36
)
Total
$
17,922

 
$
989
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Derivatives (Details)
Dec. 31, 2019
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ (143,000)
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative Liability, Notional Amount $ 40,000,000
Derivative, Fixed Interest Rate 2.611%
Derivative Liability $ 313,000
XML 87 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Other Income (Expense), Net (Details) - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Other expense, net        
Interest income   $ 250 $ 334 $ 425
Interest expense   (4,941) (6,794) (5,081)
Foreign currency gain (loss) $ 900 (765) (800) 1,013
Other   (135) (438) 76
Total other expense, net   $ (5,591) $ (7,698) $ (3,567)
XML 88 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation - Stock Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Number of Shares    
Outstanding, beginning of period (shares) 201,542  
Granted (shares)   0
Exercised (shares)   (124,303)
Cancelled (shares)   0
Expired (shares)   (3,150)
Outstanding, end of period (shares) 74,089 201,542
Weighted Average Exercise Price    
Outstanding, beginning of period (in dollars per share) $ 24.48  
Granted (in dollars per share) 0  
Exercised (in dollars per share) 18.35  
Cancelled (in dollars per share) 0  
Expired (in dollars per share) 13.35  
Outstanding, end of period (in dollars per share) $ 35.25 $ 24.48
XML 89 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Other Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Other Liabilities Disclosure [Abstract]    
Contingent tax obligations $ 12,330 $ 15,425
Non-current deferred revenue 4,563 4,338
Finance Lease, Liability, Noncurrent 599 0
Other 124 82
Total $ 17,616 $ 19,845
XML 90 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Schedule Of Income Taxes [Line Items]        
Statutory tax rate 21.00% 21.00% 35.00%  
Tax net operating loss carryforwards $ 23,700,000      
Valuation allowances 606,000 $ 637,000    
Increase in valuation allowance 31,000.0      
Deferred tax liabilities related to foreign earnings 800,000      
Increase in unrecognized tax benefits 3,300,000      
Increases for tax positions related to the current year 495,000 699,000 $ 1,712,000  
Unrecognized Tax Benefits 3,917,000 7,227,000 7,017,000 $ 5,898,000
Unrecognized tax would impact effective tax rate 3,600,000 6,500,000 4,000,000.0  
Lapse of statutes of limitations 3,763,000 965,000 1,393,000  
Interest and penalties related to uncertain tax positions 400,000 500,000 600,000  
Total Interest and penalties related to uncertain tax positions (80,000.0) $ (80,000.0) $ (10,000.0)  
Income Tax Provision [Member]        
Schedule Of Income Taxes [Line Items]        
Increases for tax positions related to the current year 3,500,000      
Minimum        
Schedule Of Income Taxes [Line Items]        
Lapse of statutes of limitations 0      
Maximum        
Schedule Of Income Taxes [Line Items]        
Lapse of statutes of limitations 2,400,000      
GERMANY        
Schedule Of Income Taxes [Line Items]        
Tax net operating loss carryforwards 100,000      
France [Member]        
Schedule Of Income Taxes [Line Items]        
Tax net operating loss carryforwards 1,000,000.0      
Canada [Member]        
Schedule Of Income Taxes [Line Items]        
Tax net operating loss carryforwards 400,000      
DENMARK        
Schedule Of Income Taxes [Line Items]        
Tax net operating loss carryforwards 400,000      
Significant foreign jurisdictions [Member]        
Schedule Of Income Taxes [Line Items]        
Tax credits carryforwards $ 100,000      
Canada [Member]        
Schedule Of Income Taxes [Line Items]        
Withholding Tax, Percent 5.00%      
Ireland [Member]        
Schedule Of Income Taxes [Line Items]        
Withholding Tax, Percent 0.00%      
United States        
Schedule Of Income Taxes [Line Items]        
Tax credits carryforwards $ 1,200,000      
Research Tax Credit Carryforward [Member]        
Schedule Of Income Taxes [Line Items]        
Tax credits carryforwards $ 600,000      
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation - Share-based Compensation Expense Allocation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total expense $ 8,315 $ 17,003 $ 9,445
Cost of revenue [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total expense 264 218 232
Marketing and sales [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total expense 800 801 540
Research and development [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total expense 1,024 1,039 1,332
General and administrative [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total expense $ 6,227 $ 14,945 $ 7,341
XML 92 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Narrative (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Liability, Current $ 20.2
Contract with Customer, Liability, Noncurrent 4.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 20.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 2.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 1.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 0.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 4 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 0.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
XML 93 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross $ 66,753 $ 62,646
Finance Lease, Right-of-Use Asset 2,377 0
Accumulated depreciation (42,051) (39,733)
Total 24,702 22,913
Land [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 1,719 1,828
Buildings [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 6,943 7,036
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 8,664 4,649
Office furniture and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 22,819 23,487
Computer software and hardware [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 12,610 12,803
Demonstration and loaned equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross $ 11,621 $ 12,843
XML 94 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
The carrying amount of goodwill and the changes in those balances are as follows (in thousands): 
As of December 31, 2017
$
172,998

Purchase Accounting Adjustments
(7,324
)
Impairment charge
(14,846
)
Foreign currency translation
(3,184
)
As of December 31, 2018
$
147,644

Foreign currency translation
(1,277
)
As of December 31, 2019
$
146,367
XML 95 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Asset and Liability [Table Text Block]
The following table summarized the changes in the contract assets and contract liability balances for the year ended December 31, 2019 (in thousands):
Unbilled AR, December 31, 2018
$
3,012

Additions
354

Transferred to Trade Receivable
(699
)
Unbilled AR, December 31, 2019
$
2,667

Deferred Revenue, December 31, 2018
$
21,410

Additions
19,465

Revenue Recognized
(16,067
)
Deferred Revenue, December 31, 2019
$
24,808
XML 96 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Label Element Value
Common Stock [Member]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised 134,102
Accounting Standards Update 2018-02 [Member] | AOCI Attributable to Parent [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (1,332,000)
XML 97 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Comprehensive Income (Loss) Consolidated Statement of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
Net loss $ (15,671) $ (22,935) $ (20,293)
Unrealized losses on available-for-sale investments 0 0 (45)
Foreign currency translation adjustment (1,576) (14,360) 21,470
Interest rate swap designated as a cash flow hedge 180 77 0
Reclassification of stranded tax effects upon adoption of ASU 2018-02 1,332 0 0
Reclassification of deferred foreign currency related adjustments related to the sale of Medix (See FN 23) (24,845) 0 0
Total other comprehensive income (loss) 21,757 (14,437) 21,425
Comprehensive income (loss) $ 6,086 $ (37,372) $ 1,132
XML 98 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue (Notes)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue REVENUE
Contract assets for the periods presented primarily represent the difference between revenue recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented was primarily related to extended service contracts, installation, and training, for which the service fees are billed up-front. The associated deferred revenue is generally recognized ratably over the extended service period or when installation and training are complete.

The following table summarized the changes in the contract assets and contract liability balances for the year ended December 31, 2019 (in thousands):
Unbilled AR, December 31, 2018
$
3,012

Additions
354

Transferred to Trade Receivable
(699
)
Unbilled AR, December 31, 2019
$
2,667

Deferred Revenue, December 31, 2018
$
21,410

Additions
19,465

Revenue Recognized
(16,067
)
Deferred Revenue, December 31, 2019
$
24,808


At December 31, 2019, the contract assets of $2.7 million were included in accounts receivable in the consolidated balance sheet. At December 31, 2019, the short-term portion of the contract liability of $20.2 million and the long-term portion of $4.6 million were included in deferred revenue and other long-term liabilities respectively, in the consolidated balance sheet. As of December 31, 2019, we expect to recognize revenue associated with deferred revenue of approximately $20.2 million in 2020, $2.2 million in 2021, $1.2 million in 2022, $0.7 million in 2023, and $0.5 million thereafter.
XML 99 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill GOODWILL
The carrying amount of goodwill and the changes in those balances are as follows (in thousands): 
As of December 31, 2017
$
172,998

Purchase Accounting Adjustments
(7,324
)
Impairment charge
(14,846
)
Foreign currency translation
(3,184
)
As of December 31, 2018
$
147,644

Foreign currency translation
(1,277
)
As of December 31, 2019
$
146,367
XML 100 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2019
Feb. 19, 2020
Jun. 30, 2019
Cover page.      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 000-33001    
Entity Registrant Name NATUS MEDICAL INC    
Entity Central Index Key 0000878526    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0154833    
Entity Address, Address Line One 6701 Koll Center Parkway, Suite 120    
Entity Address, City or Town Pleasanton    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94566    
City Area Code 925    
Local Phone Number 223-6700    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol NTUS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 874,493,509
Entity Common Stock, Shares Outstanding   34,105,116  
Documents Incorporated by Reference Certain portions of the Registrant's Definitive Proxy Statement for the 2020 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K, to be filed with the Securities and Exchange Commission, are incorporated by reference into Part III of this Annual Report on Form 10-K.    
XML 101 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Organization and Significant Accounting Policies ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
Organization
Natus Medical Incorporated (“we”, “our”, “us”) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. We are a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, software systems for managing and tracking disorders and diseases for public health laboratories, computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals.
Basis of Presentation and Principles of Consolidation
The accompanying Consolidated Financial Statements includes our accounts and accounts of our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.
Revenue recognition
Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services.
For the majority of devices and supplies, we transfer control and recognize revenue when products ship from the warehouse to the customer. We generally do not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue.
Depending on the terms of the arrangement, we may also defer the recognition of a portion of the consideration received because we have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price for each distinct performance obligation. Our estimate of SSP is a point estimate.  The estimate is calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs.
We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond the base agreements to customers. The separately priced service contracts range from 12 months to 60 months. We receive payment at the inception of the contract and recognize revenue ratably over the service period.
For products containing embedded software, we have determined that the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products.
Inventory Valuation
Inventories are carried at the lower of cost or net realizable value, with cost being determined using the first-in, first-out method. The carrying value of our inventory is reduced for any difference between cost and estimated net realizable value of the inventory. We determine net realizable value by evaluating ending inventories for excess quantities, obsolescence, and other factors that could impact our ability to consume inventory for its intended use. Our evaluation includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, we may sell inventory that had previously been written down.
Intangible assets
We amortize intangible assets with finite lives over the estimate of their useful lives. Any future changes that would limit their useful lives or any determination that these assets are carried at amounts greater than their estimated fair value could result in acceleration of amortization over a revised useful life.
We review intangible assets with finite lives for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of the finite-lived intangible assets is assessed based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the finite-lived intangible assets are considered to be impaired. The amount of the impairment loss, if any, is measured as the difference between the carrying amount of the asset and its fair value. We estimate the fair value of finite-lived intangible assets by using an income approach or, when available and appropriate, using a market approach.
Goodwill
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired.
Goodwill is tested for impairment at the reporting unit level. In 2018 and 2017 we had four reporting units for purposes of goodwill impairment testing. In early 2019 we announced the implementation of a new organizational structure which consolidated our three strategic business units, Neuro, Newborn Care and Hearing & Balance into “One Natus”. As a result of these organizational changes we have concluded we have one operating segment and one reporting unit for purposes of goodwill impairment testing in 2019.
In accordance with accounting standards we perform a qualitative assessment to test goodwill for impairment prior to the performing the first step of the goodwill impairment process. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting the reporting unit.
Prior to the adoption of ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) in 2019, which simplified the goodwill impairment test, if the fair value of a reporting unit was less than its carrying amount, we would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Based on the qualitative assessment in 2019 and 2017, we determined the fair value of goodwill was more likely than not greater than its carrying amount, and no further analysis was needed.
Due to organizational changes announced in late 2018 our evaluation of our GND reporting unit, which was part of our Neuro business unit, was determined to be impaired. Prior to calculating the goodwill impairment loss, we analyzed the recoverability of GND long-lived assets (other than goodwill). As a result, we recorded a goodwill impairment charge of $14.8 million within restructuring expense on our income statement. There was no remaining goodwill in the GND reporting unit as of December 31, 2018.
In 2019 we elected to early adopt ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The adoption of this standard eliminates the second step of the two-step impairment test described above and allows a Company to expense the difference between carrying amount in excess of the fair value of the reporting unit as a reduction in goodwill. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements as we concluded based on the qualitative assessment performed in 2019 that the fair value of the reporting unit was more likely than not to be greater than its carrying amount, and no further analysis was needed.
Leases
We determine if an arrangement is a lease at inception of the lease. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the
lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit borrowing rate, generally we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the lease commencement date. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term.
Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet.
We have lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, we account for these components separately. For equipment leases, such as office equipment and vehicles, we account for the lease and non-lease components as a single lease component.
Long lived assets
We continually monitor events and changes in circumstances that could indicate that carrying amounts of our long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, we will assess the recoverability by determining whether the carrying value of an asset group will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of the asset group, we will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Liability for product warranties
We provide a warranty for products that is generally one year in length. In some cases, regulations may require us to provide repair or remediation beyond the typical warranty period. If any products contain defects, we may be required to incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis.
We accrue estimated product warranty costs at the time of sale based on historical experience. A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Share-based compensation
We recognize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 16 of the Consolidated Financial Statements.
For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.
We recognize share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 25% on each of the annual anniversaries. RSAs and RSUs for non-employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
We grant market stock unit (“MSU”) awards to certain employees. We estimate the fair value of MSUs at the date of grant using a Monte Carlo simulation model and amortize those fair values over the requisite service period, which is generally three years. The Monte Carlo simulation model that we use to estimate the fair value of market-based MSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the market-based MSUs, which is determined at the date of grant, must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.
We issue new shares of common stock upon the exercise of stock options and the vesting of RSAs, RSUs, and MSUs.
Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.
Cash Equivalents
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents.
Allowance for Doubtful Accounts
We estimate the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which we operate and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.
Assets and Liabilities Held for Sale
We consider assets and liabilities to be held for sale when all of the following criteria are met:
•Management approves and commits to a formal plan to sell the asset or disposal group;
•The assets or disposal group is available for immediate sale in its present condition;
•An active program to locate a buyer and other actions required to complete the sale have been initiated;
•The sale of the asset or disposal group is expected to be completed within one year;
•The asset or disposal group is being actively marketed for sale at the price that is reasonable in relation to the current fair value; and
•It is unlikely that significant changes will be made to the plan.
Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, we record the asset or disposal group at the lower of its carrying value or its estimated fair value, less estimated costs of sale. We consider deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on our income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. We assess the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and report any reduction in fair value as an adjustment to the carrying value of the assets held for sale.
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate their fair values due to the short-term maturities.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to five years for office furniture and equipment, computer software and hardware, demonstration and loaned equipment, and 30 to 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over three years.
Research & Development Costs
Costs incurred in research and development are charged to operations as incurred.
Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements carrying value of assets and liabilities and the tax basis of those assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, we adjust the valuation allowance which reduces the provision for income taxes.
We recognize the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05. 
Foreign Currency
The functional currency of our subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. We have recorded $(1.6) million, $(14.4) million, and $21.5 million of foreign currency translation gains (losses) for the years ended December 31, 2019, 2018 and 2017, respectively.
Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2019, 2018, and 2017, net foreign currency transaction gains (losses) were $(0.8) million, $(0.8) million, and $1.0 million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. dollar, Canadian dollar, Euro, British pound, and Danish kroner.
Effective July 1, 2018, Argentina's economy is considered to be highly inflationary under U.S. GAAP since it has experienced a rate of general inflation in excess of 100% over the latest three-year period, based upon the cumulative inflation rates published by Center for Audit Quality (CAQ) SEC Regulations Committee and its International Practices Task Force (IPTF). As a result, beginning July 1, 2018, the U.S. dollar is the functional currency for our subsidiary in Argentina, Medix I.C.S.A. (“Medix”). Accordingly, all gains and losses resulting from the translation of our Argentinian operations are required to be recorded directly in the statement of operations. Through June 30, 2018, prior to being designated as highly inflationary, currency translation adjustments of Medix's balance sheet are reflected in shareholders' equity as part of Accumulated Other Comprehensive Income; however subsequent to July 1, 2018, such adjustments are reflected in earnings. Currency adjustments recorded in earnings for Medix subsequent to July 1, 2018 represented a gain of $0.9 million.
We divested our wholly owned subsidiary, Medix, on April 2, 2019 via a stock sale. Included in the year ended December 31, 2019 is the impact of the sale of Medix, which was completed as of June 30, 2019, and the deferred foreign currency related translation adjustments previously in accumulated other comprehensive income have been released from the balance sheet along with the held for sale accrual (See Note 23 - Sale of a Certain Subsidiary).
Comprehensive Income
We report by major components and as a single total the change in net assets during the period as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income (loss) has been separately stated from the consolidated statements of operations. Accumulated other comprehensive loss consists of translation gains and losses on foreign subsidiary financial statements, interest rate swap designated as a cash flow hedge, reclassifications from the adoption of ASU 2018-02, and reclassification of previously recorded deferred foreign currency related translation adjustment losses upon the divestiture of Medix.
Basic and Diluted Net Income per Share
We compute net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted, shares of restricted stock, and shares of market stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires lease assets and lease liabilities arising from operating leases to be presented in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees and lessors to meet the objective of enabling users of financial statements to
assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. In July 2018, FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance issued in the amendments in Update 2016-02. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements. The amendments in ASU 2018-11 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02.
The new standard provides a number of optional practical expedients in transition. We have elected the package of practical expedients, which permits an entity to not reassess prior conclusions about lease identification, lease classification and initial direct costs under the new standard. We have not elected the use-of-hindsight practical expedient or the practical expedient pertaining to land easements; the latter of which is not applicable to us. We made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term.
The new standard became effective for us on January 1, 2019. We adopted the new standard using the modified retrospective transition method with the effective date as the date of initial application. Upon adoption, we recognized additional new lease assets of approximately $19.5 million and additional lease liabilities of approximately $22.3 million as of January 1, 2019. The standard did not materially affect consolidated net earnings. By electing the effective date as the date of initial application, financial performance has not been adjusted and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019. See Significant Accounting Policies and Note 8 for additional discussion and disclosure.
The adoption of the new standard did not impact our liquidity or debt-covenant compliance under its current agreements.
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for our annual and any interim goodwill impairment tests performed on or after January 1, 2020. We elected to early adopt. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements.
In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220). This update permits a company to reclassify its disproportionate income tax effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) on items within accumulated other comprehensive income (“AOCI”) to retained earnings (termed “stranded tax effects”). Only the stranded tax effects resulting from the 2017 Act are eligible for reclassification. The ASU was effective for us on January 1, 2019. Upon adoption, we reclassified its stranded tax effects resulting from the 2017 Act of $1.3 million, resulting in a decrease to AOCI and an increase to retained earnings as of January 1, 2019.
XML 102 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt and Credit Arrangements
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Debt and Credit Arrangements DEBT AND CREDIT ARRANGEMENTS
We have a Credit Agreement with JP Morgan, Citibank and Wells Fargo. The Credit Agreement provides for an aggregate $150 million of secured revolving credit facility. In the third quarter of 2017, we exercised the right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of our assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have no other significant credit facilities.
In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require us to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:
•Leverage Ratio, as defined, to be no higher than 2.75 to 1.00.
•Interest Coverage Ratio, as defined, to be at least 1.75 to 1.00 at all times.
As of December 31, 2019, we were in compliance with the Leverage Ratio and the Interest Coverage Ratio covenants as defined in the Credit Agreement.
As of December 31, 2019, we have $55 million outstanding under the Credit Agreement.
Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on the leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between 1.75% to 2.75%. The effective interest rate during the twelve months ended December 31, 2019 was 4.54%.
The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable.

Long-term debt consists of (in thousands):
 
December 31,
 
2019
 
2018
Revolving credit facility
$
55,000

 
$
105,000

Debt issuance costs
(335
)
 
(526
)
Less: current portion of long-term debt
35,000

 
35,000

Total long-term debt
$
19,665

 
$
69,474


Maturities of long-term debt as of December 31, 2019 are as follows (in thousands):
 
December 31,
 
2019
 
2018
2019
$
—

 
$
—

2020
—

 
—

2021
55,000

 
105,000

Thereafter
—

 
—

Total
$
55,000

 
$
105,000


As of December 31, 2019, the carrying value of the total debt approximated fair market value.
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Federal statutory tax expense $ (4,464) $ (6,775) $ 1,802
State tax expense (300) (1,160) (318)
Foreign taxes at rates less than U.S. rates (2,205) (1,071) (3,101)
Deferred charges on sales of U.S. intellectual property 0 0 980
Equity compensation 824 519 606
Tax credits (1,428) (2,021) (1,498)
Uncertain tax position 2,910 1,311 2,048
Lapse of statute (3,961) (1,214) (1,521)
Change of valuation allowance on foreign tax credit 0 0 314
Earnout adjustment 0 0 (190)
Repatriation tax net of foreign tax credits 172 0 16,564
Net deferred tax asset re-measurement 0 0 3,883
Withholding taxes 0 658 726
Withholding taxes 1,107 1,185 2,880
Global intangible low-taxed income net of foreign tax credits 1,601 2,326 0
Return to provision 560 (1,417) 711
AMT on acquisition 0 0 621
SAB 118 adjustments 0 (2,676) 0
Other (402) 1,010 936
Total expense (benefit) $ (5,586) $ (9,325) $ 25,443
XML 104 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares available for future awards 2,764,603    
Unrecognized compensation expense related to unvested portion of stock options $ 500,000    
Intrinsic value of options exercised $ 1,400,000 $ 13,600,000 $ 3,100,000
Weighted average vested options 70,990    
Weighted average exercise price of vested stock $ 35.25    
Weighted average remaining contractual term 4 years 6 months    
Weighted average exercise price (in dollars per share) $ 35.25    
Intrinsic value of options exercisable $ 0.0    
Weighted average remaining contractual term, exercisable 4 years 6 months    
Weighted average period of recognition of unrecognized compensation expense 2 years 8 months 12 days    
Compensation expense associated with the ESPP $ 200,000 300,000 300,000
Share-based Payment Arrangement, Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share based compensation, expiration period 10 years    
Share based compensation, vesting period 4 years    
Intrinsic value of options vested and expected to vest $ 0.0    
Restricted Stock Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Fair value, vested in period 4,700,000 12,900,000 12,700,000
Intrinsic value of options vested and expected to vest $ 4,000,000.0 $ 11,200,000 $ 14,300,000
Weighted average shares exercisable 18,531    
Unrecognized compensation of unvested awards $ 6,400,000    
Weighted average period of recognition of unrecognized compensation expense 2 years 3 months 18 days    
Fair market value of outstanding awards $ 11,200,000    
Granted, Weighted - average grant date fair value $ 31.53 $ 37.22 $ 34.94
Restricted Stock Units [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Fair value, vested in period $ 1,400,000 $ 10,000.0 $ 1,200,000
Intrinsic value of options vested and expected to vest 1,300,000 $ 8,700 $ 1,300,000
Unrecognized compensation of unvested awards $ 3,700,000    
Weighted average period of recognition of unrecognized compensation expense 2 years    
Granted, Weighted - average grant date fair value $ 38.62 $ 36.77 $ 35.16
Aggregate intrinsic value of outstanding restricted stock units $ 5,700,000    
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Employee maximum withholding rate (percent) 15.00%    
Eligible compensation of employees $ 10,625    
Purchase price for shares acquired 85.00%    
Shares reserved for future issuance 499,431    
Offering price, percentage of fair market value 85.00%    
Director [Member] | Share-based Payment Arrangement, Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share based compensation, expiration period 6 years    
Share based compensation, vesting period 4 years    
XML 105 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Reserve for Product Warranties (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
Product Warranties Disclosures [Abstract]  
Product warranty period 1 year
Product reserve warranty $ 6.4
XML 106 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
U.S. $ (22,851) $ (54,370) $ (18,059)
Foreign 1,594 22,110 23,209
Income (loss) before provision (benefit) for income tax $ (21,257) $ (32,260) $ 5,150
XML 107 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation - Valuation Inputs (Details)
 12 Months Ended
Dec. 31, 2018
$ / shares
Share-based Payment Arrangement [Abstract]  
Weighted-average fair value of options granted $ 11.03
Expected life in years 4 years
Risk-free interest rate 2.70%
Expected volatility 35.00%
Dividend yield 0.00%
XML 108 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt and Credit Arrangements - Narrative (Details)
 3 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Revolving credit facility [Member] | Line of Credit [Member]      
Debt Instrument [Line Items]      
Revolving credit facility with Wells Fargo Bank     $ 150,000,000
Available amount under credit facility   $ 55,000,000  
Credit Agreement [Member] | Citibank, National Association [Member]      
Debt Instrument [Line Items]      
Revolving credit facility with Wells Fargo Bank $ 225,000,000.0    
Line of Credit Facility, Increase (Decrease), Net $ 75,000,000.0    
Debt Instrument, Interest Rate, Effective Percentage   4.54%  
Maximum | Credit Agreement [Member] | Citibank, National Association [Member]      
Debt Instrument [Line Items]      
Ratio of Indebtedness to Net Capital   2.75  
Minimum | Credit Agreement [Member] | Citibank, National Association [Member]      
Debt Instrument [Line Items]      
Ratio of Interest Coverage   1.75  
London Interbank Offered Rate (LIBOR) [Member] | Maximum | Credit Agreement [Member] | Citibank, National Association [Member]      
Debt Instrument [Line Items]      
Debt Instrument, Basis Spread on Variable Rate   2.75%  
London Interbank Offered Rate (LIBOR) [Member] | Minimum | Credit Agreement [Member] | Citibank, National Association [Member]      
Debt Instrument [Line Items]      
Debt Instrument, Basis Spread on Variable Rate   1.75%  
XML 109 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Combinations - NeuroQuest Acquisition (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]      
Goodwill $ 146,367 $ 147,644 $ 172,998
XML 110 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Inventory Disclosure [Abstract]    
Non-current Inventories $ 18,192 $ 18,079
XML 111 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 261,788 $ 278,027
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (9,455) (13,259)
Accumulated Amortization (137,534) (125,315)
Total expected amortization expense 114,799 139,453
Technology [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 108,400 111,198
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (6,035) (6,768)
Accumulated Amortization (55,408) (50,046)
Total expected amortization expense 46,957 54,384
Customer related [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 90,351 99,440
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (50) (1,961)
Accumulated Amortization (40,527) (38,574)
Total expected amortization expense 49,774 58,905
Trade Names [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 45,874 47,217
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (3,237) (4,397)
Accumulated Amortization (25,355) (19,250)
Total expected amortization expense 17,282 23,570
Internally Developed Software [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 13,281 16,264
Impairment of Intangible Assets Defined Lived (excluding Goodwill) 0 0
Accumulated Amortization (12,606) (14,164)
Total expected amortization expense 675 2,100
Patents [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,692 2,718
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (133) (133)
Accumulated Amortization (2,559) (2,524)
Total expected amortization expense 0 61
Service Agreements [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 1,190 1,190
Impairment of Intangible Assets Defined Lived (excluding Goodwill) 0 0
Accumulated Amortization (1,079) (757)
Total expected amortization expense $ 111 $ 433
XML 112 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning-Unrecognized Tax Benefits $ 7,227 $ 7,017 $ 5,898
Decreases for tax positions related to prior years (48) (526) (747)
Increases for tax positions related to the current year 495 699 1,712
Lapse of statutes of limitations (3,763) (965) (1,393)
Foreign exchange difference 6   53
Foreign exchange difference   (50)  
Ending-Unrecognized Tax Benefits $ 3,917 $ 7,227 $ 7,017
XML 113 R94.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments And Contingencies - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Purchase commitments for inventory, total $ 45.0
XML 114 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Narrative (Details)
Dec. 31, 2019
Operating Leased Assets [Line Items]  
Remaining lease term 3 years 9 months
Lease renewal term 10 years
Minimum  
Operating Leased Assets [Line Items]  
Remaining lease term 1 year
Maximum  
Operating Leased Assets [Line Items]  
Remaining lease term 8 years
XML 115 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Lease Maturities (Details)
$ in Thousands
Dec. 31, 2019
USD ($)
Operating Leases  
2020 $ 6,788
2021 5,302
2022 3,657
2023 2,498
2024 1,277
Thereafter 842
Total lease payments 20,364
Less imputed interest (2,442)
Total 17,922
Finance Leases  
2020 401
2021 346
2022 176
2023 97
2024 5
Thereafter 0
Total lease payments 1,025
Less imputed interest (36)
Total $ 989
XML 116 ntus12311910-k_htm.xml IDEA: XBRL DOCUMENT 0000878526 2019-01-01 2019-12-31 0000878526 2018-01-01 2018-12-31 0000878526 2020-02-19 0000878526 2019-06-30 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2019-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000878526 us-gaap:WarrantyReservesMember 2018-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2016-12-31 0000878526 us-gaap:WarrantyReservesMember 2019-01-01 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2017-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000878526 us-gaap:WarrantyReservesMember 2017-01-01 2017-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000878526 us-gaap:WarrantyReservesMember 2018-01-01 2018-12-31 0000878526 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000878526 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000878526 2018-12-31 0000878526 2019-12-31 0000878526 2017-01-01 2017-12-31 0000878526 us-gaap:CommonStockMember 2017-12-31 0000878526 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000878526 2019-01-01 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000878526 us-gaap:RetainedEarningsMember 2019-12-31 0000878526 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 2018-12-31 0000878526 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000878526 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000878526 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0000878526 us-gaap:CommonStockMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000878526 2016-12-31 0000878526 us-gaap:RetainedEarningsMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000878526 us-gaap:RetainedEarningsMember 2018-12-31 0000878526 us-gaap:CommonStockMember 2019-12-31 0000878526 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 0000878526 us-gaap:CommonStockMember 2018-12-31 0000878526 us-gaap:RetainedEarningsMember 2017-12-31 0000878526 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2019-01-01 0000878526 2017-12-31 0000878526 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000878526 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000878526 srt:MaximumMember us-gaap:BuildingMember 2019-01-01 2019-12-31 0000878526 srt:MinimumMember us-gaap:BuildingMember 2019-01-01 2019-12-31 0000878526 srt:MinimumMember 2019-01-01 2019-12-31 0000878526 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000878526 srt:MaximumMember 2019-01-01 2019-12-31 0000878526 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000878526 srt:DirectorMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000878526 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000878526 2018-07-01 2018-12-31 0000878526 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000878526 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000878526 ntus:EmployeesMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000878526 ntus:IntegraMember 2017-10-06 0000878526 ntus:IntegraMember 2017-01-01 2017-12-31 0000878526 ntus:IntegraMember 2017-10-06 2017-10-06 0000878526 ntus:OtometricsMember 2017-01-03 2017-01-03 0000878526 us-gaap:UnbilledRevenuesMember 2019-12-31 0000878526 2022-01-01 2019-12-31 0000878526 2021-01-01 2019-12-31 0000878526 2020-01-01 2019-12-31 0000878526 2019-01-01 2019-12-31 0000878526 2023-01-01 2019-12-31 0000878526 us-gaap:UnbilledRevenuesMember 2019-01-01 2019-12-31 0000878526 us-gaap:UnbilledRevenuesMember 2018-12-31 0000878526 us-gaap:ComputerEquipmentMember 2018-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2018-12-31 0000878526 ntus:DemonstrationAndLoanedEquipmentMember 2018-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000878526 ntus:DemonstrationAndLoanedEquipmentMember 2019-12-31 0000878526 us-gaap:LandMember 2019-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2019-12-31 0000878526 us-gaap:LandMember 2018-12-31 0000878526 us-gaap:BuildingMember 2018-12-31 0000878526 us-gaap:ComputerEquipmentMember 2019-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000878526 us-gaap:BuildingMember 2019-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000878526 us-gaap:CoreMember 2018-01-01 2018-12-31 0000878526 us-gaap:PatentsMember 2019-01-01 2019-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000878526 us-gaap:ServiceAgreementsMember 2019-01-01 2019-12-31 0000878526 us-gaap:NonCoreMember 2018-01-01 2018-12-31 0000878526 2018-10-01 2018-12-31 0000878526 us-gaap:TradeNamesMember 2019-01-01 2019-12-31 0000878526 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2019-01-01 2019-12-31 0000878526 us-gaap:ServiceAgreementsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000878526 us-gaap:ServiceAgreementsMember 2018-01-01 2018-12-31 0000878526 us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000878526 us-gaap:PatentsMember 2018-01-01 2018-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2017-01-01 2017-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2018-01-01 2018-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000878526 us-gaap:PatentsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000878526 us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2018-12-31 0000878526 us-gaap:PatentsMember 2019-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2019-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2019-12-31 0000878526 us-gaap:ServiceAgreementsMember 2019-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2018-12-31 0000878526 us-gaap:TradeNamesMember 2019-12-31 0000878526 us-gaap:TradeNamesMember 2018-12-31 0000878526 us-gaap:ServiceAgreementsMember 2018-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000878526 us-gaap:PatentsMember 2018-12-31 0000878526 srt:MaximumMember 2019-12-31 0000878526 srt:MinimumMember 2019-12-31 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-12-31 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2017-07-01 2017-09-30 0000878526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000878526 srt:MinimumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-12-31 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2017-09-30 0000878526 srt:MaximumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0000878526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-12-31 0000878526 srt:MinimumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0000878526 srt:MaximumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-12-31 0000878526 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-12-31 0000878526 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000878526 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000878526 us-gaap:EmployeeStockMember 2019-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000878526 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000878526 us-gaap:EmployeeStockOptionMember 2019-12-31 0000878526 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000878526 us-gaap:RestrictedStockMember 2017-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000878526 us-gaap:RestrictedStockMember 2018-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000878526 country:DE 2019-12-31 0000878526 country:FR 2019-12-31 0000878526 us-gaap:ResearchMember 2019-12-31 0000878526 country:IE 2019-01-01 2019-12-31 0000878526 us-gaap:ForeignCountryMember 2019-12-31 0000878526 country:CA 2019-01-01 2019-12-31 0000878526 ntus:IncomeTaxProvisionMember 2019-01-01 2019-12-31 0000878526 country:DK 2019-12-31 0000878526 country:US 2019-12-31 0000878526 country:CA 2019-12-31 0000878526 ntus:ForeignCountriesMember 2019-12-31 0000878526 country:IE 2019-12-31 0000878526 country:AR 2019-12-31 0000878526 ntus:ForeignCountriesMember 2018-12-31 0000878526 country:US 2019-12-31 0000878526 country:CA 2018-12-31 0000878526 country:DK 2018-12-31 0000878526 country:AR 2018-12-31 0000878526 country:IE 2018-12-31 0000878526 country:US 2018-12-31 0000878526 ntus:ServicesMember ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 us-gaap:NonUsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 ntus:ServicesMember ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:ServicesMember ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 ntus:SuppliesMember ntus:OtometricsProductsMember 2018-01-01 2018-12-31 0000878526 ntus:SuppliesMember ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 us-gaap:NonUsMember 2017-01-01 2017-12-31 0000878526 country:US 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:NeurologyProductsMember 2018-01-01 2018-12-31 0000878526 ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:OtometricsProductsMember 2019-01-01 2019-12-31 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 us-gaap:NonUsMember 2019-01-01 2019-12-31 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 ntus:SuppliesMember ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 ntus:SuppliesMember ntus:NeurologyProductsMember 2019-01-01 2019-12-31 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2018-01-01 2018-12-31 0000878526 country:US 2018-01-01 2018-12-31 0000878526 country:US 2017-01-01 2017-12-31 0000878526 ntus:SuppliesMember ntus:NewbornCareProductsMember 2019-01-01 2019-12-31 0000878526 ntus:SuppliesMember ntus:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 ntus:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-01-01 2019-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2018-12-31 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-04-02 2019-04-02 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-08-02 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-04-02 pure iso4217:USD iso4217:USD shares shares ntus:Segment false --12-31 FY 2019 0000878526 6960000 7384000 0.001 120000000 33804379 34148700 33804379 34148700 P1Y 0.001 10000000 0 0 0 0 P3Y P1Y P2Y P3Y P4Y P3Y P1Y P4Y P4Y P10Y 10-K true 2019-12-31 false 000-33001 NATUS MEDICAL INC DE 77-0154833 6701 Koll Center Parkway, Suite 120 Pleasanton CA 94566 925 223-6700 Common Stock, $0.001 par value per share NTUS NASDAQ Yes No Yes Yes Large Accelerated Filer false false false 874493509 34105116 Certain portions of the Registrant's Definitive Proxy Statement for the 2020 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K, to be filed with the Securities and Exchange Commission, are incorporated by reference into Part III of this Annual Report on Form 10-K. <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the years ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at<br/>Beginning<br/>of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions<br/>Charged to<br/>Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance<br/>at End<br/>of Period</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,960</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,384</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warranty reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,936</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Year ended December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,441</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,960</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warranty reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,091</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Year ended December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,221</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,706</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warranty reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,045</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6960000 1584000 1160000 7384000 637000 0 31000 606000 9391000 3949000 6936000 6404000 8978000 6423000 8441000 6960000 5862000 0 5225000 637000 10995000 4487000 6091000 9391000 4182000 10017000 5221000 8978000 3706000 2156000 0 5862000 10670000 5370000 5045000 10995000 63297000 56373000 115889000 127041000 71368000 79736000 19195000 22625000 269749000 285775000 24702000 22913000 15046000 0 114799000 139453000 146367000 147644000 30355000 22639000 21509000 19716000 622527000 638140000 27253000 28805000 35000000 35000000 5871000 0 54451000 52568000 20246000 17073000 142821000 133446000 17616000 19845000 19665000 69474000 12051000 0 14251000 16931000 206404000 239696000 344476000 334215000 0 0 87922000 102261000 -16275000 -38032000 416123000 398444000 622527000 638140000 495175000 530891000 500970000 196551000 217952000 213376000 6916000 8924000 6380000 291708000 304015000 281214000 129109000 136680000 126166000 58733000 61482000 51822000 59649000 70599000 74424000 15144000 22585000 19171000 44739000 37231000 914000 307374000 328577000 272497000 -15666000 -24562000 8717000 -5591000 -7698000 -3567000 -21257000 -32260000 5150000 -5586000 -9325000 25443000 -15671000 -22935000 -20293000 -0.47 -0.69 -0.62 -0.47 -0.69 -0.62 33696000 33111000 32564000 33696000 33111000 32564000 -15671000 -22935000 -20293000 0 0 -45000 -1576000 -14360000 21470000 180000 77000 0 1332000 0 0 -24845000 0 0 21757000 -14437000 21425000 6086000 -37372000 1132000 32920246 312986000 149408000 -45020000 417374000 35929 0 249366 0 48470 1581000 1581000 9445000 9445000 60800 2268000 2268000 193212 7052000 7052000 134102 1885000 1885000 21425000 21425000 -20293000 -20293000 33134101 316577000 129115000 -23595000 422097000 -3919000 -3919000 266 0 272941 0 63649 1700000 1700000 17003000 17003000 173545 5630000 5630000 160700 5183000 5183000 667667 9748000 9748000 -14437000 -14437000 -22935000 -22935000 33804379 334215000 102261000 -38032000 398444000 1332000 -1332000 0 42130 0 175833 0 53839 1354000 1354000 0 8315000 8315000 51784 1689000 1689000 124303 2281000 2281000 23089000 23089000 -15671000 -15671000 34148700 344476000 87922000 -16275000 416123000 -15671000 -22935000 -20293000 1584000 6909000 10017000 30722000 33863000 30098000 -449000 -746000 21000 0 8192000 1674000 24571000 0 0 0 14846000 0 2886000 2168000 5370000 8352000 17051000 9445000 5364000 13714000 -4032000 -9817000 5199000 30473000 -7185000 7443000 -7581000 2486000 5118000 -5492000 -1367000 4105000 -1385000 -4010000 -2527000 5421000 3392000 2076000 -7232000 60060000 33020000 19726000 0 -151000 190888000 5326000 7875000 4066000 13000 665000 0 0 0 34019000 -5339000 -8389000 -160935000 3635000 11448000 3466000 478000 0 0 0 5630000 2268000 1689000 5183000 7052000 0 0 60000000 0 0 354000 0 -147000 -2966000 50000000 50000000 45000000 -48532000 -49512000 5826000 735000 -7696000 10782000 6924000 -32577000 -124601000 56373000 88950000 213551000 63297000 56373000 88950000 4580000 6169000 4464000 6445000 9247000 5740000 69000 167000 148000 300000 1211000 1006000 ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natus Medical Incorporated (“we”, “our”, “us”) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. We are a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, software systems for managing and tracking disorders and diseases for public health laboratories, computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Consolidated Financial Statements includes our accounts and accounts of our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the majority of devices and supplies, we transfer control and recognize revenue when products ship from the warehouse to the customer. We generally do not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depending on the terms of the arrangement, we may also defer the recognition of a portion of the consideration received because we have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price for each distinct performance obligation. Our estimate of SSP is a point estimate.  The estimate is calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond the base agreements to customers. The separately priced service contracts range from </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> months to </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> months. We receive payment at the inception of the contract and recognize revenue ratably over the service period. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For products containing embedded software, we have determined that the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory Valuation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are carried at the lower of cost or net realizable value, with cost being determined using the first-in, first-out method. The carrying value of our inventory is reduced for any difference between cost and estimated net realizable value of the inventory. We determine net realizable value by evaluating ending inventories for excess quantities, obsolescence, and other factors that could impact our ability to consume inventory for its intended use. Our evaluation includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, we may sell inventory that had previously been written down.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible assets</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We amortize intangible assets with finite lives over the estimate of their useful lives. Any future changes that would limit their useful lives or any determination that these assets are carried at amounts greater than their estimated fair value could result in acceleration of amortization over a revised useful life.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review intangible assets with finite lives for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of the finite-lived intangible assets is assessed based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the finite-lived intangible assets are considered to be impaired. The amount of the impairment loss, if any, is measured as the difference between the carrying amount of the asset and its fair value. We estimate the fair value of finite-lived intangible assets by using an income approach or, when available and appropriate, using a market approach. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is tested for impairment at the reporting unit level. In 2018 and 2017 we had four reporting units for purposes of goodwill impairment testing. In early 2019 we announced the implementation of a new organizational structure which consolidated our three strategic business units, Neuro, Newborn Care and Hearing &amp; Balance into “One Natus”. As a result of these organizational changes we have concluded we have one operating segment and one reporting unit for purposes of goodwill impairment testing in 2019.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with accounting standards we perform a qualitative assessment to test goodwill for impairment prior to the performing the first step of the goodwill impairment process. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting the reporting unit. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) in 2019, which simplified the goodwill impairment test, if the fair value of a reporting unit was less than its carrying amount, we would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the qualitative assessment in 2019 and 2017, we determined the fair value of goodwill was more likely than not greater than its carrying amount, and no further analysis was needed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to organizational changes announced in late 2018 our evaluation of our GND reporting unit, which was part of our Neuro business unit, was determined to be impaired. Prior to calculating the goodwill impairment loss, we analyzed the recoverability of GND long-lived assets (other than goodwill). As a result, we recorded a goodwill impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> within restructuring expense on our income statement. There was no remaining goodwill in the GND reporting unit as of December 31, 2018. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019 we elected to early adopt ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The adoption of this standard eliminates the second step of the two-step impairment test described above and allows a Company to expense the difference between carrying amount in excess of the fair value of the reporting unit as a reduction in goodwill. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements as we concluded based on the qualitative assessment performed in 2019 that the fair value of the reporting unit was more likely than not to be greater than its carrying amount, and no further analysis was needed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement is a lease at inception of the lease. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit borrowing rate, generally we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the lease commencement date. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, we account for these components separately. For equipment leases, such as office equipment and vehicles, we account for the lease and non-lease components as a single lease component.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long lived assets</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continually monitor events and changes in circumstances that could indicate that carrying amounts of our long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, we will assess the recoverability by determining whether the carrying value of an asset group will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of the asset group, we will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability for product warranties</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide a warranty for products that is generally one year in length. In some cases, regulations may require us to provide repair or remediation beyond the typical warranty period. If any products contain defects, we may be required to incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue estimated product warranty costs at the time of sale based on historical experience. A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-based compensation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year vesting period and </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;">-year contractual term pursuant to ASC Topic 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</span><span style="font-family:inherit;font-size:10pt;">. See Note 16 of the Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period for employees. RSAs and RSUs for executives vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year period; </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> on each of the annual anniversaries. RSAs and RSUs for non-employees (Board of Directors) vest over a </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year period; </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We grant market stock unit (“MSU”) awards to certain employees. We estimate the fair value of MSUs at the date of grant using a Monte Carlo simulation model and amortize those fair values over the requisite service period, which is generally three years. The Monte Carlo simulation model that we use to estimate the fair value of market-based MSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the market-based MSUs, which is determined at the date of grant, must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We issue new shares of common stock upon the exercise of stock options and the vesting of RSAs, RSUs, and MSUs.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for Doubtful Accounts</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which we operate and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets and Liabilities Held for Sale</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consider assets and liabilities to be held for sale when all of the following criteria are met:</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">Management approves and commits to a formal plan to sell the asset or disposal group;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">The assets or disposal group is available for immediate sale in its present condition;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">An active program to locate a buyer and other actions required to complete the sale have been initiated;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">The sale of the asset or disposal group is expected to be completed within one year;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">The asset or disposal group is being actively marketed for sale at the price that is reasonable in relation to the current fair value; and</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">It is unlikely that significant changes will be made to the plan. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, we record the asset or disposal group at the lower of its carrying value or its estimated fair value, less estimated costs of sale. We consider deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on our income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. We assess the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and report any reduction in fair value as an adjustment to the carrying value of the assets held for sale. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate their fair values due to the short-term maturities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> for office furniture and equipment, computer software and hardware, demonstration and loaned equipment, and </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>40 years</span></span><span style="font-family:inherit;font-size:10pt;"> for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over </span><span style="font-family:inherit;font-size:10pt;">three years</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research &amp; Development Costs</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs incurred in research and development are charged to operations as incurred. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements carrying value of assets and liabilities and the tax basis of those assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, we adjust the valuation allowance which reduces the provision for income taxes.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05.</span><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of our subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. We have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$(1.6) million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$(14.4) million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of foreign currency translation gains (losses) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, net foreign currency transaction gains (losses) were </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.8)</span></span><span style="font-family:inherit;font-size:10pt;"> million, </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.8)</span></span><span style="font-family:inherit;font-size:10pt;"> million, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. dollar, Canadian dollar, Euro, British pound, and Danish kroner.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective July 1, 2018, Argentina's economy is considered to be highly inflationary under U.S. GAAP since it has experienced a rate of general inflation in excess of 100% over the latest three-year period, based upon the cumulative inflation rates published by Center for Audit Quality (CAQ) SEC Regulations Committee and its International Practices Task Force (IPTF). As a result, beginning July 1, 2018, the U.S. dollar is the functional currency for our subsidiary in Argentina, Medix I.C.S.A. (“Medix”). Accordingly, all gains and losses resulting from the translation of our Argentinian operations are required to be recorded directly in the statement of operations. Through June 30, 2018, prior to being designated as highly inflationary, currency translation adjustments of Medix's balance sheet are reflected in shareholders' equity as part of Accumulated Other Comprehensive Income; however subsequent to July 1, 2018, such adjustments are reflected in earnings. Currency adjustments recorded in earnings for Medix subsequent to July 1, 2018 represented a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We divested our wholly owned subsidiary, Medix, on April 2, 2019 via a stock sale. Included in the year ended December 31, 2019 is the impact of the sale of Medix, which was completed as of June 30, 2019, and the deferred foreign currency related translation adjustments previously in accumulated other comprehensive income have been released from the balance sheet along with the held for sale accrual (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">See Note 23 - Sale of a Certain Subsidiary).</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Income</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We report by major components and as a single total the change in net assets during the period as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income (loss) has been separately stated from the consolidated statements of operations. Accumulated other comprehensive loss consists of translation gains and losses on foreign subsidiary financial statements, interest rate swap designated as a cash flow hedge, reclassifications from the adoption of ASU 2018-02, and reclassification of previously recorded deferred foreign currency related translation adjustment losses upon the divestiture of Medix.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Net Income per Share</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted, shares of restricted stock, and shares of market stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires lease assets and lease liabilities arising from operating leases to be presented in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees and lessors to meet the objective of enabling users of financial statements to </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. In July 2018, FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance issued in the amendments in Update 2016-02. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements. The amendments in ASU 2018-11 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard provides a number of optional practical expedients in transition. We have elected the package of practical expedients, which permits an entity to not reassess prior conclusions about lease identification, lease classification and initial direct costs under the new standard. We have not elected the use-of-hindsight practical expedient or the practical expedient pertaining to land easements; the latter of which is not applicable to us. We made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard became effective for us on January 1, 2019. We adopted the new standard using the modified retrospective transition method with the effective date as the date of initial application. Upon adoption, we recognized additional new lease assets of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$19.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and additional lease liabilities of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of January 1, 2019. The standard did not materially affect consolidated net earnings. By electing the effective date as the date of initial application, financial performance has not been adjusted and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019. See Significant Accounting Policies and Note 8 for additional discussion and disclosure.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adoption of the new standard did not impact our liquidity or debt-covenant compliance under its current agreements.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for our annual and any interim goodwill impairment tests performed on or after January 1, 2020. We elected to early adopt. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220). This update permits a company to reclassify its disproportionate income tax effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) on items within accumulated other comprehensive income (“AOCI”) to retained earnings (termed “stranded tax effects”). Only the stranded tax effects resulting from the 2017 Act are eligible for reclassification. The ASU was effective for us on January 1, 2019. Upon adoption, we reclassified its stranded tax effects resulting from the 2017 Act of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, resulting in a decrease to AOCI and an increase to retained earnings as of January 1, 2019.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Consolidated Financial Statements includes our accounts and accounts of our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation. </span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the majority of devices and supplies, we transfer control and recognize revenue when products ship from the warehouse to the customer. We generally do not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depending on the terms of the arrangement, we may also defer the recognition of a portion of the consideration received because we have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price for each distinct performance obligation. Our estimate of SSP is a point estimate.  The estimate is calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond the base agreements to customers. The separately priced service contracts range from </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> months to </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> months. We receive payment at the inception of the contract and recognize revenue ratably over the service period. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For products containing embedded software, we have determined that the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products. </span></div> P12M P60M Inventory <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is tested for impairment at the reporting unit level. In 2018 and 2017 we had four reporting units for purposes of goodwill impairment testing. In early 2019 we announced the implementation of a new organizational structure which consolidated our three strategic business units, Neuro, Newborn Care and Hearing &amp; Balance into “One Natus”. As a result of these organizational changes we have concluded we have one operating segment and one reporting unit for purposes of goodwill impairment testing in 2019.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with accounting standards we perform a qualitative assessment to test goodwill for impairment prior to the performing the first step of the goodwill impairment process. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting the reporting unit. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) in 2019, which simplified the goodwill impairment test, if the fair value of a reporting unit was less than its carrying amount, we would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the qualitative assessment in 2019 and 2017, we determined the fair value of goodwill was more likely than not greater than its carrying amount, and no further analysis was needed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to organizational changes announced in late 2018 our evaluation of our GND reporting unit, which was part of our Neuro business unit, was determined to be impaired. Prior to calculating the goodwill impairment loss, we analyzed the recoverability of GND long-lived assets (other than goodwill). As a result, we recorded a goodwill impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> within restructuring expense on our income statement. There was no remaining goodwill in the GND reporting unit as of December 31, 2018. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019 we elected to early adopt ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The adoption of this standard eliminates the second step of the two-step impairment test described above and allows a Company to expense the difference between carrying amount in excess of the fair value of the reporting unit as a reduction in goodwill. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements as we concluded based on the qualitative assessment performed in 2019 that the fair value of the reporting unit was more likely than not to be greater than its carrying amount, and no further analysis was needed.</span></div> 14800000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement is a lease at inception of the lease. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit borrowing rate, generally we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the lease commencement date. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, we account for these components separately. For equipment leases, such as office equipment and vehicles, we account for the lease and non-lease components as a single lease component.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long lived assets</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continually monitor events and changes in circumstances that could indicate that carrying amounts of our long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, we will assess the recoverability by determining whether the carrying value of an asset group will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of the asset group, we will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability for product warranties</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide a warranty for products that is generally one year in length. In some cases, regulations may require us to provide repair or remediation beyond the typical warranty period. If any products contain defects, we may be required to incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue estimated product warranty costs at the time of sale based on historical experience. A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.</span></div> <div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-based compensation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year vesting period and </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;">-year contractual term pursuant to ASC Topic 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</span><span style="font-family:inherit;font-size:10pt;">. See Note 16 of the Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period for employees. RSAs and RSUs for executives vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year period; </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> on each of the annual anniversaries. RSAs and RSUs for non-employees (Board of Directors) vest over a </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year period; </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We grant market stock unit (“MSU”) awards to certain employees. We estimate the fair value of MSUs at the date of grant using a Monte Carlo simulation model and amortize those fair values over the requisite service period, which is generally three years. The Monte Carlo simulation model that we use to estimate the fair value of market-based MSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the market-based MSUs, which is determined at the date of grant, must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We issue new shares of common stock upon the exercise of stock options and the vesting of RSAs, RSUs, and MSUs.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.</span></div> 0.25 1 <div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. </span></div> <div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. </span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for Doubtful Accounts</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which we operate and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets and Liabilities Held for Sale</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consider assets and liabilities to be held for sale when all of the following criteria are met:</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">Management approves and commits to a formal plan to sell the asset or disposal group;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">The assets or disposal group is available for immediate sale in its present condition;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">An active program to locate a buyer and other actions required to complete the sale have been initiated;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">The sale of the asset or disposal group is expected to be completed within one year;</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">The asset or disposal group is being actively marketed for sale at the price that is reasonable in relation to the current fair value; and</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">It is unlikely that significant changes will be made to the plan. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, we record the asset or disposal group at the lower of its carrying value or its estimated fair value, less estimated costs of sale. We consider deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on our income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. We assess the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and report any reduction in fair value as an adjustment to the carrying value of the assets held for sale. </span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate their fair values due to the short-term maturities.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</span></div><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> for office furniture and equipment, computer software and hardware, demonstration and loaned equipment, and </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>40 years</span></span><span style="font-family:inherit;font-size:10pt;"> for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over </span><span style="font-family:inherit;font-size:10pt;">three years</span>. P5Y P30Y P40Y <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research &amp; Development Costs</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs incurred in research and development are charged to operations as incurred. </span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements carrying value of assets and liabilities and the tax basis of those assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, we adjust the valuation allowance which reduces the provision for income taxes.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05.</span><span style="font-family:inherit;font-size:8pt;"> </span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of our subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. We have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$(1.6) million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$(14.4) million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of foreign currency translation gains (losses) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, net foreign currency transaction gains (losses) were </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.8)</span></span><span style="font-family:inherit;font-size:10pt;"> million, </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.8)</span></span><span style="font-family:inherit;font-size:10pt;"> million, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. dollar, Canadian dollar, Euro, British pound, and Danish kroner.</span></div><span style="font-family:inherit;font-size:10pt;">Effective July 1, 2018, Argentina's economy is considered to be highly inflationary under U.S. GAAP since it has experienced a rate of general inflation in excess of 100% over the latest three-year period, based upon the cumulative inflation rates published by Center for Audit Quality (CAQ) SEC Regulations Committee and its International Practices Task Force (IPTF). As a result, beginning July 1, 2018, the U.S. dollar is the functional currency for our subsidiary in Argentina, Medix I.C.S.A. (“Medix”). Accordingly, all gains and losses resulting from the translation of our Argentinian operations are required to be recorded directly in the statement of operations. Through June 30, 2018, prior to being designated as highly inflationary, currency translation adjustments of Medix's balance sheet are reflected in shareholders' equity as part of Accumulated Other Comprehensive Income; however subsequent to July 1, 2018, such adjustments are reflected in earnings. Currency adjustments recorded in earnings for Medix subsequent to July 1, 2018 represented a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span>. -1600000 -14400000 21500000 -800000 -800000 1000000.0 900000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Income</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We report by major components and as a single total the change in net assets during the period as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income (loss) has been separately stated from the consolidated statements of operations. Accumulated other comprehensive loss consists of translation gains and losses on foreign subsidiary financial statements, interest rate swap designated as a cash flow hedge, reclassifications from the adoption of ASU 2018-02, and reclassification of previously recorded deferred foreign currency related translation adjustment losses upon the divestiture of Medix.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Net Income per Share</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted, shares of restricted stock, and shares of market stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.</span></div> 19500000 22300000 1300000 . BUSINESS COMBINATIONS<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The assets acquired and liabilities assumed at the date of acquisition are recorded in the Consolidated Financial Statements at the respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets is recorded as goodwill.</span><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. We determine the fair value by applying established valuation techniques, based on information that management believes to be relevant to this determination. We also utilize independent third parties to assist in the valuation of goodwill and intangible assets.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations from acquisitions are included in the Consolidated Financial Statements from the date of the acquisition.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Integra</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 6, 2017, we acquired certain neurosurgery business assets from Integra LifeSciences (“Integra” or “Neurosurgery”) for </span><span style="font-family:inherit;font-size:10pt;"><span>$46.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash. As part of the acquisition, we acquired a global product line, including the manufacturing facility it leases from a third party and the U.S. rights related to four other product lines. The total purchase price has been allocated to </span><span style="font-family:inherit;font-size:10pt;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of tangible assets, </span><span style="font-family:inherit;font-size:10pt;"><span>$25.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of intangible assets with an associated weighted average life of </span><span style="font-family:inherit;font-size:10pt;"><span>9</span></span><span style="font-family:inherit;font-size:10pt;"> years being </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amortized on the straight line method, and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill, offset by </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net liabilities. Besides pro forma revenue, pro forma financial information for the Integra acquisition is not presented as certain Integra expense data necessary to present pro forma net income and pro forma earnings per share is not available. Pro forma revenue assuming the acquisition occurred on January 1, 2017 would be </span><span style="font-family:inherit;font-size:10pt;"><span>$539.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2017. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Otometrics</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 3, 2017, we acquired the Otometrics business from GN Store Nord A/S for a cash purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$149.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> net working capital adjustment. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software. Otometrics provides computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms to hearing and balance care professionals worldwide. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets. </span></div>Management worked with an independent valuation firm to determine fair values of the identifiable intangible assets. We used a combination of income approaches including relief from royalty and multi-period excess earnings methods. The valuation models were based on estimates of future operating projections of the acquired business and rights to sell products as well as judgments on the discount rates used and other variables. We determined the forecasts based on a number of factors, including our best estimate of near-term net sales expectations and long-term projections, which included a review of internal and independent market analyses. 46200000 13700000 25700000 P9Y 8100000 1300000 539100000 149200000 4200000 REVENUE<div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Contract assets for the periods presented primarily represent the difference between revenue recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented was primarily related to extended service contracts, installation, and training, for which the service fees are billed up-front. The associated deferred revenue is generally recognized ratably over the extended service period or when installation and training are complete.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the changes in the contract assets and contract liability balances for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unbilled AR, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,012</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Transferred to Trade Receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unbilled AR, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred Revenue, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21,410</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenue Recognized</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(16,067</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred Revenue, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the contract assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> were included in accounts receivable in the consolidated balance sheet. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the short-term portion of the contract liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the long-term portion of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> were included in deferred revenue and other long-term liabilities respectively, in the consolidated balance sheet. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we expect to recognize revenue associated with deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$20.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2021, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2022, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2023, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span> thereafter. <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the changes in the contract assets and contract liability balances for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unbilled AR, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,012</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Transferred to Trade Receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unbilled AR, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred Revenue, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21,410</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenue Recognized</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(16,067</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred Revenue, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3012000 354000 699000 2667000 21410000 19465000 16067000 24808000 2700000 20200000 4600000 20200000 2200000 1200000 700000 500000 INVENTORIES<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and subassemblies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,259</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,932</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,560</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,815</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Non-current Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,368</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Non-current inventory consists of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products that we no longer sell, inventory purchased for lifetime buys, inventory built as a last-time build, and inventory that is turning at a slow rate. We believe that these inventories will be utilized for their intended purpose. <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and subassemblies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,259</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,932</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,560</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,815</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Non-current Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,368</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 37259000 31459000 1780000 2424000 50521000 63932000 89560000 97815000 18192000 18079000 71368000 79736000 PROPERTY AND EQUIPMENT<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,943</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Office furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software and hardware</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,610</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,803</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Demonstration and loaned equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,646</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense of property and equipment was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the years ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,943</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Office furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software and hardware</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,610</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,803</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Demonstration and loaned equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,646</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1719000 1828000 6943000 7036000 8664000 4649000 2377000 0 22819000 23487000 12610000 12803000 11621000 12843000 66753000 62646000 42051000 39733000 24702000 22913000 6600000 6000000.0 4100000 INTANGIBLE ASSETS<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the components of gross and net intangible asset balances (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"/></tr><tr><td style="width:13%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br/>Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br/>Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>108,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,035</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(55,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>46,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>111,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(50,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>54,384</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Customer related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>90,351</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(40,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>49,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>99,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,961</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(38,574</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>58,905</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>45,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(3,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(25,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>17,282</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>47,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(19,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>23,570</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Internally developed software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>13,281</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(12,606</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>16,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(14,164</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Service Agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,190</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,190</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(757</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>433</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Definite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>261,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(9,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(137,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>114,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>278,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(13,259</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(125,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>139,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite lived intangible assets are amortized over their weighted average lives, which are </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> years for technology, </span><span style="font-family:inherit;font-size:10pt;"><span>13</span></span><span style="font-family:inherit;font-size:10pt;"> years for patents, </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years for customer-related intangibles, </span><span style="font-family:inherit;font-size:10pt;"><span>7</span></span><span style="font-family:inherit;font-size:10pt;"> years for trade names, </span><span style="font-family:inherit;font-size:10pt;"><span>6</span></span><span style="font-family:inherit;font-size:10pt;"> years for internally developed software, </span><span style="font-family:inherit;font-size:10pt;"><span>2</span></span><span style="font-family:inherit;font-size:10pt;"> years for service agreements, and </span><span style="font-family:inherit;font-size:10pt;"><span>11</span></span><span style="font-family:inherit;font-size:10pt;"> years weighted average in total. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internally developed software consists of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to costs incurred for development of internal use computer software and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for development of software to be sold.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018 we recorded an impairment charge related to intangible assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. These impairments relate to end of life decisions for the core technology utilized in our Bio-logic products and our GND and Neurocom product lines. We acquired Bio-logic core technology as part of the acquisition of Bio-logic Systems Corp in 2006 and have maintained the technology since its acquisition. In 2018 we partnered with one of our contract manufacturers to develop and manufacture the next generation technology to be used in its Bio-logic products. The decision to develop this new technology resulted in an impairment of the originally acquired core technology of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded within intangibles amortization expense on our income statement.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 15, 2019, we announced the implementation of a new organizational structure, "One Natus." As a result of this new organizational structure, we announced we exited two of our non-core businesses, GND and Neurocom. The decision to exit these non-core businesses resulted in the impairment of intangible assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018. These impairments were the result of deterioration of expected future cash flows as compared to the carrying value of the assets. Impairments were determined by performing an undiscounted cash flow analysis on intangibles assets. The impairment charge for GND and Neurocom is recorded on our income statement within restructuring expense. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense related to intangible assets with finite lives, including impairment charges described above, was as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,705</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internally developed software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service Agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>757</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,499</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amortization expense amounts shown above include internally developed software not held for sale of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The amortization expense for internally developed software not held for sale is recorded within our income statement as a general and administrative operating expense. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:0px;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,272</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total expected amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the components of gross and net intangible asset balances (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"/></tr><tr><td style="width:13%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br/>Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br/>Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>108,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,035</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(55,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>46,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>111,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(50,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>54,384</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Customer related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>90,351</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(40,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>49,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>99,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,961</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(38,574</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>58,905</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>45,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(3,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(25,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>17,282</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>47,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(19,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>23,570</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Internally developed software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>13,281</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(12,606</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>16,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(14,164</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Service Agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,190</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,190</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(757</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>433</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Definite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>261,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(9,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(137,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>114,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>278,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(13,259</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(125,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>139,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 108400000 6035000 55408000 46957000 111198000 6768000 50046000 54384000 90351000 50000 40527000 49774000 99440000 1961000 38574000 58905000 45874000 3237000 25355000 17282000 47217000 4397000 19250000 23570000 13281000 0 12606000 675000 16264000 0 14164000 2100000 2692000 133000 2559000 0 2718000 133000 2524000 61000 1190000 0 1079000 111000 1190000 0 757000 433000 261788000 9455000 137534000 114799000 278027000 13259000 125315000 139453000 P14Y P13Y P10Y P7Y P6Y P2Y P11Y 11100000 2200000 8200000 5600000 2600000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense related to intangible assets with finite lives, including impairment charges described above, was as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,705</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internally developed software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service Agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>757</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,499</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6906000 14100000 7705000 8662000 12244000 10945000 6111000 6736000 6479000 1438000 2123000 2117000 60000 84000 244000 322000 757000 0 23499000 36044000 27490000 1300000 1900000 1900000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:0px;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,272</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total expected amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 21616000 20724000 17329000 16375000 14483000 24272000 114799000 GOODWILL<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of goodwill and the changes in those balances are as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase Accounting Adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,324</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment charge</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,277</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of goodwill and the changes in those balances are as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase Accounting Adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,324</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment charge</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,277</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 172998000 -7324000 14846000 -3184000 147644000 -1277000 146367000 LEASES<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to </span><span style="font-family:inherit;font-size:10pt;"><span>eight years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. Our leases do not have any residual value guarantees or any restrictions or covenants imposed by leases. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of lease cost were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended <br/> December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of right-of-use assets (principal payments)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.7578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended <br/> December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,697</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>959</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.75 years</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.92 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31, </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> LEASES<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to </span><span style="font-family:inherit;font-size:10pt;"><span>eight years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. Our leases do not have any residual value guarantees or any restrictions or covenants imposed by leases. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of lease cost were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended <br/> December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of right-of-use assets (principal payments)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.7578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended <br/> December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,697</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>959</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.75 years</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.92 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31, </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P8Y P10Y <div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of lease cost were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended <br/> December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of right-of-use assets (principal payments)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.7578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended <br/> December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,697</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6823000 466000 58000 51000 2836000 179000 10055000 13612000 42000 478000 2697000 300000 <div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>959</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.75 years</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.92 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 15046000 5871000 12051000 17922000 2377000 1418000 959000 390000 599000 989000 P3Y9M P2Y11M1D 0.053 0.051 <div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31, </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31, </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6788000 401000 5302000 346000 3657000 176000 2498000 97000 1277000 5000 842000 0 20364000 1025000 2442000 36000 17922000 989000 ACCRUED LIABILITIES<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and related benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warranty reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued federal, state, and local taxes</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued amounts due to customers</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued selling expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Self-funded insurance expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued travel</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,022</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and related benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warranty reserve</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued federal, state, and local taxes</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued amounts due to customers</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued selling expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Self-funded insurance expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued travel</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,022</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 26991000 24891000 6404000 9391000 11156000 8285000 3008000 5507000 2083000 1820000 507000 246000 950000 0 224000 201000 0 205000 3128000 2022000 54451000 52568000 LONG-TERM OTHER LIABILITIES<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term other liabilities consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,563</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term other liabilities consist of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,563</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 12330000 15425000 4563000 4338000 599000 0 124000 82000 17616000 19845000 DEBT AND CREDIT ARRANGEMENTS<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a Credit Agreement with JP Morgan, Citibank and Wells Fargo. The Credit Agreement provides for an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> of secured revolving credit facility. In the third quarter of 2017, we exercised the right to increase the amount available under the facility by </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, bringing the aggregate revolving credit facility to </span><span style="font-family:inherit;font-size:10pt;"><span>$225.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Credit Agreement contains covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of our assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have no other significant credit facilities. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require us to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">Leverage Ratio, as defined, to be no higher than </span><span style="font-family:inherit;font-size:10pt;text-transform:default;"><span>2.75</span></span><span style="font-family:inherit;font-size:10pt;"> to 1.00.</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><span style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">•</span><span style="font-family:inherit;font-size:10pt;">Interest Coverage Ratio, as defined, to be at least </span><span style="font-family:inherit;font-size:10pt;text-transform:default;"><span>1.75</span></span><span style="font-family:inherit;font-size:10pt;"> to 1.00 at all times.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we were in compliance with the Leverage Ratio and the Interest Coverage Ratio covenants as defined in the Credit Agreement.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have </span><span style="font-family:inherit;font-size:10pt;"><span>$55 million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under the Credit Agreement. </span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on the leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>2.75%</span></span><span style="font-family:inherit;font-size:10pt;">. The effective interest rate during the twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>4.54%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consists of (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving credit facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(335</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(526</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less: current portion of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of long-term debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span>, the carrying value of the total debt approximated fair market value. 150000000 75000000.0 225000000.0 2.75 1.75 55000000 0.0175 0.0275 0.0454 <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consists of (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving credit facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(335</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(526</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less: current portion of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 55000000 105000000 335000 526000 35000000 35000000 19665000 69474000 <div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of long-term debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 0 0 55000000 105000000 0 0 55000000 105000000 FINANCIAL INSTRUMENTS AND DERIVATIVES<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">We use interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of our expected LIBOR-indexed floating-rate borrowings. We held the following interest rate swaps as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:10%;"/><td style="width:12%;"/><td style="width:11%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Hedged Item</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Current Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Designation Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fixed Interest Rate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Floating Rate</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1-month USD LIBOR loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">May 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">September 23, 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.611%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1-month USD LIBOR</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total interest rate derivatives designated as cash flow hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We designated these derivative instruments as cash flow hedges. We assess the effectiveness of these derivative instruments and record the changes in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income, net of tax. Once the hedged item affects earnings, the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, we will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we expect that approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$143 thousand</span></span> of losses associated with the cash flow hedge, net of tax, could be reclassified from AOCI into earnings within the next twelve months. held the following interest rate swaps as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:10%;"/><td style="width:12%;"/><td style="width:11%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Hedged Item</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Current Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Designation Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fixed Interest Rate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Floating Rate</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1-month USD LIBOR loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">May 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">September 23, 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.611%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1-month USD LIBOR</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total interest rate derivatives designated as cash flow hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 40000000 0.02611 -313000 40000000 -313000 -143000 RESERVE FOR PRODUCT WARRANTIES<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide a warranty for products that is generally </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> in length and in some cases, regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, we may be required to </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incur additional repair and remediation costs. Service, repair and calibration services are provided by a combination of our owned facilities and vendors on a contract basis. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management's best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have accrued </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for product related warranties. The estimates we use in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations.</span></div> P1Y 6400000 STOCKHOLDERS’ EQUITY<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</span><span style="font-family:inherit;font-size:10pt;">—We have </span><span style="font-family:inherit;font-size:10pt;"><span>120,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock authorized at a par value or </span><span style="font-family:inherit;font-size:10pt;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> per share.</span><span style="font-family:inherit;font-size:8pt;"> </span></div><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</span><span style="font-family:inherit;font-size:10pt;">—We have </span><span style="font-family:inherit;font-size:10pt;"><span>10,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock authorized at a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span>, no shares of preferred stock were issued and outstanding. 120000000 0.001 10000000 0.001 EARNINGS PER SHARE<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of basic and diluted EPS are as follows (in thousands, except per share amounts):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive effect of stock based awards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted Shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares excluded from calculation of diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of basic and diluted EPS are as follows (in thousands, except per share amounts):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive effect of stock based awards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted Shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares excluded from calculation of diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -15671000 -22935000 -20293000 33696000 33111000 32564000 0 0 0 33696000 33111000 32564000 -0.47 -0.69 -0.62 -0.47 -0.69 -0.62 104000 343000 565000 SHARE-BASED COMPENSATION<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation Expense</span><span style="font-family:inherit;font-size:10pt;">—We account for share-based compensation in accordance with ASC Topic 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Stock Compensation</span><span style="font-family:inherit;font-size:10pt;">. Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketing and selling</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,945</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,445</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Awards Plans</span><span style="font-family:inherit;font-size:10pt;">—Natus' 2018 Stock Awards Plan (the “Plan”) provides for the granting of the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incentive stock options to employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-statutory stock options to employees, directors and consultants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock awards and restricted stock units;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Market stock units;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock bonuses; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>2,764,603</span></span><span style="font-family:inherit;font-size:10pt;"> shares available for future awards under the plan.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than </span><span style="font-family:inherit;font-size:10pt;"><span>six years</span></span><span style="font-family:inherit;font-size:10pt;"> after the date of grant. Most options vest ratably over </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Activity</span><span style="font-family:inherit;font-size:10pt;">—Stock option activity under the stock awards plans for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is summarized as follows: </span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018 (127,453 shares exercisable at a weighted average exercise price of $18.22 per share)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(124,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2019 (18,531 shares exercisable at a weighted average exercise price of $35.25 per share)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, unrecognized compensation related to the unvested portion of stock options was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span><span style="font-family:inherit;font-size:10pt;"> years. The intrinsic value of options exercised, representing the difference between the closing stock price of common stock on the date of the exercise and the exercise price, in the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were: (i) </span><span style="font-family:inherit;font-size:10pt;"><span>70,990</span></span><span style="font-family:inherit;font-size:10pt;"> options vested and expected to vest with a weighted average exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$35.25</span></span><span style="font-family:inherit;font-size:10pt;">, an intrinsic value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and a weighted average remaining contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span><span style="font-family:inherit;font-size:10pt;"> years; and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>18,531</span></span><span style="font-family:inherit;font-size:10pt;"> options exercisable with a weighted average exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$35.25</span></span><span style="font-family:inherit;font-size:10pt;">, an intrinsic value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and a weighted average remaining contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Black-Scholes Inputs</span><span style="font-family:inherit;font-size:10pt;">—The fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.00584795321637%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life in years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>None</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not grant any stock options during the years ended December 31, 2019 and December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected life of options is based primarily on historical share option exercise experience of the employees for options granted. All options are treated as a single group in the determination of expected life, as we do not currently expect substantially different exercise or post-vesting termination behavior among the employee population. The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based primarily on historical volatility data of our common stock. We have no history or expectation of paying dividends on common stock.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, we estimate the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated we will record additional expense and if the actual forfeiture is higher than estimated we will record a recovery of prior expense.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards Activity</span><span style="font-family:inherit;font-size:10pt;">—The following table summarizes the activity for restricted stock awards during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293,588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, unrecognized compensation related to the unvested portion of stock awards was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span><span style="font-family:inherit;font-size:10pt;"> years. The fair market value of outstanding restricted stock awards at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. For the restricted stock awards granted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the weighted average grant date fair values were </span><span style="font-family:inherit;font-size:10pt;"><span>$31.53</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$37.22</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$34.94</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total grant date fair value of restricted stock awards vested during fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the restricted stock awards that vested during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the total intrinsic value was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Units Activity</span><span style="font-family:inherit;font-size:10pt;">—The following table summarizes restricted stock units activity for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*Includes the MSUs granted at the valuation date, which may be subject to additional awards or forfeitures depending on the outcome of the performance measures at the end of the performance period. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, unrecognized compensation related to the unvested portion of stock units was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span><span style="font-family:inherit;font-size:10pt;"> years. The aggregate intrinsic value of outstanding restricted stock units at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. For the restricted stock units granted during the years </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the weighted average grant date fair values were </span><span style="font-family:inherit;font-size:10pt;"><span>$38.62</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$36.77</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$35.16</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total grant date fair value of restricted stock units vested during fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the restricted stock units that vested during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the total intrinsic value was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$8.7 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Stock Purchase Plan</span><span style="font-family:inherit;font-size:10pt;">—Under Natus' 2011 Employee Stock Purchase Plan (the “ESPP”), U.S. employees can elect to have salary withholdings of up to </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible compensation to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>$10,625</span></span><span style="font-family:inherit;font-size:10pt;"> per offering period, to purchase shares of common stock on April 30 and October 31 of each year. The purchase price for shares acquired under the ESPP is </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value on the last day of the offering period. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>499,431</span></span><span style="font-family:inherit;font-size:10pt;"> shares reserved for future issuance under the ESPP. </span></div><span style="font-family:inherit;font-size:10pt;">Because the ESPP does not have a “look back” feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of common stock on the last day of the offering period and the purchase price for the offering period, which is </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value. Compensation expense associated with the ESPP for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span> Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):<div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketing and selling</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,945</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,445</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 264000 218000 232000 800000 801000 540000 1024000 1039000 1332000 6227000 14945000 7341000 8315000 17003000 9445000 2764603 P6Y P4Y <div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Activity</span><span style="font-family:inherit;font-size:10pt;">—Stock option activity under the stock awards plans for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is summarized as follows: </span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018 (127,453 shares exercisable at a weighted average exercise price of $18.22 per share)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(124,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2019 (18,531 shares exercisable at a weighted average exercise price of $35.25 per share)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 201542 24.48 0 0 124303 18.35 0 0 3150 13.35 74089 35.25 500000 P2Y8M12D 1400000 13600000 3100000 70990 35.25 0.0 P4Y6M 18531 35.25 0.0 P4Y6M The fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:<div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.00584795321637%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life in years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>None</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11.03 P4Y 0.027 0.35 0 The following table summarizes the activity for restricted stock awards during the year ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293,588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 293588 37.04 197333 31.53 129659 36.46 21500 35.76 339762 34.14 6400000 P2Y3M18D 11200000 31.53 37.22 34.94 4700000 12900000 12700000 4000000.0 11200000 14300000 The following table summarizes restricted stock units activity for the year ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*Includes the MSUs granted at the valuation date, which may be subject to additional awards or forfeitures depending on the outcome of the performance measures at the end of the performance period. </span></div> 112805 36.80 118740 38.62 42130 34.11 16319 37.60 173096 38.62 3700000 P2Y 5700000 38.62 36.77 35.16 1400000 10000.0 1200000 1300000 8700 1300000 0.15 10625 0.85 499431 0.85 200000 300000 300000 OTHER INCOME (EXPENSE), NET<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net consists of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,941</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,794</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,081</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(765</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,567</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net consists of (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,941</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,794</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,081</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(765</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,567</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 250000 334000 425000 4941000 6794000 5081000 -765000 -800000 1013000 -135000 -438000 76000 -5591000 -7698000 -3567000 INCOME TAXES<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) before provision for income tax is as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(54,370</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,059</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,594</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) before provision for income tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of income tax expense (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(948</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,872</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. State and local</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. State and local</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(816</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,751</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,333</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,522</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals deductible in different periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,643</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,713</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,896</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basis difference in fixed and intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,959</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings to be repatriated</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax expense (benefit) in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively to income before taxes due to the following:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal statutory tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign taxes at rates less than U.S. rates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred charges on sales of U.S. intellectual property</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>980</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,428</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,021</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,498</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax position</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,910</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statute</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,961</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,214</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,521</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change of valuation allowance on foreign tax credit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnout adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(190</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repatriation tax net of foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax asset re-measurement</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax audits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Withholding taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global intangible low-taxed income net of foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,326</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Return to provision</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,417</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AMT on acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SAB 118 adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,676</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>936</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had U.S. state net operating loss carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which an immaterial amount will begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had U.S. federal and state R&amp;D credit carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. These R&amp;D credit carryforwards will begin to expire in 2039 and 2021, respectively. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of U.S. foreign tax credit carryforwards that can be used to offset future U.S. tax liabilities related to foreign source taxable income. The foreign tax credits will start to expire in 2022.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, certain foreign subsidiaries had deferred tax assets attributable to net operating loss carryforwards as follows: </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in France, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in Denmark, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in Canada, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in Germany. These foreign net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The decrease of </span><span style="font-family:inherit;font-size:10pt;"><span>$31.0 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> in valuation allowance was primarily due to a valuation allowance recorded against our net operating loss carryforward in Canada due to utilization in the current year. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The realizability of the deferred tax assets is primarily dependent on our ability to generate sufficient taxable income in future periods. Management weighs the aggregate effect of all positive evidence and negative evidence in determining the likelihood of realization of the deferred tax assets. The factors used by management to collect evidence included historical earnings of the applicable taxing jurisdiction, the cash refund opportunity to utilize the tax losses, and the future forecast of profitability in the jurisdiction. Weighing all the positive and negative evidence, we have recorded a valuation allowance related primarily to net operating losses in certain foreign jurisdictions and U.S. foreign tax credits where it is more likely than not that the tax benefit of the net operating losses and tax credits will not be realized. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are no changes to the position on our permanent reinvestment of earnings from foreign operations. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we intend to distribute all of the earnings from Excel-Tech and Natus Ireland in excess of their operational needs. We have recorded a deferred tax liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> accordingly for </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> Canadian withholding tax on the expected Excel-Tech distribution to Natus Ireland. Natus Ireland has </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> withholding tax under domestic exemption and therefore, no liability has been recorded. We intend on permanently reinvesting the earnings of remaining foreign subsidiaries. The other remaining foreign subsidiaries have both the intent and ability to indefinitely reinvest its undistributed earnings. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,393</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange difference</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange difference</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases for tax positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,763</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange difference</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, unrecognized tax benefits decreased by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of income tax benefit in the income tax provision were recorded. The decrease was primarily attributable to the lapse of the statute of limitations in uncertain tax positions and adjustments related to the prior years in certain jurisdictions. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrecognized tax benefits for the tax years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively which include </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively that would impact the effective tax rate if recognized.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect a range from </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized tax benefit that will impact the effective tax rate in the next </span><span style="font-family:inherit;font-size:10pt;">12 months</span><span style="font-family:inherit;font-size:10pt;"> due to the lapse of statute of limitations provided that no taxing authority conducts a new examination.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we had cumulatively accrued </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for estimated interest and penalties related to uncertain tax positions. We record interest and penalties related to unrecognized tax positions as a component of income tax expense (benefit), which totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$(80.0) thousand</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$(80.0) thousand</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$(10.0) thousand</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next </span><span style="font-family:inherit;font-size:10pt;">12 months</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our tax returns remain open to examination as follows: U.S. federal, </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">; U.S. states, generally </span><span style="font-family:inherit;font-size:10pt;">2014</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">; and significant foreign jurisdictions, generally </span><span style="font-family:inherit;font-size:10pt;">2014</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) before provision for income tax is as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(54,370</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,059</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,594</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) before provision for income tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -22851000 -54370000 -18059000 1594000 22110000 23209000 -21257000 -32260000 5150000 <div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of income tax expense (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(948</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,872</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. State and local</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. State and local</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(816</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,751</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,333</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,522</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -948000 -1872000 10110000 561000 -59000 1079000 8386000 5732000 12764000 7999000 3801000 23953000 -7491000 -8248000 6345000 -816000 -1751000 -1333000 -5278000 -3127000 -3522000 -13585000 -13126000 1490000 -5586000 -9325000 25443000 Significant components of deferred tax assets and liabilities as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals deductible in different periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,643</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,713</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,896</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basis difference in fixed and intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,959</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings to be repatriated</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3035000 3192000 2415000 2882000 23672000 15197000 1554000 1262000 4643000 0 35319000 22533000 606000 637000 34713000 21896000 13850000 15687000 3959000 0 800000 500000 18609000 16187000 16104000 5709000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax expense (benefit) in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively to income before taxes due to the following:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal statutory tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign taxes at rates less than U.S. rates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred charges on sales of U.S. intellectual property</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>980</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,428</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,021</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,498</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax position</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,910</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statute</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,961</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,214</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,521</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change of valuation allowance on foreign tax credit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnout adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(190</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repatriation tax net of foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax asset re-measurement</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax audits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Withholding taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global intangible low-taxed income net of foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,326</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Return to provision</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,417</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AMT on acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SAB 118 adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,676</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>936</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.21 0.21 0.35 -4464000 -6775000 1802000 -300000 -1160000 -318000 -2205000 -1071000 -3101000 0 0 980000 824000 519000 606000 1428000 2021000 1498000 2910000 1311000 2048000 -3961000 -1214000 -1521000 0 0 314000 0 0 -190000 172000 0 16564000 0 0 3883000 0 658000 726000 1107000 1185000 2880000 1601000 2326000 0 560000 -1417000 711000 0 0 621000 0 -2676000 0 -402000 1010000 936000 -5586000 -9325000 25443000 23700000 1200000 600000 100000 1000000.0 400000 400000 100000 600000 600000 31000.0 800000 0.05 0 <div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,393</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange difference</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange difference</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases for tax positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,763</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange difference</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5898000 747000 1712000 1393000 53000 7017000 526000 699000 965000 50000 7227000 48000 495000 3763000 6000 3917000 3300000 3500000 3900000 7200000 7000000.0 3600000 6500000 4000000.0 0 2400000 400000 500000 600000 80000.0 80000.0 10000.0 EMPLOYEE BENEFIT PLAN<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We offer pre-tax and after-tax 401(k) savings plan options under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, in the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. For new hires, employer contributions vest ratably over the first two years of employment.</span></div> 3600000 4700000 2500000 SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, our operating segments were based on its three strategic business units. In January 2019 we announced the transition of our operating structure from three strategic business units to a single, unified company with globally led operational teams in Sales and Marketing, Manufacturing, Research and Development, Quality, and General and Administrative functions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the reorganization, we operate as one operating segment and </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segment, which provides medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Financial information is reviewed on a consolidated basis for purposes of making operating decisions and assessing financial performance. Consolidated financial information is accompanied by disaggregated information about revenues by end market and geographic region. We do not assess the performance of our end markets or geographic regions on measures of profit or loss, or asset-based metrics. We have disclosed the revenues for each end market and geographic region to provide the reader of the financial statements transparency into our operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present revenue and long-lived asset information by end market and geographic region. Revenue is based on the destination of the shipments and long-lived assets are based on the physical location of the assets (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated Revenue:</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>292,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530,891</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue by End Market:</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neuro</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Devices and Systems</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,059</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Services</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Neuro Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279,787</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243,156</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Newborn Care</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Devices and Systems</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,669</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Services</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,396</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Newborn Care Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hearing &amp; Balance</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Devices and Systems</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92,050</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,068</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Services</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Hearing &amp; Balance Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530,891</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived asset information by geographic region is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.90448343079922%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ireland</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denmark</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Argentina</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, no single customer or foreign country contributed to more than </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> of revenue.</span></div> 1 The following tables present revenue and long-lived asset information by end market 292400000 300860000 270860000 202775000 230031000 230110000 495175000 530891000 500970000 220306000 200762000 171315000 66059000 67025000 59955000 871000 12000000 11886000 287236000 279787000 243156000 53465000 72807000 89027000 38264000 40669000 43928000 19183000 20396000 22325000 110912000 133872000 155280000 92050000 110597000 75466000 4977000 6635000 27068000 0 0 0 97027000 117232000 102534000 495175000 530891000 500970000 11868000 10019000 5732000 5083000 4140000 4504000 1799000 1371000 0 999000 1163000 937000 24702000 22913000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase commitments</span><span style="font-family:inherit;font-size:10pt;">—We have various purchase obligations for goods or services totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which are expected to be paid within the next year. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal matters</span><span style="font-family:inherit;font-size:10pt;">—We currently are, and may from time to time become, a party to various legal proceedings or claims that arise in the ordinary course of business. Our managements reviews these matters if and when they arise and believes that the resolution of any such matters currently known will not have a material effect on our results of operations or financial position.</span></div> 45000000.0 FAIR VALUE MEASUREMENTS<div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1</span><span style="font-family:inherit;font-size:10pt;">—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2—</span><span style="font-family:inherit;font-size:10pt;">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3</span><span style="font-family:inherit;font-size:10pt;">—Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2019, as part of the sale of our Argentinian subsidiary, Medix, we provided a loan to Medix for $2.2 million. This asset was measured at fair value less costs to sell as of December 31, 2019 and is classified as Level 3 asset. The loan is classified within other assets on our consolidated balance sheet. Subsequent changes in the fair value of the loan receivable are recorded within our income statement as an operating expense. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loan receivable</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(294</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The derivative financial instruments described in Note 12 are measured at fair value on a recurring basis and are presented on the consolidated balance sheets at fair value. The table below presents the fair value of the derivative financial instruments as well as the classification on the consolidated balance sheet (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest Rate Swap</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of the interest rate swaps by calculating the present value of the expected future cash flows of each swap. The calculation incorporated the contractual terms of the derivatives, observable market interest rates which are considered to be Level 2 inputs, and credit risk adjustments, if any, to reflect the counterpart's as well as our nonperformance risk. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there have been no events of default under the interest rate swap agreement. </span></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following financial instruments are not measured at fair value on the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, but require disclosure of fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of the relatively short maturity. </span></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of our short-term and long-term debt approximates fair value based on Level 2 inputs since the debt carries a variable interest rate that is tied to the current LIBOR rate plus a spread.</span></div> 0 2200000 0 -294000 1906000 0 2200000 0 -294000 1906000 77000 0 0 236000 313000 77000 0 0 236000 313000 SALE OF CERTAIN SUBSIDIARY<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We divested our wholly owned subsidiary, Medix, on April 2, 2019 via a stock sale to the local managing director, a related party. In exchange for the stock, we received </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and provided Medix with a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> limited-recourse loan. The loan is secured by a real estate assets of Medix and repayment is conditional upon the sale of the real estate asset.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The held for sale criteria under GAAP was met in the first quarter of 2019. As such, we completed an asset impairment analysis which resulted in the full impairment of all assets held for sale. We recognized an impairment loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$24.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> which included an accrual for the anticipated realization of deferred foreign currency related translation adjustments in accumulated other comprehensive income of </span><span style="font-family:inherit;font-size:10pt;"><span>$24.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax, and an adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for assets with a book value in excess of their fair market value. Included in the year ended December 31, 2019 is the impact of the sale of Medix, which was completed as of June 30, 2019, and the deferred foreign currency related translation adjustments previously in accumulated other comprehensive income have been released from the balance sheet along with the held for sale accrual. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2500 2200000 24600000 24800000 4600000 XML 117 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment, Customer and Geographic Information (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Revenue and long-lived asset information by geographic region The following tables present revenue and long-lived asset information by end market
XML 118 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Components of Basic and Diluted EPS
The components of basic and diluted EPS are as follows (in thousands, except per share amounts): 
 
December 31,
 
2019
 
2018
 
2017
Net loss
$
(15,671
)
 
$
(22,935
)
 
$
(20,293
)
Weighted average common shares
33,696

 
33,111

 
32,564

Dilutive effect of stock based awards
—

 
—

 
—

Diluted Shares
33,696

 
33,111

 
32,564

Basic loss per share
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Diluted loss per share
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Shares excluded from calculation of diluted EPS
104

 
343

 
565
XML 119 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Earnings Per Share EARNINGS PER SHARE
The components of basic and diluted EPS are as follows (in thousands, except per share amounts): 
 
December 31,
 
2019
 
2018
 
2017
Net loss
$
(15,671
)
 
$
(22,935
)
 
$
(20,293
)
Weighted average common shares
33,696

 
33,111

 
32,564

Dilutive effect of stock based awards
—

 
—

 
—

Diluted Shares
33,696

 
33,111

 
32,564

Basic loss per share
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Diluted loss per share
$
(0.47
)
 
$
(0.69
)
 
$
(0.62
)
Shares excluded from calculation of diluted EPS
104

 
343

 
565
XML 120 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Benefit Plan
 12 Months Ended
Dec. 31, 2019
Defined Contribution Plan [Abstract]  
Employee Benefit Plan EMPLOYEE BENEFIT PLAN
We offer pre-tax and after-tax 401(k) savings plan options under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were $3.6 million, $4.7 million, and $2.5 million respectively, in the years ended December 31, 2019, 2018, and 2017. For new hires, employer contributions vest ratably over the first two years of employment.